



908 N. Temperance Ave., Clovis, CA 93611 - Phone 559-275-2175 - www.applinc.com

NELAP Certification Number: CA00046  
DoD-ELAP Certification Number 4064.01  
State Certification Number:

December 28, 2022

Watson Tanji  
AECOM Honolulu  
1001 Bishop Street, Suite 1600  
Honolulu, HI 96813

RE: Red Hill AFFF Assessment Sampling  
22L0141

Enclosed are the results of analyses for samples received by our laboratory on 12/20/2022. If you have any questions concerning this report, please feel free to contact me.

I certify that this data package is in compliance with the terms and conditions of the contract, both technically and for completeness. These test results meet all requirements of NELAC and DoD QSM. Release of the hard copy has been authorized by the Laboratory Manager or designee, as verified by the following signature.

Sincerely,

Greg Salata For Gregory Salata  
Project Manager

# Table of Contents

Cover Letter	1
Case Narrative	4
Sample Results	6
QC Results	12
Notes and Definitions	17
Login Summary	18
Chain of Custody	19
Other Documents or Sub Lab Data	22
Fraction (PFAS)	23
Sample Data (EPA 1633)	24
Sample Results (22L0141-01)	25
Sample Results (22L0141-02)	34
Sample Results (22L0141-03)	43
Quality Control (EPA 1633)	52
Surrogate Summary (BBL0403)	53
Method Blank Summary (BBL0403)	59
Method Blank Results (BBL0403)	60
Laboratory Control Recovery (BBL0403)	62
Calibration Summary (EPA 1633)	64
Calibration (SB03941)	69
Initial Calibration Verification (SB03941)	126
CCV (SB03951)	145
Quality Control Raw Data (EPA 1633)	220
QC Results (BBL0403)	221
Preparation Bench Sheet (BBL0403)	248

## Table of Contents (continued)

Injection Log (SB03941)	255
Injection Log (SB03951)	256
Standard Traceability	257

AECOM Honolulu  
1001 Bishop Street, Suite 1600  
Honolulu, HI 96813

Project: Red Hill AFFF Assessment Sampling  
Project Number: Red Hill AFFF Assessment Sampling  
Project Manager: Watson Tanji

Reported: 12/28/2022 16:52

## Data Validatable Report

### Analysis Case Narrative

**PFAS:** Manual integrations were performed for this method in accordance with APPL's SOP. Chromatograms after manual integration are enclosed for specific samples and analytes. Abbreviated flags for technical justification are listed on the chromatogram. Some extracted internal standards recovered outside of control limits in some samples, these samples were diluted and recovered in control, unless stated otherwise.

The analyte PFTeDA recovered above the upper control limit in the SB03951-LCV1.

### Samples in this Report

Lab ID	Sample	Matrix	Date Sampled	Date Received
22L0141-01	AF-RHMW02-WGN01LF-2212W3	Water	12/19/2022 13:20	12/20/2022
22L0141-02	AF-RHMW03-WGN01LF-2212W3	Water	12/19/2022 16:20	12/20/2022
22L0141-03	AF-RHMW225401-WGN01B-2212W3	Water	12/19/2022 14:00	12/20/2022

AECOM Honolulu  
1001 Bishop Street, Suite 1600  
Honolulu, HI 96813

Project: Red Hill AFFF Assessment Sampling  
Project Number: Red Hill AFFF Assessment Sampling  
Project Manager: Watson Tanji

Reported: 12/28/2022 16:52

### Containers Received

Lab ID	Container Type	Count	Preservation Check
22L0141-01	500mL P	2	
22L0141-02	500mL P	2	
22L0141-03	500mL P	2	

AECOM Honolulu  
1001 Bishop Street, Suite 1600  
Honolulu, HI 96813

Project: Red Hill AFFF Assessment Sampling  
Project Number: Red Hill AFFF Assessment Sampling  
Project Manager: Watson Tanji

Reported: 12/28/2022 16:52

## Sample Results

**Sample: AF-RHMW02-WGN01LF-2212W3**  
**22L0141-01 (Water)**

### Per- and Polyfluoroalkyl Substances

Analyte	Result /Qual	LOQ	LOD	DL	Units	Date Analyzed	DF	Method	Prep Batch
PFBA	0.69 U	1.4	0.69	0.18	ng/L	12/22/22	1	EPA 1633	BBL0403
PFPEA	1.4	0.69	0.34	0.056	ng/L	12/22/22	1	EPA 1633	BBL0403
PFHXA	0.24 J IR2,	0.34	0.17	0.047	ng/L	12/22/22	1	EPA 1633	BBL0403
PFHPA	0.20 J	0.34	0.17	0.035	ng/L	12/22/22	1	EPA 1633	BBL0403
PFOA	0.17 U	0.34	0.17	0.13	ng/L	12/22/22	1	EPA 1633	BBL0403
PFNA	0.17 U IR1,	0.34	0.17	0.071	ng/L	12/22/22	1	EPA 1633	BBL0403
PFDA	0.17 U	0.34	0.17	0.087	ng/L	12/22/22	1	EPA 1633	BBL0403
PFUnA	0.17 U	0.34	0.17	0.14	ng/L	12/22/22	1	EPA 1633	BBL0403
PFDOA	0.17 U IR1,	0.34	0.17	0.096	ng/L	12/22/22	1	EPA 1633	BBL0403
PFTRDA	0.26 U	0.34	0.26	0.18	ng/L	12/22/22	1	EPA 1633	BBL0403
PFTEDA	0.17 U	0.34	0.17	0.17	ng/L	12/22/22	1	EPA 1633	BBL0403
PFBS	0.17 U	0.34	0.17	0.032	ng/L	12/22/22	1	EPA 1633	BBL0403
PFPEs	0.17 U	0.34	0.17	0.054	ng/L	12/22/22	1	EPA 1633	BBL0403
PFHXS	0.036 J	0.34	0.17	0.027	ng/L	12/22/22	1	EPA 1633	BBL0403
PFHPS	0.17 U	0.34	0.17	0.044	ng/L	12/22/22	1	EPA 1633	BBL0403
PFOS	0.064 J	0.34	0.17	0.055	ng/L	12/22/22	1	EPA 1633	BBL0403
PFNS	0.17 U	0.34	0.17	0.11	ng/L	12/22/22	1	EPA 1633	BBL0403
PFDS	0.17 U	0.34	0.17	0.13	ng/L	12/22/22	1	EPA 1633	BBL0403
PFDOS	0.17 U	0.34	0.17	0.11	ng/L	12/22/22	1	EPA 1633	BBL0403
4:2FTS	0.69 U	1.4	0.69	0.25	ng/L	12/22/22	1	EPA 1633	BBL0403
6:2FTS	10	1.4	0.69	0.27	ng/L	12/22/22	1	EPA 1633	BBL0403
8:2FTS	0.69 U	1.4	0.69	0.071	ng/L	12/22/22	1	EPA 1633	BBL0403
PFOSA	0.17 U	0.34	0.17	0.090	ng/L	12/22/22	1	EPA 1633	BBL0403
NMeFOSA	0.69 U	1.4	0.69	0.41	ng/L	12/22/22	1	EPA 1633	BBL0403
NEtFOSA	0.69 U	1.4	0.69	0.36	ng/L	12/22/22	1	EPA 1633	BBL0403
NMeFOSAA	0.17 U	0.34	0.17	0.091	ng/L	12/22/22	1	EPA 1633	BBL0403
NEtFOSAA	0.17 U	0.34	0.17	0.099	ng/L	12/22/22	1	EPA 1633	BBL0403
NMeFOSE	1.0 U	1.4	1.0	0.87	ng/L	12/22/22	1	EPA 1633	BBL0403
NEtFOSE	1.0 U	1.4	1.0	0.90	ng/L	12/22/22	1	EPA 1633	BBL0403
HFPO-DA	0.34 U	0.69	0.34	0.15	ng/L	12/22/22	1	EPA 1633	BBL0403
ADONA	0.34 U	0.69	0.34	0.11	ng/L	12/22/22	1	EPA 1633	BBL0403
PFEESA	0.34 U	0.69	0.34	0.094	ng/L	12/22/22	1	EPA 1633	BBL0403
PFMPA	0.34 U	0.69	0.34	0.046	ng/L	12/22/22	1	EPA 1633	BBL0403
PFMBA	0.34 U	0.69	0.34	0.078	ng/L	12/22/22	1	EPA 1633	BBL0403
NFDHA	0.34 U	0.69	0.34	0.26	ng/L	12/22/22	1	EPA 1633	BBL0403
9CL-PF3ONS	0.34 U	0.69	0.34	0.18	ng/L	12/22/22	1	EPA 1633	BBL0403
11CL-PF3OUDS	0.34 U	0.69	0.34	0.18	ng/L	12/22/22	1	EPA 1633	BBL0403
3:3FTCA	0.69 U	1.4	0.69	0.50	ng/L	12/22/22	1	EPA 1633	BBL0403
5:3FTCA	0.69 U	1.4	0.69	0.38	ng/L	12/22/22	1	EPA 1633	BBL0403
7:3FTCA	0.69 U	1.4	0.69	0.48	ng/L	12/22/22	1	EPA 1633	BBL0403
<hr/>									
Surrogate: 13C4-PFBA	65.1%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C5-PFPEA	61.6%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C5-PFHXA	85.0%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C4-PFHPA	95.1%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C8-PFOA	91.2%		20-150			12/22/22	1	EPA 1633	BBL0403

AECOM Honolulu  
1001 Bishop Street, Suite 1600  
Honolulu, HI 96813

Project: Red Hill AFFF Assessment Sampling  
Project Number: Red Hill AFFF Assessment Sampling  
Project Manager: Watson Tanji

Reported: 12/28/2022 16:52

### Sample Results (Continued)

**Sample: AF-RHMW02-WGN01LF-2212W3 (Continued)**  
**22L0141-01 (Water)**

#### Per- and Polyfluoroalkyl Substances (Continued)

Analyte	Result /Qual	LOQ	LOD	DL	Units	Date Analyzed	DF	Method	Prep Batch
Surrogate: 13C9-PFNA	87.7%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C6-PFDA	82.4%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C7-PFUnA	71.5%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C2-PFDOA	69.9%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C2-PFTEDA	72.9%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C3-PFBS	95.7%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C3-PFHXS	86.7%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C8-PFOS	79.6%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C2-4:2FTS	128%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C2-6:2FTS	136%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C2-8:2FTS	141%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C8-PFOA	51.2%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: D5-NETFOA	40.0%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: D3-NMEFOA	44.9%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: D3-NMEFOAA	87.9%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: D5-NETFOAA	93.2%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: D7-NMEFOSE	53.9%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: D9-NETFOSE	51.2%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C3-HFPO-DA	74.0%		20-150			12/22/22	1	EPA 1633	BBL0403

AECOM Honolulu  
1001 Bishop Street, Suite 1600  
Honolulu, HI 96813

Project: Red Hill AFFF Assessment Sampling  
Project Number: Red Hill AFFF Assessment Sampling  
Project Manager: Watson Tanji

Reported: 12/28/2022 16:52

### Sample Results (Continued)

**Sample: AF-RHMW03-WGN01LF-2212W3  
22L0141-02 (Water)**

#### Per- and Polyfluoroalkyl Substances

Analyte	Result /Qual	LOQ	LOD	DL	Units	Date Analyzed	DF	Method	Prep Batch
PFBA	2.9	1.4	0.70	0.18	ng/L	12/22/22	1	EPA 1633	BBL0403
PFPEA	3.7	0.70	0.35	0.057	ng/L	12/22/22	1	EPA 1633	BBL0403
PFHXA	1.4	0.35	0.18	0.048	ng/L	12/22/22	1	EPA 1633	BBL0403
PFHPA	1.1	0.35	0.18	0.036	ng/L	12/22/22	1	EPA 1633	BBL0403
PFOA	0.32 J	0.35	0.18	0.13	ng/L	12/22/22	1	EPA 1633	BBL0403
PFNA	0.17 J	0.35	0.18	0.072	ng/L	12/22/22	1	EPA 1633	BBL0403
PFDA	0.12 J IR2,	0.35	0.18	0.089	ng/L	12/22/22	1	EPA 1633	BBL0403
PFUnA	0.18 J	0.35	0.18	0.14	ng/L	12/22/22	1	EPA 1633	BBL0403
PFDOA	0.12 J	0.35	0.18	0.098	ng/L	12/22/22	1	EPA 1633	BBL0403
PFTRDA	0.26 U	0.35	0.26	0.18	ng/L	12/22/22	1	EPA 1633	BBL0403
PFTEDA	0.18 U	0.35	0.18	0.17	ng/L	12/22/22	1	EPA 1633	BBL0403
PFBS	0.18 U	0.35	0.18	0.032	ng/L	12/22/22	1	EPA 1633	BBL0403
PFPEs	0.18 U	0.35	0.18	0.055	ng/L	12/22/22	1	EPA 1633	BBL0403
PFHXS	0.039 J	0.35	0.18	0.028	ng/L	12/22/22	1	EPA 1633	BBL0403
PFHPS	0.18 U	0.35	0.18	0.045	ng/L	12/22/22	1	EPA 1633	BBL0403
PFOS	0.094 J	0.35	0.18	0.056	ng/L	12/22/22	1	EPA 1633	BBL0403
PFNS	0.18 U	0.35	0.18	0.11	ng/L	12/22/22	1	EPA 1633	BBL0403
PFDS	0.18 U	0.35	0.18	0.13	ng/L	12/22/22	1	EPA 1633	BBL0403
PFDOS	0.18 U	0.35	0.18	0.11	ng/L	12/22/22	1	EPA 1633	BBL0403
4:2FTS	0.70 U	1.4	0.70	0.25	ng/L	12/22/22	1	EPA 1633	BBL0403
6:2FTS	3.6	1.4	0.70	0.28	ng/L	12/22/22	1	EPA 1633	BBL0403
8:2FTS	0.70 U	1.4	0.70	0.072	ng/L	12/22/22	1	EPA 1633	BBL0403
PFOSA	0.18 U	0.35	0.18	0.091	ng/L	12/22/22	1	EPA 1633	BBL0403
NMeFOSA	0.70 U	1.4	0.70	0.41	ng/L	12/22/22	1	EPA 1633	BBL0403
NEtFOSA	0.70 U	1.4	0.70	0.36	ng/L	12/22/22	1	EPA 1633	BBL0403
NMeFOSAA	0.18 U	0.35	0.18	0.093	ng/L	12/22/22	1	EPA 1633	BBL0403
NEtFOSAA	0.18 U	0.35	0.18	0.10	ng/L	12/22/22	1	EPA 1633	BBL0403
NMeFOSE	1.1 U	1.4	1.1	0.89	ng/L	12/22/22	1	EPA 1633	BBL0403
NEtFOSE	1.1 U	1.4	1.1	0.92	ng/L	12/22/22	1	EPA 1633	BBL0403
HFPO-DA	0.35 U	0.70	0.35	0.15	ng/L	12/22/22	1	EPA 1633	BBL0403
ADONA	0.35 U	0.70	0.35	0.11	ng/L	12/22/22	1	EPA 1633	BBL0403
PFEESA	0.35 U	0.70	0.35	0.096	ng/L	12/22/22	1	EPA 1633	BBL0403
PFMPA	0.35 U	0.70	0.35	0.047	ng/L	12/22/22	1	EPA 1633	BBL0403
PFMBA	0.35 U	0.70	0.35	0.080	ng/L	12/22/22	1	EPA 1633	BBL0403
NFDHA	0.35 U	0.70	0.35	0.26	ng/L	12/22/22	1	EPA 1633	BBL0403
9CL-PF3ONS	0.35 U	0.70	0.35	0.18	ng/L	12/22/22	1	EPA 1633	BBL0403
11CL-PF3OUDS	0.35 U	0.70	0.35	0.18	ng/L	12/22/22	1	EPA 1633	BBL0403
3:3FTCA	0.70 U	1.4	0.70	0.50	ng/L	12/22/22	1	EPA 1633	BBL0403
5:3FTCA	0.70 U	1.4	0.70	0.39	ng/L	12/22/22	1	EPA 1633	BBL0403
7:3FTCA	0.70 U	1.4	0.70	0.49	ng/L	12/22/22	1	EPA 1633	BBL0403
<hr/>									
Surrogate: 13C4-PFBA	82.7%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C5-PFPEA	80.6%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C5-PFHXA	82.8%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C4-PFHPA	94.5%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C8-PFOA	88.7%		20-150			12/22/22	1	EPA 1633	BBL0403



AECOM Honolulu  
1001 Bishop Street, Suite 1600  
Honolulu, HI 96813

Project: Red Hill AFFF Assessment Sampling  
Project Number: Red Hill AFFF Assessment Sampling  
Project Manager: Watson Tanji

Reported: 12/28/2022 16:52

### Sample Results (Continued)

**Sample: AF-RHMW03-WGN01LF-2212W3 (Continued)**  
**22L0141-02 (Water)**

#### Per- and Polyfluoroalkyl Substances (Continued)

Analyte	Result /Qual	LOQ	LOD	DL	Units	Date Analyzed	DF	Method	Prep Batch
Surrogate: 13C9-PFNA	96.5%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C6-PFDA	82.7%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C7-PFUnA	86.6%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C2-PFDOA	79.0%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C2-PFTEDA	65.5%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C3-PFBS	90.4%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C3-PFHXS	92.3%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C8-PFOS	97.4%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C2-4:2FTS	129%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C2-6:2FTS	113%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C2-8:2FTS	106%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C8-PFOA	65.3%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: D5-NETFOA	45.2%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: D3-NMEFOA	46.1%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: D3-NMEFOAA	90.8%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: D5-NETFOAA	95.0%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: D7-NMEFOSE	54.8%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: D9-NETFOSE	56.0%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C3-HFPO-DA	85.2%		20-150			12/22/22	1	EPA 1633	BBL0403

AECOM Honolulu  
1001 Bishop Street, Suite 1600  
Honolulu, HI 96813

Project: Red Hill AFFF Assessment Sampling  
Project Number: Red Hill AFFF Assessment Sampling  
Project Manager: Watson Tanji

Reported: 12/28/2022 16:52

## Sample Results (Continued)

**Sample: AF-RHMW225401-WGN01B-2212W3  
22L0141-03 (Water)**

### Per- and Polyfluoroalkyl Substances

Analyte	Result /Qual	LOQ	LOD	DL	Units	Date Analyzed	DF	Method	Prep Batch
PFBA	0.60 J	1.4	0.71	0.19	ng/L	12/22/22	1	EPA 1633	BBL0403
PFPEA	1.2	0.71	0.36	0.058	ng/L	12/22/22	1	EPA 1633	BBL0403
PFHXA	0.96	0.36	0.18	0.049	ng/L	12/22/22	1	EPA 1633	BBL0403
PFHPA	0.73	0.36	0.18	0.036	ng/L	12/22/22	1	EPA 1633	BBL0403
PFOA	1.0	0.36	0.18	0.14	ng/L	12/22/22	1	EPA 1633	BBL0403
PFNA	0.18 J	0.36	0.18	0.073	ng/L	12/22/22	1	EPA 1633	BBL0403
PFDA	0.18 U	0.36	0.18	0.090	ng/L	12/22/22	1	EPA 1633	BBL0403
PFUnA	0.18 U	0.36	0.18	0.14	ng/L	12/22/22	1	EPA 1633	BBL0403
PFDOA	0.18 U	0.36	0.18	0.10	ng/L	12/22/22	1	EPA 1633	BBL0403
PFTRDA	0.27 U	0.36	0.27	0.18	ng/L	12/22/22	1	EPA 1633	BBL0403
PFTEDA	0.18 U IR1,	0.36	0.18	0.18	ng/L	12/22/22	1	EPA 1633	BBL0403
PFBS	0.68	0.36	0.18	0.033	ng/L	12/22/22	1	EPA 1633	BBL0403
PFPEs	0.11 J	0.36	0.18	0.056	ng/L	12/22/22	1	EPA 1633	BBL0403
PFHXS	1.2	0.36	0.18	0.028	ng/L	12/22/22	1	EPA 1633	BBL0403
PFHPS	0.18 U	0.36	0.18	0.046	ng/L	12/22/22	1	EPA 1633	BBL0403
PFOS	0.98	0.36	0.18	0.057	ng/L	12/22/22	1	EPA 1633	BBL0403
PFNS	0.18 U	0.36	0.18	0.11	ng/L	12/22/22	1	EPA 1633	BBL0403
PFDS	0.18 U	0.36	0.18	0.13	ng/L	12/22/22	1	EPA 1633	BBL0403
PFDOS	0.18 U	0.36	0.18	0.11	ng/L	12/22/22	1	EPA 1633	BBL0403
4:2FTS	0.71 U	1.4	0.71	0.26	ng/L	12/22/22	1	EPA 1633	BBL0403
6:2FTS	0.71 U	1.4	0.71	0.28	ng/L	12/22/22	1	EPA 1633	BBL0403
8:2FTS	0.71 U	1.4	0.71	0.073	ng/L	12/22/22	1	EPA 1633	BBL0403
PFOSA	0.18 U	0.36	0.18	0.093	ng/L	12/22/22	1	EPA 1633	BBL0403
NMeFOSA	0.71 U	1.4	0.71	0.42	ng/L	12/22/22	1	EPA 1633	BBL0403
NEtFOSA	0.71 U	1.4	0.71	0.37	ng/L	12/22/22	1	EPA 1633	BBL0403
NMeFOSAA	0.18 U	0.36	0.18	0.094	ng/L	12/22/22	1	EPA 1633	BBL0403
NEtFOSAA	0.18 U	0.36	0.18	0.10	ng/L	12/22/22	1	EPA 1633	BBL0403
NMeFOSE	1.1 U	1.4	1.1	0.90	ng/L	12/22/22	1	EPA 1633	BBL0403
NEtFOSE	1.1 U	1.4	1.1	0.93	ng/L	12/22/22	1	EPA 1633	BBL0403
HFPO-DA	0.36 U	0.71	0.36	0.16	ng/L	12/22/22	1	EPA 1633	BBL0403
ADONA	0.36 U	0.71	0.36	0.11	ng/L	12/22/22	1	EPA 1633	BBL0403
PFEESA	0.36 U	0.71	0.36	0.097	ng/L	12/22/22	1	EPA 1633	BBL0403
PFMPA	0.36 U	0.71	0.36	0.048	ng/L	12/22/22	1	EPA 1633	BBL0403
PFMBA	0.36 U	0.71	0.36	0.081	ng/L	12/22/22	1	EPA 1633	BBL0403
NFDHA	0.36 U	0.71	0.36	0.27	ng/L	12/22/22	1	EPA 1633	BBL0403
9CL-PF3ONS	0.36 U	0.71	0.36	0.19	ng/L	12/22/22	1	EPA 1633	BBL0403
11CL-PF3OUDS	0.36 U	0.71	0.36	0.18	ng/L	12/22/22	1	EPA 1633	BBL0403
3:3FTCA	0.71 U	1.4	0.71	0.51	ng/L	12/22/22	1	EPA 1633	BBL0403
5:3FTCA	0.71 U	1.4	0.71	0.39	ng/L	12/22/22	1	EPA 1633	BBL0403
7:3FTCA	0.71 U	1.4	0.71	0.49	ng/L	12/22/22	1	EPA 1633	BBL0403
<hr/>									
Surrogate: 13C4-PFBA	86.9%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C5-PFPEA	82.7%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C5-PFHXA	80.9%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C4-PFHPA	74.6%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C8-PFOA	87.3%		20-150			12/22/22	1	EPA 1633	BBL0403

AECOM Honolulu  
1001 Bishop Street, Suite 1600  
Honolulu, HI 96813

Project: Red Hill AFFF Assessment Sampling  
Project Number: Red Hill AFFF Assessment Sampling  
Project Manager: Watson Tanji

Reported: 12/28/2022 16:52

### Sample Results (Continued)

**Sample: AF-RHMW225401-WGN01B-2212W3 (Continued)**  
**22L0141-03 (Water)**

#### Per- and Polyfluoroalkyl Substances (Continued)

Analyte	Result /Qual	LOQ	LOD	DL	Units	Date Analyzed	DF	Method	Prep Batch
Surrogate: 13C9-PFNA	88.3%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C6-PFDA	82.8%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C7-PFUnA	85.9%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C2-PFDOA	78.0%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C2-PFTEDA	88.7%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C3-PFBS	85.9%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C3-PFHXS	91.7%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C8-PFOS	99.0%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C2-4:2FTS	113%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C2-6:2FTS	109%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C2-8:2FTS	103%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C8-PFOSA	54.2%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: D5-NETFOSA	31.3%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: D3-NMEFOSA	32.5%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: D3-NMEFOSAA	88.9%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: D5-NETFOSAA	92.4%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: D7-NMEFOSE	38.8%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: D9-NETFOSE	46.2%		20-150			12/22/22	1	EPA 1633	BBL0403
Surrogate: 13C3-HFPO-DA	76.9%		20-150			12/22/22	1	EPA 1633	BBL0403

AECOM Honolulu  
1001 Bishop Street, Suite 1600  
Honolulu, HI 96813

Project: Red Hill AFFF Assessment Sampling  
Project Number: Red Hill AFFF Assessment Sampling  
Project Manager: Watson Tanji

Reported: 12/28/2022 16:52

## Quality Control

### Per- and Polyfluoroalkyl Substances

Analyte	Result/Qual	LOQ	LOD	MDL	Spike Level	Source Result	%REC	%REC Limits	RPD	RPD Limit
---------	-------------	-----	-----	-----	-------------	---------------	------	-------------	-----	-----------

#### Batch: BBL0403 - 1633

##### Blank (BBL0403-BLK1)

Prepared: 12/20/22 15:01 Analyzed: 12/22/22 15:02

	ng/L			
PFBA	0.80 U	1.6	0.80	0.21
PFPEA	0.40 U	0.80	0.40	0.065
PFHXA	0.20 U	0.40	0.20	0.055
PFHPA	0.20 U	0.40	0.20	0.041
PFOA	0.20 U	0.40	0.20	0.15
PFNA	0.20 U	0.40	0.20	0.082
PFDA	0.20 U	0.40	0.20	0.10
PFUnA	0.20 U	0.40	0.20	0.16
PFDOA	0.20 U	0.40	0.20	0.11
PFTRDA	0.30 U	0.40	0.30	0.20
PFTEDA	0.20 U	0.40	0.20	0.20
PFBS	0.20 U	0.40	0.20	0.037
PFPEs	0.20 U	0.40	0.20	0.063
PFHXS	0.20 U	0.40	0.20	0.032
PFHPS	0.20 U	0.40	0.20	0.051
PFOS	0.0863 J	0.40	0.20	0.064
PFNS	0.20 U	0.40	0.20	0.12
PFDS	0.20 U	0.40	0.20	0.15
PFDOS	0.20 U	0.40	0.20	0.12
4:2FTS	0.80 U	1.6	0.80	0.29
6:2FTS	0.80 U	1.6	0.80	0.31
8:2FTS	0.80 U	1.6	0.80	0.082
PFOSA	0.20 U	0.40	0.20	0.10
NMeFOSA	0.80 U	1.6	0.80	0.47
NEtFOSA	0.80 U	1.6	0.80	0.41
NMeFOSAA	0.20 U	0.40	0.20	0.11
NEtFOSAA	0.20 U	0.40	0.20	0.11
NMeFOSE	1.2 U	1.6	1.2	1.0
NEtFOSE	1.2 U	1.6	1.2	1.0
HFPO-DA	0.40 U	0.80	0.40	0.17
ADONA	0.40 U	0.80	0.40	0.12
PFEESA	0.40 U	0.80	0.40	0.11
PFMPA	0.40 U	0.80	0.40	0.054
PFMBA	0.40 U	0.80	0.40	0.091
NFDHA	0.40 U	0.80	0.40	0.30
9CL-PF3ONS	0.40 U	0.80	0.40	0.21
11CL-PF3OUDS	0.40 U	0.80	0.40	0.21
3:3FTCA	0.80 U	1.6	0.80	0.57
5:3FTCA	0.80 U	1.6	0.80	0.44
7:3FTCA	0.80 U	1.6	0.80	0.55

#### Surrogates

13C4-PFBA	30.3	32.0	94.6	20-150
13C5-PFPEA	15.1	16.0	94.3	20-150
13C5-PFHXA	7.37	8.00	92.2	20-150
13C4-PFHPA	7.26	8.00	90.7	20-150
13C8-PFOA	7.70	8.00	96.2	20-150

AECOM Honolulu  
1001 Bishop Street, Suite 1600  
Honolulu, HI 96813

Project: Red Hill AFFF Assessment Sampling  
Project Number: Red Hill AFFF Assessment Sampling  
Project Manager: Watson Tanji

Reported: 12/28/2022 16:52

### Quality Control (Continued)

#### Per- and Polyfluoroalkyl Substances (Continued)

Analyte	Result/Qual	LOQ	LOD	MDL	Spike Level	Source Result	%REC	%REC Limits	RPD	RPD Limit
---------	-------------	-----	-----	-----	-------------	---------------	------	-------------	-----	-----------

#### Batch: BBL0403 - 1633 (Continued)

##### Blank (BBL0403-BLK1)

Prepared: 12/20/22 15:01 Analyzed: 12/22/22 15:02

ng/L

##### Surrogates

13C9-PFNA	3.84				4.00		96.0	20-150		
13C6-PFDA	3.59				4.00		89.8	20-150		
13C7-PFUnA	3.67				4.00		91.8	20-150		
13C2-PFDOA	4.25				4.00		106	20-150		
13C2-PFTEDA	3.12				4.00		78.0	20-150		
13C3-PFBS	6.90				8.00		86.3	20-150		
13C3-PFHXS	7.18				8.00		89.7	20-150		
13C8-PFOS	6.91				8.00		86.4	20-150		
13C2-4:2FTS	14.3				16.0		89.3	20-150		
13C2-6:2FTS	17.7				16.0		111	20-150		
13C2-8:2FTS	14.0				16.0		87.3	20-150		
13C8-PFOA	6.46				8.00		80.7	20-150		
D5-NETFOA	2.54				8.00		31.7	20-150		
D3-NMEFOA	3.05				8.00		38.2	20-150		
D3-NMEFOA	11.8				16.0		73.5	20-150		
D5-NETFOA	13.2				16.0		82.3	20-150		
D7-NMEFOA	47.7				80.0		59.6	20-150		
D9-NETFOA	47.9				80.0		59.9	20-150		
13C3-HFPO-DA	28.5				32.0		89.1	20-150		

##### LCS (BBL0403-BS1)

Prepared: 12/20/22 15:01 Analyzed: 12/22/22 15:15

ng/L

PFBA	16.1				16.0		101	40-150		
PFPEA	7.93				8.00		99.1	40-150		
PFHXA	4.27				4.00		107	40-150		
PFHPA	3.87				4.00		96.8	40-150		
PFOA	3.50				4.00		87.6	40-150		
PFNA	3.90				4.00		97.5	40-150		
PFDA	4.33				4.00		108	40-150		
PFUnA	4.74				4.00		119	40-150		
PFDOA	3.75				4.00		93.8	40-150		
PFTRDA	3.68				4.00		92.0	40-150		
PFTEDA	4.31				4.00		108	40-150		
PFBS	3.64				3.54		103	40-150		
PFPEA	3.56				3.76		94.6	40-150		
PFHXS	3.53				3.66		96.5	40-150		
PFHPS	3.57				3.82		93.4	40-150		
PFOS	3.24				3.72		87.1	40-150		
PFNS	3.62				3.84		94.4	40-150		
PFDS	3.46				3.86		89.5	40-150		
PFDOS	3.24				3.88		83.4	40-150		
4:2FTS	13.2				15.0		87.8	40-150		
6:2FTS	15.2				15.2		99.7	40-150		
8:2FTS	14.7				15.4		95.7	40-150		
PFOA	3.46				4.00		86.6	40-150		

AECOM Honolulu  
1001 Bishop Street, Suite 1600  
Honolulu, HI 96813

Project: Red Hill AFFF Assessment Sampling  
Project Number: Red Hill AFFF Assessment Sampling  
Project Manager: Watson Tanji

Reported: 12/28/2022 16:52

### Quality Control (Continued)

#### Per- and Polyfluoroalkyl Substances (Continued)

Analyte	Result/Qual	LOQ	LOD	MDL	Spike Level	Source Result	%REC	%REC Limits	RPD	RPD Limit
---------	-------------	-----	-----	-----	-------------	---------------	------	-------------	-----	-----------

#### Batch: BBL0403 - 1633 (Continued)

##### LCS (BBL0403-BS1)

Prepared: 12/20/22 15:01 Analyzed: 12/22/22 15:15

Analyte	Result/Qual	LOQ	LOD	MDL	Spike Level	Source Result	%REC	%REC Limits	RPD	RPD Limit
	ng/L									
NMeFOSA	18.4				16.0		115	40-150		
NETFOSA	16.9				16.0		106	40-150		
NMeFOSAA	3.87				4.00		96.7	40-150		
NETFOSAA	3.84				4.00		96.0	40-150		
NMeFOSE	17.8				16.0		111	40-150		
NETFOSE	15.8				16.0		98.7	40-150		
HFPO-DA	7.61				8.00		95.1	40-150		
ADONA	7.89				7.56		104	40-150		
PFEESA	7.00				7.12		98.3	40-150		
PFMPA	8.31				8.00		104	40-150		
PFMBA	7.54				8.00		94.3	40-150		
NFDHA	8.29				8.00		104	40-150		
9CL-PF3ONS	6.81				7.48		91.0	40-150		
11CL-PF3OUDS	7.94				7.56		105	40-150		
3:3FTCA	17.4				16.0		109	40-150		
5:3FTCA	17.2				16.0		108	40-150		
7:3FTCA	17.9				16.0		112	40-150		

#### Surrogates

13C4-PFBA	31.0				32.0		97.0	20-150		
13C5-PFPEA	17.4				16.0		109	20-150		
13C5-PFHXA	7.89				8.00		98.6	20-150		
13C4-PFHXA	8.58				8.00		107	20-150		
13C8-PFOA	7.77				8.00		97.1	20-150		
13C9-PFNA	3.93				4.00		98.3	20-150		
13C6-PFDA	2.96				4.00		74.0	20-150		
13C7-PFUnA	2.87				4.00		71.8	20-150		
13C2-PFDOA	2.99				4.00		74.6	20-150		
13C2-PFTEDA	2.92				4.00		73.1	20-150		
13C3-PFBS	7.04				8.00		88.0	20-150		
13C3-PFHXS	7.63				8.00		95.3	20-150		
13C8-PFOS	7.64				8.00		95.5	20-150		
13C2-4:2FTS	13.6				16.0		85.2	20-150		
13C2-6:2FTS	14.3				16.0		89.2	20-150		
13C2-8:2FTS	14.2				16.0		88.4	20-150		
13C8-PFOSA	6.73				8.00		84.2	20-150		
D5-NETFOSA	2.04				8.00		25.5	20-150		
D3-NMEFOSA	2.24				8.00		28.0	20-150		
D3-NMEFOSAA	13.8				16.0		86.5	20-150		
D5-NETFOSAA	13.3				16.0		83.3	20-150		
D7-NMEFOSE	36.0				80.0		45.0	20-150		
D9-NETFOSE	38.6				80.0		48.2	20-150		
13C3-HFPO-DA	32.6				32.0		102	20-150		

AECOM Honolulu  
1001 Bishop Street, Suite 1600  
Honolulu, HI 96813

Project: Red Hill AFFF Assessment Sampling  
Project Number: Red Hill AFFF Assessment Sampling  
Project Manager: Watson Tanji

Reported: 12/28/2022 16:52

### Quality Control (Continued)

#### Per- and Polyfluoroalkyl Substances (Continued)

Analyte	Result/Qual	LOQ	LOD	MDL	Spike Level	Source Result	%REC	%REC Limits	RPD	RPD Limit
---------	-------------	-----	-----	-----	-------------	---------------	------	-------------	-----	-----------

#### Batch: BBL0403 - 1633 (Continued)

##### MRL Check (BBL0403-MRL1)

Prepared: 12/20/22 15:01 Analyzed: 12/22/22 15:28

Analyte	Result/Qual	LOQ	LOD	MDL	Spike Level	Source Result	%REC	%REC Limits	RPD	RPD Limit
	ng/L									
PFBA	1.51 J				1.60		94.6	40-150		
PFPEA	0.801				0.800		100	40-150		
PFHXA	0.370 J				0.400		92.6	40-150		
PFHPA	0.350 J				0.400		87.6	40-150		
PFOA	0.403				0.400		101	40-150		
PFNA	0.333 J				0.400		83.2	40-150		
PFDA	0.274 J				0.400		68.5	40-150		
PFUnA	0.345 J				0.400		86.3	40-150		
PFDOA	0.342 J				0.400		85.6	40-150		
PFTRDA	0.378 J IR1,				0.400		94.6	40-150		
PFTEDA	0.329 J IR2,				0.400		82.2	40-150		
PFBS	0.328 J				0.354		92.6	40-150		
PFPEs	0.341 J				0.376		90.8	40-150		
PFHXS	0.355 J				0.366		96.9	40-150		
PFHPS	0.358 J				0.382		93.7	40-150		
PFOS	0.401				0.372		108	40-150		
PFNS	0.321 J				0.384		83.5	40-150		
PFDS	0.394 J				0.386		102	40-150		
PFDOS	0.382 J				0.388		98.6	40-150		
4:2FTS	1.43 J				1.50		95.6	40-150		
6:2FTS	1.31 J				1.52		86.0	40-150		
8:2FTS	1.16 J				1.54		75.5	40-150		
PFOSA	0.425				0.400		106	40-150		
NMeFOSA	1.69				1.60		106	40-150		
NEtFOSA	1.38 J				1.60		86.2	40-150		
NMeFOSAA	0.457				0.400		114	40-150		
NEtFOSAA	0.354 J				0.400		88.5	40-150		
NMeFOSE	1.40 J				1.60		87.7	40-150		
NEtFOSE	1.25 J				1.60		77.9	40-150		
HFPO-DA	0.686 J				0.800		85.7	40-150		
ADONA	0.768 J				0.756		102	40-150		
PFEESA	0.627 J				0.712		88.0	40-150		
PFMPA	0.784 J				0.800		98.0	40-150		
PFMBA	0.680 J				0.800		85.1	40-150		
NFDHA	0.877				0.800		110	40-150		
9CL-PF3ONS	0.598 J				0.748		80.0	40-150		
11CL-PF3OUDS	0.811				0.756		107	40-150		
3:3FTCA	1.35 J				1.60		84.4	40-150		
5:3FTCA	1.88				1.60		117	40-150		
7:3FTCA	1.79				1.60		112	40-150		

#### Surrogates

13C4-PFBA	30.7				32.0		95.9	20-150		
13C5-PFPEA	16.3				16.0		102	20-150		
13C5-PFHXA	7.09				8.00		88.6	20-150		
13C4-PFHPA	8.60				8.00		108	20-150		
13C8-PFOA	8.68				8.00		108	20-150		

AECOM Honolulu  
1001 Bishop Street, Suite 1600  
Honolulu, HI 96813

Project: Red Hill AFFF Assessment Sampling  
Project Number: Red Hill AFFF Assessment Sampling  
Project Manager: Watson Tanji

Reported: 12/28/2022 16:52

### Quality Control (Continued)

#### Per- and Polyfluoroalkyl Substances (Continued)

Analyte	Result/Qual	LOQ	LOD	MDL	Spike Level	Source Result	%REC	%REC Limits	RPD	RPD Limit
---------	-------------	-----	-----	-----	-------------	---------------	------	-------------	-----	-----------

#### Batch: BBL0403 - 1633 (Continued)

##### MRL Check (BBL0403-MRL1)

Prepared: 12/20/22 15:01 Analyzed: 12/22/22 15:28

ng/L

#### Surrogates

13C9-PFNA	4.06				4.00		102	20-150		
13C6-PFDA	3.89				4.00		97.4	20-150		
13C7-PFUnA	3.50				4.00		87.5	20-150		
13C2-PFDOA	3.76				4.00		93.9	20-150		
13C2-PFTEDA	4.09				4.00		102	20-150		
13C3-PFBS	6.76				8.00		84.5	20-150		
13C3-PFHXS	7.20				8.00		90.1	20-150		
13C8-PFOS	7.23				8.00		90.4	20-150		
13C2-4:2FTS	13.4				16.0		83.8	20-150		
13C2-6:2FTS	15.2				16.0		95.2	20-150		
13C2-8:2FTS	11.9				16.0		74.1	20-150		
13C8-PFOA	4.75				8.00		59.4	20-150		
D5-NETFOA	1.61				8.00		20.1	20-150		
D3-NMEFOA	1.92				8.00		23.9	20-150		
D3-NMEFOSAA	11.5				16.0		71.7	20-150		
D5-NETFOSAA	13.8				16.0		86.1	20-150		
D7-NMEFOSE	26.8				80.0		33.6	20-150		
D9-NETFOSE	26.4				80.0		33.0	20-150		
13C3-HFPO-DA	31.8				32.0		99.4	20-150		



AECOM Honolulu  
1001 Bishop Street, Suite 1600  
Honolulu, HI 96813

Project: Red Hill AFFF Assessment Sampling  
Project Number: Red Hill AFFF Assessment Sampling  
Project Manager: Watson Tanji

Reported: 12/28/2022 16:52

## Notes and Definitions

<b>Item</b>	<b>Definition</b>
CV2	Calibration verification recovered above the upper control limit
IR1	Ion ratio below the lower control limit
IR2	Ion ratio above the upper control limit
J	Estimated value
S1	Surrogate recovered below the lower control limit
S2	Surrogate recovered above the upper control limit
U	Not detected
Dry	Sample results reported on a dry weight basis.
DL	Dilution Factor
LOD	Limit of Detection
LOQ	Limit of Quantitation
DL	Detection Limit
*	Value outside control limits
RPD	Relative Percent Difference
%REC	Percent Recovery
Source	Sample that was matrix spiked or duplicated.



# WORK ORDER

## 22L0141

Printed: 12/28/2022 4:52 pm

**Project:** Red Hill AFFF Assessment Sampling  
**Project Number:** Red Hill AFFF Assessment Sampling  
**Project Manager:** Gregory Salata  
**PO Number:** 60697810

**Report To:**

AECOM Honolulu  
 Watson Tanji  
 1001 Bishop Street, Suite 1600  
 Honolulu, HI 96813  
 Phone: (808) 954-4512  
 Fax: (808) 523-8950

**Invoice To:**

AECOM Honolulu  
 Watson Tanji  
 1001 Bishop Street, Suite 1600  
 Honolulu, HI 96813  
 Phone: (808) 954-4512  
 Fax: (808) 523-8950

Date Received: 12/20/2022 02:00 PM  
 Date Due: 01/03/2023 (5.00 day TAT)

Logged In By: Megan Salata  
 Received By: Megan Salata

Analysis	Comments
----------	----------

**22L0141-01 AF-RHMW02-WGN01LF-2212W3 [Water] Sampled 12/19/2022 1:20:00PM**

1633	NONE	"Report relevant surrogates"
------	------	------------------------------

**22L0141-02 AF-RHMW03-WGN01LF-2212W3 [Water] Sampled 12/19/2022 4:20:00PM**

1633	NONE	"Report relevant surrogates"
------	------	------------------------------

**22L0141-03 AF-RHMW225401-WGN01B-2212W3 [Water] Sampled 12/19/2022 2:00:00PM**

1633	NONE	"Report relevant surrogates"
------	------	------------------------------

**22L0141 Sample Receipt Log**

Default Cooler

Samples Received at: **1.6°C**

Custody Seals	Yes	Were all containers sealed in separate bags?	Yes
Containers Intact	Yes	Did all containers arrive in good condition?	Yes
COC/Labels Agree	Yes	Correct containers/preserv. for tests indicated?	Yes
Preservation Confirmed	No	Sufficient volume sent for tests requested?	Yes
Received On Ice	Yes	Were bubbles absent in volatile samples?	No
Was a chain of custody received?	Yes	Sufficient remaining holding time for analyses?	Yes
COCs complete/signed in the appropriate places?	Yes	pH of non-VOA preserved containers documented?	No
Sample labels complete? Sample ID, date/time, etc.	Yes	Unpreserved vials received for VOA analysis?	No
Did all container labels agree with COCs?	Yes	If "yes", are unpreserved VOA vials noted on ARF?	No

22L0141



APPL, Inc.  
 908 N Temperance Ave  
 Clovis, CA 93611  
 www.applinc.com

ELECTRONIC CHAIN OF CUSTODY RECORD  
 Phone: (559) 275-2175  
 Fax: (559) 275-4422  
 coc@applinc.com C.O.C. 01-221219-23F0104-APL

Report to: <b>AECOM</b> Company Name: <b>1001 Bishop St ste1600</b> Address: <b>Honolulu, HI 96813</b> Attn: <b>Watson Tanji / Brant Landers</b> Email: <b>watson.tanji@aecom.com/brant.landere@aecom.com</b>	Invoice to: <b>AECOM</b> Company Name: <b>AECOM</b> Address: _____ Attn: <b>Sheree Smith</b> Email: <b>USAPimaging@aecom.com</b>
PLEASE PRINT Project Name/Number: _____ Purchase Order Number: _____ Sample Identification: _____ Location: _____ Date Collected: _____ Time Collected: _____ Time Zone: _____ Date Shipped: _____ Carrier: _____ Waybill No.: _____ Comments: _____	PLEASE PRINT Project Name/Number: _____ Purchase Order Number: _____ Sample Identification: _____ Location: _____ Date Collected: _____ Time Collected: _____ Time Zone: _____ Date Shipped: _____ Carrier: _____ Waybill No.: _____ Comments: _____

Project Name/Number	Sampler (Print)	Sampler (Signature)	Location	Date Collected	Time Collected	Time Zone	No. of Containers		Analysis Requested/Method Number		Date Shipped
							Aq	Sed	Soil	Matrix	
AF-RHMMW02-WGN01LF-2212W3	RHMMW02		HMMW02	12-19-20	1320	HST	2	1	PFAS EPA Draft 1633	1	

Turnaround Requested: <input type="checkbox"/> Standard 2-3 wk <input type="checkbox"/> 3 days <input checked="" type="checkbox"/> 24/48 Hrs <input type="checkbox"/> Other: 5 day TAT Sample Disposal: <input type="checkbox"/> Return to client <input type="checkbox"/> Disposal by Lab (30-day retention)	Relinquished by sampler: Date: 12-19-22 Time: 1618 Relinquished by:
Relinquished by: Date: 12-19-22 Time: 1400 Relinquished by:	Received by: Date: 12-19-22 Time: 1400 Received at lab by:

Note: The first sampled date of the ARF will be used as the COC number unless indicated otherwise.



APPL, Inc.  
908 N Temperance Ave  
Clovis, CA 93611  
www.applinc.com

**ELECTRONIC CHAIN OF CUSTODY RECORD**  
Phone: (559) 275-2175  
Fax: (559) 275-4422  
coc@applinc.com C.O.C. 02-221219-23F0104-APL

Report to: **AECOM** Invoice to: **AECOM** PLEASE PRINT  
Company Name: **1001 Bishop St ste1600** Phone: \_\_\_\_\_  
Address: **Honolulu, HI 96813** Fax: \_\_\_\_\_  
Attn: **Watson Tanji / Brant Landers** Attn: **Sheree Smith**  
Email: **watson.tanji@aecom.com/brant.landiers@aecom.com** Email: **USAPimaging@aecom.com**

Project Name/Number: **CTO N6274223F0104 / 60697810** Analysis Requested/Method Number: \_\_\_\_\_  
Purchase Order Number: \_\_\_\_\_ Date Shipped: \_\_\_\_\_  
Sampler (Print): **Tianzhou Nie** Carrier: \_\_\_\_\_  
Sampler (Signature): *Tianzhou Nie* Waybill No.: \_\_\_\_\_  
Location: \_\_\_\_\_ Comments: \_\_\_\_\_  
Date Collected: **12/19/22** Time Collected: **1620** Time Zone: **HST**  
No. of Containers: **2** Matrix: **Aq**  **Soil**  **Other:** \_\_\_\_\_  
Sample Identification: **AF-RHMW03-WGN01LF-2212W3** **RHMW03** **12/19/22** **1620** **HST** **2** **✓** **PFAS EPA Draft 1633** **✓**

Shuttle Temperature: \_\_\_\_\_ Turnaround Requested: Check one  Standard 2-3 wk  One week  3 days  24/48 Hrs.  Other: **5 day TAT**  
Relinquished by sampler: **Tianzhou Nie** Date: **12/19/22** Time: **1620** Received by: *[Signature]* Date: **12/19/22** Time: **1430**  
Relinquished by: \_\_\_\_\_ Date: \_\_\_\_\_ Time: \_\_\_\_\_ Received by: \_\_\_\_\_ Date: **12-20-22** Time: **1400**

Note: The first sampled date of the ARF will be used as the COC number unless indicated otherwise.



**ELECTRONIC CHAIN OF CUSTODY RECORD**

APPL, Inc.  
908 N Temperance Ave  
Clovis, CA 93611  
www.applinc.com

Phone: (559) 275-2175

Fax: (559) 275-4422

C.O.C. 03-221219-23F0104-APL

PLEASE PRINT

Invoice to: PLEASE PRINT

Report to: AECOM

Company Name: AECOM

Address: 1001 Bishop St ste1600

Company Name: AECOM

Honolulu, HI 96813

Address:

Attn: Watson Tanji / Brant Landers

Attn: Sheree Smith

Email: watson.tanji@aecom.com / brant.landiers@aecom.com

Email: USAPI Imaging@aecom.com

Project Name/Number

Analysis Requested/Method Number

CTO N6274223F0104 / 60697810

Carrier:

Purchase Order Number

Waybill No.:

Sampler (Print)

Comments:

NOAH TURNER

Matrix

Sampler (Signature)

Aq

Location

Soil

RHMW 225H-01

Sed

Date Collected

No. of Containers

12/19/2022 1400

Time Collected

HST 2

Time Zone

Turnaround Requested:

Date

Standard 2-3 wk

Time

3 days

Other: 5 day TAT

One week

24/48 Hrs:

Check one

Returned by:

12/19/2022 1530

Received by: Miranda DeCarimo

Relinquished by:

Relinquished by:

12/19/2022 1400

Received by: Miranda DeCarimo

Sample Disposal:

Received by:

Return to client

Received at lab by:

Disposition by Lab (30-day retention)

Time

Time

Time


Time

Time

Time

Time

Note: The first sampled date of the ARF will be used as the COC number unless indicated otherwise.



# PFAS

# SAMPLE DATA



# FORM I

## ANALYSIS DATA SHEET

AF-RHMW02-WGN01LF-2212W3

Laboratory:	APPL, LLC	Work Order:	22L0141
Client:	AECOM	Project:	Red Hill AFFF Assessment Sampling
Matrix:	Water	Laboratory ID:	22L0141-01
		File ID:	S2022-12-22A (27)
Sampled:	12/19/22 13:20	Prepared:	12/20/22 15:01
		Analyzed:	12/22/22 16:57
Solids:		Preparation:	1633
		Dilution:	1
Initial/Final:	580.17 g / 2 ml	Instrument:	Saphira
Batch:	BBL0403	Sequence:	SB03951
		Calibration:	2252011






















COMPOUND	CONC. (ng/L)	LOQ	LOD	DL	Q
PFBA	0.69 U	1.4	0.69	0.18	
PFPEA	1.4	0.69	0.34	0.056	
PFHXA	0.24 J	0.34	0.17	0.047	IR2,
PFHPA	0.20 J	0.34	0.17	0.035	
PFOA	0.17 U	0.34	0.17	0.13	
PFNA	0.17 U	0.34	0.17	0.071	IR1,
PFDA	0.17 U	0.34	0.17	0.087	
PFUnA	0.17 U	0.34	0.17	0.14	
PFDOA	0.17 U	0.34	0.17	0.096	IR1,
PFTRDA	0.26 U	0.34	0.26	0.18	
PFTEDA	0.17 U	0.34	0.17	0.17	
PFBS	0.17 U	0.34	0.17	0.032	
PFPEs	0.17 U	0.34	0.17	0.054	
PFHXS	0.036 J	0.34	0.17	0.027	
PFHPS	0.17 U	0.34	0.17	0.044	
PFOS	0.064 J	0.34	0.17	0.055	
PFNS	0.17 U	0.34	0.17	0.11	
PFDS	0.17 U	0.34	0.17	0.13	
PFDOS	0.17 U	0.34	0.17	0.11	
4:2FTS	0.69 U	1.4	0.69	0.25	
6:2FTS	10	1.4	0.69	0.27	
8:2FTS	0.69 U	1.4	0.69	0.071	
PFOSA	0.17 U	0.34	0.17	0.090	
NMeFOSA	0.69 U	1.4	0.69	0.41	
NEtFOSA	0.69 U	1.4	0.69	0.36	
NMeFOSAA	0.17 U	0.34	0.17	0.091	
NEtFOSAA	0.17 U	0.34	0.17	0.099	
NMeFOSE	1.0 U	1.4	1.0	0.87	
NEtFOSE	1.0 U	1.4	1.0	0.90	
HFPO-DA	0.34 U	0.69	0.34	0.15	

# FORM I ANALYSIS DATA SHEET

AF-RHMW02-WGN01LF-2212W3

Laboratory:	APPL, LLC	Work Order:	22L0141
Client:	AECOM	Project:	Red Hill AFFF Assessment Sampling
Matrix:	Water	Laboratory ID:	22L0141-01
		File ID:	S2022-12-22A (27)
Sampled:	12/19/22 13:20	Prepared:	12/20/22 15:01
		Analyzed:	12/22/22 16:57
Solids:		Preparation:	1633
		Dilution:	1
Initial/Final:	580.17 g / 2 ml	Instrument:	Saphira
Batch:	BBL0403	Sequence:	SB03951
		Calibration:	2252011

COMPOUND	CONC. (ng/L)	LOQ	LOD	DL	Q
ADONA	0.34 U	0.69	0.34	0.11	
PFEESA	0.34 U	0.69	0.34	0.094	
PFMPA	0.34 U	0.69	0.34	0.046	
PFMBA	0.34 U	0.69	0.34	0.078	
NFDHA	0.34 U	0.69	0.34	0.26	
9CL-PF3ONS	0.34 U	0.69	0.34	0.18	
11CL-PF3OUDS	0.34 U	0.69	0.34	0.18	
3:3FTCA	0.69 U	1.4	0.69	0.50	
5:3FTCA	0.69 U	1.4	0.69	0.38	
7:3FTCA	0.69 U	1.4	0.69	0.48	

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT-CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBA	(212.9 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A	N/A 0.0 0.0	0.0000	N/A			
PFPeA	(262.9 / 219.0) 40467 (262.9 / 69.0) 344	(4.96, 1.00) (-0.01, N/A, -0.8)	28.8 6.0	0.0085 75.9 81.7	0.4007	N/A			
PFHxA	(313.0 / 269.0) 15682 (313.0 / 119.0) 4907	(6.12, 1.00) (-0.01, N/A, 0.9)	18.6 11.4	0.3129 320.0 350.2	0.0696	N/A			IR2,
PFHpA	(363.0 / 319.0) 13317 (363.0 / 169.0) 3398	(7.07, 1.00) (0.01, N/A, 0.9)	33.4 19.1	0.2552 81.9 82.8	0.0570	N/A			
PFOA	(413.0 / 369.0) 7167 (413.0 / 169.0) 2357	(7.87, 1.00) (-0.01, N/A, 0.0)	18.0 47.4	0.3289 100.6 111.2	0.0267	N/A			
PFNA	(463.0 / 419.0) 3777 (463.0 / 169.0) N/A	(8.63, 1.00) (0.02, N/A, #Value)	32.2 N/A	N/A 0.0 0.0	0.0187	N/A			IR1,
PFDA	(513.0 / 469.0) 4466 (513.0 / 169.0) 267	(9.33, 1.00) (0.04, N/A, 1.2)	12.6 259.8	0.0599 62.6 60.9	0.0132	N/A			
PFUnA	(563.0 / 519.0) N/A (563.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFDoA	(613.0 / 569.0) 4547 (613.0 / 169.0) 269	(9.88, 1.00) (-0.01, N/A, -0.1)	31.7 8.4	0.0591 42.4 44.9	0.0123	N/A			IR1,
PFTrDA	(663.0 / 619.0) N/A (663.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFTeDA	(713.0 / 669.0) N/A (713.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			



Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500

Sample I.D.: 22L0141-01  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (27)  
 Acquired: 2022/12/22 - 16:57

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-I[min], ΔRT-CV[min], ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBS	( 298.9 / 80.0 ) N/A ( 298.9 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFPeS	( 349.0 / 80.0 ) N/A ( 349.0 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFHxS	( 399.0 / 80.0 ) 6468 ( 399.0 / 99.0 ) 2068	( 7.99 , 1.00 ) ( -0.01 , N/A , 0.7 )	21.2 27.6	0.3198 95.1 96.6	0.0103	N/A			
PFHpS	( 449.0 / 80.0 ) N/A ( 449.0 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFOS	( 499.0 / 80.0 ) 13735 ( 499.0 / 99.0 ) 4219	( 9.43 , 1.00 ) ( 0.00 , N/A , -1.3 )	9.4 31.2	0.3072 126.3 134.3	0.0186	N/A			
PFNS	( 549.0 / 80.0 ) N/A ( 549.0 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFDS	( 599.0 / 80.0 ) N/A ( 599.0 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFDoS	( 698.9 / 80.0 ) N/A ( 698.9 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
4:2FTS	( 327.0 / 307.0 ) N/A ( 327.0 / 81.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
6:2FTS	( 427.0 / 407.0 ) 568322 ( 427.0 / 81.0 ) 427492	( 7.54 , 1.00 ) ( 0.00 , N/A , -0.2 )	672.5 510.7	0.7522 96.7 107.9	3.0443	N/A			
8:2FTS	( 527.0 / 507.0 ) N/A ( 527.0 / 81.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			



Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500

Sample I.D.: 22L0141-01  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (27)  
 Acquired: 2022/12/22 - 16:57

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT-CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFOSA	( 498.0 / 78.0 ) N/A ( 498.0 / 478.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NMeFOSA	( 511.9 / 219.0 ) N/A ( 511.9 / 169.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NEIFOSA	( 526.0 / 219.0 ) N/A ( 526.0 / 169.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NMeFOSAA	( 570.0 / 419.0 ) N/A ( 570.0 / 483.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NEIFOSAA	( 584.0 / 419.0 ) N/A ( 584.0 / 526.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NMeFOSE	( 616.1 / 59.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A	N/A 0.0 0.0	0.0000	N/A			
NEIFOSE	( 630.0 / 59.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A	N/A 0.0 0.0	0.0000	N/A			
HFPO-DA	( 285.0 / 169.0 ) N/A ( 285.0 / 185.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
ADONA	( 377.0 / 85.0 ) N/A ( 377.0 / 251.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
9CI-Pf3ONS	( 531.0 / 351.0 ) N/A ( 533.0 / 353.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
11CI-PF3OUDS	( 631.0 / 451.0 ) N/A ( 633.0 / 453.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			

























Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500

Sample I.D.: 22L0141-01  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam






Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (27)  
 Acquired: 2022/12/22 - 16:57

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-I[min], ΔRT-CV[min], ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
3:3FTCA	(241.0 / 177.0) N/A (241.0 / 117.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
5:3FTCA	(341.0 / 236.7) N/A (341.0 / 217.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
7:3FTCA	(441.0 / 317.0) N/A (441.0 / 337.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFEESA	(315.0 / 135.0) N/A (315.0 / 83.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFMPA	(229.0 / 85.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A	N/A 0.0 0.0	0.0000	N/A			
PFMBA	(279.0 / 85.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A	N/A 0.0 0.0	0.0000	N/A			
NFDHA	(295.0 / 201.0) N/A (295.0 / 85.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
13C3_PFBA_IIS	(216.0 / 172.0) 89603	(3.68, N/A) (N/A, 0.03, N/A)	268.5	N/A	0.6437 [ 1.0000 ]	64.4% { 57.1% }			
13C2_PFHxA_IIS	(315.1 / 270.0) 268425	(6.13, N/A) (N/A, 0.00, N/A)	528.3	N/A	1.1624 [ 1.0000 ]	116.2% { 113.8% }			
13C4_PFOA_IIS	(417.0 / 372.0) 273124	(7.88, N/A) (N/A, 0.01, N/A)	649.4	N/A	1.2423 [ 1.0000 ]	124.2% { 106.3% }			
13C5_PFNA_IIS	(468.0 / 423.0) 243949	(8.61, N/A) (N/A, 0.00, N/A)	392.9	N/A	1.3174 [ 1.0000 ]	131.7% { 104.0% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT- CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDA_IIS	(515.1 / 470.1) 302733	(9.29, N/A) (N/A, 0.00, N/A)	548.1	N/A	1.6381 [ 1.0000 ]	163.8% { 161.7% }			
18O2_PFHxS_IIS	(403.0 / 83.9) 516834	(8.00, N/A) (N/A, 0.00, N/A)	779.5	N/A	1.2802 [ 1.0000 ]	128.0% { 115.8% }			
13C4_PFOS_IIS	(502.8 / 79.9) 499537	(9.43, N/A) (N/A, -0.01, N/A)	486.6	N/A	1.5651 [ 1.0000 ]	156.5% { 144.1% }			
13C4_PFBA_EIS	(217.0 / 172.0) 480326	(3.68, N/A) (N/A, 0.03, N/A)	796.0	N/A	5.2084 [ 8.0000 ]	65.1% { 38.3% }			
13C5_PFPeA_EIS	(267.9 / 223.0) 459906	(4.97, N/A) (N/A, 0.00, N/A)	785.9	N/A	2.4625 [ 4.0000 ]	61.6% { 67.6% }			
13C5_PFHxA_EIS	(318.0 / 273.0) 524996	(6.12, N/A) (N/A, 0.00, N/A)	595.8	N/A	1.6996 [ 2.0000 ]	85.0% { 97.9% }			
13C4_PFHpA_EIS	(367.0 / 322.0) 512512	(7.06, N/A) (N/A, 0.01, N/A)	476.5	N/A	1.9019 [ 2.0000 ]	95.1% { 114.0% }			
13C8_PFOA_EIS	(421.0 / 376.0) 546277	(7.88, N/A) (N/A, 0.01, N/A)	623.0	N/A	1.8238 [ 2.0000 ]	91.2% { 91.7% }			
13C9_PFNA_EIS	(472.0 / 427.0) 235170	(8.61, N/A) (N/A, 0.00, N/A)	442.2	N/A	0.8767 [ 1.0000 ]	87.7% { 101.5% }			
13C6_PFDA_EIS	(519.0 / 474.0) 354627	(9.29, N/A) (N/A, 0.00, N/A)	393.0	N/A	0.8236 [ 1.0000 ]	82.4% { 128.9% }			
13C7_PFUnA_EIS	(570.0 / 525.0) 437842	(9.70, N/A) (N/A, 0.00, N/A)	368.7	N/A	0.7149 [ 1.0000 ]	71.5% { 117.7% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT- CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDa_EIS	(615.0 / 570.0) 427554	(9.88, N/A) (N/A, -0.01, N/A)	773.1	N/A	0.6995 [ 1.0000 ]	69.9% { 116.7% }			
13C2_PFTeDA_EIS	(715.0 / 670.0) 295811	(10.11, N/A) (N/A, 0.00, N/A)	632.4	N/A	0.7287 [ 1.0000 ]	72.9% { 115.9% }			
13C3_PFBs_EIS	(302.0 / 80.0) 1672710	(6.08, N/A) (N/A, 0.00, N/A)	409.2	N/A	1.9142 [ 2.0000 ]	95.7% { 125.5% }			
13C3_PFHxS_EIS	(402.0 / 80.0) 806469	(8.00, N/A) (N/A, 0.00, N/A)	806.1	N/A	1.7346 [ 2.0000 ]	86.7% { 105.0% }			
13C8_PFOS_EIS	(507.0 / 80.0) 1364232	(9.43, N/A) (N/A, 0.00, N/A)	536.6	N/A	1.5912 [ 2.0000 ]	79.6% { 122.1% }			
13C2_4:2FTS_EIS	(329.0 / 81.0) 379162	(5.79, N/A) (N/A, 0.00, N/A)	308.2	N/A	5.1230 [ 4.0000 ]	128.1% { 168.4% }			
13C2_6:2FTS_EIS	(429.0 / 81.0) 485676	(7.54, N/A) (N/A, 0.01, N/A)	640.1	N/A	5.4504 [ 4.0000 ]	136.3% { 144.4% }			
13C2_8:2FTS_EIS	(529.0 / 81.0) 502480	(8.95, N/A) (N/A, 0.00, N/A)	538.6	N/A	5.6331 [ 4.0000 ]	140.8% { 159.0% }			
13C8_PFOsa_EIS	(506.0 / 78.0) 1109429	(10.17, N/A) (N/A, -0.01, N/A)	758.1	N/A	1.0237 [ 2.0000 ]	51.2% { 81.3% }			
D3_NMeFOSA_EIS	(515.0 / 169.0) 212303	(10.60, N/A) (N/A, 0.00, N/A)	624.9	N/A	0.8973 [ 2.0000 ]	44.9% { 73.9% }			
D5_NeIFOSA_EIS	(531.1 / 169.0) 174665	(10.69, N/A) (N/A, 0.00, N/A)	879.0	N/A	0.7997 [ 2.0000 ]	40.0% { 57.5% }			



Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT- CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
D3_MeFOSAA_EIS	( 573.0 / 419.0 ) 717145	( 9.48 , N/A ) ( N/A , -0.01 , N/A )	296.1	N/A	3.5177 [ 4.0000 ]	87.9% { 135.7% }			
D5_EtFOSAA_EIS	( 589.0 / 419.0 ) 670194	( 9.67 , N/A ) ( N/A , -0.01 , N/A )	569.2	N/A	3.7297 [ 4.0000 ]	93.2% { 161.5% }			
D7_NMeFOSE_EIS	( 623.2 / 58.9 ) 358346	( 10.57 , N/A ) ( N/A , 0.00 , N/A )	1037.7	N/A	10.7859 [ 20.0000 ]	53.9% { 82.4% }			
D9_NEtFOSE_EIS	( 639.2 / 58.9 ) 154926	( 10.67 , N/A ) ( N/A , -0.01 , N/A )	1093.6	N/A	10.2430 [ 20.0000 ]	51.2% { 78.2% }			
13C3_HFPODA_EIS	( 287.0 / 169.0 ) 972852	( 6.47 , N/A ) ( N/A , 0.01 , N/A )	665.8	N/A	5.9237 [ 8.0000 ]	74.0% { 79.9% }			

# FORM I

## ANALYSIS DATA SHEET

AF-RHMW03-WGN01LF-2212W3

Laboratory:	APPL, LLC	Work Order:	22L0141
Client:	AECOM	Project:	Red Hill AFFF Assessment Sampling
Matrix:	Water	Laboratory ID:	22L0141-02
		File ID:	S2022-12-22A (29)
Sampled:	12/19/22 16:20	Prepared:	12/20/22 15:01
		Analyzed:	12/22/22 17:22
Solids:		Preparation:	1633
		Dilution:	1
Initial/Final:	570.34 g / 2 ml	Instrument:	Saphira
Batch:	BBL0403	Sequence:	SB03951
		Calibration:	2252011

COMPOUND	CONC. (ng/L)	LOQ	LOD	DL	Q
PFBA	2.9	1.4	0.70	0.18	
PFPEA	3.7	0.70	0.35	0.057	
PFHXA	1.4	0.35	0.18	0.048	
PFHPA	1.1	0.35	0.18	0.036	
PFOA	0.32 J	0.35	0.18	0.13	
PFNA	0.17 J	0.35	0.18	0.072	
PFDA	0.12 J	0.35	0.18	0.089	IR2,
PFUnA	0.18 J	0.35	0.18	0.14	
PFDOA	0.12 J	0.35	0.18	0.098	
PFTRDA	0.26 U	0.35	0.26	0.18	
PFTEDA	0.18 U	0.35	0.18	0.17	
PFBS	0.18 U	0.35	0.18	0.032	
PFPEs	0.18 U	0.35	0.18	0.055	
PFHXS	0.039 J	0.35	0.18	0.028	
PFHPS	0.18 U	0.35	0.18	0.045	
PFOS	0.094 J	0.35	0.18	0.056	
PFNS	0.18 U	0.35	0.18	0.11	
PFDS	0.18 U	0.35	0.18	0.13	
PFDOS	0.18 U	0.35	0.18	0.11	
4:2FTS	0.70 U	1.4	0.70	0.25	
6:2FTS	3.6	1.4	0.70	0.28	
8:2FTS	0.70 U	1.4	0.70	0.072	
PFOSA	0.18 U	0.35	0.18	0.091	
NMeFOSA	0.70 U	1.4	0.70	0.41	
NEtFOSA	0.70 U	1.4	0.70	0.36	
NMeFOSAA	0.18 U	0.35	0.18	0.093	
NEtFOSAA	0.18 U	0.35	0.18	0.10	
NMeFOSE	1.1 U	1.4	1.1	0.89	
NEtFOSE	1.1 U	1.4	1.1	0.92	
HFPO-DA	0.35 U	0.70	0.35	0.15	

# FORM I ANALYSIS DATA SHEET

AF-RHMW03-WGN01LF-2212W3

Laboratory:	APPL, LLC	Work Order:	22L0141
Client:	AECOM	Project:	Red Hill AFFF Assessment Sampling
Matrix:	Water	Laboratory ID:	22L0141-02
		File ID:	S2022-12-22A (29)
Sampled:	12/19/22 16:20	Prepared:	12/20/22 15:01
		Analyzed:	12/22/22 17:22
Solids:		Preparation:	1633
		Dilution:	1
Initial/Final:	570.34 g / 2 ml	Instrument:	Saphira
Batch:	BBL0403	Sequence:	SB03951
		Calibration:	2252011

COMPOUND	CONC. (ng/L)	LOQ	LOD	DL	Q
ADONA	0.35 U	0.70	0.35	0.11	
PFEESA	0.35 U	0.70	0.35	0.096	
PFMPA	0.35 U	0.70	0.35	0.047	
PFMBA	0.35 U	0.70	0.35	0.080	
NFDHA	0.35 U	0.70	0.35	0.26	
9CL-PF3ONS	0.35 U	0.70	0.35	0.18	
11CL-PF3OUDS	0.35 U	0.70	0.35	0.18	
3:3FTCA	0.70 U	1.4	0.70	0.50	
5:3FTCA	0.70 U	1.4	0.70	0.39	
7:3FTCA	0.70 U	1.4	0.70	0.49	

























Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500

Sample I.D.: 22L0141-02  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (29)  
 Acquired: 2022/12/22 - 17:22

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-I[min], ΔRT-CV[min], ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBA	(212.9 / 169.0) 51367	(3.71, 1.00) (0.00, N/A, 0.0)	47.1	N/A 0.0 0.0	0.8396	N/A			
PFPeA	(262.9 / 219.0) 147340 (262.9 / 69.0) 1466	(5.00, 1.00) (0.00, N/A, -0.3)	284.2 16.4	0.0100 88.9 95.7	1.0590	N/A			
PFHxA	(313.0 / 269.0) 93328 (313.0 / 119.0) 8638	(6.14, 1.00) (0.00, N/A, 0.3)	95.8 53.1	0.0926 94.7 103.6	0.4040	N/A			
PFHpA	(363.0 / 319.0) 77722 (363.0 / 169.0) 20023	(7.07, 1.00) (0.00, N/A, -0.2)	137.1 127.7	0.2576 82.7 83.6	0.3183	N/A			
PFOA	(413.0 / 369.0) 26318 (413.0 / 169.0) 9669	(7.88, 1.00) (0.00, N/A, 0.1)	83.8 989.8	0.3674 112.4 124.2	0.0920	N/A			
PFNA	(463.0 / 419.0) 9948 (463.0 / 169.0) 2090	(8.61, 1.00) (0.00, N/A, 0.0)	27.4 24.5	0.2101 109.0 100.9	0.0480	N/A			
PFDA	(513.0 / 469.0) 10945 (513.0 / 169.0) 2390	(9.29, 1.00) (0.01, N/A, 0.0)	29.5 24.8	0.2184 228.4 222.3	0.0339	N/A			IR2,
PFUnA	(563.0 / 519.0) 20089 (563.0 / 169.0) 2125	(9.70, 1.00) (0.00, N/A, -0.3)	78.2 41.3	0.1058 121.8 118.0	0.0504	N/A			
PFDoA	(613.0 / 569.0) 13060 (613.0 / 169.0) 1579	(9.87, 1.00) (-0.01, N/A, 1.0)	42.5 14.7	0.1209 86.8 91.9	0.0329	N/A			
PFTTrDA	(663.0 / 619.0) 5069 (663.0 / 169.0) 1493	(10.02, 1.01) (N/A, 0.00, 4.2)	43.3 33.9	0.2946 143.9 128.9	0.0148	N/A			
PFTeDA	(713.0 / 669.0) N/A (713.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[min], $\Delta$ RT-CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBS	(298.9 / 80.0) N/A (298.9 / 99.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFPeS	(349.0 / 80.0) N/A (349.0 / 99.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFHxS	(399.0 / 80.0) 7243 (399.0 / 99.0) 2229	(8.00, 1.00) (0.00, N/A, 0.8)	21.4 67.3	0.3078 91.6 93.0	0.0110	N/A			
PFHpS	(449.0 / 80.0) N/A (449.0 / 99.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFOS	(499.0 / 80.0) 21750 (499.0 / 99.0) 4892	(9.44, 1.00) (0.00, N/A, 1.1)	10.7 28.9	0.2249 92.5 98.3	0.0268	N/A			
PFNS	(549.0 / 80.0) N/A (549.0 / 99.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFDS	(599.0 / 80.0) N/A (599.0 / 99.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFDoS	(698.9 / 80.0) N/A (698.9 / 99.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
4:2FTS	(327.0 / 307.0) N/A (327.0 / 81.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
6:2FTS	(427.0 / 407.0) 158899 (427.0 / 81.0) 114582	(7.54, 1.00) (0.00, N/A, -0.2)	385.5 179.0	0.7211 92.7 103.4	1.0374	N/A			
8:2FTS	(527.0 / 507.0) N/A (527.0 / 81.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			



Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500

Sample I.D.: 22L0141-02  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (29)  
 Acquired: 2022/12/22 - 17:22

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-I[min], ΔRT-CV[min], ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFOSA	( 498.0 / 78.0 ) N/A ( 498.0 / 478.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NMeFOSA	( 511.9 / 219.0 ) N/A ( 511.9 / 169.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NEIFOSA	( 526.0 / 219.0 ) N/A ( 526.0 / 169.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NMeFOSAA	( 570.0 / 419.0 ) N/A ( 570.0 / 483.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NEIFOSAA	( 584.0 / 419.0 ) N/A ( 584.0 / 526.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NMeFOSE	( 616.1 / 59.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A	N/A 0.0 0.0	0.0000	N/A			
NEIFOSE	( 630.0 / 59.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A	N/A 0.0 0.0	0.0000	N/A			
HFPO-DA	( 285.0 / 169.0 ) N/A ( 285.0 / 185.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
ADONA	( 377.0 / 85.0 ) N/A ( 377.0 / 251.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
9CI-PI3ONS	( 531.0 / 351.0 ) N/A ( 533.0 / 353.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
11CI-PF3OUDS	( 631.0 / 451.0 ) N/A ( 633.0 / 453.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			














Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500












Sample I.D.: 22L0141-02  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (29)  
 Acquired: 2022/12/22 - 17:22

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-I[min], ΔRT-CV[min], ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
3:3FTCA	(241.0 / 177.0) N/A (241.0 / 117.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
5:3FTCA	(341.0 / 236.7) N/A (341.0 / 217.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
7:3FTCA	(441.0 / 317.0) N/A (441.0 / 337.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFEESA	(315.0 / 135.0) N/A (315.0 / 83.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFMPA	(229.0 / 85.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A	N/A 0.0 0.0	0.0000	N/A			
PFMBA	(279.0 / 85.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A	N/A 0.0 0.0	0.0000	N/A			
NFDHA	(295.0 / 201.0) N/A (295.0 / 85.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
13C3_PFBA_IIS	(216.0 / 172.0) 110137	(3.71, N/A) (N/A, 0.06, N/A)	600.6	N/A	0.7912 [ 1.0000 ]	79.1% { 70.1% }			
13C2_PFHxA_IIS	(315.1 / 270.0) 282369	(6.14, N/A) (N/A, 0.02, N/A)	674.1	N/A	1.2228 [ 1.0000 ]	122.3% { 119.7% }			
13C4_PFOA_IIS	(417.0 / 372.0) 299191	(7.88, N/A) (N/A, 0.00, N/A)	655.3	N/A	1.3609 [ 1.0000 ]	136.1% { 116.5% }			
13C5_PFNA_IIS	(468.0 / 423.0) 227692	(8.61, N/A) (N/A, 0.00, N/A)	456.7	N/A	1.2296 [ 1.0000 ]	123.0% { 97.1% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT- CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDA_IIS	(515.1 / 470.1) 288275	(9.29, N/A) (N/A, 0.00, N/A)	370.9	N/A	1.5599 [ 1.0000 ]	156.0% { 154.0% }			
18O2_PFHxS_IIS	(403.0 / 83.9) 510300	(8.00, N/A) (N/A, 0.01, N/A)	667.6	N/A	1.2640 [ 1.0000 ]	126.4% { 114.4% }			
13C4_PFOS_IIS	(502.8 / 79.9) 446357	(9.43, N/A) (N/A, 0.00, N/A)	490.1	N/A	1.3985 [ 1.0000 ]	139.8% { 128.8% }			
13C4_PFBA_EIS	(217.0 / 172.0) 750278	(3.71, N/A) (N/A, 0.06, N/A)	897.7	N/A	6.6189 [ 8.0000 ]	82.7% { 59.8% }			
13C5_PFPeA_EIS	(267.9 / 223.0) 633665	(4.99, N/A) (N/A, 0.03, N/A)	712.6	N/A	3.2253 [ 4.0000 ]	80.6% { 93.2% }			
13C5_PFHxA_EIS	(318.0 / 273.0) 537977	(6.15, N/A) (N/A, 0.02, N/A)	635.9	N/A	1.6556 [ 2.0000 ]	82.8% { 100.4% }			
13C4_PFHpA_EIS	(367.0 / 322.0) 535747	(7.07, N/A) (N/A, 0.01, N/A)	685.3	N/A	1.8900 [ 2.0000 ]	94.5% { 119.1% }			
13C8_PFOA_EIS	(421.0 / 376.0) 581818	(7.88, N/A) (N/A, 0.00, N/A)	770.7	N/A	1.7732 [ 2.0000 ]	88.7% { 97.7% }			
13C9_PFNA_EIS	(472.0 / 427.0) 241496	(8.61, N/A) (N/A, 0.00, N/A)	454.8	N/A	0.9645 [ 1.0000 ]	96.5% { 104.2% }			
13C6_PFDA_EIS	(519.0 / 474.0) 339230	(9.29, N/A) (N/A, 0.00, N/A)	302.8	N/A	0.8274 [ 1.0000 ]	82.7% { 123.3% }			
13C7_PFUnA_EIS	(570.0 / 525.0) 504877	(9.71, N/A) (N/A, 0.00, N/A)	666.4	N/A	0.8657 [ 1.0000 ]	86.6% { 135.7% }			



Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT- CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDa_EIS	(615.0 / 570.0) 459797	(9.88, N/A) (N/A, -0.01, N/A)	789.2	N/A	0.7899 [ 1.0000 ]	79.0% { 125.5% }			
13C2_PFTeDA_EIS	(715.0 / 670.0) 253115	(10.12, N/A) (N/A, 0.00, N/A)	460.2	N/A	0.6548 [ 1.0000 ]	65.5% { 99.2% }			
13C3_PFBs_EIS	(302.0 / 80.0) 1559793	(6.10, N/A) (N/A, 0.03, N/A)	218.8	N/A	1.8078 [ 2.0000 ]	90.4% { 117.0% }			
13C3_PFHxS_EIS	(402.0 / 80.0) 847289	(8.00, N/A) (N/A, 0.01, N/A)	740.6	N/A	1.8457 [ 2.0000 ]	92.3% { 110.4% }			
13C8_PFOS_EIS	(507.0 / 80.0) 1492854	(9.43, N/A) (N/A, 0.00, N/A)	429.4	N/A	1.9487 [ 2.0000 ]	97.4% { 133.6% }			
13C2_4:2FTS_EIS	(329.0 / 81.0) 376521	(5.82, N/A) (N/A, 0.03, N/A)	153.2	N/A	5.1524 [ 4.0000 ]	128.8% { 167.3% }			
13C2_6:2FTS_EIS	(429.0 / 81.0) 398497	(7.54, N/A) (N/A, 0.01, N/A)	551.5	N/A	4.5293 [ 4.0000 ]	113.2% { 118.5% }			
13C2_8:2FTS_EIS	(529.0 / 81.0) 373046	(8.95, N/A) (N/A, 0.00, N/A)	356.2	N/A	4.2356 [ 4.0000 ]	105.9% { 118.1% }			
13C8_PFOsa_EIS	(506.0 / 78.0) 1263747	(10.17, N/A) (N/A, 0.00, N/A)	761.2	N/A	1.3051 [ 2.0000 ]	65.3% { 92.6% }			
D3_NMeFOSA_EIS	(515.0 / 169.0) 194832	(10.61, N/A) (N/A, 0.00, N/A)	841.4	N/A	0.9215 [ 2.0000 ]	46.1% { 67.9% }			
D5_NeIFOSA_EIS	(531.1 / 169.0) 176279	(10.70, N/A) (N/A, 0.00, N/A)	1175.3	N/A	0.9032 [ 2.0000 ]	45.2% { 58.0% }			



Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500

Sample I.D.: 22L0141-02  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (29)  
 Acquired: 2022/12/22 - 17:22

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-I[min], ΔRT-CV[min], ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
D3_MeFOSAA_EIS	( 573.0 / 419.0 ) 661866	( 9.49, N/A ) ( N/A, 0.00, N/A )	311.1	N/A	3.6334 [ 4.0000 ]	90.8% { 125.2% }			
D5_EtFOSAA_EIS	( 589.0 / 419.0 ) 610353	( 9.67, N/A ) ( N/A, -0.01, N/A )	426.4	N/A	3.8014 [ 4.0000 ]	95.0% { 147.1% }			
D7_NMeFOSE_EIS	( 623.2 / 58.9 ) 325406	( 10.57, N/A ) ( N/A, 0.00, N/A )	1043.8	N/A	10.9614 [ 20.0000 ]	54.8% { 74.9% }			
D9_NEtFOSE_EIS	( 639.2 / 58.9 ) 151396	( 10.67, N/A ) ( N/A, 0.00, N/A )	1376.6	N/A	11.2021 [ 20.0000 ]	56.0% { 76.4% }			
13C3_HFPODA_EIS	( 287.0 / 169.0 ) 1177949	( 6.49, N/A ) ( N/A, 0.02, N/A )	788.9	N/A	6.8183 [ 8.0000 ]	85.2% { 96.8% }			

# FORM I

## ANALYSIS DATA SHEET

AF-RHMW225401-WGN01B-2212W3

Laboratory:	APPL, LLC	Work Order:	22L0141
Client:	AECOM	Project:	Red Hill AFFF Assessment Sampling
Matrix:	Water	Laboratory ID:	22L0141-03
		File ID:	S2022-12-22A (31)
Sampled:	12/19/22 14:00	Prepared:	12/20/22 15:01
		Analyzed:	12/22/22 17:47
Solids:		Preparation:	1633
		Dilution:	1
Initial/Final:	561.73 g / 2 ml	Instrument:	Saphira
Batch:	BBL0403	Sequence:	SB03951
		Calibration:	2252011

COMPOUND	CONC. (ng/L)	LOQ	LOD	DL	Q
PFBA	0.60 J	1.4	0.71	0.19	
PFPEA	1.2	0.71	0.36	0.058	
PFHXA	0.96	0.36	0.18	0.049	
PFHPA	0.73	0.36	0.18	0.036	
PFOA	1.0	0.36	0.18	0.14	
PFNA	0.18 J	0.36	0.18	0.073	
PFDA	0.18 U	0.36	0.18	0.090	
PFUnA	0.18 U	0.36	0.18	0.14	
PFDOA	0.18 U	0.36	0.18	0.10	
PFTRDA	0.27 U	0.36	0.27	0.18	
PFTEDA	0.18 U	0.36	0.18	0.18	IR1,
PFBS	0.68	0.36	0.18	0.033	
PFPEs	0.11 J	0.36	0.18	0.056	
PFHXS	1.2	0.36	0.18	0.028	
PFHPS	0.18 U	0.36	0.18	0.046	
PFOS	0.98	0.36	0.18	0.057	
PFNS	0.18 U	0.36	0.18	0.11	
PFDS	0.18 U	0.36	0.18	0.13	
PFDOS	0.18 U	0.36	0.18	0.11	
4:2FTS	0.71 U	1.4	0.71	0.26	
6:2FTS	0.71 U	1.4	0.71	0.28	
8:2FTS	0.71 U	1.4	0.71	0.073	
PFOSA	0.18 U	0.36	0.18	0.093	
NMeFOSA	0.71 U	1.4	0.71	0.42	
NEtFOSA	0.71 U	1.4	0.71	0.37	
NMeFOSAA	0.18 U	0.36	0.18	0.094	
NEtFOSAA	0.18 U	0.36	0.18	0.10	
NMeFOSE	1.1 U	1.4	1.1	0.90	
NEtFOSE	1.1 U	1.4	1.1	0.93	
HFPO-DA	0.36 U	0.71	0.36	0.16	

# FORM I ANALYSIS DATA SHEET

AF-RHMW225401-WGN01B-2212W3

Laboratory:	APPL, LLC	Work Order:	22L0141
Client:	AECOM	Project:	Red Hill AFFF Assessment Sampling
Matrix:	Water	Laboratory ID:	22L0141-03
		File ID:	S2022-12-22A (31)
Sampled:	12/19/22 14:00	Prepared:	12/20/22 15:01
		Analyzed:	12/22/22 17:47
Solids:		Preparation:	1633
		Dilution:	1
Initial/Final:	561.73 g / 2 ml	Instrument:	Saphira
Batch:	BBL0403	Sequence:	SB03951
		Calibration:	2252011

COMPOUND	CONC. (ng/L)	LOQ	LOD	DL	Q
ADONA	0.36 U	0.71	0.36	0.11	
PFEESA	0.36 U	0.71	0.36	0.097	
PFMPA	0.36 U	0.71	0.36	0.048	
PFMBA	0.36 U	0.71	0.36	0.081	
NFDHA	0.36 U	0.71	0.36	0.27	
9CL-PF3ONS	0.36 U	0.71	0.36	0.19	
11CL-PF3OUDS	0.36 U	0.71	0.36	0.18	
3:3FTCA	0.71 U	1.4	0.71	0.51	
5:3FTCA	0.71 U	1.4	0.71	0.39	
7:3FTCA	0.71 U	1.4	0.71	0.49	



Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500

Sample I.D.: 22L0141-03  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (31)  
 Acquired: 2022/12/22 - 17:47

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-I[min], ΔRT-CV[min], ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBA	(212.9 / 169.0) 18246	(3.68, 1.00) (0.00, N/A, 0.0)	33.3	N/A 0.0 0.0	0.1674	N/A			
PFPeA	(262.9 / 219.0) 59427 (262.9 / 69.0) 509	(4.99, 1.00) (0.00, N/A, 0.0)	286.0 19.4	0.0086 76.5 82.3	0.3350	N/A			
PFHxA	(313.0 / 269.0) 75593 (313.0 / 119.0) 7094	(6.13, 1.00) (0.00, N/A, 0.4)	176.4 93.1	0.0938 96.0 105.0	0.2695	N/A			
PFHpA	(363.0 / 319.0) 49197 (363.0 / 169.0) 15416	(7.06, 1.00) (0.00, N/A, 0.0)	119.7 117.5	0.3134 100.6 101.7	0.2054	N/A			
PFOA	(413.0 / 369.0) 87282 (413.0 / 169.0) 30338	(7.87, 1.00) (0.00, N/A, -0.1)	585.7 598.8	0.3476 106.4 117.5	0.2934	N/A			
PFNA	(463.0 / 419.0) 12207 (463.0 / 169.0) 3146	(8.61, 1.00) (0.01, N/A, 0.3)	318.2 32.5	0.2577 133.7 123.7	0.0504	N/A			
PFDA	(513.0 / 469.0) N/A (513.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFUnA	(563.0 / 519.0) N/A (563.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFDoA	(613.0 / 569.0) N/A (613.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFTrDA	(663.0 / 619.0) N/A (663.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFTeDA	(713.0 / 669.0) 5057 (713.0 / 169.0) 309	(10.13, 1.00) (0.01, N/A, -1.9)	96.3 5.1	0.0611 30.0 29.8	0.0174	N/A			IR1,



Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500

Sample I.D.: 22L0141-03  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (31)  
 Acquired: 2022/12/22 - 17:47

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-[min], ΔRT-CV[min], ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBS	( 298.9 / 80.0 ) 87026 ( 298.9 / 99.0 ) 60643	( 6.08 , 1.00 ) ( 0.00 , N/A , 0.0 )	288.7 326.8	0.6968 113.2 106.4	0.1905	N/A			
PFPeS	( 349.0 / 80.0 ) 27168 ( 349.0 / 99.0 ) 7678	( 7.12 , 0.89 ) ( N/A , 0.01 , -0.1 )	58.8 51.5	0.2826 79.4 73.6	0.0321	N/A			
PFHxS	( 399.0 / 80.0 ) 244404 ( 399.0 / 99.0 ) 78744	( 7.99 , 1.00 ) ( 0.00 , N/A , 0.2 )	914.0 19096.5	0.3222 95.8 97.3	0.3324	N/A			
PFHpS	( 449.0 / 80.0 ) N/A ( 449.0 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFOS	( 499.0 / 80.0 ) 243864 ( 499.0 / 99.0 ) 39371	( 9.41 , 1.00 ) ( -0.02 , N/A , -0.6 )	29.0 52.8	0.1614 66.4 70.6	0.2758	N/A			MI5 DG 2022-12-27
PFNS	( 549.0 / 80.0 ) N/A ( 549.0 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFDS	( 599.0 / 80.0 ) N/A ( 599.0 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFDoS	( 698.9 / 80.0 ) N/A ( 698.9 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
4:2FTS	( 327.0 / 307.0 ) N/A ( 327.0 / 81.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
6:2FTS	( 427.0 / 407.0 ) N/A ( 427.0 / 81.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
8:2FTS	( 527.0 / 507.0 ) N/A ( 527.0 / 81.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			



Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500

Sample I.D.: 22L0141-03  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (31)  
 Acquired: 2022/12/22 - 17:47

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-I[min], ΔRT-CV[min], ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFOSA	( 498.0 / 78.0 ) N/A ( 498.0 / 478.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NMeFOSA	( 511.9 / 219.0 ) N/A ( 511.9 / 169.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NEiFOSA	( 526.0 / 219.0 ) N/A ( 526.0 / 169.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NMeFOSAA	( 570.0 / 419.0 ) N/A ( 570.0 / 483.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NEiFOSAA	( 584.0 / 419.0 ) N/A ( 584.0 / 526.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NMeFOSE	( 616.1 / 59.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A	N/A 0.0 0.0	0.0000	N/A			
NEiFOSE	( 630.0 / 59.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A	N/A 0.0 0.0	0.0000	N/A			
HFPO-DA	( 285.0 / 169.0 ) N/A ( 285.0 / 185.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
ADONA	( 377.0 / 85.0 ) N/A ( 377.0 / 251.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
9CI-Pf3ONS	( 531.0 / 351.0 ) N/A ( 533.0 / 353.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
11CI-PF3OUDS	( 631.0 / 451.0 ) N/A ( 633.0 / 453.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			














Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500












Sample I.D.: 22L0141-03  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam






Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (31)  
 Acquired: 2022/12/22 - 17:47

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-I[min], ΔRT-CV[min], ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
3:3FTCA	(241.0 / 177.0) N/A (241.0 / 117.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
5:3FTCA	(341.0 / 236.7) N/A (341.0 / 217.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
7:3FTCA	(441.0 / 317.0) N/A (441.0 / 337.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFEESA	(315.0 / 135.0) N/A (315.0 / 83.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFMPA	(229.0 / 85.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A	N/A 0.0 0.0	0.0000	N/A			
PFMBA	(279.0 / 85.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A	N/A 0.0 0.0	0.0000	N/A			
NFDHA	(295.0 / 201.0) N/A (295.0 / 85.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
13C3_PFBA_IIS	(216.0 / 172.0) 186757	(3.68, N/A) (N/A, 0.03, N/A)	888.6	N/A	1.3417 [ 1.0000 ]	134.2% { 118.9% }			
13C2_PFHxA_IIS	(315.1 / 270.0) 350959	(6.13, N/A) (N/A, 0.01, N/A)	689.9	N/A	1.5198 [ 1.0000 ]	152.0% { 148.7% }			
13C4_PFOA_IIS	(417.0 / 372.0) 316117	(7.87, N/A) (N/A, 0.00, N/A)	528.0	N/A	1.4379 [ 1.0000 ]	143.8% { 123.1% }			
13C5_PFNxA_IIS	(468.0 / 423.0) 290854	(8.61, N/A) (N/A, -0.01, N/A)	516.0	N/A	1.5706 [ 1.0000 ]	157.1% { 124.0% }			



Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT-CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDA_IIS	(515.1 / 470.1) 275789	(9.29, N/A) (N/A, 0.00, N/A)	354.6	N/A	1.4923 [ 1.0000 ]	149.2% { 147.3% }			
18O2_PFHxS_IIS	(403.0 / 83.9) 574030	(7.99, N/A) (N/A, 0.00, N/A)	650.6	N/A	1.4219 [ 1.0000 ]	142.2% { 128.6% }			
13C4_PFOS_IIS	(502.8 / 79.9) 479399	(9.42, N/A) (N/A, -0.02, N/A)	461.4	N/A	1.5020 [ 1.0000 ]	150.2% { 138.3% }			
13C4_PFBA_EIS	(217.0 / 172.0) 1336358	(3.68, N/A) (N/A, 0.03, N/A)	844.3	N/A	6.9525 [ 8.0000 ]	86.9% { 106.4% }			
13C5_PFPeA_EIS	(267.9 / 223.0) 807916	(4.98, N/A) (N/A, 0.02, N/A)	702.4	N/A	3.3085 [ 4.0000 ]	82.7% { 118.8% }			
13C5_PFHxA_EIS	(318.0 / 273.0) 653199	(6.13, N/A) (N/A, 0.01, N/A)	563.1	N/A	1.6173 [ 2.0000 ]	80.9% { 121.8% }			
13C4_PFHpA_EIS	(367.0 / 322.0) 525427	(7.06, N/A) (N/A, 0.00, N/A)	756.3	N/A	1.4913 [ 2.0000 ]	74.6% { 116.8% }			
13C8_PFOA_EIS	(421.0 / 376.0) 605019	(7.87, N/A) (N/A, 0.00, N/A)	764.2	N/A	1.7452 [ 2.0000 ]	87.3% { 101.6% }			
13C9_PFNA_EIS	(472.0 / 427.0) 282491	(8.61, N/A) (N/A, -0.01, N/A)	376.4	N/A	0.8832 [ 1.0000 ]	88.3% { 121.9% }			
13C6_PFDA_EIS	(519.0 / 474.0) 324865	(9.29, N/A) (N/A, 0.00, N/A)	498.7	N/A	0.8282 [ 1.0000 ]	82.8% { 118.0% }			
13C7_PFUnA_EIS	(570.0 / 525.0) 479306	(9.70, N/A) (N/A, -0.01, N/A)	781.2	N/A	0.8591 [ 1.0000 ]	85.9% { 128.8% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT- CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDa_EIS	(615.0 / 570.0) 434270	(9.88, N/A) (N/A, -0.01, N/A)	504.1	N/A	0.7799 [ 1.0000 ]	78.0% { 118.6% }			
13C2_PFTeDA_EIS	(715.0 / 670.0) 328086	(10.11, N/A) (N/A, 0.00, N/A)	561.6	N/A	0.8871 [ 1.0000 ]	88.7% { 128.5% }			
13C3_PFBs_EIS	(302.0 / 80.0) 1666501	(6.08, N/A) (N/A, 0.01, N/A)	720.3	N/A	1.7171 [ 2.0000 ]	85.9% { 125.1% }			
13C3_PFHxS_EIS	(402.0 / 80.0) 946670	(7.99, N/A) (N/A, 0.00, N/A)	914.3	N/A	1.8332 [ 2.0000 ]	91.7% { 123.3% }			
13C8_PFOS_EIS	(507.0 / 80.0) 1629168	(9.43, N/A) (N/A, -0.01, N/A)	617.9	N/A	1.9801 [ 2.0000 ]	99.0% { 145.8% }			
13C2_4:2FTS_EIS	(329.0 / 81.0) 372842	(5.80, N/A) (N/A, 0.01, N/A)	651.9	N/A	4.5356 [ 4.0000 ]	113.4% { 165.6% }			
13C2_6:2FTS_EIS	(429.0 / 81.0) 433015	(7.54, N/A) (N/A, 0.01, N/A)	647.0	N/A	4.3753 [ 4.0000 ]	109.4% { 128.7% }			
13C2_8:2FTS_EIS	(529.0 / 81.0) 407802	(8.94, N/A) (N/A, -0.01, N/A)	531.4	N/A	4.1162 [ 4.0000 ]	102.9% { 129.1% }			
13C8_PFOA_EIS	(506.0 / 78.0) 1126393	(10.17, N/A) (N/A, -0.01, N/A)	584.2	N/A	1.0830 [ 2.0000 ]	54.2% { 82.6% }			
D3_NMeFOA_EIS	(515.0 / 169.0) 147646	(10.61, N/A) (N/A, 0.00, N/A)	650.3	N/A	0.6502 [ 2.0000 ]	32.5% { 51.4% }			
D5_NEiFOA_EIS	(531.1 / 169.0) 131144	(10.69, N/A) (N/A, 0.00, N/A)	666.7	N/A	0.6256 [ 2.0000 ]	31.3% { 43.2% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT- CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
D3_MeFOSAA_EIS	(573.0 / 419.0) 695859	(9.48, N/A) (N/A, -0.01, N/A)	494.0	N/A	3.5567 [ 4.0000 ]	88.9% { 131.6% }			
D5_EtFOSAA_EIS	(589.0 / 419.0) 637207	(9.67, N/A) (N/A, -0.01, N/A)	512.2	N/A	3.6951 [ 4.0000 ]	92.4% { 153.6% }			
D7_NMeFOSE_EIS	(623.2 / 58.9) 247661	(10.57, N/A) (N/A, -0.01, N/A)	853.8	N/A	7.7675 [ 20.0000 ]	38.8% { 57.0% }			
D9_NEtFOSE_EIS	(639.2 / 58.9) 134066	(10.67, N/A) (N/A, -0.01, N/A)	972.8	N/A	9.2361 [ 20.0000 ]	46.2% { 67.7% }			
13C3_HFPODA_EIS	(287.0 / 169.0) 1320506	(6.48, N/A) (N/A, 0.01, N/A)	838.4	N/A	6.1496 [ 8.0000 ]	76.9% { 108.5% }			

# QUALITY CONTROL

# SURROGATE SUMMARY SHEET

EPA 1633

Client: AECOM  
 Work Order: 22L0141  
 Project: Red Hill AFFF Assessment Sampling

Surrogate Compound	Spike level	% Recovery	Recovery Limits	Q
<b>AF-RHMW02-WGN01LF-2212W3 (22L0141-01) ng/L</b>		Lab File ID: S2022-12-22A (27)		Analyzed: 12/22/22 16:57
13C4-PFBA	27.6	65.1	20 - 150	
13C5-PFPEA	13.8	61.6	20 - 150	
13C5-PFHXA	6.89	85.0	20 - 150	
13C4-PFHFA	6.89	95.1	20 - 150	
13C8-PFOA	6.89	91.2	20 - 150	
13C9-PFNA	3.45	87.7	20 - 150	
13C6-PFDA	3.45	82.4	20 - 150	
13C7-PFUnA	3.45	71.5	20 - 150	
13C2-PFDOA	3.45	69.9	20 - 150	
13C2-PFTEDA	3.45	72.9	20 - 150	
13C3-PFBS	6.89	95.7	20 - 150	
13C3-PFHXS	6.89	86.7	20 - 150	
13C8-PFOS	6.89	79.6	20 - 150	
13C2-4:2FTS	13.8	128	20 - 150	
13C2-6:2FTS	13.8	136	20 - 150	
13C2-8:2FTS	13.8	141	20 - 150	
13C8-PFOSA	6.89	51.2	20 - 150	
D5-NETFOSA	6.89	40.0	20 - 150	
D3-NMEFOSA	6.89	44.9	20 - 150	
D3-NMEFOSAA	13.8	87.9	20 - 150	
D5-NETFOSAA	13.8	93.2	20 - 150	
D7-NMEFOSE	68.9	53.9	20 - 150	
D9-NETFOSE	68.9	51.2	20 - 150	
13C3-HFPO-DA	27.6	74.0	20 - 150	

## SURROGATE SUMMARY SHEET

EPA 1633

Client: AECOM  
 Work Order: 22L0141  
 Project: Red Hill AFFF Assessment Sampling

Surrogate Compound	Spike level	% Recovery	Recovery Limits	Q
AF-RHMW03-WGN01LF-2212W3 (22L0141-02) ng/L		Lab File ID: S2022-12-22A (29)		Analyzed: 12/22/22 17:22
13C4-PFBA	28.1	82.7	20 - 150	
13C5-PFPEA	14.0	80.6	20 - 150	
13C5-PFHXA	7.01	82.8	20 - 150	
13C4-PFHPA	7.01	94.5	20 - 150	
13C8-PFOA	7.01	88.7	20 - 150	
13C9-PFNA	3.51	96.5	20 - 150	
13C6-PFDA	3.51	82.7	20 - 150	
13C7-PFUnA	3.51	86.6	20 - 150	
13C2-PFDOA	3.51	79.0	20 - 150	
13C2-PFTEDA	3.51	65.5	20 - 150	
13C3-PFBS	7.01	90.4	20 - 150	
13C3-PFHXS	7.01	92.3	20 - 150	
13C8-PFOS	7.01	97.4	20 - 150	
13C2-4:2FTS	14.0	129	20 - 150	
13C2-6:2FTS	14.0	113	20 - 150	
13C2-8:2FTS	14.0	106	20 - 150	
13C8-PFOSA	7.01	65.3	20 - 150	
D5-NETFOSA	7.01	45.2	20 - 150	
D3-NMEFOSA	7.01	46.1	20 - 150	
D3-NMEFOSAA	14.0	90.8	20 - 150	
D5-NETFOSAA	14.0	95.0	20 - 150	
D7-NMEFOSE	70.1	54.8	20 - 150	
D9-NETFOSSE	70.1	56.0	20 - 150	
13C3-HFPO-DA	28.1	85.2	20 - 150	

# SURROGATE SUMMARY SHEET

EPA 1633

Client: AECOM  
 Work Order: 22L0141  
 Project: Red Hill AFFF Assessment Sampling

Surrogate Compound	Spike level	% Recovery	Recovery Limits	Q
<b>AF-RHMW225401-WGN01B-2212W3 (22L0141-03) ng/L</b>		Lab File ID: S2022-12-22A (31)		Analyzed: 12/22/22 17:47
13C4-PFBA	28.5	86.9	20 - 150	
13C5-PFPEA	14.2	82.7	20 - 150	
13C5-PFHXA	7.12	80.9	20 - 150	
13C4-PFHPA	7.12	74.6	20 - 150	
13C8-PFOA	7.12	87.3	20 - 150	
13C9-PFNA	3.56	88.3	20 - 150	
13C6-PFDA	3.56	82.8	20 - 150	
13C7-PFUnA	3.56	85.9	20 - 150	
13C2-PFDOA	3.56	78.0	20 - 150	
13C2-PFTEDA	3.56	88.7	20 - 150	
13C3-PFBS	7.12	85.9	20 - 150	
13C3-PFHXS	7.12	91.7	20 - 150	
13C8-PFOS	7.12	99.0	20 - 150	
13C2-4:2FTS	14.2	113	20 - 150	
13C2-6:2FTS	14.2	109	20 - 150	
13C2-8:2FTS	14.2	103	20 - 150	
13C8-PFOSA	7.12	54.2	20 - 150	
D5-NETFOSA	7.12	31.3	20 - 150	
D3-NMEFOSA	7.12	32.5	20 - 150	
D3-NMEFOSAA	14.2	88.9	20 - 150	
D5-NETFOSAA	14.2	92.4	20 - 150	
D7-NMEFOSE	71.2	38.8	20 - 150	
D9-NETFOSE	71.2	46.2	20 - 150	
13C3-HFPO-DA	28.5	76.9	20 - 150	

## SURROGATE SUMMARY SHEET

EPA 1633

Client: AECOM  
 Work Order: 22L0141  
 Project: Red Hill AFFF Assessment Sampling

Surrogate Compound	Spike level	% Recovery	Recovery Limits	Q
<b>Blank (BBL0403-BLK1) . ng/L</b>				
	Lab File ID: S2022-12-22A (18)			Analyzed: 12/22/22 15:02
13C4-PFBA	32.0	94.6	20 - 150	
13C5-PFPEA	16.0	94.3	20 - 150	
13C5-PFHXA	8.00	92.2	20 - 150	
13C4-PFHPA	8.00	90.7	20 - 150	
13C8-PFOA	8.00	96.2	20 - 150	
13C9-PFNA	4.00	96.0	20 - 150	
13C6-PFDA	4.00	89.8	20 - 150	
13C7-PFUnA	4.00	91.8	20 - 150	
13C2-PFDOA	4.00	106	20 - 150	
13C2-PFTEDA	4.00	78.0	20 - 150	
13C3-PFBS	8.00	86.3	20 - 150	
13C3-PFHXS	8.00	89.7	20 - 150	
13C8-PFOS	8.00	86.4	20 - 150	
13C2-4:2FTS	16.0	89.3	20 - 150	
13C2-6:2FTS	16.0	111	20 - 150	
13C2-8:2FTS	16.0	87.3	20 - 150	
13C8-PFOSA	8.00	80.7	20 - 150	
D5-NETFOSA	8.00	31.7	20 - 150	
D3-NMEFOSA	8.00	38.2	20 - 150	
D3-NMEFOSAA	16.0	73.5	20 - 150	
D5-NETFOSAA	16.0	82.3	20 - 150	
D7-NMEFOSE	80.0	59.6	20 - 150	
D9-NETFOSE	80.0	59.9	20 - 150	
13C3-HFPO-DA	32.0	89.1	20 - 150	



# SURROGATE SUMMARY SHEET

EPA 1633

Client: AECOM  
 Work Order: 22L0141  
 Project: Red Hill AFFF Assessment Sampling

Surrogate Compound	Spike level	% Recovery	Recovery Limits	Q
<b>LCS (BBL0403-BS1) . ng/L</b>	Lab File ID: S2022-12-22A (19)			Analyzed: 12/22/22 15:15
13C4-PFBA	32.0	97.0	20 - 150	
13C5-PFPEA	16.0	109	20 - 150	
13C5-PFHXA	8.00	98.6	20 - 150	
13C4-PFHPA	8.00	107	20 - 150	
13C8-PFOA	8.00	97.1	20 - 150	
13C9-PFNA	4.00	98.3	20 - 150	
13C6-PFDA	4.00	74.0	20 - 150	
13C7-PFUnA	4.00	71.8	20 - 150	
13C2-PFDOA	4.00	74.6	20 - 150	
13C2-PFTEDA	4.00	73.1	20 - 150	
13C3-PFBS	8.00	88.0	20 - 150	
13C3-PFHXS	8.00	95.3	20 - 150	
13C8-PFOS	8.00	95.5	20 - 150	
13C2-4:2FTS	16.0	85.2	20 - 150	
13C2-6:2FTS	16.0	89.2	20 - 150	
13C2-8:2FTS	16.0	88.4	20 - 150	
13C8-PFOSA	8.00	84.2	20 - 150	
D5-NETFOSA	8.00	25.5	20 - 150	
D3-NMEFOSA	8.00	28.0	20 - 150	
D3-NMEFOSAA	16.0	86.5	20 - 150	
D5-NETFOSAA	16.0	83.3	20 - 150	
D7-NMEFOSE	80.0	45.0	20 - 150	
D9-NETFOSE	80.0	48.2	20 - 150	
13C3-HFPO-DA	32.0	102	20 - 150	

# SURROGATE SUMMARY SHEET

EPA 1633

Client: AECOM  
 Work Order: 22L0141  
 Project: Red Hill AFFF Assessment Sampling

Surrogate Compound	Spike level	% Recovery	Recovery Limits	Q
<b>MRL Check (BBL0403-MRL1) . ng/L</b>	Lab File ID: S2022-12-22A (20)			Analyzed: 12/22/22 15:28
13C4-PFBA	32.0	95.9	20 - 150	
13C5-PFPEA	16.0	102	20 - 150	
13C5-PFHXA	8.00	88.6	20 - 150	
13C4-PFHPA	8.00	108	20 - 150	
13C8-PFOA	8.00	108	20 - 150	
13C9-PFNA	4.00	102	20 - 150	
13C6-PFDA	4.00	97.4	20 - 150	
13C7-PFUnA	4.00	87.5	20 - 150	
13C2-PFDOA	4.00	93.9	20 - 150	
13C2-PFTEDA	4.00	102	20 - 150	
13C3-PFBS	8.00	84.5	20 - 150	
13C3-PFHXS	8.00	90.1	20 - 150	
13C8-PFOS	8.00	90.4	20 - 150	
13C2-4:2FTS	16.0	83.8	20 - 150	
13C2-6:2FTS	16.0	95.2	20 - 150	
13C2-8:2FTS	16.0	74.1	20 - 150	
13C8-PFOSA	8.00	59.4	20 - 150	
D5-NETFOSA	8.00	20.1	20 - 150	
D3-NMEFOSA	8.00	23.9	20 - 150	
D3-NMEFOSAA	16.0	71.7	20 - 150	
D5-NETFOSAA	16.0	86.1	20 - 150	
D7-NMEFOSE	80.0	33.6	20 - 150	
D9-NETFOSE	80.0	33.0	20 - 150	
13C3-HFPO-DA	32.0	99.4	20 - 150	



# ANALYSIS DATA SHEET

Blank

Laboratory:	APPL, LLC	Work Order:	22L0141
Client:	AECOM	Project:	Red Hill AFFF Assessment Sampling
Matrix:	Water	Laboratory ID:	BBL0403-BLK1
Sampled:		Prepared:	12/20/22 15:01
Solids:		Preparation:	1633
Batch:	BBL0403	Sequence:	SB03951
Column:	1	Calibration:	2252011
		Instrument:	Saphira
		File ID:	S2022-12-22A (18)
		Analyzed:	12/22/22 15:02
		Dilution:	1

COMPOUND	CONC. (ng/L)	LOQ	LOD	DL	Q
PFBA	0.80 U	1.6	0.80	0.21	U
PFPEA	0.40 U	0.80	0.40	0.065	U
PFHXA	0.20 U	0.40	0.20	0.055	U
PFHPA	0.20 U	0.40	0.20	0.041	U
PFOA	0.20 U	0.40	0.20	0.15	U
PFNA	0.20 U	0.40	0.20	0.082	U
PFDA	0.20 U	0.40	0.20	0.10	U
PFUnA	0.20 U	0.40	0.20	0.16	U
PFDOA	0.20 U	0.40	0.20	0.11	U
PFTRDA	0.30 U	0.40	0.30	0.20	U
PFTEDA	0.20 U	0.40	0.20	0.20	U
PFBS	0.20 U	0.40	0.20	0.037	U
PFPEs	0.20 U	0.40	0.20	0.063	U
PFHXS	0.20 U	0.40	0.20	0.032	U
PFHPS	0.20 U	0.40	0.20	0.051	U
PFOS	0.0863 J	0.40	0.20	0.064	J
PFNS	0.20 U	0.40	0.20	0.12	U
PFDS	0.20 U	0.40	0.20	0.15	U
PFDOS	0.20 U	0.40	0.20	0.12	U
4:2FTS	0.80 U	1.6	0.80	0.29	U
6:2FTS	0.80 U	1.6	0.80	0.31	U
8:2FTS	0.80 U	1.6	0.80	0.082	U
PFOSA	0.20 U	0.40	0.20	0.10	U
NMeFOSA	0.80 U	1.6	0.80	0.47	U
NEtFOSA	0.80 U	1.6	0.80	0.41	U
NMeFOSAA	0.20 U	0.40	0.20	0.11	U
NEtFOSAA	0.20 U	0.40	0.20	0.11	U
NMeFOSE	1.2 U	1.6	1.2	1.0	U
NEtFOSE	1.2 U	1.6	1.2	1.0	U
HFPO-DA	0.40 U	0.80	0.40	0.17	U

**ANALYSIS DATA SHEET**

Blank

Laboratory:	APPL, LLC	Work Order:	22L0141
Client:	AECOM	Project:	Red Hill AFFF Assessment Sampling
Matrix:	Water	Laboratory ID:	BBL0403-BLK1
Sampled:		Prepared:	12/20/22 15:01
Solids:		Preparation:	1633
Batch:	BBL0403	Sequence:	SB03951
Column:	1	Calibration:	2252011
			Instrument: Saphira
			File ID: S2022-12-22A (18)
			Analyzed: 12/22/22 15:02
			Dilution: 1

COMPOUND	CONC. (ng/L)	LOQ	LOD	DL	Q
ADONA	0.40 U	0.80	0.40	0.12	U
PFEESA	0.40 U	0.80	0.40	0.11	U
PFMPA	0.40 U	0.80	0.40	0.054	U
PFMBA	0.40 U	0.80	0.40	0.091	U
NFDHA	0.40 U	0.80	0.40	0.30	U
9CL-PF3ONS	0.40 U	0.80	0.40	0.21	U
11CL-PF3OUDS	0.40 U	0.80	0.40	0.21	U
3:3FTCA	0.80 U	1.6	0.80	0.57	U
5:3FTCA	0.80 U	1.6	0.80	0.44	U
7:3FTCA	0.80 U	1.6	0.80	0.55	U

**LCS / LCS DUPLICATE RECOVERY**

EPA 1633

Laboratory: APPL, LLC

Work Order: 22L0141

Client: AECOM

Project: Red Hill AFFF Assessment Sampling

Matrix: Water

Preparation: 1633

Batch: BBL0403

Laboratory ID: BBL0403-BS1

Column:

<b>ANALYTE</b>	<b>SPIKE ADDED (ng/L)</b>	<b>LCS CONCENTRATION (ng/L)</b>	<b>LCS % REC.</b>	<b>QC LIMITS REC.</b>
PFBA	16.0	16.1	101	40 - 150
PFPEA	8.00	7.93	99.1	40 - 150
PFHXA	4.00	4.27	107	40 - 150
PFHPA	4.00	3.87	96.8	40 - 150
PFOA	4.00	3.50	87.6	40 - 150
PFNA	4.00	3.90	97.5	40 - 150
PFDA	4.00	4.33	108	40 - 150
PFUnA	4.00	4.74	119	40 - 150
PFDOA	4.00	3.75	93.8	40 - 150
PFTRDA	4.00	3.68	92.0	40 - 150
PFTEDA	4.00	4.31	108	40 - 150
PFBS	3.54	3.64	103	40 - 150
PFPEs	3.76	3.56	94.6	40 - 150
PFHXS	3.66	3.53	96.5	40 - 150
PFHPS	3.82	3.57	93.4	40 - 150
PFOS	3.72	3.24	87.1	40 - 150
PFNS	3.84	3.62	94.4	40 - 150
PFDS	3.86	3.46	89.5	40 - 150
PFDOS	3.88	3.24	83.4	40 - 150
4:2FTS	15.0	13.2	87.8	40 - 150
6:2FTS	15.2	15.2	99.7	40 - 150
8:2FTS	15.4	14.7	95.7	40 - 150
PFOSA	4.00	3.46	86.6	40 - 150
NMeFOSA	16.0	18.4	115	40 - 150
NEtFOSA	16.0	16.9	106	40 - 150
NMeFOSAA	4.00	3.87	96.7	40 - 150
NEtFOSAA	4.00	3.84	96.0	40 - 150
NMeFOSE	16.0	17.8	111	40 - 150
NEtFOSE	16.0	15.8	98.7	40 - 150
HFPO-DA	8.00	7.61	95.1	40 - 150
ADONA	7.56	7.89	104	40 - 150
PFEESA	7.12	7.00	98.3	40 - 150
PFMPA	8.00	8.31	104	40 - 150
PFMBA	8.00	7.54	94.3	40 - 150

**LCS / LCS DUPLICATE RECOVERY**

EPA 1633

Laboratory: APPL, LLC

Work Order: 22L0141

Client: AECOM

Project: Red Hill AFFF Assessment Sampling

Matrix: Water

Preparation: 1633

Batch: BBL0403

Laboratory ID: BBL0403-BS1

Column:

<b>ANALYTE</b>	<b>SPIKE ADDED (ng/L)</b>	<b>LCS CONCENTRATION (ng/L)</b>	<b>LCS % REC.</b>	<b>QC LIMITS REC.</b>
NFDHA	8.00	8.29	104	40 - 150
9CL-PF3ONS	7.48	6.81	91.0	40 - 150
11CL-PF3OUDS	7.56	7.94	105	40 - 150
3:3FTCA	16.0	17.4	109	40 - 150
5:3FTCA	16.0	17.2	108	40 - 150
7:3FTCA	16.0	17.9	112	40 - 150

# CALIBRATION SUMMARY



Analyte	( Q1 / Q3 )	Internal Standard	Multiplier	AcidFactor	Function	Qualifier
PFBA	( 212.9 / 169.0 )	13C4_PFBA_EIS	4.0000	1.0000	y = 0.32619 x (std. dev. = 0.01628) (weighting: None)	%RSE=5.0
PFPeA	( 262.9 / 219.0 )	13C5_PFPeA_EIS	2.0000	1.0000	y = 0.43913 x (std. dev. = 0.01863) (weighting: None)	%RSE=4.2
PFHxA	( 313.0 / 269.0 )	13C5_PFHxA_EIS	1.0000	1.0000	y = 0.42941 x (std. dev. = 0.01769) (weighting: None)	%RSE=4.1
PFHpA	( 363.0 / 319.0 )	13C4_PFHpA_EIS	1.0000	1.0000	y = 0.45577 x (std. dev. = 0.01668) (weighting: None)	%RSE=3.7
PFOA	( 413.0 / 369.0 )	13C8_PFOA_EIS	1.0000	1.0000	y = 0.49169 x (std. dev. = 0.02929) (weighting: None)	%RSE=6.0
PFNA	( 463.0 / 419.0 )	13C9_PFNA_EIS	1.0000	1.0000	y = 0.85807 x (std. dev. = 0.06798) (weighting: None)	%RSE=7.9
PFDA	( 513.0 / 469.0 )	13C6_PFDA_EIS	1.0000	1.0000	y = 0.95185 x (std. dev. = 0.07020) (weighting: None)	%RSE=7.4
PFUnA	( 563.0 / 519.0 )	13C7_PFUnA_EIS	1.0000	1.0000	y = 0.79028 x (std. dev. = 0.12920) (weighting: None)	%RSE=16.3
PFDoA	( 613.0 / 569.0 )	13C2_PFDoA_EIS	1.0000	1.0000	y = 0.86208 x (std. dev. = 0.12117) (weighting: None)	%RSE=14.1
PFTrDA	( 663.0 / 619.0 )	13C2_PFDoA_EIS	1.0000	1.0000	y = 0.74691 x (std. dev. = 0.10467) (weighting: None)	%RSE=14.0
PFTeDA	( 713.0 / 669.0 )	13C2_PFTeDA_EIS	1.0000	1.0000	y = 0.88627 x (std. dev. = 0.09361) (weighting: None)	%RSE=10.6
PFBS	( 298.9 / 80.0 )	13C3_PFBS_EIS	1.0000	0.8847	y = 0.24253 x (std. dev. = 0.01275) (weighting: None)	%RSE=5.3
PFPeS	( 349.0 / 80.0 )	13C3_PFHxS_EIS	1.0000	0.9384	y = 0.83819 x (std. dev. = 0.04088) (weighting: None)	%RSE=4.9
PFHxS	( 399.0 / 80.0 )	13C3_PFHxS_EIS	1.0000	0.9110	y = 0.70765 x (std. dev. = 0.03393) (weighting: None)	%RSE=4.8
PFHpS	( 449.0 / 80.0 )	13C8_PFOS_EIS	1.0000	0.9514	y = 0.41508 x (std. dev. = 0.03452) (weighting: None)	%RSE=8.3
PFOS	( 499.0 / 80.0 )	13C8_PFOS_EIS	1.0000	0.9275	y = 0.50337 x (std. dev. = 0.03410) (weighting: None)	%RSE=6.8
PFNS	( 549.0 / 80.0 )	13C8_PFOS_EIS	1.0000	0.9599	y = 0.57789 x (std. dev. = 0.04314) (weighting: None)	%RSE=7.5
PFDS	( 599.0 / 80.0 )	13C8_PFOS_EIS	1.0000	0.9631	y = 0.64371 x (std. dev. = 0.05256) (weighting: None)	%RSE=8.2
PFDoS	( 698.9 / 80.0 )	13C8_PFOS_EIS	1.0000	0.9696	y = 0.27084 x (std. dev. = 0.02152) (weighting: None)	%RSE=7.9
4:2FTS	( 327.0 / 307.0 )	13C2_4:2FTS_EIS	4.0000	0.9345	y = 3.09002 x (std. dev. = 0.26815) (weighting: None)	%RSE=8.7
6:2FTS	( 427.0 / 407.0 )	13C2_6:2FTS_EIS	4.0000	0.9490	y = 1.45919 x (std. dev. = 0.11873) (weighting: None)	%RSE=8.1
8:2FTS	( 527.0 / 507.0 )	13C2_8:2FTS_EIS	4.0000	0.9583	y = 1.51823 x (std. dev. = 0.27229) (weighting: None)	%RSE=17.9
PFOSA	( 498.0 / 78.0 )	13C8_PFOSA_EIS	1.0000	1.0000	y = 0.47254 x (std. dev. = 0.03538) (weighting: None)	%RSE=7.5
NMeFOSA	( 511.9 / 219.0 )	D3_NMeFOSA_EIS	4.0000	1.0000	y = 1.63031 x (std. dev. = 0.18278) (weighting: None)	%RSE=11.2
NEiFOSA	( 526.0 / 219.0 )	D5_NEiFOSA_EIS	4.0000	1.0000	y = 1.80404 x (std. dev. = 0.10773) (weighting: None)	%RSE=6.0
NMeFOSAA	( 570.0 / 419.0 )	D3_MeFOSAA_EIS	1.0000	1.0000	y = 0.19482 x (std. dev. = 0.02187) (weighting: None)	%RSE=11.2
NEiFOSAA	( 584.0 / 419.0 )	D5_EiFOSAA_EIS	1.0000	1.0000	y = 0.22445 x (std. dev. = 0.03244) (weighting: None)	%RSE=14.5
NMeFOSE	( 616.1 / 59.0 )	D7_NMeFOSE_EIS	4.0000	1.0000	y = 0.25244 x (std. dev. = 0.02362) (weighting: None)	%RSE=9.4
NEiFOSE	( 630.0 / 59.0 )	D9_NEiFOSE_EIS	4.0000	1.0000	y = 0.10241 x (std. dev. = 0.01427) (weighting: None)	%RSE=13.9
HFPO-DA	( 285.0 / 169.0 )	13C3_HFPODA_EIS	2.0000	1.0000	y = 0.15195 x (std. dev. = 0.00913) (weighting: None)	%RSE=6.0
ADONA	( 377.0 / 85.0 )	13C3_HFPODA_EIS	2.0000	0.9427	y = 0.63625 x (std. dev. = 0.02798) (weighting: None)	%RSE=4.4
9Cl-Pf3ONS	( 531.0 / 351.0 )	13C3_HFPODA_EIS	2.0000	0.9333	y = -0.01255 x <sup>2</sup> + 1.77065 x + 0.01174 (r = 0.99899) (weighting: 1 / x <sup>2</sup> )	%RSE=4.6
11Cl-Pf3OUDS	( 631.0 / 451.0 )	13C3_HFPODA_EIS	2.0000	0.9432	y = 0.88975 x (std. dev. = 0.09345) (weighting: None)	%RSE=10.5
3:3FTCA	( 241.0 / 177.0 )	13C5_PFPeA_EIS	4.0000	1.0000	y = 0.03031 x (std. dev. = 0.00217) (weighting: None)	%RSE=7.2
5:3FTCA	( 341.0 / 236.7 )	13C5_PFHxA_EIS	4.0000	1.0000	y = 0.30350 x (std. dev. = 0.02546) (weighting: None)	%RSE=8.4
7:3FTCA	( 441.0 / 317.0 )	13C5_PFHxA_EIS	4.0000	1.0000	y = 0.34922 x (std. dev. = 0.01514) (weighting: None)	%RSE=4.3
PFEESA	( 315.0 / 135.0 )	13C5_PFHxA_EIS	2.0000	0.8925	y = 0.83914 x (std. dev. = 0.06120) (weighting: None)	%RSE=7.3
PFMPA	( 229.0 / 85.0 )	13C5_PFPeA_EIS	2.0000	1.0000	y = 0.12052 x (std. dev. = 0.00587) (weighting: None)	%RSE=4.9
PFMBA	( 279.0 / 85.0 )	13C5_PFPeA_EIS	2.0000	1.0000	y = 0.41658 x (std. dev. = 0.00844) (weighting: None)	%RSE=2.0
NFDHA	( 295.0 / 201.0 )	13C5_PFHxA_EIS	2.0000	1.0000	y = 0.43305 x (std. dev. = 0.01639) (weighting: None)	%RSE=3.8
13C3_PFBA_IIS	( 216.0 / 172.0 )	13C3_PFBA_IIS	1.0000	1.0000	y = 139193.5476 x	%RSD=8.2
13C2_PFHxA_IIS	( 315.1 / 270.0 )	13C2_PFHxA_IIS	1.0000	1.0000	y = 230918.4261 x	%RSD=8.2
13C4_PFOA_IIS	( 417.0 / 372.0 )	13C4_PFOA_IIS	1.0000	1.0000	y = 219848.0773 x	%RSD=7.7
13C5_PFNA_IIS	( 468.0 / 423.0 )	13C5_PFNA_IIS	1.0000	1.0000	y = 185181.4072 x	%RSD=9.2
13C2_PFDA_IIS	( 515.1 / 470.1 )	13C2_PFDA_IIS	1.0000	1.0000	y = 184809.0456 x	%RSD=11.0
18O2_PFHxS_IIS	( 403.0 / 83.9 )	18O2_PFHxS_IIS	1.0000	1.0000	y = 403709.6695 x	%RSD=4.9
13C4_PFOS_IIS	( 502.8 / 79.9 )	13C4_PFOS_IIS	1.0000	1.0000	y = 319178.8209 x	%RSD=6.9

Analyte	( Q1 / Q3 )	Internal Standard	Multiplier	AcidFactor	Function	Qualifier
13C4_PFBa_EIS	( 217.0 / 172.0 )	13C3_PFBa_IIS	8.0000	1.0000	y = 8.2337 x	%RSD=3.2
13C5_PFPaA_EIS	( 267.9 / 223.0 )	13C2_PFHxA_IIS	4.0000	1.0000	y = 2.7832 x	%RSD=7.7
13C5_PFHxA_EIS	( 318.0 / 273.0 )	13C2_PFHxA_IIS	2.0000	1.0000	y = 2.3015 x	%RSD=6.9
13C4_PFHpA_EIS	( 367.0 / 322.0 )	13C2_PFHxA_IIS	2.0000	1.0000	y = 2.0078 x	%RSD=6.4
13C8_PFOA_EIS	( 421.0 / 376.0 )	13C4_PFOA_IIS	2.0000	1.0000	y = 2.1933 x	%RSD=5.9
13C9_PFNA_EIS	( 472.0 / 427.0 )	13C5_PFNA_IIS	1.0000	1.0000	y = 1.0996 x	%RSD=3.4
13C6_PFDA_EIS	( 519.0 / 474.0 )	13C2_PFDA_IIS	1.0000	1.0000	y = 1.4222 x	%RSD=14.3
13C7_PFUaA_EIS	( 570.0 / 525.0 )	13C2_PFDA_IIS	1.0000	1.0000	y = 2.0230 x	%RSD=15.9
13C2_PFDaA_EIS	( 615.0 / 570.0 )	13C2_PFDA_IIS	1.0000	1.0000	y = 2.0192 x	%RSD=15.8
13C2_PFTeDA_EIS	( 715.0 / 670.0 )	13C2_PFDA_IIS	1.0000	1.0000	y = 1.3410 x	%RSD=16.6
13C3_PFBs_EIS	( 302.0 / 80.0 )	18O2_PFHxS_IIS	2.0000	1.0000	y = 3.3815 x	%RSD=8.1
13C3_PFHxS_EIS	( 402.0 / 80.0 )	18O2_PFHxS_IIS	2.0000	1.0000	y = 1.7992 x	%RSD=5.5
13C8_PFOs_EIS	( 507.0 / 80.0 )	13C4_PFOs_IIS	2.0000	1.0000	y = 3.4325 x	%RSD=6.1
13C2_4:2FTS_EIS	( 329.0 / 81.0 )	18O2_PFHxS_IIS	4.0000	1.0000	y = 0.5728 x	%RSD=7.1
13C2_6:2FTS_EIS	( 429.0 / 81.0 )	18O2_PFHxS_IIS	4.0000	1.0000	y = 0.6896 x	%RSD=7.7
13C2_8:2FTS_EIS	( 529.0 / 81.0 )	18O2_PFHxS_IIS	4.0000	1.0000	y = 0.6904 x	%RSD=7.1
13C8_PFOsA_EIS	( 506.0 / 78.0 )	13C4_PFOs_IIS	2.0000	1.0000	y = 4.3389 x	%RSD=5.1
D3_NMeFOsA_EIS	( 515.0 / 169.0 )	13C4_PFOs_IIS	2.0000	1.0000	y = 0.9473 x	%RSD=12.5
D5_NEtFOsA_EIS	( 531.1 / 169.0 )	13C4_PFOs_IIS	2.0000	1.0000	y = 0.8745 x	%RSD=6.8
D3_MeFOsAA_EIS	( 573.0 / 419.0 )	13C4_PFOs_IIS	4.0000	1.0000	y = 1.6324 x	%RSD=5.4
D5_EtFOsAA_EIS	( 589.0 / 419.0 )	13C4_PFOs_IIS	4.0000	1.0000	y = 1.4389 x	%RSD=12.4
D7_NMeFOsE_EIS	( 623.2 / 58.9 )	13C4_PFOs_IIS	20.0000	1.0000	y = 1.3302 x	%RSD=9.0
D9_NEtFOsE_EIS	( 639.2 / 58.9 )	13C4_PFOs_IIS	20.0000	1.0000	y = 0.6056 x	%RSD=7.0
13C3_HFOpDA_EIS	( 287.0 / 169.0 )	13C2_PFHxA_IIS	8.0000	1.0000	y = 4.8947 x	%RSD=6.9


x= Concentration Analyte

$$y = \text{Area Ratio} = \frac{\text{Area Analyte}}{\text{Area Internal Standard}}$$

$$\text{Acid Factor} = \frac{\text{Molecular weight Acid}}{\text{Molecular weight Salt}}$$


$$\text{Multiplier} = \frac{\text{Concentration of Analyte}}{\text{Concentration of PFOA}} \text{ in curve standard mix}$$

$$\text{Result} \left( \frac{\text{ng}}{\text{ml}} \right) = x * \text{Multiplier} * \text{Acid Factor}$$



Peak List for "-Q1: 1 MCA scans from Sample 1 (TuneSampleID) of MT20221111142838.wiff (Turbo Spray)"

	Target Mass (Da)	Found At (Da)	Intensity (cps)	Width (Da)	Mass Shift (Da)
1	44.9980	45.0305	1.3061e8	0.6158	-0.0325
2	411.2590	411.3148	1.5745e6	0.6085	-0.0558
3	585.3850	585.3651	3.9270e6	0.6307	0.0199
4	933.6360	933.6197	1.0205e7	0.6552	0.0163
5	1223.8450	1223.8627	3.0170e6	0.6967	-0.0177
6	1572.0970	n/a	n/a	n/a	n/a
7	1863.3060	n/a	n/a	n/a	n/a
8	1979.3890	n/a	n/a	n/a	n/a














































Peak List for "-Q3: 1 MCA scans from Sample 1 (TuneSampleID) of MT20221111142403.wiff (Turbo Spray)"





















	Target Mass (Da)	Found At (Da)	Intensity (cps)	Width (Da)	Mass Shift (Da)
1	44.9980	44.9799	1.2814e8	0.6414	0.0181
2	411.2590	411.2677	7.7810e5	0.6076	-8.6898e-3
3	585.3850	585.3784	3.9438e6	0.6511	6.5868e-3
4	933.6360	933.6279	8.7759e6	0.6302	8.0526e-3
5	1223.8450	1223.8609	2.0397e6	0.6225	-0.0159
6	1572.0970	n/a	n/a	n/a	n/a
7	1863.3060	n/a	n/a	n/a	n/a
8	1979.3890	n/a	n/a	n/a	n/a

# EPA 1633

















Initial Calibration: SB03941












Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-Imin, $\Delta$ RT-CVmin, $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration True ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBA	(212.9 / 169.0) 33232	(3.70, 1.00) (0.00, N/A, 0.0)	38.7	N/A 0.0 0.0	0.3669 [0.4000]	91.7%			
PFPeA	(262.9 / 219.0) 29292 (262.9 / 69.0) 400	(5.01, 1.00) (0.00, N/A, 0.0)	185.1 11.6	0.0136 121.9 121.9	0.2148 [0.2000]	107.4%			
PFHxA	(313.0 / 269.0) 21402 (313.0 / 119.0) 1522	(6.15, 1.00) (0.00, N/A, 0.9)	65.5 16.5	0.0711 72.7 72.7	0.0985 [0.1000]	98.5%			
PFHpA	(363.0 / 319.0) 20982 (363.0 / 169.0) 6156	(7.08, 1.00) (0.00, N/A, 0.1)	90.6 69.9	0.2934 94.2 94.2	0.1029 [0.1000]	102.9%			
PFOA	(413.0 / 369.0) 24265 (413.0 / 169.0) 8577	(7.90, 1.00) (0.00, N/A, 0.2)	63.6 78.4	0.3535 108.2 108.2	0.1081 [0.1000]	108.1%			
PFNA	(463.0 / 419.0) 12946 (463.0 / 169.0) 4470	(8.62, 1.00) (-0.01, N/A, -0.3)	48.4 29.7	0.3453 179.1 179.1	0.0879 [0.1000]	87.9%			IR2,
PFDA	(513.0 / 469.0) 23366 (513.0 / 169.0) 1070	(9.32, 1.00) (0.00, N/A, 0.1)	57.7 566.2	0.0458 47.9 47.9	0.1078 [0.1000]	107.8%			IR1,
PFUnA	(563.0 / 519.0) 38565 (563.0 / 169.0) 3911	(9.71, 1.00) (0.00, N/A, 0.1)	137.9 44.4	0.1014 116.8 116.8	0.1273 [0.1000]	127.3%			
PFDoA	(613.0 / 569.0) 35780 (613.0 / 169.0) 5060	(9.89, 1.00) (0.00, N/A, -0.1)	145.7 35.8	0.1414 101.6 101.6	0.1293 [0.1000]	129.3%			
PFTrDA	(663.0 / 619.0) 31090 (663.0 / 169.0) 6638	(10.02, 1.01) (N/A, -0.01, -0.4)	110.4 53.1	0.2135 104.3 104.3	0.1296 [0.1000]	129.6%			
PFTeDA	(713.0 / 669.0) 25589 (713.0 / 169.0) 4161	(10.12, 1.00) (0.00, N/A, -0.5)	94.3 12.4	0.1626 79.9 79.9	0.1029 [0.1000]	102.9%			












Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-Imin, $\Delta$ RT-CVmin, $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration True ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBS	(298.9 / 80.0) 31824 (298.9 / 99.0) 25667	(6.11, 1.00) (0.00, N/A, -0.1)	228.6 158.1	0.8066 131.1 131.1	0.0899 [0.0885]	101.6%			
PFPeS	(349.0 / 80.0) 61392 (349.0 / 99.0) 26354	(7.15, 0.89) (N/A, -0.03, -0.1)	200.8 251.0	0.4293 120.6 120.6	0.0959 [0.0938]	102.2%			
PFHxS	(399.0 / 80.0) 54752 (399.0 / 99.0) 16706	(8.02, 1.00) (0.00, N/A, 0.2)	16908.1 6180.4	0.3051 90.8 90.8	0.0983 [0.0911]	107.9%			
PFHpS	(449.0 / 80.0) 40149 (449.0 / 99.0) 13981	(8.79, 0.93) (N/A, -0.03, 0.3)	153.7 102.5	0.3482 127.2 127.2	0.0837 [0.0951]	88.0%			
PFOS	(499.0 / 80.0) 63112 (499.0 / 99.0) 14475	(9.45, 1.00) (0.00, N/A, -0.1)	158.9 43.2	0.2294 94.3 94.3	0.1057 [0.0927]	114.0%			
PFNS	(549.0 / 80.0) 63295 (549.0 / 99.0) 15388	(9.76, 1.03) (N/A, -0.02, -0.6)	172.2 304.3	0.2431 99.6 99.6	0.0956 [0.0960]	99.6%			
PFDS	(599.0 / 80.0) 66751 (599.0 / 99.0) 15205	(9.91, 1.05) (N/A, -0.01, 0.0)	278.7 65.1	0.2278 101.2 101.2	0.0908 [0.0963]	94.3%			
PFDoS	(698.9 / 80.0) 32302 (698.9 / 99.0) 2212	(10.11, 1.07) (N/A, -0.01, -0.4)	151.2 18.9	0.0685 28.0 28.0	0.1051 [0.0970]	108.4%			IR1,
4:2FTS	(327.0 / 307.0) 73840 (327.0 / 81.0) 44310	(5.82, 1.00) (0.00, N/A, 0.1)	398.1 178.0	0.6001 121.5 121.5	0.3917 [0.3738]	104.8%			
6:2FTS	(427.0 / 407.0) 37991 (427.0 / 81.0) 30069	(7.55, 1.00) (0.00, N/A, 0.6)	171.3 166.4	0.7915 101.7 101.7	0.3927 [0.3796]	103.4%			
8:2FTS	(527.0 / 507.0) 54208 (527.0 / 81.0) 22387	(8.96, 1.00) (0.00, N/A, -0.5)	239.2 132.1	0.4130 73.0 73.0	0.5390 [0.3833]	140.6%			QC,






Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-Imin, $\Delta$ RT-CVmin, $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration True ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFOSA	(498.0 / 78.0) 58943 (498.0 / 478.0) 1534	(10.17, 1.00) (0.00, N/A, -0.2)	160.7 16.7	0.0260 124.9 124.9	0.1005 [0.1000]	100.5%			
NMeFOSA	(511.9 / 219.0) 43872 (511.9 / 169.0) 26519	(10.60, 1.00) (0.00, N/A, 0.1)	298.9 244.3	0.6045 83.9 83.9	0.4219 [0.4000]	105.5%			
NEtFOSA	(526.0 / 219.0) 44346 (526.0 / 169.0) 51516	(10.69, 1.00) (0.00, N/A, 0.0)	466.2 369.0	1.1617 109.8 109.8	0.3771 [0.4000]	94.3%			
NMeFOSAA	(570.0 / 419.0) 8400 (570.0 / 483.0) 3567	(9.51, 1.00) (0.01, N/A, 0.9)	51.6 212.6	0.4247 69.1 69.1	0.0791 [0.1000]	79.1%			
NEtFOSAA	(584.0 / 419.0) 14604 (584.0 / 526.0) 5838	(9.69, 1.00) (0.01, N/A, 0.0)	4382.3 108.5	0.3998 54.5 54.5	0.1309 [0.1000]	130.9%			QC,
NMeFOSE	(616.1 / 59.0) 9057	(10.57, 1.00) (0.00, N/A, 0.0)	71.0	N/A 0.0 0.0	0.3368 [0.4000]	84.2%			
NEtFOSE	(630.0 / 59.0) 2592	(10.67, 1.00) (0.01, N/A, 0.0)	55.9	N/A 0.0 0.0	0.5290 [0.4000]	132.3%			QC,
HFPO-DA	(285.0 / 169.0) 18333 (285.0 / 185.0) 52126	(6.50, 1.00) (0.00, N/A, 0.2)	196.1 229.6	2.8433 103.6 103.6	0.2191 [0.2000]	109.5%			
ADONA	(377.0 / 85.0) 66900 (377.0 / 251.0) 10886	(7.40, 1.14) (N/A, -0.03, 0.0)	225.5 39.2	0.1627 130.7 130.7	0.1800 [0.1885]	95.5%			
9CI-Pf3ONS	(531.0 / 351.0) 210135 (533.0 / 353.0) 57347	(9.72, 1.49) (N/A, -0.01, 0.2)	525.6 173.1	0.2729 92.2 92.2	0.1889 [0.1867]	101.2%			
11CI-PF3OUDS	(631.0 / 451.0) 110528 (633.0 / 453.0) 41123	(10.00, 1.54) (N/A, -0.01, -0.3)	422.1 246.1	0.3721 112.5 112.5	0.2127 [0.1886]	112.8%			














































Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-Imin, $\Delta$ RT-CVmin, $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration True ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
3:3FTCA	(241.0 / 177.0) 1752 (241.0 / 117.0) 3522	(4.50, 0.90) (N/A, -0.02, -0.1)	83.0 47.1	2.0106 120.1 120.1	0.3722 [0.4000]	93.0%			
5:3FTCA	(341.0 / 236.7) 13037 (341.0 / 217.0) 28648	(6.79, 1.10) (N/A, -0.03, 0.1)	86.9 98.3	2.1975 150.1 150.1	0.3394 [0.4000]	84.9%			IR2,
7:3FTCA	(441.0 / 317.0) 16935 (441.0 / 337.0) 16853	(8.60, 1.40) (N/A, -0.03, 0.2)	63.0 96.2	0.9952 118.8 118.8	0.3832 [0.4000]	95.8%			
PFEESA	(315.0 / 135.0) 48752 (315.0 / 83.0) 14590	(6.61, 1.07) (N/A, -0.03, 0.3)	297.4 57.3	0.2993 97.5 97.5	0.2049 [0.1785]	114.8%			
PFMPA	(229.0 / 85.0) 8084	(4.21, 0.84) (N/A, -0.02, 0.0)	159.7	N/A 0.0 0.0	0.2160 [0.2000]	108.0%			
PFMBA	(279.0 / 85.0) 26278	(5.40, 1.08) (N/A, -0.03, 0.0)	279.2	N/A 0.0 0.0	0.2031 [0.2000]	101.6%			
NFDHA	(295.0 / 201.0) 22691 (295.0 / 85.0) 23611	(6.04, 0.98) (N/A, -0.03, 0.3)	161.6 125.5	1.0405 117.9 117.9	0.2070 [0.2000]	103.5%			
13C3_PFBa_IIS	(216.0 / 172.0) 129665	(3.71, N/A) (N/A, -0.01, N/A)	734.9	N/A	0.9315 [1.0000]	93.2% {85.4%}			
13C2_PFHxA_IIS	(315.1 / 270.0) 201573	(6.16, N/A) (N/A, -0.03, N/A)	556.3	N/A	0.8729 [1.0000]	87.3% {86.2%}			
13C4_PFOA_IIS	(417.0 / 372.0) 188558	(7.90, N/A) (N/A, -0.03, N/A)	449.6	N/A	0.8577 [1.0000]	85.8% {79.2%}			
13C5_PFNA_IIS	(468.0 / 423.0) 150014	(8.63, N/A) (N/A, -0.04, N/A)	351.9	N/A	0.8101 [1.0000]	81.0% {74.2%}			





















Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-Imin, $\Delta$ RT-CVmin, $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration True ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDA_IIS	(515.1 / 470.1) 182339	(9.31, N/A) (N/A, -0.03, N/A)	393.6	N/A	0.9866 [1.0000]	98.7% {104.9%}			
18O2_PFHxS_IIS	(403.0 / 83.9) 376592	(8.02, N/A) (N/A, -0.03, N/A)	863.0	N/A	0.9328 [1.0000]	93.3% {89.1%}			
13C4_PFOS_IIS	(502.8 / 79.9) 319349	(9.45, N/A) (N/A, -0.03, N/A)	441.2	N/A	1.0005 [1.0000]	100.1% {97.4%}			
13C4_PFBA_EIS	(217.0 / 172.0) 1110686	(3.71, N/A) (N/A, -0.01, N/A)	922.4	N/A	8.3227 [8.0000]	104.0% {93.3%}			
13C5_PFPeA_EIS	(267.9 / 223.0) 621129	(5.01, N/A) (N/A, -0.03, N/A)	742.0	N/A	4.4287 [4.0000]	110.7% {89.2%}			
13C5_PFHxA_EIS	(318.0 / 273.0) 506172	(6.15, N/A) (N/A, -0.03, N/A)	648.4	N/A	2.1821 [2.0000]	109.1% {93.9%}			
13C4_PFHpA_EIS	(367.0 / 322.0) 447320	(7.08, N/A) (N/A, -0.03, N/A)	438.8	N/A	2.2105 [2.0000]	110.5% {91.1%}			
13C8_PFOA_EIS	(421.0 / 376.0) 456439	(7.89, N/A) (N/A, -0.03, N/A)	477.0	N/A	2.2073 [2.0000]	110.4% {91.7%}			
13C9_PFNA_EIS	(472.0 / 427.0) 171585	(8.63, N/A) (N/A, -0.04, N/A)	503.1	N/A	1.0402 [1.0000]	104.0% {78.4%}			
13C6_PFDA_EIS	(519.0 / 474.0) 227812	(9.31, N/A) (N/A, -0.03, N/A)	316.3	N/A	0.8785 [1.0000]	87.8% {81.0%}			
13C7_PFUnA_EIS	(570.0 / 525.0) 383307	(9.71, N/A) (N/A, -0.01, N/A)	510.8	N/A	1.0391 [1.0000]	103.9% {96.2%}			

















Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-Imin, $\Delta$ RT-CVmin, $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration True ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDa_EIS	(615.0 / 570.0) 321089	(9.89, N/A) (N/A, -0.01, N/A)	437.4	N/A	0.8721 [1.0000]	87.2% {82.8%}			
13C2_PFTeDA_EIS	(715.0 / 670.0) 280643	(10.12, N/A) (N/A, -0.01, N/A)	381.3	N/A	1.1478 [1.0000]	114.8% {116.0%}			
13C3_PFBs_EIS	(302.0 / 80.0) 1291973	(6.11, N/A) (N/A, -0.03, N/A)	870.8	N/A	2.0291 [2.0000]	101.5% {94.1%}			
13C3_PFHxS_EIS	(402.0 / 80.0) 716988	(8.02, N/A) (N/A, -0.03, N/A)	976.1	N/A	2.1164 [2.0000]	105.8% {95.1%}			
13C8_PFOS_EIS	(507.0 / 80.0) 1099756	(9.45, N/A) (N/A, -0.03, N/A)	492.9	N/A	2.0065 [2.0000]	100.3% {92.4%}			
13C2_4:2FTS_EIS	(329.0 / 81.0) 228032	(5.82, N/A) (N/A, -0.03, N/A)	818.1	N/A	4.2284 [4.0000]	105.7% {101.7%}			
13C2_6:2FTS_EIS	(429.0 / 81.0) 251709	(7.55, N/A) (N/A, -0.03, N/A)	625.3	N/A	3.8767 [4.0000]	96.9% {91.7%}			
13C2_8:2FTS_EIS	(529.0 / 81.0) 253898	(8.96, N/A) (N/A, -0.04, N/A)	403.4	N/A	3.9063 [4.0000]	97.7% {85.8%}			
13C8_PFOsa_EIS	(506.0 / 78.0) 1240858	(10.17, N/A) (N/A, -0.01, N/A)	815.5	N/A	1.7911 [2.0000]	89.6% {84.7%}			
D3_NMeFOSA_EIS	(515.0 / 169.0) 255122	(10.60, N/A) (N/A, -0.01, N/A)	937.9	N/A	1.6866 [2.0000]	84.3% {77.3%}			
D5_NEiFOSA_EIS	(531.1 / 169.0) 260767	(10.69, N/A) (N/A, -0.01, N/A)	1231.1	N/A	1.8675 [2.0000]	93.4% {91.6%}			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-Imin, $\Delta$ RT-CVmin, $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration True ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
D3_MeFOSAA_EIS	(573.0 / 419.0) 544985	(9.50, N/A) (N/A, -0.03, N/A)	407.2	N/A	4.1816 [4.0000]	104.5% {106.7%}			
D5_EtFOSAA_EIS	(589.0 / 419.0) 497176	(9.68, N/A) (N/A, -0.02, N/A)	540.1	N/A	4.3280 [4.0000]	108.2% {105.5%}			
D7_NMeFOSE_EIS	(623.2 / 58.9) 426059	(10.56, N/A) (N/A, -0.01, N/A)	1224.8	N/A	20.0598 [20.0000]	100.3% {98.7%}			
D9_NEtFOSE_EIS	(639.2 / 58.9) 191338	(10.66, N/A) (N/A, -0.01, N/A)	1253.8	N/A	19.7881 [20.0000]	98.9% {104.9%}			
13C3_HFPODA_EIS	(287.0 / 169.0) 1101544	(6.50, N/A) (N/A, -0.03, N/A)	840.6	N/A	8.9317 [8.0000]	111.6% {93.8%}			












Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBA	(212.9 / 169.0) 188421	(3.65, 1.00) (0.00, N/A, 0.0)	60.5	N/A 0.0 0.0	1.9028 [2.0000]	95.1%			
PFPeA	(262.9 / 219.0) 139219 (262.9 / 69.0) 1694	(4.95, 1.00) (0.00, N/A, 0.1)	388.4 40.0	0.0122 108.7 108.7	0.9614 [1.0000]	96.1%			
PFHxA	(313.0 / 269.0) 115909 (313.0 / 119.0) 10897	(6.10, 1.00) (0.00, N/A, 0.2)	310.0 98.6	0.0940 96.2 96.2	0.4941 [0.5000]	98.8%			
PFHpA	(363.0 / 319.0) 110782 (363.0 / 169.0) 29592	(7.03, 1.00) (0.00, N/A, 0.0)	210.6 163.1	0.2671 85.8 85.8	0.5195 [0.5000]	103.9%			
PFOA	(413.0 / 369.0) 131268 (413.0 / 169.0) 45112	(7.85, 1.00) (0.00, N/A, 0.2)	272.1 247.3	0.3437 105.2 105.2	0.5483 [0.5000]	109.7%			
PFNA	(463.0 / 419.0) 93190 (463.0 / 169.0) 19066	(8.59, 1.00) (0.00, N/A, -0.1)	270.2 71.5	0.2046 106.2 106.2	0.4982 [0.5000]	99.6%			
PFDA	(513.0 / 469.0) 116985 (513.0 / 169.0) 7443	(9.27, 1.00) (0.01, N/A, 0.2)	179.0 455.7	0.0636 66.6 66.6	0.4923 [0.5000]	98.5%			
PFUnA	(563.0 / 519.0) 112638 (563.0 / 169.0) 16433	(9.70, 1.00) (0.00, N/A, -0.2)	261.9 192.3	0.1459 168.0 168.0	0.3772 [0.5000]	75.4%			IR2,
PFDoA	(613.0 / 569.0) 170817 (613.0 / 169.0) 22966	(9.88, 1.00) (0.00, N/A, -0.1)	386.2 148.3	0.1344 96.6 96.6	0.5314 [0.5000]	106.3%			
PFTrDA	(663.0 / 619.0) 139394 (663.0 / 169.0) 23330	(10.00, 1.01) (N/A, -0.02, -0.6)	293.8 128.9	0.1674 81.8 81.8	0.5005 [0.5000]	100.1%			
PFTeDA	(713.0 / 669.0) 107548 (713.0 / 169.0) 13556	(10.12, 1.00) (0.00, N/A, 0.0)	266.4 52.5	0.1260 62.0 62.0	0.5082 [0.5000]	101.6%			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBS	(298.9 / 80.0) 169308 (298.9 / 99.0) 116887	(6.06, 1.00) (0.00, N/A, 0.1)	532.3 438.0	0.6904 112.2 112.2	0.4218 [0.4424]	95.4%			
PFPeS	(349.0 / 80.0) 303756 (349.0 / 99.0) 113877	(7.10, 0.89) (N/A, -0.08, 0.0)	643.5 533.0	0.3749 105.3 105.3	0.4401 [0.4692]	93.8%			
PFHxS	(399.0 / 80.0) 254653 (399.0 / 99.0) 87687	(7.97, 1.00) (0.00, N/A, 0.0)	2864.9 16565.2	0.3443 102.4 102.4	0.4242 [0.4555]	93.1%			
PFHpS	(449.0 / 80.0) 232130 (449.0 / 99.0) 63281	(8.74, 0.93) (N/A, -0.07, 0.2)	720.8 355.5	0.2726 99.6 99.6	0.4831 [0.4757]	101.5%			
PFOS	(499.0 / 80.0) 271232 (499.0 / 99.0) 55582	(9.42, 1.00) (0.00, N/A, 0.2)	71.7 84.7	0.2049 84.3 84.3	0.4537 [0.4637]	97.8%			
PFNS	(549.0 / 80.0) 326430 (549.0 / 99.0) 76899	(9.75, 1.03) (N/A, -0.03, 0.0)	700.8 332.3	0.2356 96.5 96.5	0.4923 [0.4799]	102.6%			
PFDS	(599.0 / 80.0) 361311 (599.0 / 99.0) 88020	(9.90, 1.05) (N/A, -0.02, 0.0)	528.4 257.7	0.2436 108.2 108.2	0.4908 [0.4816]	101.9%			
PFDoS	(698.9 / 80.0) 143379 (698.9 / 99.0) 39342	(10.10, 1.07) (N/A, -0.01, 0.0)	394.0 390.0	0.2744 112.1 112.1	0.4660 [0.4848]	96.1%			
4:2FTS	(327.0 / 307.0) 369834 (327.0 / 81.0) 206873	(5.77, 1.00) (0.00, N/A, -0.2)	740.7 453.5	0.5594 113.2 113.2	1.8624 [1.8691]	99.6%			
6:2FTS	(427.0 / 407.0) 212400 (427.0 / 81.0) 133719	(7.50, 1.00) (0.00, N/A, 0.2)	557.0 426.3	0.6296 80.9 80.9	1.8471 [1.8981]	97.3%			
8:2FTS	(527.0 / 507.0) 187570 (527.0 / 81.0) 119060	(8.92, 1.00) (0.00, N/A, -0.3)	288.9 320.4	0.6348 112.1 112.1	1.8629 [1.9166]	97.2%			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFOSA	(498.0 / 78.0) 352198 (498.0 / 478.0) 8651	(10.16, 1.00) (0.00, N/A, 0.4)	513.9 157.2	0.0246 117.8 117.8	0.4906 [0.5000]	98.1%			
NMeFOSA	(511.9 / 219.0) 263260 (511.9 / 169.0) 153613	(10.60, 1.00) (0.00, N/A, 0.0)	638.7 672.6	0.5835 81.0 81.0	2.2704 [2.0000]	113.5%			
NEiFOSA	(526.0 / 219.0) 251838 (526.0 / 169.0) 278757	(10.68, 1.00) (0.00, N/A, 0.0)	1012.6 877.2	1.1069 104.7 104.7	1.9774 [2.0000]	98.9%			
NMeFOSAA	(570.0 / 419.0) 51544 (570.0 / 483.0) 33073	(9.48, 1.00) (0.00, N/A, -0.3)	116.9 95.9	0.6416 104.4 104.4	0.5096 [0.5000]	101.9%			
NEiFOSAA	(584.0 / 419.0) 57365 (584.0 / 526.0) 31030	(9.66, 1.00) (0.00, N/A, -0.4)	562.4 124.4	0.5409 73.8 73.8	0.5544 [0.5000]	110.9%			
NMeFOSE	(616.1 / 59.0) 54315	(10.56, 1.00) (0.00, N/A, 0.0)	454.0	N/A 0.0 0.0	1.8098 [2.0000]	90.5%			
NEiFOSE	(630.0 / 59.0) 10545	(10.66, 1.00) (0.01, N/A, 0.0)	298.7	N/A 0.0 0.0	1.8678 [2.0000]	93.4%			
HFPO-DA	(285.0 / 169.0) 90628 (285.0 / 185.0) 244184	(6.45, 1.00) (0.00, N/A, 0.3)	355.2 511.8	2.6944 98.2 98.2	1.0286 [1.0000]	102.9%			
ADONA	(377.0 / 85.0) 360241 (377.0 / 251.0) 45845	(7.35, 1.14) (N/A, -0.08, 0.0)	653.3 198.6	0.1273 102.2 102.2	0.9205 [0.9427]	97.6%			
9CI-Pf3ONS	(531.0 / 351.0) 951547 (533.0 / 353.0) 308143	(9.70, 1.50) (N/A, -0.03, 0.0)	461.5 485.9	0.3238 109.4 109.4	0.8553 [0.9333]	91.7%			
11CI-PF3OUDS	(631.0 / 451.0) 560809 (633.0 / 453.0) 162858	(9.99, 1.55) (N/A, -0.02, 0.0)	818.9 500.2	0.2904 87.8 87.8	1.0253 [0.9432]	108.7%			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
3:3FTCA	(241.0 / 177.0) 8941 (241.0 / 117.0) 17863	(4.43, 0.89) (N/A, -0.08, -0.1)	270.0 173.3	1.9979 119.4 119.4	1.7890 [2.0000]	89.5%			
5:3FTCA	(341.0 / 236.7) 83112 (341.0 / 217.0) 121575	(6.74, 1.10) (N/A, -0.08, 0.0)	282.1 320.5	1.4628 99.9 99.9	2.0050 [2.0000]	100.2%			
7:3FTCA	(441.0 / 317.0) 94595 (441.0 / 337.0) 73967	(8.56, 1.40) (N/A, -0.07, 0.0)	212.2 275.3	0.7819 93.4 93.4	1.9833 [2.0000]	99.2%			
PFEESA	(315.0 / 135.0) 227230 (315.0 / 83.0) 64514	(6.56, 1.07) (N/A, -0.08, 0.1)	666.6 216.3	0.2839 92.5 92.5	0.8847 [0.8925]	99.1%			
PFMPA	(229.0 / 85.0) 38716	(4.15, 0.84) (N/A, -0.08, 0.0)	651.7	N/A 0.0 0.0	0.9742 [1.0000]	97.4%			
PFMBA	(279.0 / 85.0) 138545	(5.34, 1.08) (N/A, -0.09, 0.0)	716.8	N/A 0.0 0.0	1.0085 [1.0000]	100.9%			
NFDHA	(295.0 / 201.0) 109976 (295.0 / 85.0) 101086	(5.98, 0.98) (N/A, -0.08, 0.0)	530.5 312.3	0.9192 104.1 104.1	0.9297 [1.0000]	93.0%			
13C3_PFBA_IIS	(216.0 / 172.0) 145032	(3.65, N/A) (N/A, -0.07, N/A)	748.9	N/A	1.0419 [1.0000]	104.2% {95.6%}			
13C2_PFHxA_IIS	(315.1 / 270.0) 249645	(6.11, N/A) (N/A, -0.08, N/A)	617.2	N/A	1.0811 [1.0000]	108.1% {106.7%}			
13C4_PFOA_IIS	(417.0 / 372.0) 223206	(7.85, N/A) (N/A, -0.08, N/A)	653.2	N/A	1.0153 [1.0000]	101.5% {93.8%}			
13C5_PFNA_IIS	(468.0 / 423.0) 192740	(8.59, N/A) (N/A, -0.08, N/A)	339.0	N/A	1.0408 [1.0000]	104.1% {95.3%}			



Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDA_IIS	(515.1 / 470.1) 201200	(9.28, N/A) (N/A, -0.07, N/A)	450.6	N/A	1.0887 [ 1.0000 ]	108.9% { 115.7% }			
18O2_PFHxS_IIS	(403.0 / 83.9) 391808	(7.98, N/A) (N/A, -0.07, N/A)	810.8	N/A	0.9705 [ 1.0000 ]	97.1% { 92.7% }			
13C4_PFOS_IIS	(502.8 / 79.9) 350992	(9.42, N/A) (N/A, -0.06, N/A)	464.9	N/A	1.0997 [ 1.0000 ]	110.0% { 107.1% }			
13C4_PFBA_EIS	(217.0 / 172.0) 1214259	(3.65, N/A) (N/A, -0.07, N/A)	905.9	N/A	8.1347 [ 8.0000 ]	101.7% { 102.0% }			
13C5_PFPeA_EIS	(267.9 / 223.0) 659529	(4.95, N/A) (N/A, -0.08, N/A)	789.0	N/A	3.7969 [ 4.0000 ]	94.9% { 94.8% }			
13C5_PFHxA_EIS	(318.0 / 273.0) 546323	(6.10, N/A) (N/A, -0.08, N/A)	742.9	N/A	1.9017 [ 2.0000 ]	95.1% { 101.4% }			
13C4_PFHpA_EIS	(367.0 / 322.0) 467878	(7.03, N/A) (N/A, -0.08, N/A)	943.4	N/A	1.8669 [ 2.0000 ]	93.3% { 95.3% }			
13C8_PFOA_EIS	(421.0 / 376.0) 486948	(7.85, N/A) (N/A, -0.08, N/A)	788.4	N/A	1.9893 [ 2.0000 ]	99.5% { 97.9% }			
13C9_PFNA_EIS	(472.0 / 427.0) 217999	(8.59, N/A) (N/A, -0.08, N/A)	418.4	N/A	1.0286 [ 1.0000 ]	102.9% { 99.7% }			
13C6_PFDA_EIS	(519.0 / 474.0) 249666	(9.26, N/A) (N/A, -0.08, N/A)	346.2	N/A	0.8725 [ 1.0000 ]	87.2% { 88.8% }			
13C7_PFUnA_EIS	(570.0 / 525.0) 377869	(9.70, N/A) (N/A, -0.03, N/A)	445.6	N/A	0.9284 [ 1.0000 ]	92.8% { 94.9% }			



Chemist: ABK  
 Instrument: Saphira  
 Type: Sciex Q3 5500

Sample I.D.: SB03941-CAL2  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - S2022-12-21A  
 Path: S2022-12-21A (2)  
 Acquired: 2022/12/21 - 14:39

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDa_EIS	(615.0 / 570.0) 372869	(9.89, N/A) (N/A, -0.02, N/A)	424.9	N/A	0.9178 [ 1.0000 ]	91.8% { 96.2% }			
13C2_PFTeDA_EIS	(715.0 / 670.0) 238784	(10.12, N/A) (N/A, -0.01, N/A)	386.9	N/A	0.8850 [ 1.0000 ]	88.5% { 98.7% }			
13C3_PFBs_EIS	(302.0 / 80.0) 1464188	(6.06, N/A) (N/A, -0.08, N/A)	862.0	N/A	2.2103 [ 2.0000 ]	110.5% { 106.6% }			
13C3_PFHxS_EIS	(402.0 / 80.0) 772747	(7.97, N/A) (N/A, -0.08, N/A)	946.5	N/A	2.1924 [ 2.0000 ]	109.6% { 102.5% }			
13C8_PFOS_EIS	(507.0 / 80.0) 1101471	(9.42, N/A) (N/A, -0.06, N/A)	400.8	N/A	1.8285 [ 2.0000 ]	91.4% { 92.5% }			
13C2_4:2FTS_EIS	(329.0 / 81.0) 240226	(5.77, N/A) (N/A, -0.08, N/A)	728.1	N/A	4.2815 [ 4.0000 ]	107.0% { 107.2% }			
13C2_6:2FTS_EIS	(429.0 / 81.0) 299151	(7.50, N/A) (N/A, -0.08, N/A)	829.8	N/A	4.4285 [ 4.0000 ]	110.7% { 109.0% }			
13C2_8:2FTS_EIS	(529.0 / 81.0) 254209	(8.93, N/A) (N/A, -0.07, N/A)	387.1	N/A	3.7592 [ 4.0000 ]	94.0% { 85.9% }			
13C8_PFOsa_EIS	(506.0 / 78.0) 1519271	(10.16, N/A) (N/A, -0.02, N/A)	650.9	N/A	1.9952 [ 2.0000 ]	99.8% { 103.7% }			
D3_NMeFOSA_EIS	(515.0 / 169.0) 284500	(10.59, N/A) (N/A, -0.02, N/A)	1128.4	N/A	1.7113 [ 2.0000 ]	85.6% { 86.2% }			
D5_NEtFOSA_EIS	(531.1 / 169.0) 282389	(10.68, N/A) (N/A, -0.01, N/A)	1021.0	N/A	1.8400 [ 2.0000 ]	92.0% { 99.2% }			














































Chemist: ABK  
 Instrument: Saphira  
 Type: Sciex Q3 5500





















Sample I.D.: SB03941-CAL2  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

















Quant Method: 1633 - S2022-12-21A  
 Path: S2022-12-21A (2)  
 Acquired: 2022/12/21 - 14:39












Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT- CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
D3_MeFOSAA_EIS	(573.0 / 419.0) 519161	(9.47, N/A) (N/A, -0.06, N/A)	335.3	N/A	3.6243 [ 4.0000 ]	90.6% { 101.7% }			
D5_EtFOSAA_EIS	(589.0 / 419.0) 461032	(9.66, N/A) (N/A, -0.03, N/A)	492.8	N/A	3.6515 [ 4.0000 ]	91.3% { 97.8% }			
D7_NMeFOSE_EIS	(623.2 / 58.9) 475546	(10.56, N/A) (N/A, -0.02, N/A)	945.0	N/A	20.3712 [ 20.0000 ]	101.9% { 110.2% }			
D9_NEtFOSE_EIS	(639.2 / 58.9) 220531	(10.65, N/A) (N/A, -0.02, N/A)	1126.5	N/A	20.7511 [ 20.0000 ]	103.8% { 120.9% }			
13C3_HFPODA_EIS	(287.0 / 169.0) 1159691	(6.45, N/A) (N/A, -0.08, N/A)	900.5	N/A	7.5925 [ 8.0000 ]	94.9% { 98.7% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBA	(212.9 / 169.0) 364131	(3.65, 1.00) (0.00, N/A, 0.0)	70.2	N/A 0.0 0.0	3.8803 [4.0000]	97.0%			
PFPeA	(262.9 / 219.0) 278554 (262.9 / 69.0) 3213	(4.96, 1.00) (0.00, N/A, -0.1)	617.6 57.0	0.0115 103.0 103.0	1.9980 [2.0000]	99.9%			
PFHxA	(313.0 / 269.0) 230736 (313.0 / 119.0) 17813	(6.11, 1.00) (0.00, N/A, 0.3)	411.0 127.8	0.0772 79.0 79.0	1.0595 [1.0000]	106.0%			
PFHpA	(363.0 / 319.0) 200810 (363.0 / 169.0) 53734	(7.04, 1.00) (0.00, N/A, 0.1)	368.9 203.8	0.2676 85.9 85.9	0.9983 [1.0000]	99.8%			
PFOA	(413.0 / 369.0) 205143 (413.0 / 169.0) 72948	(7.86, 1.00) (0.00, N/A, 0.0)	303.6 404.0	0.3556 108.8 108.8	0.9507 [1.0000]	95.1%			
PFNA	(463.0 / 419.0) 167406 (463.0 / 169.0) 35020	(8.60, 1.00) (0.00, N/A, 0.2)	279.7 86.6	0.2092 108.5 108.5	1.0679 [1.0000]	106.8%			
PFDA	(513.0 / 469.0) 260310 (513.0 / 169.0) 19191	(9.28, 1.00) (0.00, N/A, -0.3)	246.9 388.3	0.0737 77.1 77.1	0.9614 [1.0000]	96.1%			
PFUnA	(563.0 / 519.0) 242766 (563.0 / 169.0) 29112	(9.71, 1.00) (0.00, N/A, 0.0)	470.3 179.8	0.1199 138.1 138.1	0.8605 [1.0000]	86.1%			
PFDoA	(613.0 / 569.0) 276870 (613.0 / 169.0) 37204	(9.89, 1.00) (0.00, N/A, 0.1)	510.1 202.8	0.1344 96.5 96.5	0.8423 [1.0000]	84.2%			
PFTrDA	(663.0 / 619.0) 272310 (663.0 / 169.0) 51052	(10.01, 1.01) (N/A, -0.01, 0.2)	518.4 210.4	0.1875 91.6 91.6	0.9561 [1.0000]	95.6%			
PFTeDA	(713.0 / 669.0) 202539 (713.0 / 169.0) 35837	(10.12, 1.00) (0.00, N/A, -0.1)	464.6 111.3	0.1769 87.0 87.0	0.9914 [1.0000]	99.1%			












Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBS	(298.9 / 80.0) 319512 (298.9 / 99.0) 214428	(6.06, 1.00) (0.00, N/A, 0.1)	552.7 573.6	0.6711 109.0 109.0	0.8374 [0.8847]	94.7%			
PFPeS	(349.0 / 80.0) 558156 (349.0 / 99.0) 204172	(7.11, 0.89) (N/A, -0.07, -0.2)	726.6 707.2	0.3658 102.8 102.8	0.9319 [0.9384]	99.3%			
PFHxS	(399.0 / 80.0) 460645 (399.0 / 99.0) 168480	(7.99, 1.00) (0.00, N/A, 0.2)	4071.9 6022.7	0.3657 108.8 108.8	0.8844 [0.9110]	97.1%			
PFHpS	(449.0 / 80.0) 399999 (449.0 / 99.0) 119983	(8.76, 0.93) (N/A, -0.06, -0.2)	473.2 390.9	0.3000 109.6 109.6	0.8477 [0.9514]	89.1%			
PFOS	(499.0 / 80.0) 510216 (499.0 / 99.0) 119134	(9.43, 1.00) (0.00, N/A, 0.3)	371.9 120.6	0.2335 96.0 96.0	0.8692 [0.9275]	93.7%			
PFNS	(549.0 / 80.0) 600745 (549.0 / 99.0) 129442	(9.75, 1.03) (N/A, -0.02, 0.2)	640.1 539.0	0.2155 88.3 88.3	0.9226 [0.9599]	96.1%			
PFDS	(599.0 / 80.0) 650063 (599.0 / 99.0) 165992	(9.90, 1.05) (N/A, -0.02, -0.4)	597.2 555.1	0.2553 113.4 113.4	0.8993 [0.9631]	93.4%			
PFDoS	(698.9 / 80.0) 310556 (698.9 / 99.0) 62440	(10.10, 1.07) (N/A, -0.01, 0.2)	612.5 270.2	0.2011 82.2 82.2	1.0279 [0.9696]	106.0%			
4:2FTS	(327.0 / 307.0) 734838 (327.0 / 81.0) 391330	(5.78, 1.00) (0.00, N/A, 0.0)	955.1 537.9	0.5325 107.8 107.8	3.8805 [3.7381]	103.8%			
6:2FTS	(427.0 / 407.0) 417365 (427.0 / 81.0) 267446	(7.52, 1.00) (0.00, N/A, -0.3)	653.9 548.6	0.6408 82.3 82.3	3.6814 [3.7962]	97.0%			
8:2FTS	(527.0 / 507.0) 398366 (527.0 / 81.0) 261360	(8.94, 1.00) (0.00, N/A, -0.3)	438.4 397.1	0.6561 115.9 115.9	3.3122 [3.8332]	86.4%			






Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFOSA	(498.0 / 78.0) 634394 (498.0 / 478.0) 14236	(10.16, 1.00) (0.00, N/A, 0.3)	672.1 142.6	0.0224 107.7 107.7	1.0186 [1.0000]	101.9%			
NMeFOSA	(511.9 / 219.0) 481844 (511.9 / 169.0) 311400	(10.60, 1.00) (0.00, N/A, 0.1)	1243.8 1242.2	0.6463 89.7 89.7	3.9784 [4.0000]	99.5%			
NEiFOSA	(526.0 / 219.0) 509457 (526.0 / 169.0) 556544	(10.69, 1.00) (0.00, N/A, 0.0)	1029.5 1040.4	1.0924 103.3 103.3	3.8752 [4.0000]	96.9%			
NMeFOSAA	(570.0 / 419.0) 98460 (570.0 / 483.0) 45291	(9.48, 1.00) (0.00, N/A, -0.2)	201.1 368.1	0.4600 74.8 74.8	0.9589 [1.0000]	95.9%			
NEiFOSAA	(584.0 / 419.0) 100078 (584.0 / 526.0) 64349	(9.67, 1.00) (0.00, N/A, 0.1)	308.0 11085.9	0.6430 87.7 87.7	0.9729 [1.0000]	97.3%			
NMeFOSE	(616.1 / 59.0) 109477	(10.57, 1.00) (0.00, N/A, 0.0)	635.3	N/A 0.0 0.0	4.0466 [4.0000]	101.2%			
NEiFOSE	(630.0 / 59.0) 18470	(10.67, 1.00) (0.01, N/A, 0.0)	332.3	N/A 0.0 0.0	3.6420 [4.0000]	91.1%			
HFPO-DA	(285.0 / 169.0) 157217 (285.0 / 185.0) 447290	(6.45, 1.00) (0.00, N/A, 0.0)	473.3 607.4	2.8450 103.7 103.7	1.8500 [2.0000]	92.5%			
ADONA	(377.0 / 85.0) 712997 (377.0 / 251.0) 91158	(7.36, 1.14) (N/A, -0.07, 0.0)	873.4 270.7	0.1279 102.7 102.7	1.8890 [1.8854]	100.2%			
9CI-Pf3ONS	(531.0 / 351.0) 2025171 (533.0 / 353.0) 608975	(9.71, 1.50) (N/A, -0.03, 0.1)	727.3 554.2	0.3007 101.6 101.6	1.9101 [1.8665]	102.3%			
11CI-PF3OUDS	(631.0 / 451.0) 945192 (633.0 / 453.0) 304735	(10.00, 1.55) (N/A, -0.01, -0.1)	1065.3 837.5	0.3224 97.5 97.5	1.7916 [1.8864]	95.0%			






















Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
3:3FTCA	(241.0 / 177.0) 19424 (241.0 / 117.0) 28656	(4.43, 0.89) (N/A, -0.08, 0.0)	383.0 238.7	1.4753 88.2 88.2	4.0370 [4.0000]	100.9%			
5:3FTCA	(341.0 / 236.7) 163618 (341.0 / 217.0) 258573	(6.74, 1.10) (N/A, -0.08, -0.1)	567.6 530.2	1.5803 108.0 108.0	4.2520 [4.0000]	106.3%			
7:3FTCA	(441.0 / 317.0) 173439 (441.0 / 337.0) 148204	(8.57, 1.40) (N/A, -0.06, 0.2)	277.8 265.5	0.8545 102.0 102.0	3.9172 [4.0000]	97.9%			
PFEESA	(315.0 / 135.0) 425676 (315.0 / 83.0) 120482	(6.57, 1.08) (N/A, -0.07, 0.1)	558.7 464.3	0.2830 92.2 92.2	1.7854 [1.7849]	100.0%			
PFMPA	(229.0 / 85.0) 73196	(4.15, 0.84) (N/A, -0.08, 0.0)	797.4	N/A 0.0 0.0	1.9130 [2.0000]	95.6%			
PFMBA	(279.0 / 85.0) 259517	(5.34, 1.08) (N/A, -0.08, 0.0)	721.2	N/A 0.0 0.0	1.9622 [2.0000]	98.1%			
NFDHA	(295.0 / 201.0) 219791 (295.0 / 85.0) 199407	(5.99, 0.98) (N/A, -0.08, -0.1)	614.7 459.5	0.9073 102.8 102.8	2.0016 [2.0000]	100.1%			
13C3_PFBA_IIS	(216.0 / 172.0) 133715	(3.65, N/A) (N/A, -0.07, N/A)	699.9	N/A	0.9606 [1.0000]	96.1% {88.1%}			
13C2_PFHxA_IIS	(315.1 / 270.0) 210807	(6.11, N/A) (N/A, -0.08, N/A)	520.8	N/A	0.9129 [1.0000]	91.3% {90.1%}			
13C4_PFOA_IIS	(417.0 / 372.0) 203834	(7.86, N/A) (N/A, -0.07, N/A)	799.6	N/A	0.9272 [1.0000]	92.7% {85.6%}			
13C5_PFNA_IIS	(468.0 / 423.0) 176714	(8.60, N/A) (N/A, -0.07, N/A)	380.6	N/A	0.9543 [1.0000]	95.4% {87.4%}			























Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDA_IIS	(515.1 / 470.1) 164172	(9.29, N/A) (N/A, -0.05, N/A)	395.8	N/A	0.8883 [ 1.0000 ]	88.8% { 94.4% }			
18O2_PFHxS_IIS	(403.0 / 83.9) 382941	(7.99, N/A) (N/A, -0.06, N/A)	781.0	N/A	0.9486 [ 1.0000 ]	94.9% { 90.6% }			
13C4_PFOS_IIS	(502.8 / 79.9) 302129	(9.43, N/A) (N/A, -0.05, N/A)	425.5	N/A	0.9466 [ 1.0000 ]	94.7% { 92.2% }			
13C4_PFBA_EIS	(217.0 / 172.0) 1150744	(3.65, N/A) (N/A, -0.07, N/A)	926.2	N/A	8.3617 [ 8.0000 ]	104.5% { 96.7% }			
13C5_PFPeA_EIS	(267.9 / 223.0) 634958	(4.96, N/A) (N/A, -0.08, N/A)	725.6	N/A	4.3289 [ 4.0000 ]	108.2% { 91.2% }			
13C5_PFHxA_EIS	(318.0 / 273.0) 507144	(6.11, N/A) (N/A, -0.08, N/A)	760.2	N/A	2.0905 [ 2.0000 ]	104.5% { 94.1% }			
13C4_PFHpA_EIS	(367.0 / 322.0) 441364	(7.04, N/A) (N/A, -0.07, N/A)	592.1	N/A	2.0856 [ 2.0000 ]	104.3% { 89.9% }			
13C8_PFOA_EIS	(421.0 / 376.0) 438874	(7.86, N/A) (N/A, -0.06, N/A)	718.6	N/A	1.9633 [ 2.0000 ]	98.2% { 88.2% }			
13C9_PFNA_EIS	(472.0 / 427.0) 182699	(8.60, N/A) (N/A, -0.07, N/A)	305.7	N/A	0.9402 [ 1.0000 ]	94.0% { 83.5% }			
13C6_PFDA_EIS	(519.0 / 474.0) 284465	(9.29, N/A) (N/A, -0.06, N/A)	596.1	N/A	1.2183 [ 1.0000 ]	121.8% { 101.1% }			
13C7_PFUnA_EIS	(570.0 / 525.0) 356973	(9.71, N/A) (N/A, -0.02, N/A)	765.7	N/A	1.0748 [ 1.0000 ]	107.5% { 89.6% }			







































Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDa_EIS	(615.0 / 570.0) 381316	(9.89, N/A) (N/A, -0.02, N/A)	333.2	N/A	1.1503 [ 1.0000 ]	115.0% { 98.4% }			
13C2_PFTeDA_EIS	(715.0 / 670.0) 230518	(10.12, N/A) (N/A, -0.02, N/A)	370.4	N/A	1.0471 [ 1.0000 ]	104.7% { 95.3% }			
13C3_PFBs_EIS	(302.0 / 80.0) 1391867	(6.06, N/A) (N/A, -0.08, N/A)	799.8	N/A	2.1497 [ 2.0000 ]	107.5% { 101.3% }			
13C3_PFHxS_EIS	(402.0 / 80.0) 670509	(7.98, N/A) (N/A, -0.07, N/A)	1003.2	N/A	1.9464 [ 2.0000 ]	97.3% { 88.9% }			
13C8_PFOS_EIS	(507.0 / 80.0) 1081560	(9.43, N/A) (N/A, -0.05, N/A)	480.5	N/A	2.0858 [ 2.0000 ]	104.3% { 90.9% }			
13C2_4:2FTS_EIS	(329.0 / 81.0) 229082	(5.78, N/A) (N/A, -0.08, N/A)	619.0	N/A	4.1774 [ 4.0000 ]	104.4% { 102.2% }			
13C2_6:2FTS_EIS	(429.0 / 81.0) 294946	(7.52, N/A) (N/A, -0.06, N/A)	799.8	N/A	4.4673 [ 4.0000 ]	111.7% { 107.5% }			
13C2_8:2FTS_EIS	(529.0 / 81.0) 303660	(8.94, N/A) (N/A, -0.06, N/A)	479.0	N/A	4.5945 [ 4.0000 ]	114.9% { 102.6% }			
13C8_PFOsa_EIS	(506.0 / 78.0) 1318009	(10.16, N/A) (N/A, -0.02, N/A)	652.5	N/A	2.0109 [ 2.0000 ]	100.5% { 89.9% }			
D3_NMeFOSA_EIS	(515.0 / 169.0) 297155	(10.60, N/A) (N/A, -0.01, N/A)	855.7	N/A	2.0764 [ 2.0000 ]	103.8% { 90.0% }			
D5_NeIFOSA_EIS	(531.1 / 169.0) 291494	(10.69, N/A) (N/A, -0.01, N/A)	862.4	N/A	2.2065 [ 2.0000 ]	110.3% { 102.4% }			












Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT- CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
D3_MeFOSAA_EIS	(573.0 / 419.0) 527024	(9.48, N/A) (N/A, -0.05, N/A)	346.8	N/A	4.2742 [ 4.0000 ]	106.9% { 103.2% }			
D5_EtFOSAA_EIS	(589.0 / 419.0) 458315	(9.67, N/A) (N/A, -0.02, N/A)	278.5	N/A	4.2171 [ 4.0000 ]	105.4% { 97.2% }			
D7_NMeFOSE_EIS	(623.2 / 58.9) 428676	(10.56, N/A) (N/A, -0.01, N/A)	1166.0	N/A	21.3333 [ 20.0000 ]	106.7% { 99.3% }			
D9_NEtFOSE_EIS	(639.2 / 58.9) 198093	(10.66, N/A) (N/A, -0.01, N/A)	1164.8	N/A	21.6544 [ 20.0000 ]	108.3% { 108.6% }			
13C3_HFPODA_EIS	(287.0 / 169.0) 1118507	(6.45, N/A) (N/A, -0.07, N/A)	638.3	N/A	8.6720 [ 8.0000 ]	108.4% { 95.2% }			












Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBA	(212.9 / 169.0) 819896	(3.67, 1.00) (0.00, N/A, 0.0)	63.2	N/A 0.0 0.0	8.3322 [ 8.0000 ]	104.2%			
PFPeA	(262.9 / 219.0) 603288 (262.9 / 69.0) 6873	(4.99, 1.00) (0.00, N/A, 0.1)	714.5 139.6	0.0114 101.8 101.8	4.1560 [ 4.0000 ]	103.9%			
PFHxA	(313.0 / 269.0) 494481 (313.0 / 119.0) 48652	(6.14, 1.00) (0.00, N/A, -0.1)	480.7 302.7	0.0984 100.6 100.6	1.9728 [ 2.0000 ]	98.6%			
PFHpA	(363.0 / 319.0) 430799 (363.0 / 169.0) 129319	(7.07, 1.00) (0.00, N/A, -0.1)	617.2 361.9	0.3002 96.4 96.4	1.9616 [ 2.0000 ]	98.1%			
PFOA	(413.0 / 369.0) 498516 (413.0 / 169.0) 142531	(7.89, 1.00) (0.00, N/A, 0.1)	597.7 530.3	0.2859 87.5 87.5	1.9165 [ 2.0000 ]	95.8%			
PFNA	(463.0 / 419.0) 393754 (463.0 / 169.0) 83708	(8.63, 1.00) (0.00, N/A, 0.1)	416.4 106.0	0.2126 110.3 110.3	2.1745 [ 2.0000 ]	108.7%			
PFDA	(513.0 / 469.0) 564787 (513.0 / 169.0) 47750	(9.31, 1.00) (0.01, N/A, 0.1)	378.6 169.7	0.0845 88.5 88.5	2.2443 [ 2.0000 ]	112.2%			
PFUnA	(563.0 / 519.0) 658503 (563.0 / 169.0) 61653	(9.72, 1.00) (0.00, N/A, 0.4)	479.7 518.5	0.0936 107.8 107.8	2.0992 [ 2.0000 ]	105.0%			
PFDoA	(613.0 / 569.0) 675921 (613.0 / 169.0) 81123	(9.89, 1.00) (0.00, N/A, 0.2)	691.3 232.1	0.1200 86.2 86.2	1.9103 [ 2.0000 ]	95.5%			
PFTrDA	(663.0 / 619.0) 588988 (663.0 / 169.0) 110050	(10.02, 1.01) (N/A, 0.00, 0.1)	577.9 302.6	0.1868 91.3 91.3	1.9213 [ 2.0000 ]	96.1%			
PFTeDA	(713.0 / 669.0) 446345 (713.0 / 169.0) 83837	(10.13, 1.00) (0.00, N/A, 0.2)	486.0 629.5	0.1878 92.4 92.4	2.0034 [ 2.0000 ]	100.2%			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBS	(298.9 / 80.0) 711903 (298.9 / 99.0) 484739	(6.09, 1.00) (0.00, N/A, 0.1)	731.9 757.9	0.6809 110.6 110.6	1.7756 [ 1.7695 ]	100.3%			
PFPeS	(349.0 / 80.0) 1288227 (349.0 / 99.0) 474774	(7.14, 0.89) (N/A, -0.04, 0.1)	707.6 705.0	0.3685 103.5 103.5	2.0076 [ 1.8768 ]	107.0%			
PFHxS	(399.0 / 80.0) 1027828 (399.0 / 99.0) 345011	(8.01, 1.00) (0.00, N/A, 0.0)	4264.5 49182.2	0.3357 99.9 99.9	1.8419 [ 1.8220 ]	101.1%			
PFHpS	(449.0 / 80.0) 977429 (449.0 / 99.0) 288763	(8.78, 0.93) (N/A, -0.04, 0.1)	730.0 481.1	0.2954 107.9 107.9	1.9191 [ 1.9028 ]	100.9%			
PFOS	(499.0 / 80.0) 1204037 (499.0 / 99.0) 223557	(9.45, 1.00) (0.00, N/A, 0.0)	87.9 105.3	0.1857 76.3 76.3	1.9004 [ 1.8550 ]	102.4%			
PFNS	(549.0 / 80.0) 1450440 (549.0 / 99.0) 305867	(9.76, 1.03) (N/A, -0.01, 0.0)	792.8 564.7	0.2109 86.4 86.4	2.0637 [ 1.9198 ]	107.5%			
PFDS	(599.0 / 80.0) 1519940 (599.0 / 99.0) 390353	(9.91, 1.05) (N/A, -0.01, -0.1)	861.1 462.0	0.2568 114.1 114.1	1.9480 [ 1.9262 ]	101.1%			
PFDoS	(698.9 / 80.0) 616036 (698.9 / 99.0) 122817	(10.11, 1.07) (N/A, -0.01, 0.2)	806.8 368.4	0.1994 81.5 81.5	1.8891 [ 1.9391 ]	97.4%			
4:2FTS	(327.0 / 307.0) 1460214 (327.0 / 81.0) 931969	(5.81, 1.00) (0.00, N/A, 0.3)	781.6 741.8	0.6382 129.2 129.2	7.3058 [ 7.4762 ]	97.7%			
6:2FTS	(427.0 / 407.0) 816068 (427.0 / 81.0) 629698	(7.55, 1.00) (0.00, N/A, 0.2)	696.5 806.5	0.7716 99.2 99.2	8.1240 [ 7.5923 ]	107.0%			
8:2FTS	(527.0 / 507.0) 874574 (527.0 / 81.0) 575440	(8.96, 1.00) (0.00, N/A, 0.1)	521.2 496.1	0.6580 116.2 116.2	7.8272 [ 7.6663 ]	102.1%			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFOSA	(498.0 / 78.0) 1485959 (498.0 / 478.0) 31674	(10.17, 1.00) (0.00, N/A, 0.2)	990.0 142.4	0.0213 102.3 102.3	2.1663 [2.0000]	108.3%			
NMeFOSA	(511.9 / 219.0) 1078575 (511.9 / 169.0) 708121	(10.61, 1.00) (0.00, N/A, 0.0)	1225.7 994.7	0.6565 91.2 91.2	8.7756 [8.0000]	109.7%			
NEIFOSA	(526.0 / 219.0) 1148331 (526.0 / 169.0) 1200365	(10.70, 1.00) (0.00, N/A, 0.0)	776.2 1306.9	1.0453 98.8 98.8	8.6933 [8.0000]	108.7%			
NMeFOSAA	(570.0 / 419.0) 241345 (570.0 / 483.0) 110259	(9.50, 1.00) (0.00, N/A, -0.4)	387.8 310.6	0.4569 74.3 74.3	2.3829 [2.0000]	119.1%			
NEIFOSAA	(584.0 / 419.0) 216496 (584.0 / 526.0) 131164	(9.68, 1.00) (0.00, N/A, -0.3)	488.0 17276.9	0.6059 82.6 82.6	1.8426 [2.0000]	92.1%			
NMeFOSE	(616.1 / 59.0) 263519	(10.58, 1.00) (0.01, N/A, 0.0)	1098.0	N/A 0.0 0.0	8.8080 [8.0000]	110.1%			
NEtFOSE	(630.0 / 59.0) 44341	(10.68, 1.00) (0.01, N/A, 0.0)	785.9	N/A 0.0 0.0	8.2657 [8.0000]	103.3%			
HFPO-DA	(285.0 / 169.0) 361196 (285.0 / 185.0) 1050555	(6.49, 1.00) (0.00, N/A, 0.1)	772.7 816.6	2.9085 106.0 106.0	4.2149 [4.0000]	105.4%			
ADONA	(377.0 / 85.0) 1531070 (377.0 / 251.0) 192620	(7.39, 1.14) (N/A, -0.04, 0.0)	808.7 452.2	0.1258 101.0 101.0	4.0224 [3.7708]	106.7%			
9CI-Pf3ONS	(531.0 / 351.0) 4127226 (533.0 / 353.0) 1353329	(9.72, 1.50) (N/A, -0.01, 0.1)	633.0 677.8	0.3279 110.8 110.8	3.9027 [3.7330]	104.5%			
11CI-PF3OUDS	(631.0 / 451.0) 2164994 (633.0 / 453.0) 639114	(10.00, 1.54) (N/A, -0.01, 0.2)	1045.2 822.2	0.2952 89.2 89.2	4.0695 [3.7728]	107.9%			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
3:3FTCA	(241.0 / 177.0) 40453 (241.0 / 117.0) 66448	(4.47, 0.90) (N/A, -0.05, 0.1)	490.7 413.9	1.6426 98.2 98.2	8.0746 [ 8.0000 ]	100.9%			
5:3FTCA	(341.0 / 236.7) 329758 (341.0 / 217.0) 527254	(6.77, 1.10) (N/A, -0.05, 0.1)	661.0 537.3	1.5989 109.2 109.2	7.4457 [ 8.0000 ]	93.1%			
7:3FTCA	(441.0 / 317.0) 392499 (441.0 / 337.0) 316116	(8.59, 1.40) (N/A, -0.04, 0.1)	337.8 309.6	0.8054 96.2 96.2	7.7021 [ 8.0000 ]	96.3%			
PFEESA	(315.0 / 135.0) 963848 (315.0 / 83.0) 290484	(6.59, 1.07) (N/A, -0.05, 0.0)	701.2 684.7	0.3014 98.2 98.2	3.5124 [ 3.5698 ]	98.4%			
PFMPA	(229.0 / 85.0) 159859	(4.18, 0.84) (N/A, -0.05, 0.0)	785.7	N/A 0.0 0.0	4.0125 [ 4.0000 ]	100.3%			
PFMBA	(279.0 / 85.0) 557038	(5.38, 1.08) (N/A, -0.05, 0.0)	765.0	N/A 0.0 0.0	4.0451 [ 4.0000 ]	101.1%			
NFDHA	(295.0 / 201.0) 513792 (295.0 / 85.0) 442175	(6.02, 0.98) (N/A, -0.05, 0.0)	639.9 677.3	0.8606 97.5 97.5	4.0653 [ 4.0000 ]	101.6%			
13C3_PFBA_IIS	(216.0 / 172.0) 147062	(3.67, N/A) (N/A, -0.05, N/A)	798.2	N/A	1.0565 [ 1.0000 ]	105.7% { 96.9% }			
13C2_PFHxA_IIS	(315.1 / 270.0) 235070	(6.14, N/A) (N/A, -0.04, N/A)	582.4	N/A	1.0180 [ 1.0000 ]	101.8% { 100.5% }			
13C4_PFOA_IIS	(417.0 / 372.0) 228180	(7.89, N/A) (N/A, -0.04, N/A)	542.9	N/A	1.0379 [ 1.0000 ]	103.8% { 95.9% }			
13C5_PFNA_IIS	(468.0 / 423.0) 190318	(8.63, N/A) (N/A, -0.04, N/A)	398.2	N/A	1.0277 [ 1.0000 ]	102.8% { 94.1% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDA_IIS	(515.1 / 470.1) 163196	(9.30, N/A) (N/A, -0.04, N/A)	351.2	N/A	0.8831 [ 1.0000 ]	88.3% { 93.9% }			
18O2_PFHxS_IIS	(403.0 / 83.9) 399114	(8.01, N/A) (N/A, -0.04, N/A)	644.1	N/A	0.9886 [ 1.0000 ]	98.9% { 94.4% }			
13C4_PFOS_IIS	(502.8 / 79.9) 313371	(9.45, N/A) (N/A, -0.03, N/A)	470.2	N/A	0.9818 [ 1.0000 ]	98.2% { 95.6% }			
13C4_PFBA_EIS	(217.0 / 172.0) 1206655	(3.67, N/A) (N/A, -0.05, N/A)	920.8	N/A	7.9721 [ 8.0000 ]	99.7% { 101.3% }			
13C5_PFPeA_EIS	(267.9 / 223.0) 661139	(4.99, N/A) (N/A, -0.05, N/A)	803.5	N/A	4.0422 [ 4.0000 ]	101.1% { 95.0% }			
13C5_PFHxA_EIS	(318.0 / 273.0) 583697	(6.14, N/A) (N/A, -0.05, N/A)	813.5	N/A	2.1578 [ 2.0000 ]	107.9% { 108.3% }			
13C4_PFHpA_EIS	(367.0 / 322.0) 481858	(7.07, N/A) (N/A, -0.04, N/A)	625.4	N/A	2.0419 [ 2.0000 ]	102.1% { 98.1% }			
13C8_PFOA_EIS	(421.0 / 376.0) 529026	(7.89, N/A) (N/A, -0.04, N/A)	717.1	N/A	2.1141 [ 2.0000 ]	105.7% { 106.3% }			
13C9_PFNA_EIS	(472.0 / 427.0) 211031	(8.63, N/A) (N/A, -0.04, N/A)	522.0	N/A	1.0084 [ 1.0000 ]	100.8% { 96.5% }			
13C6_PFDA_EIS	(519.0 / 474.0) 264380	(9.30, N/A) (N/A, -0.04, N/A)	286.1	N/A	1.1391 [ 1.0000 ]	113.9% { 94.0% }			
13C7_PFUnA_EIS	(570.0 / 525.0) 396942	(9.72, N/A) (N/A, -0.01, N/A)	636.0	N/A	1.2023 [ 1.0000 ]	120.2% { 99.7% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDa_EIS	(615.0 / 570.0) 410435	(9.89, N/A) (N/A, -0.01, N/A)	625.4	N/A	1.2456 [ 1.0000 ]	124.6% { 105.9% }			
13C2_PFTeDA_EIS	(715.0 / 670.0) 251385	(10.12, N/A) (N/A, -0.01, N/A)	364.3	N/A	1.1487 [ 1.0000 ]	114.9% { 103.9% }			
13C3_PFBs_EIS	(302.0 / 80.0) 1462627	(6.09, N/A) (N/A, -0.05, N/A)	798.2	N/A	2.1675 [ 2.0000 ]	108.4% { 106.5% }			
13C3_PFHxS_EIS	(402.0 / 80.0) 718366	(8.01, N/A) (N/A, -0.04, N/A)	884.3	N/A	2.0008 [ 2.0000 ]	100.0% { 95.3% }			
13C8_PFOS_EIS	(507.0 / 80.0) 1167403	(9.45, N/A) (N/A, -0.03, N/A)	347.8	N/A	2.1706 [ 2.0000 ]	108.5% { 98.1% }			
13C2_4:2FTS_EIS	(329.0 / 81.0) 241790	(5.80, N/A) (N/A, -0.05, N/A)	780.0	N/A	4.2305 [ 4.0000 ]	105.8% { 107.9% }			
13C2_6:2FTS_EIS	(429.0 / 81.0) 261330	(7.54, N/A) (N/A, -0.04, N/A)	519.2	N/A	3.7978 [ 4.0000 ]	94.9% { 95.2% }			
13C2_8:2FTS_EIS	(529.0 / 81.0) 282103	(8.96, N/A) (N/A, -0.04, N/A)	454.9	N/A	4.0954 [ 4.0000 ]	102.4% { 95.3% }			
13C8_PFOsa_EIS	(506.0 / 78.0) 1451627	(10.17, N/A) (N/A, -0.01, N/A)	856.3	N/A	2.1353 [ 2.0000 ]	106.8% { 99.1% }			
D3_NMeFOSA_EIS	(515.0 / 169.0) 301552	(10.60, N/A) (N/A, 0.00, N/A)	1022.7	N/A	2.0316 [ 2.0000 ]	101.6% { 91.4% }			
D5_NEtFOSA_EIS	(531.1 / 169.0) 292885	(10.69, N/A) (N/A, 0.00, N/A)	1224.3	N/A	2.1375 [ 2.0000 ]	106.9% { 102.9% }			
















































Chemist: ABK  
 Instrument: Saphira  
 Type: Sciex Q3 5500





















Sample I.D.: SB03941-CAL4  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

















Quant Method: 1633 - S2022-12-21A  
 Path: S2022-12-21A (4)  
 Acquired: 2022/12/21 - 15:04












Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT-CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
D3_MeFOSAA_EIS	(573.0 / 419.0) 519867	(9.50, N/A) (N/A, -0.03, N/A)	351.6	N/A	4.0649 [ 4.0000 ]	101.6% { 101.8% }			
D5_EtFOSAA_EIS	(589.0 / 419.0) 523494	(9.68, N/A) (N/A, -0.01, N/A)	328.8	N/A	4.6440 [ 4.0000 ]	116.1% { 111.1% }			
D7_NMeFOSE_EIS	(623.2 / 58.9) 474063	(10.57, N/A) (N/A, 0.00, N/A)	906.7	N/A	22.7456 [ 20.0000 ]	113.7% { 109.8% }			
D9_NEtFOSE_EIS	(639.2 / 58.9) 209537	(10.67, N/A) (N/A, -0.01, N/A)	1132.4	N/A	22.0836 [ 20.0000 ]	110.4% { 114.8% }			
13C3_HFPODA_EIS	(287.0 / 169.0) 1127924	(6.49, N/A) (N/A, -0.04, N/A)	814.1	N/A	7.8424 [ 8.0000 ]	98.0% { 96.0% }			












Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBA	(212.9 / 169.0) 1990225	(3.72, 1.00) (0.00, N/A, 0.0)	64.8	N/A 0.0 0.0	20.4982 [ 20.0000 ]	102.5%			
PFPeA	(262.9 / 219.0) 1442100 (262.9 / 69.0) 16141	(5.04, 1.00) (0.00, N/A, 0.1)	681.9 331.7	0.0112 100.0 100.0	9.4373 [ 10.0000 ]	94.4%			
PFHxA	(313.0 / 269.0) 1106970 (313.0 / 119.0) 108235	(6.19, 1.00) (0.00, N/A, 0.1)	659.6 460.1	0.0978 100.0 100.0	4.7836 [ 5.0000 ]	95.7%			
PFHpA	(363.0 / 319.0) 1091562 (363.0 / 169.0) 339999	(7.11, 1.00) (0.00, N/A, 0.0)	794.0 590.8	0.3115 100.0 100.0	4.8774 [ 5.0000 ]	97.5%			
PFOA	(413.0 / 369.0) 1178218 (413.0 / 169.0) 385050	(7.93, 1.00) (0.00, N/A, 0.1)	590.9 623.3	0.3268 100.0 100.0	4.8153 [ 5.0000 ]	96.3%			
PFNA	(463.0 / 419.0) 1009822 (463.0 / 169.0) 194634	(8.66, 1.00) (0.00, N/A, -0.5)	531.9 118.3	0.1927 100.0 100.0	5.3804 [ 5.0000 ]	107.6%			
PFDA	(513.0 / 469.0) 1239600 (513.0 / 169.0) 118484	(9.34, 1.00) (0.00, N/A, 0.1)	438.5 380.8	0.0956 100.0 100.0	4.6297 [ 5.0000 ]	92.6%			
PFUnA	(563.0 / 519.0) 1546203 (563.0 / 169.0) 134285	(9.73, 1.00) (0.00, N/A, -0.2)	836.4 434.5	0.0868 100.0 100.0	4.9118 [ 5.0000 ]	98.2%			
PFDoA	(613.0 / 569.0) 1581806 (613.0 / 169.0) 220234	(9.90, 1.00) (0.00, N/A, 0.1)	474.2 387.0	0.1392 100.0 100.0	4.7333 [ 5.0000 ]	94.7%			
PFTrDA	(663.0 / 619.0) 1328428 (663.0 / 169.0) 271899	(10.03, 1.01) (N/A, 0.00, 0.0)	609.2 325.8	0.2047 100.0 100.0	4.5881 [ 5.0000 ]	91.8%			
PFTeDA	(713.0 / 669.0) 1063699 (713.0 / 169.0) 216340	(10.13, 1.00) (0.00, N/A, -0.2)	630.3 402.5	0.2034 100.0 100.0	4.9622 [ 5.0000 ]	99.2%			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBS	(298.9 / 80.0) 1813615 (298.9 / 99.0) 1116198	(6.14, 1.00) (0.00, N/A, 0.0)	768.3 703.2	0.6155 100.0 100.0	4.8171 [4.4237]	108.9%			
PFPeS	(349.0 / 80.0) 3187262 (349.0 / 99.0) 1134601	(7.18, 0.89) (N/A, 0.00, 0.0)	946.8 863.6	0.3560 100.0 100.0	4.7330 [4.6919]	100.9%			
PFHxS	(399.0 / 80.0) 2633681 (399.0 / 99.0) 885281	(8.05, 1.00) (0.00, N/A, 0.1)	3311.5 3041.5	0.3361 100.0 100.0	4.4972 [4.5549]	98.7%			
PFHpS	(449.0 / 80.0) 2438304 (449.0 / 99.0) 667404	(8.82, 0.93) (N/A, 0.00, 0.1)	775.3 642.6	0.2737 100.0 100.0	4.6954 [4.7570]	98.7%			
PFOS	(499.0 / 80.0) 2788138 (499.0 / 99.0) 678060	(9.48, 1.00) (0.00, N/A, 0.1)	106.0 147.7	0.2432 100.0 100.0	4.3161 [4.6375]	93.1%			
PFNS	(549.0 / 80.0) 3204059 (549.0 / 99.0) 781912	(9.77, 1.03) (N/A, 0.00, -0.2)	897.4 623.4	0.2440 100.0 100.0	4.4712 [4.7994]	93.2%			
PFDS	(599.0 / 80.0) 3838984 (599.0 / 99.0) 864091	(9.92, 1.05) (N/A, 0.00, -0.1)	900.9 980.5	0.2251 100.0 100.0	4.8256 [4.8155]	100.2%			
PFDoS	(698.9 / 80.0) 1471553 (698.9 / 99.0) 360040	(10.12, 1.07) (N/A, 0.00, 0.1)	998.7 645.8	0.2447 100.0 100.0	4.4257 [4.8478]	91.3%			
4:2FTS	(327.0 / 307.0) 4028733 (327.0 / 81.0) 1990132	(5.85, 1.00) (0.00, N/A, -0.1)	873.0 781.7	0.4940 100.0 100.0	21.7465 [18.6906]	116.4%			
6:2FTS	(427.0 / 407.0) 1996255 (427.0 / 81.0) 1553538	(7.58, 1.00) (0.00, N/A, 0.1)	795.2 949.1	0.7782 100.0 100.0	18.9232 [18.9808]	99.7%			
8:2FTS	(527.0 / 507.0) 2012330 (527.0 / 81.0) 1139036	(9.00, 1.00) (0.00, N/A, 0.0)	497.7 645.4	0.5660 100.0 100.0	17.1622 [19.1658]	89.5%			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFOSA	(498.0 / 78.0) 3270792 (498.0 / 478.0) 68177	(10.18, 1.00) (0.00, N/A, 0.2)	829.1 239.1	0.0208 100.0 100.0	4.7234 [ 5.0000 ]	94.5%			
NMeFOSA	(511.9 / 219.0) 2491137 (511.9 / 169.0) 1794272	(10.61, 1.00) (0.00, N/A, 0.0)	1462.0 1077.7	0.7203 100.0 100.0	18.5213 [ 20.0000 ]	92.6%			
NEIFOSA	(526.0 / 219.0) 2678351 (526.0 / 169.0) 2632868	(10.70, 1.00) (0.00, N/A, 0.1)	1554.8 1249.8	1.0577 100.0 100.0	20.8662 [ 20.0000 ]	104.3%			
NMeFOSAA	(570.0 / 419.0) 486745 (570.0 / 483.0) 299202	(9.53, 1.00) (0.00, N/A, -0.2)	573.1 562.9	0.6147 100.0 100.0	4.8937 [ 5.0000 ]	97.9%			
NEIFOSAA	(584.0 / 419.0) 490783 (584.0 / 526.0) 359842	(9.70, 1.00) (0.00, N/A, -0.1)	632.4 1809.1	0.7332 100.0 100.0	4.6394 [ 5.0000 ]	92.8%			
NMeFOSE	(616.1 / 59.0) 543390	(10.58, 1.00) (0.01, N/A, 0.0)	1051.7	N/A 0.0 0.0	19.9513 [ 20.0000 ]	99.8%			
NEtFOSE	(630.0 / 59.0) 87164	(10.68, 1.00) (0.01, N/A, 0.0)	921.6	N/A 0.0 0.0	18.6613 [ 20.0000 ]	93.3%			
HFPO-DA	(285.0 / 169.0) 898919 (285.0 / 185.0) 2467337	(6.53, 1.00) (0.00, N/A, 0.1)	856.6 806.8	2.7448 100.0 100.0	10.0733 [ 10.0000 ]	100.7%			
ADONA	(377.0 / 85.0) 3868840 (377.0 / 251.0) 481766	(7.43, 1.14) (N/A, 0.00, 0.0)	954.1 756.2	0.1245 100.0 100.0	9.7608 [ 9.4270 ]	103.5%			
9CI-Pf3ONS	(531.0 / 351.0) 10282118 (533.0 / 353.0) 3043082	(9.73, 1.49) (N/A, 0.00, 0.1)	1040.7 769.1	0.2960 100.0 100.0	9.5629 [ 9.3325 ]	102.5%			
11CI-PF3OUDS	(631.0 / 451.0) 5063261 (633.0 / 453.0) 1675005	(10.01, 1.53) (N/A, 0.00, 0.0)	1182.7 681.6	0.3308 100.0 100.0	9.1397 [ 9.4321 ]	96.9%			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
3:3FTCA	(241.0 / 177.0) 99522 (241.0 / 117.0) 166546	(4.52, 0.90) (N/A, 0.00, 0.0)	656.3 515.8	1.6734 100.0 100.0	18.8712 [ 20.0000 ]	94.4%			
5:3FTCA	(341.0 / 236.7) 874302 (341.0 / 217.0) 1279737	(6.82, 1.10) (N/A, 0.00, 0.1)	614.2 617.8	1.4637 100.0 100.0	21.3819 [ 20.0000 ]	106.9%			
7:3FTCA	(441.0 / 317.0) 962379 (441.0 / 337.0) 805964	(8.63, 1.40) (N/A, 0.00, 0.0)	516.9 404.8	0.8375 100.0 100.0	20.4549 [ 20.0000 ]	102.3%			
PFEESA	(315.0 / 135.0) 2085285 (315.0 / 83.0) 640190	(6.64, 1.07) (N/A, 0.00, 0.1)	832.1 689.8	0.3070 100.0 100.0	8.2307 [ 8.9246 ]	92.2%			
PFMPA	(229.0 / 85.0) 396790	(4.23, 0.84) (N/A, 0.00, 0.0)	1072.7	N/A 0.0 0.0	9.4611 [ 10.0000 ]	94.6%			
PFMBA	(279.0 / 85.0) 1416279	(5.42, 1.08) (N/A, 0.00, 0.0)	830.4	N/A 0.0 0.0	9.7700 [ 10.0000 ]	97.7%			
NFDHA	(295.0 / 201.0) 1199740 (295.0 / 85.0) 1059117	(6.07, 0.98) (N/A, 0.00, 0.0)	939.5 917.5	0.8828 100.0 100.0	10.2818 [ 10.0000 ]	102.8%			
13C3_PFBA_IIS	(216.0 / 172.0) 151758	(3.72, N/A) (N/A, 0.00, N/A)	805.9	N/A	1.0903 [ 1.0000 ]	109.0% { 100.0% }			
13C2_PFHxA_IIS	(315.1 / 270.0) 233958	(6.18, N/A) (N/A, 0.00, N/A)	558.9	N/A	1.0132 [ 1.0000 ]	101.3% { 100.0% }			
13C4_PFOA_IIS	(417.0 / 372.0) 238020	(7.93, N/A) (N/A, 0.00, N/A)	686.2	N/A	1.0827 [ 1.0000 ]	108.3% { 100.0% }			
13C5_PFNA_IIS	(468.0 / 423.0) 202298	(8.67, N/A) (N/A, 0.00, N/A)	356.6	N/A	1.0924 [ 1.0000 ]	109.2% { 100.0% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDA_IIS	(515.1 / 470.1) 173856	(9.34, N/A) (N/A, 0.00, N/A)	302.9	N/A	0.9407 [ 1.0000 ]	94.1% { 100.0% }			
18O2_PFHxS_IIS	(403.0 / 83.9) 422692	(8.05, N/A) (N/A, 0.00, N/A)	772.0	N/A	1.0470 [ 1.0000 ]	104.7% { 100.0% }			
13C4_PFOS_IIS	(502.8 / 79.9) 327849	(9.48, N/A) (N/A, 0.00, N/A)	486.2	N/A	1.0272 [ 1.0000 ]	102.7% { 100.0% }			
13C4_PFBA_EIS	(217.0 / 172.0) 1190617	(3.72, N/A) (N/A, 0.00, N/A)	806.1	N/A	7.6228 [ 8.0000 ]	95.3% { 100.0% }			
13C5_PFPeA_EIS	(267.9 / 223.0) 695964	(5.04, N/A) (N/A, 0.00, N/A)	743.0	N/A	4.2753 [ 4.0000 ]	106.9% { 100.0% }			
13C5_PFHxA_EIS	(318.0 / 273.0) 538902	(6.19, N/A) (N/A, 0.00, N/A)	577.5	N/A	2.0016 [ 2.0000 ]	100.1% { 100.0% }			
13C4_PFHpA_EIS	(367.0 / 322.0) 491038	(7.11, N/A) (N/A, 0.00, N/A)	663.4	N/A	2.0907 [ 2.0000 ]	104.5% { 100.0% }			
13C8_PFOA_EIS	(421.0 / 376.0) 497637	(7.93, N/A) (N/A, 0.00, N/A)	494.4	N/A	1.9065 [ 2.0000 ]	95.3% { 100.0% }			
13C9_PFNA_EIS	(472.0 / 427.0) 218730	(8.67, N/A) (N/A, 0.00, N/A)	468.8	N/A	0.9833 [ 1.0000 ]	98.3% { 100.0% }			
13C6_PFDA_EIS	(519.0 / 474.0) 281293	(9.34, N/A) (N/A, 0.00, N/A)	304.6	N/A	1.1376 [ 1.0000 ]	113.8% { 100.0% }			
13C7_PFUnA_EIS	(570.0 / 525.0) 398330	(9.73, N/A) (N/A, 0.00, N/A)	590.9	N/A	1.1326 [ 1.0000 ]	113.3% { 100.0% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDa_EIS	(615.0 / 570.0) 387652	(9.91, N/A) (N/A, 0.00, N/A)	408.6	N/A	1.1043 [ 1.0000 ]	110.4% { 100.0% }			
13C2_PFTeDA_EIS	(715.0 / 670.0) 241867	(10.13, N/A) (N/A, 0.00, N/A)	473.7	N/A	1.0375 [ 1.0000 ]	103.7% { 100.0% }			
13C3_PFBs_EIS	(302.0 / 80.0) 1373432	(6.14, N/A) (N/A, 0.00, N/A)	693.8	N/A	1.9218 [ 2.0000 ]	96.1% { 100.0% }			
13C3_PFHxS_EIS	(402.0 / 80.0) 753903	(8.05, N/A) (N/A, 0.00, N/A)	856.1	N/A	1.9827 [ 2.0000 ]	99.1% { 100.0% }			
13C8_PFOS_EIS	(507.0 / 80.0) 1190292	(9.48, N/A) (N/A, 0.00, N/A)	261.7	N/A	2.1154 [ 2.0000 ]	105.8% { 100.0% }			
13C2_4:2FTS_EIS	(329.0 / 81.0) 224114	(5.85, N/A) (N/A, 0.00, N/A)	886.7	N/A	3.7025 [ 4.0000 ]	92.6% { 100.0% }			
13C2_6:2FTS_EIS	(429.0 / 81.0) 274445	(7.58, N/A) (N/A, 0.00, N/A)	671.5	N/A	3.7659 [ 4.0000 ]	94.1% { 100.0% }			
13C2_8:2FTS_EIS	(529.0 / 81.0) 296038	(9.00, N/A) (N/A, 0.00, N/A)	428.2	N/A	4.0579 [ 4.0000 ]	101.4% { 100.0% }			
13C8_PFOsa_EIS	(506.0 / 78.0) 1465391	(10.18, N/A) (N/A, 0.00, N/A)	879.9	N/A	2.0603 [ 2.0000 ]	103.0% { 100.0% }			
D3_NMeFOSA_EIS	(515.0 / 169.0) 330001	(10.61, N/A) (N/A, 0.00, N/A)	806.2	N/A	2.1251 [ 2.0000 ]	106.3% { 100.0% }			
D5_NEiFOSA_EIS	(531.1 / 169.0) 284603	(10.70, N/A) (N/A, 0.00, N/A)	963.7	N/A	1.9853 [ 2.0000 ]	99.3% { 100.0% }			
























Chemist: ABK  
 Instrument: Saphira  
 Type: Sciex Q3 5500























Sample I.D.: SB03941-CAL5  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam





















Quant Method: 1633 - S2022-12-21A  
 Path: S2022-12-21A (5)  
 Acquired: 2022/12/21 - 15:17

















Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-I[min], ΔRT-CV[min], ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
D3_MeFOSAA_EIS	( 573.0 / 419.0 ) 510539	( 9.53 , N/A ) ( N/A , 0.00 , N/A )	423.7	N/A	3.8157 [ 4.0000 ]	95.4% { 100.0% }			
D5_EtFOSAA_EIS	( 589.0 / 419.0 ) 471317	( 9.69 , N/A ) ( N/A , 0.00 , N/A )	312.2	N/A	3.9965 [ 4.0000 ]	99.9% { 100.0% }			
D7_NMeFOSE_EIS	( 623.2 / 58.9 ) 431560	( 10.58 , N/A ) ( N/A , 0.00 , N/A )	1437.5	N/A	19.7920 [ 20.0000 ]	99.0% { 100.0% }			
D9_NEtFOSE_EIS	( 639.2 / 58.9 ) 182445	( 10.67 , N/A ) ( N/A , 0.00 , N/A )	924.0	N/A	18.3793 [ 20.0000 ]	91.9% { 100.0% }			
13C3_HFPODA_EIS	( 287.0 / 169.0 ) 1174542	( 6.53 , N/A ) ( N/A , 0.00 , N/A )	891.8	N/A	8.2053 [ 8.0000 ]	102.6% { 100.0% }			

























Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBA	(212.9 / 169.0) 4050226	(3.69, 1.00) (0.00, N/A, 0.0)	65.3	N/A 0.0 0.0	42.6736 [ 40.0000 ]	106.7%			
PFPeA	(262.9 / 219.0) 2824768 (262.9 / 69.0) 30797	(5.01, 1.00) (0.00, N/A, 0.2)	725.3 354.5	0.0109 97.4 97.4	19.8721 [ 20.0000 ]	99.4%			
PFHxA	(313.0 / 269.0) 2355853 (313.0 / 119.0) 216426	(6.16, 1.00) (0.00, N/A, 0.1)	630.0 576.1	0.0919 94.0 94.0	9.7663 [ 10.0000 ]	97.7%			
PFHpA	(363.0 / 319.0) 2097907 (363.0 / 169.0) 669756	(7.08, 1.00) (0.00, N/A, 0.1)	650.6 555.8	0.3192 102.5 102.5	9.6572 [ 10.0000 ]	96.6%			
PFOA	(413.0 / 369.0) 2460865 (413.0 / 169.0) 754807	(7.90, 1.00) (0.00, N/A, 0.0)	797.2 515.8	0.3067 93.9 93.9	10.0578 [ 10.0000 ]	100.6%			
PFNA	(463.0 / 419.0) 1917681 (463.0 / 169.0) 398931	(8.64, 1.00) (0.00, N/A, 0.0)	698.0 110.9	0.2080 107.9 107.9	9.9870 [ 10.0000 ]	99.9%			
PFDA	(513.0 / 469.0) 2731475 (513.0 / 169.0) 237718	(9.32, 1.00) (0.01, N/A, 0.1)	431.9 384.2	0.0870 91.1 91.1	10.5011 [ 10.0000 ]	105.0%			
PFUnA	(563.0 / 519.0) 2762959 (563.0 / 169.0) 281752	(9.71, 1.00) (0.00, N/A, 0.0)	678.3 368.4	0.1020 117.4 117.4	10.3620 [ 10.0000 ]	103.6%			
PFDoA	(613.0 / 569.0) 3158081 (613.0 / 169.0) 408270	(9.89, 1.00) (0.00, N/A, -0.3)	740.9 505.8	0.1293 92.9 92.9	10.5649 [ 10.0000 ]	105.6%			
PFTrDA	(663.0 / 619.0) 2750923 (663.0 / 169.0) 615527	(10.01, 1.01) (N/A, -0.01, -0.3)	922.1 622.7	0.2238 109.3 109.3	10.6219 [ 10.0000 ]	106.2%			
PFTeDA	(713.0 / 669.0) 2392662 (713.0 / 169.0) 396949	(10.12, 1.00) (0.00, N/A, 0.2)	784.4 530.3	0.1659 81.6 81.6	12.1566 [ 10.0000 ]	121.6%			






Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBS	(298.9 / 80.0) 3499294 (298.9 / 99.0) 2162960	(6.11, 1.00) (0.00, N/A, 0.0)	782.7 712.1	0.6181 100.4 100.4	9.3608 [ 8.8473 ]	105.8%			
PFPeS	(349.0 / 80.0) 6311120 (349.0 / 99.0) 2220135	(7.15, 0.89) (N/A, -0.03, 0.0)	774.9 858.6	0.3518 98.8 98.8	9.3269 [ 9.3838 ]	99.4%			
PFHxS	(399.0 / 80.0) 5497046 (399.0 / 99.0) 1809522	(8.02, 1.00) (0.00, N/A, 0.2)	3843.8 4067.6	0.3292 97.9 97.9	9.3415 [ 9.1098 ]	102.5%			
PFHpS	(449.0 / 80.0) 4655282 (449.0 / 99.0) 1364079	(8.79, 0.93) (N/A, -0.03, 0.1)	660.3 545.6	0.2930 107.1 107.1	10.1795 [ 9.5141 ]	107.0%			
PFOS	(499.0 / 80.0) 5408135 (499.0 / 99.0) 1245798	(9.45, 1.00) (0.00, N/A, -0.1)	107.2 128.5	0.2304 94.7 94.7	9.5064 [ 9.2749 ]	102.5%			
PFNS	(549.0 / 80.0) 6857872 (549.0 / 99.0) 1607367	(9.76, 1.03) (N/A, -0.01, 0.1)	779.5 870.0	0.2344 96.0 96.0	10.8669 [ 9.5989 ]	113.2%			
PFDS	(599.0 / 80.0) 7907397 (599.0 / 99.0) 1810025	(9.91, 1.05) (N/A, -0.01, 0.2)	1173.5 1014.3	0.2289 101.7 101.7	11.2866 [ 9.6311 ]	117.2%			
PFDoS	(698.9 / 80.0) 2945783 (698.9 / 99.0) 628808	(10.11, 1.07) (N/A, -0.01, 0.1)	1059.1 1043.2	0.2135 87.2 87.2	10.0602 [ 9.6956 ]	103.8%			
4:2FTS	(327.0 / 307.0) 7219424 (327.0 / 81.0) 3962590	(5.83, 1.00) (0.00, N/A, 0.3)	742.8 891.9	0.5489 111.1 111.1	35.0389 [ 37.3811 ]	93.7%			
6:2FTS	(427.0 / 407.0) 4387404 (427.0 / 81.0) 2952550	(7.56, 1.00) (0.00, N/A, -0.1)	852.0 1014.4	0.6730 86.5 86.5	42.2664 [ 37.9617 ]	111.3%			
8:2FTS	(527.0 / 507.0) 4299071 (527.0 / 81.0) 2483349	(8.97, 1.00) (0.00, N/A, 0.1)	581.6 491.2	0.5776 102.1 102.1	39.3656 [ 38.3315 ]	102.7%			






















Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFOSA	(498.0 / 78.0) 7323816 (498.0 / 478.0) 156082	(10.17, 1.00) (0.00, N/A, -0.1)	1220.2 517.0	0.0213 102.2 102.2	11.2339 [ 10.0000 ]	112.3%			
NMeFOSA	(511.9 / 219.0) 5018962 (511.9 / 169.0) 3409088	(10.60, 1.00) (0.00, N/A, -0.1)	1068.1 1194.8	0.6792 94.3 94.3	41.0228 [ 40.0000 ]	102.6%			
NEIFOSA	(526.0 / 219.0) 5202781 (526.0 / 169.0) 5559747	(10.69, 1.00) (0.00, N/A, 0.0)	1128.4 1454.6	1.0686 101.0 101.0	41.3031 [ 40.0000 ]	103.3%			
NMeFOSAA	(570.0 / 419.0) 1047253 (570.0 / 483.0) 528303	(9.50, 1.00) (0.01, N/A, 0.0)	505.4 486.7	0.5045 82.1 82.1	9.6770 [ 10.0000 ]	96.8%			
NEIFOSAA	(584.0 / 419.0) 1028405 (584.0 / 526.0) 603316	(9.68, 1.00) (0.01, N/A, 0.0)	933.5 1079.0	0.5867 80.0 80.0	8.7467 [ 10.0000 ]	87.5%			
NMeFOSE	(616.1 / 59.0) 1066666	(10.57, 1.00) (0.01, N/A, 0.0)	1245.3	N/A 0.0 0.0	43.1436 [ 40.0000 ]	107.9%			
NEtFOSE	(630.0 / 59.0) 190429	(10.67, 1.00) (0.01, N/A, 0.0)	952.6	N/A 0.0 0.0	39.7759 [ 40.0000 ]	99.4%			
HFPO-DA	(285.0 / 169.0) 1706844 (285.0 / 185.0) 4940740	(6.50, 1.00) (0.00, N/A, 0.0)	940.9 950.3	2.8947 105.5 105.5	19.4163 [ 20.0000 ]	97.1%			
ADONA	(377.0 / 85.0) 7625070 (377.0 / 251.0) 966765	(7.40, 1.14) (N/A, -0.03, 0.0)	848.9 734.0	0.1268 101.8 101.8	19.5285 [ 18.8540 ]	103.6%			
9CI-Pf3ONS	(531.0 / 351.0) 18752532 (533.0 / 353.0) 6070274	(9.71, 1.49) (N/A, -0.02, 0.0)	653.0 661.6	0.3237 109.4 109.4	18.3510 [ 18.6651 ]	98.3%			
11CI-PF3OUDS	(631.0 / 451.0) 10830263 (633.0 / 453.0) 3030278	(10.00, 1.54) (N/A, -0.01, 0.1)	1577.4 1022.7	0.2798 84.6 84.6	19.8453 [ 18.8642 ]	105.2%			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
3:3FTCA	(241.0 / 177.0) 204327 (241.0 / 117.0) 336062	(4.49, 0.90) (N/A, -0.03, 0.1)	792.9 648.3	1.6447 98.3 98.3	41.6496 [ 40.0000 ]	104.1%			
5:3FTCA	(341.0 / 236.7) 1619148 (341.0 / 217.0) 2611063	(6.79, 1.10) (N/A, -0.03, -0.1)	703.3 612.1	1.6126 110.2 110.2	37.9872 [ 40.0000 ]	95.0%			
7:3FTCA	(441.0 / 317.0) 1906765 (441.0 / 337.0) 1608500	(8.60, 1.40) (N/A, -0.03, -0.1)	523.3 597.0	0.8436 100.7 100.7	38.8788 [ 40.0000 ]	97.2%			
PFEESA	(315.0 / 135.0) 4593030 (315.0 / 83.0) 1327802	(6.61, 1.07) (N/A, -0.03, -0.1)	844.1 795.4	0.2891 94.2 94.2	17.3915 [ 17.8492 ]	97.4%			
PFMPA	(229.0 / 85.0) 810629	(4.20, 0.84) (N/A, -0.03, 0.0)	1061.6	N/A 0.0 0.0	20.7783 [ 20.0000 ]	103.9%			
PFMBA	(279.0 / 85.0) 2665168	(5.40, 1.08) (N/A, -0.03, 0.0)	868.7	N/A 0.0 0.0	19.7641 [ 20.0000 ]	98.8%			
NFDHA	(295.0 / 201.0) 2388001 (295.0 / 85.0) 2094961	(6.04, 0.98) (N/A, -0.03, 0.0)	636.9 870.9	0.8773 99.4 99.4	19.6329 [ 20.0000 ]	98.2%			
13C3_PFBA_IIS	(216.0 / 172.0) 145548	(3.70, N/A) (N/A, -0.02, N/A)	760.7	N/A	1.0457 [ 1.0000 ]	104.6% { 95.9% }			
13C2_PFHxA_IIS	(315.1 / 270.0) 251161	(6.16, N/A) (N/A, -0.03, N/A)	573.8	N/A	1.0877 [ 1.0000 ]	108.8% { 107.4% }			
13C4_PFOA_IIS	(417.0 / 372.0) 228422	(7.90, N/A) (N/A, -0.03, N/A)	604.8	N/A	1.0390 [ 1.0000 ]	103.9% { 96.0% }			
13C5_PFNA_IIS	(468.0 / 423.0) 199253	(8.63, N/A) (N/A, -0.03, N/A)	633.0	N/A	1.0760 [ 1.0000 ]	107.6% { 98.5% }			























Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDA_IIS	(515.1 / 470.1) 224539	(9.31, N/A) (N/A, -0.03, N/A)	595.4	N/A	1.2150 [ 1.0000 ]	121.5% { 129.2% }			
18O2_PFHxS_IIS	(403.0 / 83.9) 425062	(8.02, N/A) (N/A, -0.03, N/A)	758.0	N/A	1.0529 [ 1.0000 ]	105.3% { 100.6% }			
13C4_PFOS_IIS	(502.8 / 79.9) 327789	(9.45, N/A) (N/A, -0.03, N/A)	437.5	N/A	1.0270 [ 1.0000 ]	102.7% { 100.0% }			
13C4_PFBA_EIS	(217.0 / 172.0) 1163869	(3.69, N/A) (N/A, -0.02, N/A)	943.4	N/A	7.7695 [ 8.0000 ]	97.1% { 97.8% }			
13C5_PFPeA_EIS	(267.9 / 223.0) 647411	(5.01, N/A) (N/A, -0.03, N/A)	744.3	N/A	3.7047 [ 4.0000 ]	92.6% { 93.0% }			
13C5_PFHxA_EIS	(318.0 / 273.0) 561752	(6.16, N/A) (N/A, -0.03, N/A)	573.9	N/A	1.9436 [ 2.0000 ]	97.2% { 104.2% }			
13C4_PFHpA_EIS	(367.0 / 322.0) 476643	(7.08, N/A) (N/A, -0.03, N/A)	661.3	N/A	1.8904 [ 2.0000 ]	94.5% { 97.1% }			
13C8_PFOA_EIS	(421.0 / 376.0) 497619	(7.90, N/A) (N/A, -0.03, N/A)	689.7	N/A	1.9865 [ 2.0000 ]	99.3% { 100.0% }			
13C9_PFNA_EIS	(472.0 / 427.0) 223778	(8.64, N/A) (N/A, -0.03, N/A)	409.0	N/A	1.0213 [ 1.0000 ]	102.1% { 102.3% }			
13C6_PFDA_EIS	(519.0 / 474.0) 273272	(9.31, N/A) (N/A, -0.03, N/A)	311.9	N/A	0.8557 [ 1.0000 ]	85.6% { 97.1% }			
13C7_PFUnA_EIS	(570.0 / 525.0) 337405	(9.71, N/A) (N/A, -0.01, N/A)	389.2	N/A	0.7428 [ 1.0000 ]	74.3% { 84.7% }			





















Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDa_EIS	(615.0 / 570.0) 346746	(9.89, N/A) (N/A, -0.02, N/A)	642.1	N/A	0.7648 [ 1.0000 ]	76.5% { 89.4% }			
13C2_PFTeDA_EIS	(715.0 / 670.0) 222076	(10.12, N/A) (N/A, -0.01, N/A)	456.1	N/A	0.7376 [ 1.0000 ]	73.8% { 91.8% }			
13C3_PFBs_EIS	(302.0 / 80.0) 1363704	(6.11, N/A) (N/A, -0.03, N/A)	654.6	N/A	1.8975 [ 2.0000 ]	94.9% { 99.3% }			
13C3_PFHxS_EIS	(402.0 / 80.0) 757540	(8.02, N/A) (N/A, -0.03, N/A)	799.7	N/A	1.9811 [ 2.0000 ]	99.1% { 100.5% }			
13C8_PFOS_EIS	(507.0 / 80.0) 1048231	(9.45, N/A) (N/A, -0.03, N/A)	180.4	N/A	1.8633 [ 2.0000 ]	93.2% { 88.1% }			
13C2_4:2FTS_EIS	(329.0 / 81.0) 249254	(5.83, N/A) (N/A, -0.03, N/A)	640.7	N/A	4.0948 [ 4.0000 ]	102.4% { 111.2% }			
13C2_6:2FTS_EIS	(429.0 / 81.0) 270052	(7.56, N/A) (N/A, -0.03, N/A)	709.3	N/A	3.6849 [ 4.0000 ]	92.1% { 98.4% }			
13C2_8:2FTS_EIS	(529.0 / 81.0) 275725	(8.97, N/A) (N/A, -0.03, N/A)	445.9	N/A	3.7584 [ 4.0000 ]	94.0% { 93.1% }			
13C8_PFOA_EIS	(506.0 / 78.0) 1379635	(10.17, N/A) (N/A, -0.01, N/A)	959.9	N/A	1.9401 [ 2.0000 ]	97.0% { 94.1% }			
D3_NMeFOA_EIS	(515.0 / 169.0) 300177	(10.60, N/A) (N/A, -0.01, N/A)	888.1	N/A	1.9334 [ 2.0000 ]	96.7% { 91.0% }			
D5_NEtFOA_EIS	(531.1 / 169.0) 279297	(10.69, N/A) (N/A, -0.01, N/A)	926.2	N/A	1.9487 [ 2.0000 ]	97.4% { 98.1% }			

















Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT- CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
D3_MeFOSAA_EIS	(573.0 / 419.0) 555492	(9.50, N/A) (N/A, -0.03, N/A)	414.0	N/A	4.1525 [ 4.0000 ]	103.8% { 108.8% }			
D5_EtFOSAA_EIS	(589.0 / 419.0) 523855	(9.68, N/A) (N/A, -0.02, N/A)	484.6	N/A	4.4428 [ 4.0000 ]	111.1% { 111.1% }			
D7_NMeFOSE_EIS	(623.2 / 58.9) 391753	(10.56, N/A) (N/A, -0.01, N/A)	1314.7	N/A	17.9697 [ 20.0000 ]	89.8% { 90.8% }			
D9_NEtFOSE_EIS	(639.2 / 58.9) 187004	(10.66, N/A) (N/A, -0.01, N/A)	901.5	N/A	18.8420 [ 20.0000 ]	94.2% { 102.5% }			
13C3_HFPODA_EIS	(287.0 / 169.0) 1157042	(6.50, N/A) (N/A, -0.03, N/A)	770.4	N/A	7.5294 [ 8.0000 ]	94.1% { 98.5% }			












Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBA	(212.9 / 169.0) 7729586	(3.66, 1.00) (0.00, N/A, 0.0)	67.9	N/A 0.0 0.0	81.7379 [ 80.0000 ]	102.2%			
PFPeA	(262.9 / 219.0) 5643399 (262.9 / 69.0) 60722	(4.98, 1.00) (0.00, N/A, 0.0)	694.2 520.3	0.0108 96.1 96.1	40.6136 [ 40.0000 ]	101.5%			
PFHxA	(313.0 / 269.0) 4661260 (313.0 / 119.0) 458438	(6.14, 1.00) (0.00, N/A, 0.3)	740.9 630.9	0.0984 100.6 100.6	21.3969 [ 20.0000 ]	107.0%			
PFHpA	(363.0 / 319.0) 4440128 (363.0 / 169.0) 1284143	(7.06, 1.00) (0.00, N/A, 0.0)	668.8 659.4	0.2892 92.9 92.9	21.0935 [ 20.0000 ]	105.5%			
PFOA	(413.0 / 369.0) 4641747 (413.0 / 169.0) 1487003	(7.88, 1.00) (0.00, N/A, -0.3)	945.5 720.9	0.3204 98.0 98.0	20.0481 [ 20.0000 ]	100.2%			
PFNA	(463.0 / 419.0) 3537219 (463.0 / 169.0) 723244	(8.62, 1.00) (0.00, N/A, -0.2)	600.2 105.2	0.2045 106.1 106.1	20.0197 [ 20.0000 ]	100.1%			
PFDA	(513.0 / 469.0) 4550414 (513.0 / 169.0) 407049	(9.29, 1.00) (0.00, N/A, 0.3)	458.4 340.9	0.0895 93.6 93.6	18.7496 [ 20.0000 ]	93.7%			
PFUnA	(563.0 / 519.0) 5474685 (563.0 / 169.0) 489769	(9.70, 1.00) (0.00, N/A, 0.3)	796.9 670.2	0.0895 103.0 103.0	20.8759 [ 20.0000 ]	104.4%			
PFDoA	(613.0 / 569.0) 6253442 (613.0 / 169.0) 780811	(9.88, 1.00) (0.00, N/A, 0.0)	838.3 526.7	0.1249 89.7 89.7	19.2908 [ 20.0000 ]	96.5%			
PFTrDA	(663.0 / 619.0) 5585067 (663.0 / 169.0) 1021977	(10.01, 1.01) (N/A, -0.02, -0.4)	939.9 794.3	0.1830 89.4 89.4	19.8858 [ 20.0000 ]	99.4%			
PFTeDA	(713.0 / 669.0) 4569846 (713.0 / 169.0) 904045	(10.11, 1.00) (0.00, N/A, 0.2)	734.0 687.4	0.1978 97.3 97.3	17.5178 [ 20.0000 ]	87.6%			



















Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBS	(298.9 / 80.0) 6221305 (298.9 / 99.0) 4130206	(6.09, 1.00) (0.00, N/A, 0.1)	735.2 716.1	0.6639 107.9 107.9	17.4196 [ 17.6947 ]	98.4%			
PFPeS	(349.0 / 80.0) 12435170 (349.0 / 99.0) 4513587	(7.13, 0.89) (N/A, -0.05, 0.0)	731.5 788.8	0.3630 102.0 102.0	19.6427 [ 18.7676 ]	104.7%			
PFHxS	(399.0 / 80.0) 10414987 (399.0 / 99.0) 3525485	(8.01, 1.00) (0.00, N/A, 0.2)	3224.1 4892.8	0.3385 100.7 100.7	18.9174 [ 18.2197 ]	103.8%			
PFHpS	(449.0 / 80.0) 9724229 (449.0 / 99.0) 2826299	(8.76, 0.93) (N/A, -0.05, -0.1)	693.4 620.9	0.2906 106.2 106.2	19.4303 [ 19.0281 ]	102.1%			
PFOS	(499.0 / 80.0) 11033465 (499.0 / 99.0) 2411819	(9.44, 1.00) (0.00, N/A, 0.2)	102.1 160.8	0.2186 89.9 89.9	17.7225 [ 18.5499 ]	95.5%			
PFNS	(549.0 / 80.0) 12066925 (549.0 / 99.0) 3200250	(9.75, 1.03) (N/A, -0.02, 0.0)	748.7 678.2	0.2652 108.7 108.7	17.4726 [ 19.1977 ]	91.0%			
PFDS	(599.0 / 80.0) 13381834 (599.0 / 99.0) 3299330	(9.90, 1.05) (N/A, -0.02, 0.1)	1052.2 1451.8	0.2466 109.5 109.5	17.4537 [ 19.2621 ]	90.6%			
PFDoS	(698.9 / 80.0) 5470070 (698.9 / 99.0) 1315874	(10.10, 1.07) (N/A, -0.02, 0.0)	1218.8 960.3	0.2406 98.3 98.3	17.0703 [ 19.3913 ]	88.0%			
4:2FTS	(327.0 / 307.0) 13496630 (327.0 / 81.0) 7417812	(5.80, 1.00) (0.00, N/A, 0.1)	849.9 833.0	0.5496 111.3 111.3	72.4566 [ 74.7622 ]	96.9%			
6:2FTS	(427.0 / 407.0) 8307126 (427.0 / 81.0) 5171329	(7.54, 1.00) (0.00, N/A, 0.0)	820.9 695.6	0.6225 80.0 80.0	76.1349 [ 75.9234 ]	100.3%			
8:2FTS	(527.0 / 507.0) 8258969 (527.0 / 81.0) 4745404	(8.95, 1.00) (0.00, N/A, 0.3)	609.9 658.7	0.5746 101.5 101.5	75.3496 [ 76.6631 ]	98.3%			






















Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFOSA	(498.0 / 78.0) 12934205 (498.0 / 478.0) 273418	(10.16, 1.00) (0.00, N/A, 0.0)	1019.0 675.2	0.0211 101.4 101.4	18.9126 [ 20.0000 ]	94.6%			
NMeFOSA	(511.9 / 219.0) 10047403 (511.9 / 169.0) 6239729	(10.59, 1.00) (0.00, N/A, 0.0)	963.4 963.6	0.6210 86.2 86.2	79.4328 [ 80.0000 ]	99.3%			
NEIFOSA	(526.0 / 219.0) 10330116 (526.0 / 169.0) 10487941	(10.69, 1.00) (0.00, N/A, 0.0)	1549.4 1526.7	1.0153 96.0 96.0	82.6028 [ 80.0000 ]	103.3%			
NMeFOSAA	(570.0 / 419.0) 2160138 (570.0 / 483.0) 1120189	(9.49, 1.00) (0.01, N/A, 0.0)	519.4 506.9	0.5186 84.4 84.4	21.0347 [ 20.0000 ]	105.2%			
NEIFOSAA	(584.0 / 419.0) 1755294 (584.0 / 526.0) 1179499	(9.67, 1.00) (0.01, N/A, 0.2)	1046.0 2541.1	0.6720 91.6 91.6	19.8369 [ 20.0000 ]	99.2%			
NMeFOSE	(616.1 / 59.0) 2100981	(10.57, 1.00) (0.01, N/A, 0.0)	1163.7	N/A 0.0 0.0	87.8464 [ 80.0000 ]	109.8%			
NEtFOSE	(630.0 / 59.0) 379057	(10.66, 1.00) (0.01, N/A, 0.0)	1328.5	N/A 0.0 0.0	79.1545 [ 80.0000 ]	98.9%			
HFPO-DA	(285.0 / 169.0) 3403206 (285.0 / 185.0) 9550202	(6.48, 1.00) (0.00, N/A, 0.0)	822.2 932.2	2.8062 102.2 102.2	39.8571 [ 40.0000 ]	99.6%			
ADONA	(377.0 / 85.0) 14175645 (377.0 / 251.0) 1888186	(7.39, 1.14) (N/A, -0.04, -0.1)	782.5 715.9	0.1332 107.0 107.0	37.3778 [ 37.7080 ]	99.1%			
9CI-Pf3ONS	(531.0 / 351.0) 33927453 (533.0 / 353.0) 11818760	(9.70, 1.50) (N/A, -0.03, 0.1)	767.5 701.4	0.3484 117.7 117.7	37.0127 [ 37.3302 ]	99.1%			
11CI-PF3OUDS	(631.0 / 451.0) 18459375 (633.0 / 453.0) 6096113	(9.99, 1.54) (N/A, -0.02, 0.1)	875.1 1257.4	0.3302 99.8 99.8	34.8243 [ 37.7283 ]	92.3%			























Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
3:3FTCA	(241.0 / 177.0) 413530 (241.0 / 117.0) 684831	(4.46, 0.90) (N/A, -0.06, 0.0)	763.7 842.4	1.6561 99.0 99.0	86.2307 [ 80.0000 ]	107.8%			
5:3FTCA	(341.0 / 236.7) 3356741 (341.0 / 217.0) 5218130	(6.77, 1.10) (N/A, -0.05, -0.2)	736.7 741.6	1.5545 106.2 106.2	87.2034 [ 80.0000 ]	109.0%			
7:3FTCA	(441.0 / 317.0) 3849941 (441.0 / 337.0) 3225448	(8.58, 1.40) (N/A, -0.05, 0.0)	479.5 551.2	0.8378 100.0 100.0	86.9230 [ 80.0000 ]	108.7%			
PFEESA	(315.0 / 135.0) 8973610 (315.0 / 83.0) 2426863	(6.59, 1.07) (N/A, -0.05, 0.2)	892.6 762.9	0.2704 88.1 88.1	37.6244 [ 35.6984 ]	105.4%			
PFMPA	(229.0 / 85.0) 1587857	(4.17, 0.84) (N/A, -0.06, 0.0)	1007.1	N/A 0.0 0.0	41.6361 [ 40.0000 ]	104.1%			
PFMBA	(279.0 / 85.0) 5452093	(5.37, 1.08) (N/A, -0.06, 0.0)	936.0	N/A 0.0 0.0	41.3605 [ 40.0000 ]	103.4%			
NFDHA	(295.0 / 201.0) 4564595 (295.0 / 85.0) 4173432	(6.02, 0.98) (N/A, -0.05, -0.1)	742.5 3610.4	0.9143 103.6 103.6	41.5544 [ 40.0000 ]	103.9%			
13C3_PFBA_IIS	(216.0 / 172.0) 143451	(3.66, N/A) (N/A, -0.06, N/A)	719.9	N/A	1.0306 [ 1.0000 ]	103.1% { 94.5% }			
13C2_PFHxA_IIS	(315.1 / 270.0) 248043	(6.13, N/A) (N/A, -0.05, N/A)	661.9	N/A	1.0742 [ 1.0000 ]	107.4% { 106.0% }			
13C4_PFOA_IIS	(417.0 / 372.0) 234938	(7.88, N/A) (N/A, -0.05, N/A)	713.0	N/A	1.0686 [ 1.0000 ]	106.9% { 98.7% }			
13C5_PFNA_IIS	(468.0 / 423.0) 193387	(8.62, N/A) (N/A, -0.05, N/A)	335.2	N/A	1.0443 [ 1.0000 ]	104.4% { 95.6% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDA_IIS	(515.1 / 470.1) 186408	(9.29, N/A) (N/A, -0.05, N/A)	664.1	N/A	1.0087 [ 1.0000 ]	100.9% { 107.2% }			
18O2_PFHxS_IIS	(403.0 / 83.9) 428893	(8.00, N/A) (N/A, -0.05, N/A)	824.8	N/A	1.0624 [ 1.0000 ]	106.2% { 101.5% }			
13C4_PFOS_IIS	(502.8 / 79.9) 333901	(9.43, N/A) (N/A, -0.05, N/A)	344.0	N/A	1.0461 [ 1.0000 ]	104.6% { 101.8% }			
13C4_PFBA_EIS	(217.0 / 172.0) 1159624	(3.66, N/A) (N/A, -0.06, N/A)	908.2	N/A	7.8543 [ 8.0000 ]	98.2% { 97.4% }			
13C5_PFPeA_EIS	(267.9 / 223.0) 632863	(4.97, N/A) (N/A, -0.06, N/A)	720.4	N/A	3.6669 [ 4.0000 ]	91.7% { 90.9% }			
13C5_PFHxA_EIS	(318.0 / 273.0) 507317	(6.13, N/A) (N/A, -0.05, N/A)	683.8	N/A	1.7773 [ 2.0000 ]	88.9% { 94.1% }			
13C4_PFHpA_EIS	(367.0 / 322.0) 461855	(7.06, N/A) (N/A, -0.04, N/A)	556.4	N/A	1.8548 [ 2.0000 ]	92.7% { 94.1% }			
13C8_PFOA_EIS	(421.0 / 376.0) 470888	(7.88, N/A) (N/A, -0.05, N/A)	672.4	N/A	1.8276 [ 2.0000 ]	91.4% { 94.6% }			
13C9_PFNA_EIS	(472.0 / 427.0) 205912	(8.61, N/A) (N/A, -0.05, N/A)	479.7	N/A	0.9683 [ 1.0000 ]	96.8% { 94.1% }			
13C6_PFDA_EIS	(519.0 / 474.0) 254972	(9.29, N/A) (N/A, -0.06, N/A)	408.6	N/A	0.9617 [ 1.0000 ]	96.2% { 90.6% }			
13C7_PFUnA_EIS	(570.0 / 525.0) 331844	(9.70, N/A) (N/A, -0.02, N/A)	703.9	N/A	0.8800 [ 1.0000 ]	88.0% { 83.3% }			





















Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDa_EIS	(615.0 / 570.0) 376028	(9.88, N/A) (N/A, -0.02, N/A)	523.5	N/A	0.9990 [ 1.0000 ]	99.9% { 97.0% }			
13C2_PFTeDA_EIS	(715.0 / 670.0) 294342	(10.11, N/A) (N/A, -0.02, N/A)	600.7	N/A	1.1775 [ 1.0000 ]	117.8% { 121.7% }			
13C3_PFBs_EIS	(302.0 / 80.0) 1302850	(6.09, N/A) (N/A, -0.05, N/A)	735.8	N/A	1.7967 [ 2.0000 ]	89.8% { 94.9% }			
13C3_PFHxS_EIS	(402.0 / 80.0) 708742	(8.01, N/A) (N/A, -0.05, N/A)	751.5	N/A	1.8369 [ 2.0000 ]	91.8% { 94.0% }			
13C8_PFOS_EIS	(507.0 / 80.0) 1147133	(9.43, N/A) (N/A, -0.05, N/A)	153.7	N/A	2.0018 [ 2.0000 ]	100.1% { 96.4% }			
13C2_4:2FTS_EIS	(329.0 / 81.0) 225340	(5.80, N/A) (N/A, -0.05, N/A)	720.4	N/A	3.6689 [ 4.0000 ]	91.7% { 100.5% }			
13C2_6:2FTS_EIS	(429.0 / 81.0) 283858	(7.54, N/A) (N/A, -0.04, N/A)	652.9	N/A	3.8387 [ 4.0000 ]	96.0% { 103.4% }			
13C2_8:2FTS_EIS	(529.0 / 81.0) 276735	(8.95, N/A) (N/A, -0.05, N/A)	514.2	N/A	3.7385 [ 4.0000 ]	93.5% { 93.5% }			
13C8_PFOsa_EIS	(506.0 / 78.0) 1447254	(10.16, N/A) (N/A, -0.02, N/A)	722.4	N/A	1.9979 [ 2.0000 ]	99.9% { 98.8% }			
D3_NMeFOSA_EIS	(515.0 / 169.0) 310344	(10.59, N/A) (N/A, -0.01, N/A)	1001.9	N/A	1.9623 [ 2.0000 ]	98.1% { 94.0% }			
D5_NEiFOSA_EIS	(531.1 / 169.0) 277284	(10.68, N/A) (N/A, -0.01, N/A)	799.4	N/A	1.8992 [ 2.0000 ]	95.0% { 97.4% }			

















Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT- CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
D3_MeFOSAA_EIS	(573.0 / 419.0) 527124	(9.48, N/A) (N/A, -0.05, N/A)	391.6	N/A	3.8683 [ 4.0000 ]	96.7% { 103.2% }			
D5_EtFOSAA_EIS	(589.0 / 419.0) 394245	(9.67, N/A) (N/A, -0.03, N/A)	343.6	N/A	3.2824 [ 4.0000 ]	82.1% { 83.6% }			
D7_NMeFOSE_EIS	(623.2 / 58.9) 378964	(10.56, N/A) (N/A, -0.02, N/A)	878.6	N/A	17.0648 [ 20.0000 ]	85.3% { 87.8% }			
D9_NEtFOSE_EIS	(639.2 / 58.9) 187054	(10.66, N/A) (N/A, -0.02, N/A)	1005.6	N/A	18.5020 [ 20.0000 ]	92.5% { 102.5% }			
13C3_HFPODA_EIS	(287.0 / 169.0) 1123837	(6.48, N/A) (N/A, -0.05, N/A)	699.6	N/A	7.4053 [ 8.0000 ]	92.6% { 95.7% }			












Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBA	(212.9 / 169.0) 15778457	(3.66, 1.00) (0.00, N/A, 0.0)	61.8	N/A 0.0 0.0	201.2526 [ 200.0000 ]	100.6%			
PFPeA	(262.9 / 219.0) 12133479 (262.9 / 69.0) 132475	(4.95, 1.00) (0.00, N/A, 0.1)	828.8 567.2	0.0109 97.5 97.5	97.3969 [ 100.0000 ]	97.4%			
PFHxA	(313.0 / 269.0) 10205443 (313.0 / 119.0) 948352	(6.10, 1.00) (0.00, N/A, -0.2)	779.4 798.1	0.0929 95.0 95.0	48.9028 [ 50.0000 ]	97.8%			
PFHpA	(363.0 / 319.0) 9310576 (363.0 / 169.0) 2680356	(7.03, 1.00) (0.00, N/A, 0.2)	724.8 594.8	0.2879 92.4 92.4	47.8422 [ 50.0000 ]	95.7%			
PFOA	(413.0 / 369.0) 10880930 (413.0 / 169.0) 3245631	(7.85, 1.00) (0.00, N/A, 0.1)	767.4 928.5	0.2983 91.3 91.3	47.1047 [ 50.0000 ]	94.2%			
PFNA	(463.0 / 419.0) 7522680 (463.0 / 169.0) 1650478	(8.59, 1.00) (0.00, N/A, 0.3)	453.6 145.2	0.2194 113.8 113.8	44.6746 [ 50.0000 ]	89.3%			
PFDA	(513.0 / 469.0) 10901269 (513.0 / 169.0) 1054782	(9.27, 1.00) (0.00, N/A, 0.0)	475.9 419.2	0.0968 101.2 101.2	47.0411 [ 50.0000 ]	94.1%			
PFUnA	(563.0 / 519.0) N/A (563.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000 [ 50.0000 ]	N/A%			QC,
PFDoA	(613.0 / 569.0) 13234710 (613.0 / 169.0) 1677806	(9.88, 1.00) (0.00, N/A, 0.0)	801.8 797.3	0.1268 91.1 91.1	43.9737 [ 50.0000 ]	87.9%			
PFTrDA	(663.0 / 619.0) 10582859 (663.0 / 169.0) 2206188	(10.01, 1.01) (N/A, -0.01, 0.1)	667.9 1097.1	0.2085 101.9 101.9	40.5849 [ 50.0000 ]	81.2%			
PFTeDA	(713.0 / 669.0) 7805760 (713.0 / 169.0) 1615620	(10.12, 1.00) (0.00, N/A, 0.2)	709.6 922.1	0.2070 101.8 101.8	43.8879 [ 50.0000 ]	87.8%			












Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBS	(298.9 / 80.0) 14320384 (298.9 / 99.0) 9157257	(6.05, 1.00) (0.00, N/A, 0.0)	609.6 755.2	0.6395 103.9 103.9	41.9991 [ 44.2367 ]	94.9%			
PFPeS	(349.0 / 80.0) 27380308 (349.0 / 99.0) 10684632	(7.10, 0.89) (N/A, -0.08, 0.0)	716.4 803.4	0.3902 109.6 109.6	43.5556 [ 46.9191 ]	92.8%			
PFHxS	(399.0 / 80.0) 23822711 (399.0 / 99.0) 8501412	(7.97, 1.00) (0.00, N/A, 0.2)	3206.8 4858.3	0.3569 106.2 106.2	43.5764 [ 45.5491 ]	95.7%			
PFHpS	(449.0 / 80.0) 21526516 (449.0 / 99.0) 6225213	(8.74, 0.93) (N/A, -0.08, -0.2)	807.9 582.9	0.2892 105.7 105.7	53.6267 [ 47.5703 ]	112.7%			
PFOS	(499.0 / 80.0) 23361916 (499.0 / 99.0) 5350161	(9.42, 1.00) (0.00, N/A, 0.2)	90.6 158.6	0.2290 94.2 94.2	46.7847 [ 46.3746 ]	100.9%			
PFNS	(549.0 / 80.0) 25746195 (549.0 / 99.0) 6429920	(9.75, 1.04) (N/A, -0.02, -0.1)	637.6 712.8	0.2497 102.3 102.3	46.4790 [ 47.9943 ]	96.8%			
PFDS	(599.0 / 80.0) 29991360 (599.0 / 99.0) 7324275	(9.90, 1.05) (N/A, -0.02, 0.0)	1114.1 872.9	0.2442 108.5 108.5	48.7700 [ 48.1553 ]	101.3%			
PFDoS	(698.9 / 80.0) 13570418 (698.9 / 99.0) 2668933	(10.10, 1.07) (N/A, -0.02, 0.0)	1153.0 1114.8	0.1967 80.4 80.4	52.7987 [ 48.4781 ]	108.9%			
4:2FTS	(327.0 / 307.0) 28030184 (327.0 / 81.0) 16838889	(5.77, 1.00) (0.00, N/A, -0.1)	791.1 776.4	0.6007 121.6 121.6	162.6637 [ 186.9055 ]	87.0%			
6:2FTS	(427.0 / 407.0) 17601598 (427.0 / 81.0) 12202144	(7.51, 1.00) (0.01, N/A, 0.1)	1049.9 926.0	0.6932 89.1 89.1	159.3520 [ 189.8085 ]	84.0%			
8:2FTS	(527.0 / 507.0) 17933024 (527.0 / 81.0) 10716573	(8.93, 1.00) (0.00, N/A, 0.1)	442.8 462.7	0.5976 105.6 105.6	159.3327 [ 191.6577 ]	83.1%			








Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFOSA	( 498.0 / 78.0 ) 26488352 ( 498.0 / 478.0 ) 712333	( 10.16 , 1.00 ) ( 0.00 , N/A , 0.0 )	898.9 465.3	0.0269 129.0 129.0	44.9093 [ 50.0000 ]	89.8%			
NMeFOSA	( 511.9 / 219.0 ) 20550926 ( 511.9 / 169.0 ) 14258423	( 10.60 , 1.00 ) ( 0.00 , N/A , 0.0 )	1415.7 1392.1	0.6938 96.3 96.3	154.7837 [ 200.0000 ]	77.4%			
NEIFOSA	( 526.0 / 219.0 ) 20990611 ( 526.0 / 169.0 ) 22220555	( 10.69 , 1.00 ) ( 0.00 , N/A , 0.0 )	1261.8 1236.0	1.0586 100.1 100.1	180.9576 [ 200.0000 ]	90.5%			
NMeFOSAA	( 570.0 / 419.0 ) 4624057 ( 570.0 / 483.0 ) 2546681	( 9.48 , 1.00 ) ( 0.00 , N/A , 0.1 )	612.4 699.2	0.5507 89.6 89.6	52.0507 [ 50.0000 ]	104.1%			
NEIFOSAA	( 584.0 / 419.0 ) 3449541 ( 584.0 / 526.0 ) 2257461	( 9.66 , 1.00 ) ( 0.01 , N/A , 0.1 )	2584.8 1657.6	0.6544 89.3 89.3	44.6984 [ 50.0000 ]	89.4%			
NMeFOSE	( 616.1 / 59.0 ) 4659899	( 10.57 , 1.00 ) ( 0.01 , N/A , 0.0 )	1409.7	N/A 0.0 0.0	193.2279 [ 200.0000 ]	96.6%			
NEtFOSE	( 630.0 / 59.0 ) 761135	( 10.67 , 1.00 ) ( 0.01 , N/A , 0.0 )	1449.6	N/A 0.0 0.0	176.5757 [ 200.0000 ]	88.3%			
HFPO-DA	( 285.0 / 169.0 ) 7283624 ( 285.0 / 185.0 ) 21015218	( 6.45 , 1.00 ) ( 0.00 , N/A , 0.0 )	819.6 766.3	2.8853 105.1 105.1	92.2819 [ 100.0000 ]	92.3%			
ADONA	( 377.0 / 85.0 ) 30997851 ( 377.0 / 251.0 ) 4228517	( 7.35 , 1.14 ) ( N/A , -0.08 , -0.1 )	720.3 754.4	0.1364 109.5 109.5	88.4207 [ 94.2700 ]	93.8%			
9CI-Pf3ONS	( 531.0 / 351.0 ) 59541631 ( 533.0 / 353.0 ) 22562888	( 9.70 , 1.51 ) ( N/A , -0.03 , 0.0 )	623.2 593.5	0.3789 128.0 128.0	93.8486 [ 93.3254 ]	100.6%			
11CI-PF3OUDS	( 631.0 / 451.0 ) 37565149 ( 633.0 / 453.0 ) 12408034	( 9.99 , 1.55 ) ( N/A , -0.02 , 0.0 )	851.2 754.0	0.3303 99.8 99.8	76.6659 [ 94.3208 ]	81.3%			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
3:3FTCA	(241.0 / 177.0) 940591 (241.0 / 117.0) 1590971	(4.43, 0.90) (N/A, -0.08, 0.1)	760.7 709.5	1.6915 101.1 101.1	218.7688 [200.0000]	109.4%			
5:3FTCA	(341.0 / 236.7) 7717092 (341.0 / 217.0) 13002088	(6.73, 1.10) (N/A, -0.09, 0.0)	773.6 732.5	1.6848 115.1 115.1	209.2781 [200.0000]	104.6%			
7:3FTCA	(441.0 / 317.0) 8714946 (441.0 / 337.0) 7497720	(8.55, 1.40) (N/A, -0.08, -0.1)	569.5 568.2	0.8603 102.7 102.7	205.3998 [200.0000]	102.7%			
PFEESA	(315.0 / 135.0) 18885479 (315.0 / 83.0) 5523428	(6.56, 1.07) (N/A, -0.08, 0.1)	779.0 865.9	0.2925 95.3 95.3	82.6581 [89.2459]	92.6%			
PFMPA	(229.0 / 85.0) 3283850	(4.15, 0.84) (N/A, -0.07, 0.0)	1205.9	N/A 0.0 0.0	96.0441 [100.0000]	96.0%			
PFMBA	(279.0 / 85.0) 11632442	(5.34, 1.08) (N/A, -0.09, 0.0)	841.8	N/A 0.0 0.0	98.4289 [100.0000]	98.4%			
NFDHA	(295.0 / 201.0) 10199642 (295.0 / 85.0) 9290082	(5.98, 0.98) (N/A, -0.09, 0.0)	742.8 3901.2	0.9108 103.2 103.2	96.9290 [100.0000]	96.9%			
13C3_PFBA_IIS	(216.0 / 172.0) 117318	(3.66, N/A) (N/A, -0.06, N/A)	626.3	N/A	0.8428 [1.0000]	84.3% {77.3%}			
13C2_PFHxA_IIS	(315.1 / 270.0) 217089	(6.10, N/A) (N/A, -0.08, N/A)	517.0	N/A	0.9401 [1.0000]	94.0% {92.8%}			
13C4_PFOA_IIS	(417.0 / 372.0) 213627	(7.85, N/A) (N/A, -0.08, N/A)	585.4	N/A	0.9717 [1.0000]	97.2% {89.8%}			
13C5_PFNA_IIS	(468.0 / 423.0) 176727	(8.59, N/A) (N/A, -0.07, N/A)	679.2	N/A	0.9543 [1.0000]	95.4% {87.4%}			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDA_IIS	(515.1 / 470.1) 182763	(9.28, N/A) (N/A, -0.07, N/A)	341.1	N/A	0.9889 [ 1.0000 ]	98.9% { 105.1% }			
18O2_PFHxS_IIS	(403.0 / 83.9) 402575	(7.97, N/A) (N/A, -0.08, N/A)	727.1	N/A	0.9972 [ 1.0000 ]	99.7% { 95.2% }			
13C4_PFOS_IIS	(502.8 / 79.9) 278049	(9.42, N/A) (N/A, -0.06, N/A)	306.0	N/A	0.8711 [ 1.0000 ]	87.1% { 84.8% }			
13C4_PFBA_EIS	(217.0 / 172.0) 961408	(3.66, N/A) (N/A, -0.06, N/A)	859.7	N/A	7.9622 [ 8.0000 ]	99.5% { 80.7% }			
13C5_PFPeA_EIS	(267.9 / 223.0) 567388	(4.95, N/A) (N/A, -0.09, N/A)	677.6	N/A	3.7563 [ 4.0000 ]	93.9% { 81.5% }			
13C5_PFHxA_EIS	(318.0 / 273.0) 485987	(6.10, N/A) (N/A, -0.09, N/A)	662.7	N/A	1.9454 [ 2.0000 ]	97.3% { 90.2% }			
13C4_PFHpA_EIS	(367.0 / 322.0) 426996	(7.03, N/A) (N/A, -0.08, N/A)	645.9	N/A	1.9593 [ 2.0000 ]	98.0% { 87.0% }			
13C8_PFOA_EIS	(421.0 / 376.0) 469799	(7.85, N/A) (N/A, -0.08, N/A)	623.6	N/A	2.0053 [ 2.0000 ]	100.3% { 94.4% }			
13C9_PFNA_EIS	(472.0 / 427.0) 196241	(8.59, N/A) (N/A, -0.08, N/A)	331.3	N/A	1.0098 [ 1.0000 ]	101.0% { 89.7% }			
13C6_PFDA_EIS	(519.0 / 474.0) 243463	(9.27, N/A) (N/A, -0.07, N/A)	373.7	N/A	0.9366 [ 1.0000 ]	93.7% { 86.6% }			
13C7_PFUnA_EIS	(570.0 / 525.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A	N/A	0.0000 [ 1.0000 ]	0.0% { 0.0% }			S1,

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDa_EIS	(615.0 / 570.0) 349119	(9.88, N/A) (N/A, -0.02, N/A)	640.2	N/A	0.9461 [ 1.0000 ]	94.6% { 90.1% }			
13C2_PFTeDA_EIS	(715.0 / 670.0) 200679	(10.12, N/A) (N/A, -0.01, N/A)	414.7	N/A	0.8188 [ 1.0000 ]	81.9% { 83.0% }			
13C3_PFBs_EIS	(302.0 / 80.0) 1243843	(6.05, N/A) (N/A, -0.09, N/A)	653.6	N/A	1.8274 [ 2.0000 ]	91.4% { 90.6% }			
13C3_PFHxS_EIS	(402.0 / 80.0) 703772	(7.97, N/A) (N/A, -0.08, N/A)	1021.2	N/A	1.9433 [ 2.0000 ]	97.2% { 93.4% }			
13C8_PFOS_EIS	(507.0 / 80.0) 920090	(9.42, N/A) (N/A, -0.07, N/A)	82.3	N/A	1.9281 [ 2.0000 ]	96.4% { 77.3% }			
13C2_4:2FTS_EIS	(329.0 / 81.0) 208461	(5.77, N/A) (N/A, -0.09, N/A)	614.0	N/A	3.6160 [ 4.0000 ]	90.4% { 93.0% }			
13C2_6:2FTS_EIS	(429.0 / 81.0) 287362	(7.50, N/A) (N/A, -0.08, N/A)	693.3	N/A	4.1402 [ 4.0000 ]	103.5% { 104.7% }			
13C2_8:2FTS_EIS	(529.0 / 81.0) 284164	(8.92, N/A) (N/A, -0.08, N/A)	462.0	N/A	4.0898 [ 4.0000 ]	102.2% { 96.0% }			
13C8_PFOsa_EIS	(506.0 / 78.0) 1248175	(10.16, N/A) (N/A, -0.02, N/A)	697.4	N/A	2.0692 [ 2.0000 ]	103.5% { 85.2% }			
D3_NMeFOSA_EIS	(515.0 / 169.0) 325759	(10.60, N/A) (N/A, -0.01, N/A)	1257.7	N/A	2.4735 [ 2.0000 ]	123.7% { 98.7% }			
D5_NEtFOSA_EIS	(531.1 / 169.0) 257195	(10.69, N/A) (N/A, -0.01, N/A)	672.7	N/A	2.1155 [ 2.0000 ]	105.8% { 90.4% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT- CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
D3_MeFOSAA_EIS	(573.0 / 419.0) 455998	(9.47, N/A) (N/A, -0.06, N/A)	320.1	N/A	4.0185 [ 4.0000 ]	100.5% { 89.3% }			
D5_EtFOSAA_EIS	(589.0 / 419.0) 343842	(9.66, N/A) (N/A, -0.04, N/A)	325.4	N/A	3.4378 [ 4.0000 ]	85.9% { 73.0% }			
D7_NMeFOSE_EIS	(623.2 / 58.9) 382126	(10.56, N/A) (N/A, -0.01, N/A)	1054.7	N/A	20.6637 [ 20.0000 ]	103.3% { 88.5% }			
D9_NEtFOSE_EIS	(639.2 / 58.9) 168371	(10.66, N/A) (N/A, -0.01, N/A)	1121.1	N/A	19.9994 [ 20.0000 ]	100.0% { 92.3% }			
13C3_HFPODA_EIS	(287.0 / 169.0) 1038848	(6.44, N/A) (N/A, -0.08, N/A)	965.8	N/A	7.8213 [ 8.0000 ]	97.8% { 88.4% }			

**SECOND-SOURCE CALIBRATION VERIFICATION****EPA 1633****Laboratory:** APPL, LLC**SDG:****Client:** AECOM**Project:** Red Hill AFFF Assessment Sampling**Calibration:** 2252011**Laboratory ID:** SB03941-SCV1**Sequence:** SB03941**Standard ID:** 22L0308

<b>ANALYTE</b>	<b>EXPECTED (ng/mL)</b>	<b>FOUND (ng/mL)</b>	<b>% DRIFT</b>	<b>QC LIMIT</b>
PFBA	8.00	7.99	-0.1	30.00
PFPEA	4.00	4.05	1.3	30.00
PFHXA	2.00	2.06	2.9	30.00
PFHPA	2.00	1.83	-8.4	30.00
PFOA	2.00	1.92	-4.0	30.00
PFNA	2.00	1.98	-1.0	30.00
PFDA	2.00	1.94	-3.0	30.00
PFUnA	2.00	2.01	0.6	30.00
PFDOA	2.00	1.94	-2.8	30.00
PFTRDA	2.00	2.06	3.0	30.00
PFTEDA	2.00	2.52	25.9	30.00
PFBS	1.77	1.80	1.7	30.00
PFPEs	1.88	1.90	1.2	30.00
PFHXS	1.83	1.70	-7.0	30.00
PFHPS	1.91	1.91	-0.1	30.00
PFOS	1.86	1.92	3.4	30.00
PFNS	1.92	2.20	14.7	30.00
PFDS	1.93	2.24	16.0	30.00
PFDOS	1.94	2.09	7.7	30.00
4:2FTS	7.50	7.40	-1.3	30.00
6:2FTS	7.60	7.32	-3.6	30.00
8:2FTS	7.68	8.45	10.0	30.00
PFOSA	2.00	1.87	-6.3	30.00
NMeFOSA	8.00	7.40	-7.5	30.00
NEtFOSA	8.00	7.80	-2.5	30.00
NMeFOSAA	2.00	2.24	11.9	30.00
NEtFOSAA	2.00	1.95	-2.5	30.00

**SECOND-SOURCE CALIBRATION VERIFICATION****EPA 1633****Laboratory:** APPL, LLC**SDG:****Client:** AECOM**Project:** Red Hill AFFF Assessment Sampling**Calibration:** 2252011**Laboratory ID:** SB03941-SCV1**Sequence:** SB03941**Standard ID:** 22L0308






















NMeFOSE	8.00	7.20	-10.0	30.00
NEtFOSE	8.00	7.47	-6.6	30.00
HFPO-DA	4.00	3.77	-5.8	30.00
ADONA	3.78	3.68	-2.6	30.00
PFEESA	3.56	3.55	-0.3	30.00
PFMPA	4.00	3.70	-7.5	30.00
PFMBA	4.00	3.61	-9.8	30.00
NFDHA	4.00	3.97	-0.8	30.00
9CL-PF3ONS	3.74	3.62	-3.2	30.00
11CL-PF3OUDS	3.78	3.53	-6.6	30.00
3:3FTCA	8.00	7.48	-6.5	30.00
5:3FTCA	8.00	8.11	1.4	30.00
7:3FTCA	8.00	8.03	0.3	30.00
13C4-PFBA	8.00	8.64	8.0	30.00
13C5-PFPEA	4.00	4.71	17.7	30.00
13C5-PFHXA	2.00	2.18	8.9	30.00
13C4-PFHPA	2.00	2.44	22.0	30.00
13C8-PFOA	2.00	2.51	25.6	30.00
13C9-PFNA	1.00	1.15	15.1	30.00
13C6-PFDA	1.00	1.02	1.6	30.00
13C7-PFUnA	1.00	1.01	0.9	30.00
13C2-PFDOA	1.00	1.12	12.1	30.00
13C2-PFTEDA	1.00	0.926	-7.4	30.00
13C3-PFBS	2.00	2.14	7.0	30.00
13C3-PFHXS	2.00	2.11	5.5	30.00
13C8-PFOS	2.00	2.03	1.7	30.00
13C2-4:2FTS	4.00	4.28	7.0	30.00
13C2-6:2FTS	4.00	4.19	4.8	30.00
13C2-8:2FTS	4.00	4.81	20.3	30.00























**SECOND-SOURCE CALIBRATION VERIFICATION****EPA 1633****Laboratory:** APPL, LLC**SDG:****Client:** AECOM**Project:** Red Hill AFFF Assessment Sampling**Calibration:** 2252011**Laboratory ID:** SB03941-SCV1**Sequence:** SB03941**Standard ID:** 22L0308

13C8-PFOSA	2.00	2.54	26.8	30.00
D5-NETFOSA	2.00	2.46	23.2	30.00
D3-NMEFOSA	2.00	2.31	15.5	30.00
D3-NMEFOSAA	4.00	3.87	-3.3	30.00
D5-NETFOSAA	4.00	4.12	3.0	30.00
D7-NMEFOSE	20.0	22.3	11.5	30.00
D9-NETFOSSE	20.0	21.7	8.5	30.00
13C3-HFPO-DA	8.00	9.26	15.7	30.00

\* Values outside of QC limits



Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBA	(212.9 / 169.0) 826160	(3.82, 1.00) (0.00, N/A, 0.0)	66.3	N/A 0.0 0.0	7.9908 [ 8.0000 ]	99.9%			
PFPeA	(262.9 / 219.0) 615408 (262.9 / 69.0) 7099	(5.15, 1.00) (0.00, N/A, 0.4)	793.3 166.5	0.0115 103.1 103.1	4.0518 [ 4.0000 ]	101.3%			
PFHxA	(313.0 / 269.0) 467843 (313.0 / 119.0) 45951	(6.26, 1.00) (0.00, N/A, 0.1)	507.4 322.7	0.0982 100.5 100.5	2.0587 [ 2.0000 ]	102.9%			
PFHpA	(363.0 / 319.0) 432075 (363.0 / 169.0) 138649	(7.15, 1.00) (0.00, N/A, 0.1)	541.7 385.0	0.3209 103.0 103.0	1.8321 [ 2.0000 ]	91.6%			
PFOA	(413.0 / 369.0) 540570 (413.0 / 169.0) 167693	(7.94, 1.00) (0.00, N/A, -0.3)	662.9 505.8	0.3102 94.9 94.9	1.9199 [ 2.0000 ]	96.0%			
PFNA	(463.0 / 419.0) 409308 (463.0 / 169.0) 78936	(8.66, 1.00) (0.00, N/A, -0.2)	495.2 94.8	0.1929 100.1 100.1	1.9793 [ 2.0000 ]	99.0%			
PFDA	(513.0 / 469.0) 482820 (513.0 / 169.0) 47535	(9.32, 1.00) (0.00, N/A, -0.3)	450.3 235.5	0.0985 103.0 103.0	1.9394 [ 2.0000 ]	97.0%			
PFUnA	(563.0 / 519.0) 587146 (563.0 / 169.0) 44298	(9.72, 1.00) (0.00, N/A, 0.0)	626.0 279.6	0.0754 86.9 86.9	2.0110 [ 2.0000 ]	100.6%			
PFDoA	(613.0 / 569.0) 686509 (613.0 / 169.0) 89917	(9.89, 1.00) (0.00, N/A, 0.0)	663.9 317.2	0.1310 94.1 94.1	1.9439 [ 2.0000 ]	97.2%			
PFTrDA	(663.0 / 619.0) 630517 (663.0 / 169.0) 105737	(10.02, 1.01) (N/A, -0.01, -0.3)	802.7 413.6	0.1677 81.9 81.9	2.0607 [ 2.0000 ]	103.0%			
PFTeDA	(713.0 / 669.0) 501366 (713.0 / 169.0) 87460	(10.12, 1.00) (0.00, N/A, 0.2)	703.1 221.5	0.1744 85.8 85.8	2.5178 [ 2.0000 ]	125.9%			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBS	(298.9 / 80.0) 721250 (298.9 / 99.0) 444102	(6.22, 1.00) (0.00, N/A, 0.0)	841.6 645.4	0.6157 100.0 100.0	1.7993 [ 1.7695 ]	101.7%			
PFPeS	(349.0 / 80.0) 1304493 (349.0 / 99.0) 488870	(7.22, 0.90) (N/A, 0.04, -0.1)	955.5 884.4	0.3748 105.3 105.3	1.9033 [ 1.8768 ]	101.4%			
PFHxS	(399.0 / 80.0) 1014894 (399.0 / 99.0) 344027	(8.06, 1.00) (0.00, N/A, 0.0)	2419.1 74677.8	0.3390 100.8 100.8	1.7027 [ 1.8220 ]	93.5%			
PFHpS	(449.0 / 80.0) 879262 (449.0 / 99.0) 257815	(8.81, 0.93) (N/A, -0.01, -0.3)	667.5 488.6	0.2932 107.1 107.1	1.9077 [ 1.9028 ]	100.3%			
PFOS	(499.0 / 80.0) 1102928 (499.0 / 99.0) 236253	(9.46, 1.00) (0.00, N/A, 0.1)	115.1 129.8	0.2142 88.1 88.1	1.9236 [ 1.8550 ]	103.7%			
PFNS	(549.0 / 80.0) 1400580 (549.0 / 99.0) 348700	(9.77, 1.03) (N/A, -0.01, 0.0)	867.1 541.9	0.2490 102.0 102.0	2.2021 [ 1.9198 ]	114.7%			
PFDS	(599.0 / 80.0) 1581305 (599.0 / 99.0) 390095	(9.91, 1.05) (N/A, -0.01, 0.2)	992.5 464.1	0.2467 109.6 109.6	2.2395 [ 1.9262 ]	116.3%			
PFDoS	(698.9 / 80.0) 616747 (698.9 / 99.0) 133778	(10.11, 1.07) (N/A, -0.01, 0.0)	738.0 572.8	0.2169 88.7 88.7	2.0898 [ 1.9391 ]	107.8%			
4:2FTS	(327.0 / 307.0) 1514379 (327.0 / 81.0) 770935	(5.94, 1.00) (0.00, N/A, -0.1)	803.6 624.3	0.5091 103.1 103.1	7.3999 [ 7.4762 ]	99.0%			
6:2FTS	(427.0 / 407.0) 821840 (427.0 / 81.0) 567834	(7.60, 1.00) (0.00, N/A, 0.1)	946.6 705.6	0.6909 88.8 88.8	7.3229 [ 7.5923 ]	96.5%			
8:2FTS	(527.0 / 507.0) 1122259 (527.0 / 81.0) 538134	(8.98, 1.00) (0.00, N/A, -0.3)	414.3 515.2	0.4795 84.7 84.7	8.4461 [ 7.6663 ]	110.2%			






























Chemist: ABK  
 Instrument: Saphira  
 Type: Sciex Q3 5500












Sample I.D.: SB03941-SCV1  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - S2022-12-21A  
 Path: S2022-12-21A (10)  
 Acquired: 2022/12/21 - 16:20

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-[min], ΔRT-CV[min], ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFOSA	( 498.0 / 78.0 ) 1474063 ( 498.0 / 478.0 ) 37178	( 10.17 , 1.00 ) ( 0.00 , N/A , -0.1)	843.1 534.3	0.0252 121.0 121.0	1.8741 [ 2.0000 ]	93.7%			
NMeFOSA	( 511.9 / 219.0 ) 999598 ( 511.9 / 169.0 ) 689735	( 10.60 , 1.00 ) ( 0.00 , N/A , 0.0)	861.8 1151.0	0.6900 95.8 95.8	7.4034 [ 8.0000 ]	92.5%			
NEIFOSA	( 526.0 / 219.0 ) 1146883 ( 526.0 / 169.0 ) 1178077	( 10.69 , 1.00 ) ( 0.00 , N/A , 0.0)	1268.4 1089.4	1.0272 97.1 97.1	7.8009 [ 8.0000 ]	97.5%			
NMeFOSAA	( 570.0 / 419.0 ) 208249 ( 570.0 / 483.0 ) 104771	( 9.51 , 1.00 ) ( 0.00 , N/A , 0.2)	375.1 198.5	0.5031 81.8 81.8	2.2376 [ 2.0000 ]	111.9%			
NEIFOSAA	( 584.0 / 419.0 ) 196413 ( 584.0 / 526.0 ) 111297	( 9.69 , 1.00 ) ( 0.01 , N/A , 0.2)	455.1 117896.6	0.5666 77.3 77.3	1.9508 [ 2.0000 ]	97.5%			
NMeFOSE	( 616.1 / 59.0 ) 203936	( 10.57 , 1.00 ) ( 0.01 , N/A , 0.0)	1358.7	N/A 0.0 0.0	7.2019 [ 8.0000 ]	90.0%			
NEtFOSE	( 630.0 / 59.0 ) 38033	( 10.67 , 1.00 ) ( 0.01 , N/A , 0.0)	607.4	N/A 0.0 0.0	7.4728 [ 8.0000 ]	93.4%			
HFPO-DA	( 285.0 / 169.0 ) 342689 ( 285.0 / 185.0 ) 1020987	( 6.59 , 1.00 ) ( 0.00 , N/A , -0.1)	626.5 698.6	2.9793 108.5 108.5	3.7699 [ 4.0000 ]	94.2%			
ADONA	( 377.0 / 85.0 ) 1486505 ( 377.0 / 251.0 ) 199325	( 7.46 , 1.13 ) ( N/A , 0.03 , 0.1)	678.2 385.1	0.1341 107.7 107.7	3.6817 [ 3.7708 ]	97.6%			
9CI-Pf3ONS	( 531.0 / 351.0 ) 4066455 ( 533.0 / 353.0 ) 1234707	( 9.72 , 1.47 ) ( N/A , -0.01 , 0.0)	855.0 727.0	0.3036 102.6 102.6	3.6202 [ 3.7330 ]	97.0%			
11CI-PF3OUDS	( 631.0 / 451.0 ) 1991501 ( 633.0 / 453.0 ) 617773	( 10.00 , 1.52 ) ( N/A , -0.01 , 0.0)	1070.3 1217.2	0.3102 93.8 93.8	3.5291 [ 3.7728 ]	93.5%			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
3:3FTCA	(241.0 / 177.0) 39196 (241.0 / 117.0) 66770	(4.64, 0.90) (N/A, 0.12, 0.0)	403.7 453.1	1.7035 101.8 101.8	7.4773 [ 8.0000 ]	93.5%			
5:3FTCA	(341.0 / 236.7) 325755 (341.0 / 217.0) 500274	(6.87, 1.10) (N/A, 0.05, 0.0)	422.5 555.2	1.5357 104.9 104.9	8.1123 [ 8.0000 ]	101.4%			
7:3FTCA	(441.0 / 317.0) 370796 (441.0 / 337.0) 321550	(8.63, 1.38) (N/A, 0.00, 0.0)	380.2 406.9	0.8672 103.5 103.5	8.0251 [ 8.0000 ]	100.3%			
PFEESA	(315.0 / 135.0) 883452 (315.0 / 83.0) 263398	(6.70, 1.07) (N/A, 0.06, 0.2)	692.7 623.8	0.2981 97.1 97.1	3.5508 [ 3.5698 ]	99.5%			
PFMPA	(229.0 / 85.0) 154156	(4.34, 0.84) (N/A, 0.12, 0.0)	850.9	N/A 0.0 0.0	3.6980 [ 4.0000 ]	92.5%			
PFMBA	(279.0 / 85.0) 519912	(5.53, 1.07) (N/A, 0.11, 0.0)	881.8	N/A 0.0 0.0	3.6083 [ 4.0000 ]	90.2%			
NFDHA	(295.0 / 201.0) 454901 (295.0 / 85.0) 446222	(6.14, 0.98) (N/A, 0.08, -0.1)	909.2 665.8	0.9809 111.1 111.1	3.9698 [ 4.0000 ]	99.2%			
13C3_PFBA_IIS	(216.0 / 172.0) 142617	(3.82, N/A) (N/A, 0.11, N/A)	772.3	N/A	1.0246 [ 1.0000 ]	102.5% { 94.0% }			
13C2_PFHxA_IIS	(315.1 / 270.0) 211230	(6.26, N/A) (N/A, 0.07, N/A)	637.8	N/A	0.9147 [ 1.0000 ]	91.5% { 90.3% }			
13C4_PFOA_IIS	(417.0 / 372.0) 207848	(7.94, N/A) (N/A, 0.01, N/A)	791.1	N/A	0.9454 [ 1.0000 ]	94.5% { 87.3% }			
13C5_PFNA_IIS	(468.0 / 423.0) 190473	(8.66, N/A) (N/A, -0.01, N/A)	365.8	N/A	1.0286 [ 1.0000 ]	102.9% { 94.2% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDA_IIS	(515.1 / 470.1) 180965	(9.33, N/A) (N/A, -0.02, N/A)	300.8	N/A	0.9792 [ 1.0000 ]	97.9% { 104.1% }			
18O2_PFHxS_IIS	(403.0 / 83.9) 404075	(8.06, N/A) (N/A, 0.01, N/A)	755.5	N/A	1.0009 [ 1.0000 ]	100.1% { 95.6% }			
13C4_PFOS_IIS	(502.8 / 79.9) 302637	(9.46, N/A) (N/A, -0.02, N/A)	490.6	N/A	0.9482 [ 1.0000 ]	94.8% { 92.3% }			
13C4_PFBA_EIS	(217.0 / 172.0) 1267826	(3.82, N/A) (N/A, 0.10, N/A)	950.4	N/A	8.6374 [ 8.0000 ]	108.0% { 106.5% }			
13C5_PFPeA_EIS	(267.9 / 223.0) 691765	(5.15, N/A) (N/A, 0.12, N/A)	655.0	N/A	4.7068 [ 4.0000 ]	117.7% { 99.4% }			
13C5_PFHxA_EIS	(318.0 / 273.0) 529227	(6.26, N/A) (N/A, 0.07, N/A)	586.3	N/A	2.1772 [ 2.0000 ]	108.9% { 98.2% }			
13C4_PFHpA_EIS	(367.0 / 322.0) 517454	(7.15, N/A) (N/A, 0.04, N/A)	625.4	N/A	2.4402 [ 2.0000 ]	122.0% { 105.4% }			
13C8_PFOA_EIS	(421.0 / 376.0) 572643	(7.94, N/A) (N/A, 0.01, N/A)	628.4	N/A	2.5123 [ 2.0000 ]	125.6% { 115.1% }			
13C9_PFNA_EIS	(472.0 / 427.0) 241000	(8.66, N/A) (N/A, -0.01, N/A)	482.3	N/A	1.1506 [ 1.0000 ]	115.1% { 110.2% }			
13C6_PFDA_EIS	(519.0 / 474.0) 261552	(9.32, N/A) (N/A, -0.02, N/A)	324.9	N/A	1.0162 [ 1.0000 ]	101.6% { 93.0% }			
13C7_PFUnA_EIS	(570.0 / 525.0) 369444	(9.72, N/A) (N/A, -0.01, N/A)	383.8	N/A	1.0092 [ 1.0000 ]	100.9% { 92.7% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDa_EIS	(615.0 / 570.0) 409663	(9.90, N/A) (N/A, -0.01, N/A)	784.5	N/A	1.1211 [ 1.0000 ]	112.1% { 105.7% }			
13C2_PFTeDA_EIS	(715.0 / 670.0) 224684	(10.12, N/A) (N/A, -0.01, N/A)	303.5	N/A	0.9259 [ 1.0000 ]	92.6% { 92.9% }			
13C3_PFBs_EIS	(302.0 / 80.0) 1462249	(6.22, N/A) (N/A, 0.08, N/A)	885.8	N/A	2.1403 [ 2.0000 ]	107.0% { 106.5% }			
13C3_PFHxS_EIS	(402.0 / 80.0) 767313	(8.06, N/A) (N/A, 0.01, N/A)	732.1	N/A	2.1109 [ 2.0000 ]	105.5% { 101.8% }			
13C8_PFOS_EIS	(507.0 / 80.0) 1056462	(9.46, N/A) (N/A, -0.02, N/A)	326.6	N/A	2.0340 [ 2.0000 ]	101.7% { 88.8% }			
13C2_4:2FTS_EIS	(329.0 / 81.0) 247570	(5.94, N/A) (N/A, 0.09, N/A)	728.4	N/A	4.2784 [ 4.0000 ]	107.0% { 110.5% }			
13C2_6:2FTS_EIS	(429.0 / 81.0) 291971	(7.60, N/A) (N/A, 0.02, N/A)	611.1	N/A	4.1910 [ 4.0000 ]	104.8% { 106.4% }			
13C2_8:2FTS_EIS	(529.0 / 81.0) 335471	(8.99, N/A) (N/A, -0.02, N/A)	757.5	N/A	4.8103 [ 4.0000 ]	120.3% { 113.3% }			
13C8_PFOsa_EIS	(506.0 / 78.0) 1664459	(10.17, N/A) (N/A, -0.01, N/A)	652.8	N/A	2.5352 [ 2.0000 ]	126.8% { 113.6% }			
D3_NMeFOSA_EIS	(515.0 / 169.0) 331270	(10.60, N/A) (N/A, -0.01, N/A)	916.6	N/A	2.3109 [ 2.0000 ]	115.5% { 100.4% }			
D5_NEiFOSA_EIS	(531.1 / 169.0) 325977	(10.69, N/A) (N/A, -0.01, N/A)	1349.4	N/A	2.4634 [ 2.0000 ]	123.2% { 114.5% }			



Chemist: ABK  
 Instrument: Saphira  
 Type: Sciex Q3 5500

Sample I.D.: SB03941-SCV1  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - S2022-12-21A  
 Path: S2022-12-21A (10)  
 Acquired: 2022/12/21 - 16:20

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-I[min], ΔRT-CV[min], ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
D3_MeFOSAA_EIS	(573.0 / 419.0) 477723	(9.51, N/A) (N/A, -0.02, N/A)	407.1	N/A	3.8679 [ 4.0000 ]	96.7% { 93.6% }			
D5_EtFOSAA_EIS	(589.0 / 419.0) 448595	(9.68, N/A) (N/A, -0.01, N/A)	368.4	N/A	4.1207 [ 4.0000 ]	103.0% { 95.2% }			
D7_NMeFOSE_EIS	(623.2 / 58.9) 448688	(10.57, N/A) (N/A, -0.01, N/A)	1653.3	N/A	22.2917 [ 20.0000 ]	111.5% { 104.0% }			
D9_NEtFOSE_EIS	(639.2 / 58.9) 198798	(10.66, N/A) (N/A, -0.01, N/A)	1695.3	N/A	21.6950 [ 20.0000 ]	108.5% { 109.0% }			
13C3_HFPODA_EIS	(287.0 / 169.0) 1196436	(6.59, N/A) (N/A, 0.06, N/A)	797.8	N/A	9.2576 [ 8.0000 ]	115.7% { 101.9% }			

# LOW-CONCENTRATION CALIBRATION VERIFICATION

EPA 1633

Laboratory: APPL, LLC

SDG:

Client: AECOM

Project: Red Hill AFFF Assessment Sampling

Calibration: 2252011

Laboratory ID: SB03951-LCV1

Sequence: SB03951

Standard ID: 22L0300






















ANALYTE	EXPECTED (ng/mL)	FOUND (ng/mL)	% DRIFT	QC LIMIT
PFBA	0.400	0.398	-0.5	30.00
PFPEA	0.200	0.213	6.4	30.00
PFHXA	0.100	0.115	15.1	30.00
PFHPA	0.100	0.103	2.5	30.00
PFOA	0.100	0.109	8.8	30.00
PFNA	0.100	0.117	17.1	30.00
PFDA	0.100	0.110	9.9	30.00
PFUnA	0.100	0.106	6.3	30.00
PFDOA	0.100	0.0924	-7.6	30.00
PFTRDA	0.100	0.115	15.3	30.00
PFTEDA	0.100	0.139	38.7 *	30.00
PFBS	0.0885	0.0780	-11.8	30.00
PFPEs	0.0940	0.0881	-6.3	30.00
PFHXS	0.0915	0.0946	3.4	30.00
PFHPS	0.0955	0.110	15.0	30.00
PFOS	0.0930	0.115	24.0	30.00
PFNS	0.0960	0.106	10.8	30.00
PFDS	0.0965	0.123	28.0	30.00
PFDOS	0.0970	0.106	9.2	30.00
4:2FTS	0.375	0.314	-16.4	30.00
6:2FTS	0.380	0.410	7.8	30.00
8:2FTS	0.384	0.357	-7.1	30.00
PFOSA	0.100	0.115	14.9	30.00
NMeFOSA	0.400	0.471	17.7	30.00
NEtFOSA	0.400	0.442	10.5	30.00
NMeFOSAA	0.100	0.111	10.7	30.00
NEtFOSAA	0.100	0.0789	-21.1	30.00
NMeFOSE	0.400	0.426	6.4	30.00













































**LOW-CONCENTRATION CALIBRATION VERIFICATION****EPA 1633****Laboratory:** APPL, LLC**SDG:****Client:** AECOM**Project:** Red Hill AFFF Assessment Sampling**Calibration:** 2252011**Laboratory ID:** SB03951-LCV1**Sequence:** SB03951**Standard ID:** 22L0300

















NEFOSE	0.400	0.324	-19.0	30.00
HFPO-DA	0.200	0.180	-10.0	30.00
ADONA	0.189	0.185	-2.1	30.00
PFEESA	0.178	0.165	-7.4	30.00
PFMPA	0.200	0.205	2.6	30.00
PFMBA	0.200	0.188	-5.9	30.00
NFDHA	0.200	0.222	11.0	30.00
9CL-PF3ONS	0.187	0.164	-12.1	30.00
11CL-PF3OUDS	0.189	0.164	-13.3	30.00
3:3FTCA	0.400	0.377	-5.8	30.00
5:3FTCA	0.400	0.426	6.6	30.00
7:3FTCA	0.400	0.434	8.4	30.00












\* Values outside of QC limits












Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBA	(212.9 / 169.0) 43849	(3.72, 1.00) (0.00, N/A, 0.0)	47.4	N/A 0.0 0.0	0.3982 [0.4000]	99.5%			
PFPeA	(262.9 / 219.0) 33025 (262.9 / 69.0) 324	(5.05, 1.00) (0.00, N/A, 0.9)	187.3 9.9	0.0098 87.6 94.3	0.2128 [0.2000]	106.4%			
PFHxA	(313.0 / 269.0) 28190 (313.0 / 119.0) 2074	(6.19, 1.00) (0.00, N/A, -0.4)	102.9 39.3	0.0736 75.3 82.4	0.1151 [0.1000]	115.1%			
PFHpA	(363.0 / 319.0) 21648 (363.0 / 169.0) 5491	(7.11, 1.00) (0.00, N/A, 0.0)	89.2 55.5	0.2536 81.4 82.3	0.1025 [0.1000]	102.5%			
PFOA	(413.0 / 369.0) 27606 (413.0 / 169.0) 10696	(7.92, 1.00) (0.00, N/A, 0.3)	133.0 99.0	0.3875 118.6 131.0	0.1088 [0.1000]	108.8%			
PFNA	(463.0 / 419.0) 20286 (463.0 / 169.0) 6368	(8.65, 1.00) (0.01, N/A, 0.5)	126.3 83.9	0.3139 162.9 150.7	0.1171 [0.1000]	117.1%			IR2,
PFDA	(513.0 / 469.0) 29031 (513.0 / 169.0) 2696	(9.32, 1.00) (0.00, N/A, 0.0)	183.4 70.6	0.0929 97.2 94.5	0.1099 [0.1000]	109.9%			
PFUnA	(563.0 / 519.0) 31385 (563.0 / 169.0) 5290	(9.71, 1.00) (0.00, N/A, -1.0)	139.2 130.3	0.1686 194.1 188.0	0.1063 [0.1000]	106.3%			IR2,
PFDoA	(613.0 / 569.0) 28685 (613.0 / 169.0) 8034	(9.88, 1.00) (0.00, N/A, 0.0)	130.3 115.9	0.2801 201.2 213.0	0.0924 [0.1000]	92.4%			IR2,
PFTTrDA	(663.0 / 619.0) 31017 (663.0 / 169.0) 10350	(10.01, 1.01) (N/A, -0.01, 0.3)	367.3 68.0	0.3337 163.0 146.0	0.1153 [0.1000]	115.3%			IR2,
PFTeDA	(713.0 / 669.0) 26604 (713.0 / 169.0) 5809	(10.11, 1.00) (0.00, N/A, 0.5)	18.7 35.2	0.2183 107.3 106.4	0.1387 [0.1000]	138.7%			QC,

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBS	(298.9 / 80.0) 30593 (298.9 / 99.0) 24923	(6.14, 1.00) (0.00, N/A, 0.0)	223.0 187.4	0.8147 132.4 124.4	0.0780 [0.0885]	88.2%			
PFPeS	(349.0 / 80.0) 62381 (349.0 / 99.0) 22889	(7.18, 0.89) (N/A, 0.06, 0.0)	234.7 196.1	0.3669 103.1 95.5	0.0881 [0.0938]	93.8%			
PFHxS	(399.0 / 80.0) 58273 (399.0 / 99.0) 18743	(8.03, 1.00) (0.00, N/A, 0.1)	828.8 6172.7	0.3216 95.7 97.2	0.0946 [0.0911]	103.8%			
PFHpS	(449.0 / 80.0) 53380 (449.0 / 99.0) 15272	(8.80, 0.93) (N/A, 0.03, 0.1)	299.9 145.3	0.2861 104.5 112.5	0.1098 [0.0951]	115.4%			
PFOS	(499.0 / 80.0) 69748 (499.0 / 99.0) 13321	(9.45, 1.00) (0.00, N/A, 0.2)	144.6 68.1	0.1910 78.5 83.5	0.1153 [0.0927]	124.4%			
PFNS	(549.0 / 80.0) 71336 (549.0 / 99.0) 12422	(9.76, 1.03) (N/A, 0.00, 0.1)	277.5 189.8	0.1741 71.4 68.2	0.1063 [0.0960]	110.8%			
PFDS	(599.0 / 80.0) 91956 (599.0 / 99.0) 16604	(9.91, 1.05) (N/A, 0.00, 0.3)	317.6 111.6	0.1806 80.2 77.2	0.1235 [0.0963]	128.2%			
PFDoS	(698.9 / 80.0) 32962 (698.9 / 99.0) 9833	(10.11, 1.07) (N/A, 0.00, 1.3)	264.4 17.8	0.2983 121.9 153.7	0.1059 [0.0970]	109.2%			IR2,
4:2FTS	(327.0 / 307.0) 70063 (327.0 / 81.0) 46903	(5.87, 1.00) (0.01, N/A, 0.0)	399.9 154.7	0.6694 135.5 116.9	0.3137 [0.3738]	83.9%			
6:2FTS	(427.0 / 407.0) 48949 (427.0 / 81.0) 40250	(7.58, 1.00) (0.00, N/A, 0.1)	138.4 212.7	0.8223 105.7 117.9	0.4098 [0.3796]	107.9%			
8:2FTS	(527.0 / 507.0) 39792 (527.0 / 81.0) 32476	(8.98, 1.00) (0.00, N/A, 0.1)	340.0 177.0	0.8161 144.2 148.2	0.3567 [0.3833]	93.1%			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT-CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFOSA	(498.0 / 78.0) 84737 (498.0 / 478.0) 2413	(10.17, 1.00) (0.00, N/A, -0.7)	370.7 66.5	0.0285 136.6 117.4	0.1149 [0.1000]	114.9%			
NMeFOSA	(511.9 / 219.0) 60872 (511.9 / 169.0) 33917	(10.60, 1.00) (0.00, N/A, -0.1)	625.6 398.7	0.5572 77.4 82.4	0.4706 [0.4000]	117.7%			
NEIFOSA	(526.0 / 219.0) 58190 (526.0 / 169.0) 61870	(10.69, 1.00) (0.00, N/A, -0.1)	585.9 547.8	1.0633 100.5 100.3	0.4419 [0.4000]	110.5%			
NMeFOSAA	(570.0 / 419.0) 11247 (570.0 / 483.0) 3240	(9.51, 1.00) (0.01, N/A, -0.1)	88.9 44.7	0.2881 46.9 57.6	0.1107 [0.1000]	110.7%			IR1,
NEIFOSAA	(584.0 / 419.0) 8264 (584.0 / 526.0) 8267	(9.69, 1.00) (0.01, N/A, 0.2)	47.4 51.5	1.0004 136.4 137.7	0.0789 [0.1000]	78.9%			
NMeFOSE	(616.1 / 59.0) 10857	(10.57, 1.00) (0.01, N/A, 0.0)	203.2	N/A 0.0 0.0	0.4256 [0.4000]	106.4%			
NEIFOSE	(630.0 / 59.0) 1665	(10.67, 1.00) (0.01, N/A, 0.0)	793.9	N/A 0.0 0.0	0.3238 [0.4000]	81.0%			
HFPO-DA	(285.0 / 169.0) 16385 (285.0 / 185.0) 49552	(6.53, 1.00) (0.00, N/A, -0.1)	232.5 275.5	3.0242 110.2 116.2	0.1799 [0.2000]	90.0%			
ADONA	(377.0 / 85.0) 74840 (377.0 / 251.0) 10655	(7.43, 1.14) (N/A, 0.05, 0.5)	405.7 56.9	0.1424 114.3 111.5	0.1850 [0.1885]	98.1%			
9CI-Pf3ONS	(531.0 / 351.0) 200793 (533.0 / 353.0) 65513	(9.71, 1.49) (N/A, 0.00, 0.3)	354.5 256.5	0.3263 110.2 112.4	0.1643 [0.1867]	88.0%			
11CI-PF3OUDS	(631.0 / 451.0) 92694 (633.0 / 453.0) 27149	(9.99, 1.53) (N/A, -0.01, 0.2)	463.1 763.6	0.2929 88.5 91.1	0.1639 [0.1886]	86.9%			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT-CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
3:3FTCA	(241.0 / 177.0) 2017 (241.0 / 117.0) 4545	(4.52, 0.90) (N/A, 0.08, -0.3)	79.7 55.8	2.2528 134.6 134.2	0.3766 [0.4000]	94.2%			
5:3FTCA	(341.0 / 236.7) 18450 (341.0 / 217.0) 24814	(6.83, 1.10) (N/A, 0.07, 0.3)	173.8 126.1	1.3449 91.9 83.7	0.4263 [0.4000]	106.6%			
7:3FTCA	(441.0 / 317.0) 21598 (441.0 / 337.0) 15586	(8.62, 1.39) (N/A, 0.03, -0.5)	92.5 129.6	0.7216 86.2 86.5	0.4337 [0.4000]	108.4%			
PFEESA	(315.0 / 135.0) 44202 (315.0 / 83.0) 14794	(6.64, 1.07) (N/A, 0.06, 0.1)	423.1 109.0	0.3347 109.0 113.3	0.1648 [0.1785]	92.3%			
PFMPA	(229.0 / 85.0) 8741	(4.23, 0.84) (N/A, 0.07, 0.0)	234.4	N/A 0.0 0.0	0.2052 [0.2000]	102.6%			
PFMBA	(279.0 / 85.0) 27711	(5.43, 1.08) (N/A, 0.08, 0.0)	438.5	N/A 0.0 0.0	0.1882 [0.2000]	94.1%			
NFDHA	(295.0 / 201.0) 27421 (295.0 / 85.0) 23355	(6.07, 0.98) (N/A, 0.07, 0.2)	261.2 49.5	0.8517 96.5 97.2	0.2220 [0.2000]	111.0%			
13C3_PFBA_IIS	(216.0 / 172.0) 149416	(3.72, N/A) (N/A, 0.06, N/A)	849.1	N/A	1.0734 [1.0000]	107.3% {95.1%}			
13C2_PFHxA_IIS	(315.1 / 270.0) 235804	(6.19, N/A) (N/A, 0.07, N/A)	486.5	N/A	1.0212 [1.0000]	102.1% {99.9%}			
13C4_PFOA_IIS	(417.0 / 372.0) 237795	(7.92, N/A) (N/A, 0.04, N/A)	630.7	N/A	1.0816 [1.0000]	108.2% {92.6%}			
13C5_PFNA_IIS	(468.0 / 423.0) 197981	(8.64, N/A) (N/A, 0.03, N/A)	508.8	N/A	1.0691 [1.0000]	106.9% {84.4%}			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT-CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDA_IIS	(515.1 / 470.1) 198543	(9.31, N/A) (N/A, 0.02, N/A)	319.6	N/A	1.0743 [ 1.0000 ]	107.4% { 106.1% }			
18O2_PFHxS_IIS	(403.0 / 83.9) 433793	(8.04, N/A) (N/A, 0.04, N/A)	800.2	N/A	1.0745 [ 1.0000 ]	107.5% { 97.2% }			
13C4_PFOS_IIS	(502.8 / 79.9) 342798	(9.46, N/A) (N/A, 0.02, N/A)	514.7	N/A	1.0740 [ 1.0000 ]	107.4% { 98.9% }			
13C4_PFBA_EIS	(217.0 / 172.0) 1350396	(3.72, N/A) (N/A, 0.07, N/A)	854.9	N/A	8.7813 [ 8.0000 ]	109.8% { 107.5% }			
13C5_PFPeA_EIS	(267.9 / 223.0) 706916	(5.04, N/A) (N/A, 0.08, N/A)	674.5	N/A	4.3086 [ 4.0000 ]	107.7% { 104.0% }			
13C5_PFHxA_EIS	(318.0 / 273.0) 570391	(6.19, N/A) (N/A, 0.07, N/A)	517.3	N/A	2.1020 [ 2.0000 ]	105.1% { 106.4% }			
13C4_PFHpA_EIS	(367.0 / 322.0) 463373	(7.11, N/A) (N/A, 0.06, N/A)	563.5	N/A	1.9575 [ 2.0000 ]	97.9% { 103.0% }			
13C8_PFOA_EIS	(421.0 / 376.0) 516185	(7.91, N/A) (N/A, 0.04, N/A)	616.4	N/A	1.9794 [ 2.0000 ]	99.0% { 86.7% }			
13C9_PFNA_EIS	(472.0 / 427.0) 201968	(8.65, N/A) (N/A, 0.03, N/A)	455.2	N/A	0.9277 [ 1.0000 ]	92.8% { 87.2% }			
13C6_PFDA_EIS	(519.0 / 474.0) 277526	(9.32, N/A) (N/A, 0.03, N/A)	347.4	N/A	0.9828 [ 1.0000 ]	98.3% { 100.8% }			
13C7_PFUnA_EIS	(570.0 / 525.0) 373620	(9.71, N/A) (N/A, 0.00, N/A)	501.2	N/A	0.9302 [ 1.0000 ]	93.0% { 100.4% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT- CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDa_EIS	(615.0 / 570.0) 360218	(9.88, N/A) (N/A, -0.01, N/A)	670.2	N/A	0.8985 [ 1.0000 ]	89.9% { 98.3% }			
13C2_PFTeDA_EIS	(715.0 / 670.0) 216489	(10.11, N/A) (N/A, -0.01, N/A)	356.9	N/A	0.8131 [ 1.0000 ]	81.3% { 84.8% }			
13C3_PFBs_EIS	(302.0 / 80.0) 1430211	(6.14, N/A) (N/A, 0.07, N/A)	665.5	N/A	1.9500 [ 2.0000 ]	97.5% { 107.3% }			
13C3_PFHxS_EIS	(402.0 / 80.0) 793030	(8.04, N/A) (N/A, 0.04, N/A)	865.4	N/A	2.0322 [ 2.0000 ]	101.6% { 103.3% }			
13C8_PFOS_EIS	(507.0 / 80.0) 1114220	(9.45, N/A) (N/A, 0.02, N/A)	619.8	N/A	1.8939 [ 2.0000 ]	94.7% { 99.7% }			
13C2_4:2FTS_EIS	(329.0 / 81.0) 270205	(5.86, N/A) (N/A, 0.07, N/A)	647.9	N/A	4.3497 [ 4.0000 ]	108.7% { 120.0% }			
13C2_6:2FTS_EIS	(429.0 / 81.0) 310773	(7.58, N/A) (N/A, 0.05, N/A)	726.9	N/A	4.1552 [ 4.0000 ]	103.9% { 92.4% }			
13C2_8:2FTS_EIS	(529.0 / 81.0) 281638	(8.98, N/A) (N/A, 0.03, N/A)	437.7	N/A	3.7617 [ 4.0000 ]	94.0% { 89.1% }			
13C8_PFOsa_EIS	(506.0 / 78.0) 1561120	(10.17, N/A) (N/A, 0.00, N/A)	1127.8	N/A	2.0992 [ 2.0000 ]	105.0% { 114.4% }			
D3_NMeFOSA_EIS	(515.0 / 169.0) 317356	(10.60, N/A) (N/A, -0.01, N/A)	822.0	N/A	1.9545 [ 2.0000 ]	97.7% { 110.5% }			
D5_NEiFOSA_EIS	(531.1 / 169.0) 291977	(10.69, N/A) (N/A, -0.01, N/A)	1303.7	N/A	1.9479 [ 2.0000 ]	97.4% { 96.1% }			



Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500

Sample I.D.: SB03951-LCV1  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (2)  
 Acquired: 2022/12/22 - 11:14

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-I[min], ΔRT-CV[min], ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
D3_MeFOSAA_EIS	( 573.0 / 419.0 ) 521360	( 9.51, N/A ) ( N/A, 0.02, N/A )	373.5	N/A	3.7267 [ 4.0000 ]	93.2% { 98.6% }			
D5_EtFOSAA_EIS	( 589.0 / 419.0 ) 466379	( 9.68, N/A ) ( N/A, 0.00, N/A )	389.5	N/A	3.7822 [ 4.0000 ]	94.6% { 112.4% }			
D7_NMeFOSE_EIS	( 623.2 / 58.9 ) 404186	( 10.56, N/A ) ( N/A, -0.01, N/A )	1088.1	N/A	17.7282 [ 20.0000 ]	88.6% { 93.0% }			
D9_NEtFOSE_EIS	( 639.2 / 58.9 ) 200858	( 10.66, N/A ) ( N/A, -0.01, N/A )	1642.9	N/A	19.3518 [ 20.0000 ]	96.8% { 101.4% }			
13C3_HFPODA_EIS	( 287.0 / 169.0 ) 1198727	( 6.53, N/A ) ( N/A, 0.07, N/A )	676.0	N/A	8.3087 [ 8.0000 ]	103.9% { 98.5% }			



# INITIAL AND CONTINUING CALIBRATION CHECK

## EPA 1633

Laboratory: APPL, LLC  
 Client: AECOM  
 Instrument ID: Saphira  
 Standard ID: 22L0304

Work Order: 22L0141  
 Project: Red Hill AFFF Assessment Sampling  
 Calibration: 2252011  
 Sequence: SB03951






















Lab Sample ID	Analyte	True	Found	%R	Units	Control Limit
SB03951-CCV1	PFBA	20.0	21.0	105	ng/mL	+/- 30.00%
	PFPEA	10.0	10.4	104	ng/mL	+/- 30.00%
	PFHXA	5.00	5.11	102	ng/mL	+/- 30.00%
	PFHPA	5.00	5.12	102	ng/mL	+/- 30.00%
	PFOA	5.00	4.41	88.2	ng/mL	+/- 30.00%
	PFNA	5.00	4.89	97.8	ng/mL	+/- 30.00%
	PFDA	5.00	4.74	94.9	ng/mL	+/- 30.00%
	PFUnA	5.00	4.61	92.3	ng/mL	+/- 30.00%
	PFDOA	5.00	4.93	98.7	ng/mL	+/- 30.00%
	PFTRDA	5.00	4.19	83.8	ng/mL	+/- 30.00%
	PFTEDA	5.00	4.85	97.0	ng/mL	+/- 30.00%
	PFBS	4.42	4.71	107	ng/mL	+/- 30.00%
	PFPEs	4.70	4.49	95.4	ng/mL	+/- 30.00%
	PFHXS	4.58	4.46	97.4	ng/mL	+/- 30.00%
	PFHPS	4.78	5.15	108	ng/mL	+/- 30.00%
	PFOS	4.65	4.43	95.3	ng/mL	+/- 30.00%
	PFNS	4.80	4.87	101	ng/mL	+/- 30.00%
	PFDS	4.82	4.73	98.2	ng/mL	+/- 30.00%
	PFDOS	4.85	5.55	114	ng/mL	+/- 30.00%
	4:2FTS	18.8	19.1	102	ng/mL	+/- 30.00%
	6:2FTS	19.0	17.4	91.8	ng/mL	+/- 30.00%
	8:2FTS	19.2	19.1	99.5	ng/mL	+/- 30.00%
	PFOSA	5.00	5.32	106	ng/mL	+/- 30.00%
	NMeFOSA	20.0	21.7	109	ng/mL	+/- 30.00%
	NEtFOSA	20.0	21.4	107	ng/mL	+/- 30.00%
	NMeFOSAA	5.00	5.32	106	ng/mL	+/- 30.00%
	NEtFOSAA	5.00	4.61	92.2	ng/mL	+/- 30.00%
	NMeFOSE	20.0	21.4	107	ng/mL	+/- 30.00%
	NEtFOSE	20.0	20.6	103	ng/mL	+/- 30.00%
	HFPO-DA	10.0	9.69	96.9	ng/mL	+/- 30.00%

# INITIAL AND CONTINUING CALIBRATION CHECK

## EPA 1633

Laboratory:	APPL, LLC	Work Order:	22L0141
Client:	AECOM	Project:	Red Hill AFFF Assessment Sampling
Instrument ID:	Saphira	Calibration:	2252011
Standard ID:	22L0304	Sequence:	SB03951

Lab Sample ID	Analyte	True	Found	%R	Units	Control Limit
SB03951-CCV1	ADONA	9.45	9.03	95.5	ng/mL	+/- 30.00%
	PFEESA	8.90	8.98	101	ng/mL	+/- 30.00%
	PFMPA	10.0	10.5	105	ng/mL	+/- 30.00%
	PFMBA	10.0	10.0	100	ng/mL	+/- 30.00%
	NFDHA	10.0	11.3	113	ng/mL	+/- 30.00%
	9CL-PF3ONS	9.35	8.53	91.2	ng/mL	+/- 30.00%
	11CL-PF3OUDS	9.45	8.36	88.5	ng/mL	+/- 30.00%
	3:3FTCA	20.0	21.4	107	ng/mL	+/- 30.00%
	5:3FTCA	20.0	19.2	96.0	ng/mL	+/- 30.00%
	7:3FTCA	20.0	22.4	112	ng/mL	+/- 30.00%

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBA	(212.9 / 169.0) 2154129	(3.65, 1.00) (0.00, N/A, 0.0)	64.9	N/A 0.0 0.0	21.0367 [ 20.0000 ]	105.2%			
PFPeA	(262.9 / 219.0) 1554031 (262.9 / 69.0) 16157	(4.97, 1.00) (0.00, N/A, 0.2)	683.0 222.9	0.0104 92.9 100.0	10.4106 [ 10.0000 ]	104.1%			
PFHxA	(313.0 / 269.0) 1175354 (313.0 / 119.0) 105025	(6.12, 1.00) (0.00, N/A, 0.3)	562.2 479.3	0.0894 91.4 100.0	5.1058 [ 5.0000 ]	102.1%			
PFHpA	(363.0 / 319.0) 1048582 (363.0 / 169.0) 323239	(7.05, 1.00) (0.00, N/A, 0.2)	690.7 564.0	0.3083 99.0 100.0	5.1153 [ 5.0000 ]	102.3%			
PFOA	(413.0 / 369.0) 1291864 (413.0 / 169.0) 382216	(7.88, 1.00) (0.00, N/A, 0.0)	788.3 627.4	0.2959 90.5 100.0	4.4112 [ 5.0000 ]	88.2%			
PFNA	(463.0 / 419.0) 972648 (463.0 / 169.0) 202653	(8.61, 1.00) (0.00, N/A, -0.1)	482.3 137.7	0.2084 108.1 100.0	4.8916 [ 5.0000 ]	97.8%			
PFDA	(513.0 / 469.0) 1242523 (513.0 / 169.0) 122058	(9.29, 1.00) (0.00, N/A, 0.0)	537.9 297.6	0.0982 102.8 100.0	4.7434 [ 5.0000 ]	94.9%			
PFUnA	(563.0 / 519.0) 1356919 (563.0 / 169.0) 121676	(9.71, 1.00) (0.00, N/A, 0.3)	795.6 343.8	0.0897 103.3 100.0	4.6144 [ 5.0000 ]	92.3%			
PFDoA	(613.0 / 569.0) 1558339 (613.0 / 169.0) 204949	(9.89, 1.00) (0.00, N/A, -0.4)	763.3 482.7	0.1315 94.5 100.0	4.9347 [ 5.0000 ]	98.7%			
PFTrDA	(663.0 / 619.0) 1146816 (663.0 / 169.0) 262166	(10.02, 1.01) (N/A, 0.00, 0.1)	754.3 589.3	0.2286 111.7 100.0	4.1915 [ 5.0000 ]	83.8%			
PFTeDA	(713.0 / 669.0) 1097292 (713.0 / 169.0) 225203	(10.12, 1.00) (0.00, N/A, -0.4)	778.9 510.8	0.2052 100.9 100.0	4.8503 [ 5.0000 ]	97.0%			



Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500

Sample I.D.: SB03951-CCV1  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (3)  
 Acquired: 2022/12/22 - 11:26

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-I[min], ΔRT-CV[min], ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBS	( 298.9 / 80.0 ) 1719634 ( 298.9 / 99.0 ) 1126162	( 6.07 , 1.00 ) ( 0.00 , N/A , 0.1 )	661.5 702.7	0.6549 106.4 100.0	4.7073 [ 4.4237 ]	106.4%			
PFPeS	( 349.0 / 80.0 ) 3076212 ( 349.0 / 99.0 ) 1181734	( 7.12 , 0.89 ) ( N/A , 0.00 , 0.0 )	784.8 967.1	0.3842 107.9 100.0	4.4854 [ 4.6919 ]	95.6%			
PFHxS	( 399.0 / 80.0 ) 2661196 ( 399.0 / 99.0 ) 880872	( 7.99 , 1.00 ) ( 0.00 , N/A , 0.1 )	2961.8 13543.7	0.3310 98.5 100.0	4.4618 [ 4.5549 ]	98.0%			
PFHpS	( 449.0 / 80.0 ) 2510606 ( 449.0 / 99.0 ) 638303	( 8.76 , 0.93 ) ( N/A , 0.00 , 0.3 )	690.2 645.6	0.2542 92.9 100.0	5.1514 [ 4.7570 ]	108.3%			
PFOS	( 499.0 / 80.0 ) 2685738 ( 499.0 / 99.0 ) 614269	( 9.43 , 1.00 ) ( 0.00 , N/A , 0.0 )	93.8 145.8	0.2287 94.0 100.0	4.4299 [ 4.6375 ]	95.5%			
PFNS	( 549.0 / 80.0 ) 3272209 ( 549.0 / 99.0 ) 835098	( 9.76 , 1.03 ) ( N/A , 0.00 , 0.0 )	766.3 864.1	0.2552 104.6 100.0	4.8654 [ 4.7994 ]	101.4%			
PFDS	( 599.0 / 80.0 ) 3533112 ( 599.0 / 99.0 ) 826737	( 9.91 , 1.05 ) ( N/A , 0.00 , -0.1 )	938.8 1176.9	0.2340 104.0 100.0	4.7321 [ 4.8155 ]	98.3%			
PFDoS	( 698.9 / 80.0 ) 1732426 ( 698.9 / 99.0 ) 336296	( 10.11 , 1.07 ) ( N/A , 0.00 , 0.0 )	1430.4 1036.4	0.1941 79.3 100.0	5.5516 [ 4.8478 ]	114.5%			
4:2FTS	( 327.0 / 307.0 ) 3560853 ( 327.0 / 81.0 ) 2038787	( 5.79 , 1.00 ) ( 0.00 , N/A , -0.1 )	728.9 733.2	0.5726 115.9 100.0	19.1366 [ 18.6906 ]	102.4%			
6:2FTS	( 427.0 / 407.0 ) 2253960 ( 427.0 / 81.0 ) 1571501	( 7.53 , 1.00 ) ( 0.00 , N/A , -0.2 )	722.9 646.0	0.6972 89.6 100.0	17.4345 [ 18.9808 ]	91.9%			
8:2FTS	( 527.0 / 507.0 ) 2389487 ( 527.0 / 81.0 ) 1315672	( 8.95 , 1.00 ) ( 0.00 , N/A , -0.1 )	525.5 684.3	0.5506 97.3 100.0	19.0958 [ 19.1658 ]	99.6%			






























Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500












Sample I.D.: SB03951-CCV1  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (3)  
 Acquired: 2022/12/22 - 11:26






Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-I[min], ΔRT-CV[min], ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFOSA	( 498.0 / 78.0 ) 3428117 ( 498.0 / 478.0 ) 83154	( 10.18 , 1.00 ) ( 0.00 , N/A , 0.0 )	763.2 679.7	0.0243 116.4 100.0	5.3181 [ 5.0000 ]	106.4%			
NMeFOSA	( 511.9 / 219.0 ) 2543194 ( 511.9 / 169.0 ) 1719715	( 10.61 , 1.00 ) ( 0.00 , N/A , 0.0 )	1285.6 1114.3	0.6762 93.9 100.0	21.7307 [ 20.0000 ]	108.7%			
NEIFOSA	( 526.0 / 219.0 ) 2929342 ( 526.0 / 169.0 ) 3106262	( 10.70 , 1.00 ) ( 0.00 , N/A , 0.1 )	1455.2 1391.4	1.0604 100.3 100.0	21.3735 [ 20.0000 ]	106.9%			
NMeFOSAA	( 570.0 / 419.0 ) 547786 ( 570.0 / 483.0 ) 273872	( 9.49 , 1.00 ) ( 0.00 , N/A , 0.1 )	449.1 332.1	0.5000 81.3 100.0	5.3192 [ 5.0000 ]	106.4%			
NEIFOSAA	( 584.0 / 419.0 ) 429443 ( 584.0 / 526.0 ) 312027	( 9.68 , 1.00 ) ( 0.00 , N/A , 0.0 )	783.8 831.4	0.7266 99.1 100.0	4.6112 [ 5.0000 ]	92.2%			
NMeFOSE	( 616.1 / 59.0 ) 588115	( 10.58 , 1.00 ) ( 0.01 , N/A , 0.0 )	930.0	N/A 0.0 0.0	21.4368 [ 20.0000 ]	107.2%			
NEtFOSE	( 630.0 / 59.0 ) 104293	( 10.68 , 1.00 ) ( 0.01 , N/A , 0.0 )	1039.0	N/A 0.0 0.0	20.5599 [ 20.0000 ]	102.8%			
HFPO-DA	( 285.0 / 169.0 ) 896427 ( 285.0 / 185.0 ) 2332694	( 6.47 , 1.00 ) ( 0.00 , N/A , 0.0 )	820.4 784.6	2.6022 94.8 100.0	9.6929 [ 10.0000 ]	96.9%			
ADONA	( 377.0 / 85.0 ) 3708989 ( 377.0 / 251.0 ) 473572	( 7.38 , 1.14 ) ( N/A , 0.00 , 0.1 )	717.9 589.3	0.1277 102.5 100.0	9.0292 [ 9.4270 ]	95.8%			
9CI-Pf3ONS	( 531.0 / 351.0 ) 9542968 ( 533.0 / 353.0 ) 2769472	( 9.71 , 1.50 ) ( N/A , 0.00 , 0.1 )	841.1 822.2	0.2902 98.1 100.0	8.5279 [ 9.3325 ]	91.4%			
11CI-PF3OUDS	( 631.0 / 451.0 ) 4800455 ( 633.0 / 453.0 ) 1542741	( 10.00 , 1.55 ) ( N/A , 0.00 , 0.3 )	681.4 800.2	0.3214 97.1 100.0	8.3612 [ 9.4321 ]	88.6%			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT-CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
3:3FTCA	(241.0 / 177.0) 110439 (241.0 / 117.0) 185455	(4.45, 0.89) (N/A, 0.00, -0.1)	609.5 582.5	1.6793 100.3 100.0	21.4369 [ 20.0000 ]	107.2%			
5:3FTCA	(341.0 / 236.7) 781378 (341.0 / 217.0) 1255633	(6.76, 1.10) (N/A, 0.00, 0.2)	641.9 545.8	1.6069 109.8 100.0	19.2098 [ 20.0000 ]	96.0%			
7:3FTCA	(441.0 / 317.0) 1048539 (441.0 / 337.0) 874782	(8.59, 1.40) (N/A, 0.00, 0.0)	437.2 460.1	0.8343 99.6 100.0	22.4032 [ 20.0000 ]	112.0%			
PFEESA	(315.0 / 135.0) 2262176 (315.0 / 83.0) 668430	(6.58, 1.07) (N/A, 0.00, 0.0)	842.5 781.6	0.2955 96.2 100.0	8.9758 [ 8.9246 ]	100.6%			
PFMPA	(229.0 / 85.0) 431797	(4.16, 0.84) (N/A, 0.00, 0.0)	1012.2	N/A 0.0 0.0	10.5396 [ 10.0000 ]	105.4%			
PFMBA	(279.0 / 85.0) 1417072	(5.36, 1.08) (N/A, 0.00, 0.0)	947.1	N/A 0.0 0.0	10.0069 [ 10.0000 ]	100.1%			
NFDHA	(295.0 / 201.0) 1316880 (295.0 / 85.0) 1153530	(6.00, 0.98) (N/A, 0.00, 0.0)	700.7 1120.2	0.8760 99.2 100.0	11.3450 [ 10.0000 ]	113.5%			
13C3_PFBA_IIS	(216.0 / 172.0) 157058	(3.65, N/A) (N/A, 0.00, N/A)	654.7	N/A	1.1283 [ 1.0000 ]	112.8% { 100.0% }			
13C2_PFHxA_IIS	(315.1 / 270.0) 235960	(6.12, N/A) (N/A, 0.00, N/A)	572.0	N/A	1.0218 [ 1.0000 ]	102.2% { 100.0% }			
13C4_PFOA_IIS	(417.0 / 372.0) 256865	(7.88, N/A) (N/A, 0.00, N/A)	493.1	N/A	1.1684 [ 1.0000 ]	116.8% { 100.0% }			
13C5_PFNA_IIS	(468.0 / 423.0) 234538	(8.62, N/A) (N/A, 0.00, N/A)	305.4	N/A	1.2665 [ 1.0000 ]	126.7% { 100.0% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT- CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDA_IIS	(515.1 / 470.1) 187181	(9.29, N/A) (N/A, 0.00, N/A)	349.6	N/A	1.0128 [ 1.0000 ]	101.3% { 100.0% }			
18O2_PFHxS_IIS	(403.0 / 83.9) 446223	(7.99, N/A) (N/A, 0.00, N/A)	1026.4	N/A	1.1053 [ 1.0000 ]	110.5% { 100.0% }			
13C4_PFOS_IIS	(502.8 / 79.9) 346561	(9.44, N/A) (N/A, 0.00, N/A)	424.1	N/A	1.0858 [ 1.0000 ]	108.6% { 100.0% }			
13C4_PFBA_EIS	(217.0 / 172.0) 1255682	(3.65, N/A) (N/A, 0.00, N/A)	744.1	N/A	7.7681 [ 8.0000 ]	97.1% { 100.0% }			
13C5_PFPeA_EIS	(267.9 / 223.0) 679867	(4.97, N/A) (N/A, 0.00, N/A)	654.2	N/A	4.1410 [ 4.0000 ]	103.5% { 100.0% }			
13C5_PFHxA_EIS	(318.0 / 273.0) 536085	(6.13, N/A) (N/A, 0.00, N/A)	604.6	N/A	1.9743 [ 2.0000 ]	98.7% { 100.0% }			
13C4_PFHpA_EIS	(367.0 / 322.0) 449767	(7.05, N/A) (N/A, 0.00, N/A)	519.7	N/A	1.8987 [ 2.0000 ]	94.9% { 100.0% }			
13C8_PFOA_EIS	(421.0 / 376.0) 595626	(7.87, N/A) (N/A, 0.00, N/A)	933.6	N/A	2.1144 [ 2.0000 ]	105.7% { 100.0% }			
13C9_PFNA_EIS	(472.0 / 427.0) 231730	(8.61, N/A) (N/A, 0.00, N/A)	407.0	N/A	0.8985 [ 1.0000 ]	89.9% { 100.0% }			
13C6_PFDA_EIS	(519.0 / 474.0) 275199	(9.29, N/A) (N/A, 0.00, N/A)	338.1	N/A	1.0337 [ 1.0000 ]	103.4% { 100.0% }			
13C7_PFUnA_EIS	(570.0 / 525.0) 372096	(9.71, N/A) (N/A, 0.00, N/A)	452.0	N/A	0.9827 [ 1.0000 ]	98.3% { 100.0% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT-CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDa_EIS	(615.0 / 570.0) 366314	(9.89, N/A) (N/A, 0.00, N/A)	634.0	N/A	0.9692 [ 1.0000 ]	96.9% { 100.0% }			
13C2_PFTeDA_EIS	(715.0 / 670.0) 255262	(10.12, N/A) (N/A, 0.00, N/A)	364.1	N/A	1.0170 [ 1.0000 ]	101.7% { 100.0% }			
13C3_PFBs_EIS	(302.0 / 80.0) 1332644	(6.07, N/A) (N/A, 0.00, N/A)	646.0	N/A	1.7664 [ 2.0000 ]	88.3% { 100.0% }			
13C3_PFHxS_EIS	(402.0 / 80.0) 767810	(7.99, N/A) (N/A, 0.00, N/A)	714.1	N/A	1.9127 [ 2.0000 ]	95.6% { 100.0% }			
13C8_PFOS_EIS	(507.0 / 80.0) 1117104	(9.43, N/A) (N/A, 0.00, N/A)	237.3	N/A	1.8782 [ 2.0000 ]	93.9% { 100.0% }			
13C2_4:2FTS_EIS	(329.0 / 81.0) 225103	(5.79, N/A) (N/A, 0.00, N/A)	498.3	N/A	3.5227 [ 4.0000 ]	88.1% { 100.0% }			
13C2_6:2FTS_EIS	(429.0 / 81.0) 336334	(7.53, N/A) (N/A, 0.00, N/A)	641.8	N/A	4.3717 [ 4.0000 ]	109.3% { 100.0% }			
13C2_8:2FTS_EIS	(529.0 / 81.0) 315927	(8.95, N/A) (N/A, 0.00, N/A)	416.9	N/A	4.1022 [ 4.0000 ]	102.6% { 100.0% }			
13C8_PFOsa_EIS	(506.0 / 78.0) 1364137	(10.18, N/A) (N/A, 0.00, N/A)	750.8	N/A	1.8144 [ 2.0000 ]	90.7% { 100.0% }			
D3_NMeFOsa_EIS	(515.0 / 169.0) 287141	(10.61, N/A) (N/A, 0.00, N/A)	1425.3	N/A	1.7492 [ 2.0000 ]	87.5% { 100.0% }			
D5_NeIFOSA_EIS	(531.1 / 169.0) 303885	(10.70, N/A) (N/A, 0.00, N/A)	1191.4	N/A	2.0054 [ 2.0000 ]	100.3% { 100.0% }			



Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT-CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
D3_MeFOSAA_EIS	(573.0 / 419.0) 528609	(9.49, N/A) (N/A, 0.00, N/A)	496.4	N/A	3.7375 [ 4.0000 ]	93.4% { 100.0% }			
D5_EtFOSAA_EIS	(589.0 / 419.0) 414934	(9.68, N/A) (N/A, 0.00, N/A)	361.3	N/A	3.3284 [ 4.0000 ]	83.2% { 100.0% }			
D7_NMeFOSE_EIS	(623.2 / 58.9) 434712	(10.58, N/A) (N/A, 0.00, N/A)	1025.6	N/A	18.8600 [ 20.0000 ]	94.3% { 100.0% }			
D9_NEtFOSE_EIS	(639.2 / 58.9) 198139	(10.67, N/A) (N/A, 0.00, N/A)	1023.3	N/A	18.8825 [ 20.0000 ]	94.4% { 100.0% }			
13C3_HFPODA_EIS	(287.0 / 169.0) 1217258	(6.47, N/A) (N/A, 0.00, N/A)	619.0	N/A	8.4316 [ 8.0000 ]	105.4% { 100.0% }			

# INITIAL AND CONTINUING CALIBRATION CHECK

## EPA 1633

Laboratory: APPL, LLC  
 Client: AECOM  
 Instrument ID: Saphira  
 Standard ID: 22L0304

Work Order: 22L0141  
 Project: Red Hill AFFF Assessment Sampling  
 Calibration: 2252011  
 Sequence: SB03951






















Lab Sample ID	Analyte	True	Found	%R	Units	Control Limit
SB03951-CCV2	PFBA	20.0	20.3	102	ng/mL	+/- 30.00%
	PFPEA	10.0	9.58	95.8	ng/mL	+/- 30.00%
	PFHXA	5.00	5.39	108	ng/mL	+/- 30.00%
	PFHPA	5.00	4.94	98.9	ng/mL	+/- 30.00%
	PFOA	5.00	4.83	96.6	ng/mL	+/- 30.00%
	PFNA	5.00	5.04	101	ng/mL	+/- 30.00%
	PFDA	5.00	4.71	94.2	ng/mL	+/- 30.00%
	PFUnA	5.00	5.41	108	ng/mL	+/- 30.00%
	PFDOA	5.00	5.49	110	ng/mL	+/- 30.00%
	PFTRDA	5.00	5.21	104	ng/mL	+/- 30.00%
	PFTEDA	5.00	4.27	85.4	ng/mL	+/- 30.00%
	PFBS	4.42	4.32	97.7	ng/mL	+/- 30.00%
	PFPEs	4.70	5.03	107	ng/mL	+/- 30.00%
	PFHXS	4.58	4.51	98.5	ng/mL	+/- 30.00%
	PFHPS	4.78	4.28	89.6	ng/mL	+/- 30.00%
	PFOS	4.65	4.47	96.1	ng/mL	+/- 30.00%
	PFNS	4.80	4.39	91.5	ng/mL	+/- 30.00%
	PFDS	4.82	4.42	91.6	ng/mL	+/- 30.00%
	PFDOS	4.85	4.71	97.1	ng/mL	+/- 30.00%
	4:2FTS	18.8	20.7	110	ng/mL	+/- 30.00%
	6:2FTS	19.0	18.8	98.8	ng/mL	+/- 30.00%
	8:2FTS	19.2	18.7	97.2	ng/mL	+/- 30.00%
	PFOSA	5.00	5.73	115	ng/mL	+/- 30.00%
	NMeFOSA	20.0	20.1	101	ng/mL	+/- 30.00%
	NEtFOSA	20.0	21.1	106	ng/mL	+/- 30.00%
	NMeFOSAA	5.00	5.85	117	ng/mL	+/- 30.00%
	NEtFOSAA	5.00	4.92	98.4	ng/mL	+/- 30.00%
	NMeFOSE	20.0	19.4	96.8	ng/mL	+/- 30.00%
	NEtFOSE	20.0	18.5	92.4	ng/mL	+/- 30.00%
	HFPO-DA	10.0	9.87	98.7	ng/mL	+/- 30.00%

# INITIAL AND CONTINUING CALIBRATION CHECK

## EPA 1633

Laboratory:	APPL, LLC	Work Order:	22L0141
Client:	AECOM	Project:	Red Hill AFFF Assessment Sampling
Instrument ID:	Saphira	Calibration:	2252011
Standard ID:	22L0304	Sequence:	SB03951

Lab Sample ID	Analyte	True	Found	%R	Units	Control Limit
SB03951-CCV2	ADONA	9.45	9.04	95.6	ng/mL	+/- 30.00%
	PFEESA	8.90	9.16	103	ng/mL	+/- 30.00%
	PFMPA	10.0	10.5	105	ng/mL	+/- 30.00%
	PFMBA	10.0	9.84	98.4	ng/mL	+/- 30.00%
	NFDHA	10.0	11.5	115	ng/mL	+/- 30.00%
	9CL-PF3ONS	9.35	8.42	90.0	ng/mL	+/- 30.00%
	11CL-PF3OUDS	9.45	9.60	102	ng/mL	+/- 30.00%
	3:3FTCA	20.0	23.2	116	ng/mL	+/- 30.00%
	5:3FTCA	20.0	22.3	111	ng/mL	+/- 30.00%
	7:3FTCA	20.0	23.2	116	ng/mL	+/- 30.00%

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT- CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBA	(212.9 / 169.0) 2353894	(3.62, 1.00) (0.00, N/A, 0.0)	66.6	N/A 0.0 0.0	20.3367 [ 20.0000 ]	101.7%			
PFPeA	(262.9 / 219.0) 1542175 (262.9 / 69.0) 15598	(4.94, 1.00) (0.00, N/A, -0.2)	723.3 241.1	0.0101 90.4 97.3	9.5756 [ 10.0000 ]	95.8%			
PFHxA	(313.0 / 269.0) 1279127 (313.0 / 119.0) 120390	(6.10, 1.00) (0.00, N/A, 0.0)	718.2 449.1	0.0941 96.3 105.3	5.3946 [ 5.0000 ]	107.9%			
PFHpA	(363.0 / 319.0) 1207342 (363.0 / 169.0) 341501	(7.04, 1.00) (0.01, N/A, 0.1)	655.5 649.4	0.2829 90.8 91.8	4.9444 [ 5.0000 ]	98.9%			
PFOA	(413.0 / 369.0) 1339728 (413.0 / 169.0) 423939	(7.85, 1.00) (0.00, N/A, 0.0)	817.0 676.4	0.3164 96.8 107.0	4.8318 [ 5.0000 ]	96.6%			
PFNA	(463.0 / 419.0) 940243 (463.0 / 169.0) 218020	(8.58, 1.00) (0.00, N/A, 0.0)	626.5 97.0	0.2319 120.3 111.3	5.0405 [ 5.0000 ]	100.8%			
PFDA	(513.0 / 469.0) 1286654 (513.0 / 169.0) 131797	(9.26, 1.00) (0.00, N/A, 0.0)	542.9 356.7	0.1024 107.2 104.3	4.7087 [ 5.0000 ]	94.2%			
PFUnA	(563.0 / 519.0) 1518770 (563.0 / 169.0) 153517	(9.69, 1.00) (0.00, N/A, 0.2)	566.6 350.1	0.1011 116.4 112.7	5.4097 [ 5.0000 ]	108.2%			
PFDoA	(613.0 / 569.0) 1810490 (613.0 / 169.0) 207740	(9.87, 1.00) (0.00, N/A, 0.0)	615.8 426.5	0.1147 82.4 87.2	5.4868 [ 5.0000 ]	109.7%			
PFTrDA	(663.0 / 619.0) 1489270 (663.0 / 169.0) 271591	(10.00, 1.01) (N/A, -0.01, 0.1)	800.5 488.8	0.1824 89.1 79.8	5.2093 [ 5.0000 ]	104.2%			
PFTeDA	(713.0 / 669.0) 1137436 (713.0 / 169.0) 167389	(10.11, 1.00) (0.00, N/A, 0.2)	909.7 267.9	0.1472 72.4 71.7	4.2692 [ 5.0000 ]	85.4%			







































Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500












Sample I.D.: SB03951-CCV2  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (16)  
 Acquired: 2022/12/22 - 14:37

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-I[min], ΔRT-CV[min], ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBS	( 298.9 / 80.0 ) 1774945 ( 298.9 / 99.0 ) 1098290	( 6.05 , 1.00 ) ( 0.00 , N/A , 0.0 )	575.2 674.9	0.6188 100.5 94.5	4.3167 [ 4.4237 ]	97.6%			
PFPeS	( 349.0 / 80.0 ) 3514660 ( 349.0 / 99.0 ) 1261990	( 7.10 , 0.89 ) ( N/A , -0.02 , 0.1 )	842.9 713.8	0.3591 100.9 93.5	5.0307 [ 4.6919 ]	107.2%			
PFHxS	( 399.0 / 80.0 ) 2741271 ( 399.0 / 99.0 ) 932563	( 7.97 , 1.00 ) ( 0.00 , N/A , 0.1 )	2993.3 17173.0	0.3402 101.2 102.8	4.5118 [ 4.5549 ]	99.1%			
PFHpS	( 449.0 / 80.0 ) 2390966 ( 449.0 / 99.0 ) 712726	( 8.73 , 0.93 ) ( N/A , -0.03 , 0.1 )	612.2 635.6	0.2981 108.9 117.2	4.2843 [ 4.7570 ]	90.1%			
PFOS	( 499.0 / 80.0 ) 3102735 ( 499.0 / 99.0 ) 654418	( 9.40 , 1.00 ) ( 0.00 , N/A , 0.0 )	103.6 121.8	0.2109 86.7 92.2	4.4693 [ 4.6375 ]	96.4%			
PFNS	( 549.0 / 80.0 ) 3383274 ( 549.0 / 99.0 ) 911710	( 9.74 , 1.04 ) ( N/A , -0.02 , 0.0 )	862.5 933.5	0.2695 110.4 105.6	4.3931 [ 4.7994 ]	91.5%			
PFDS	( 599.0 / 80.0 ) 3776713 ( 599.0 / 99.0 ) 913382	( 9.89 , 1.05 ) ( N/A , -0.02 , -0.1 )	1018.9 546.5	0.2418 107.4 103.4	4.4174 [ 4.8155 ]	91.7%			
PFDoS	( 698.9 / 80.0 ) 1682735 ( 698.9 / 99.0 ) 358973	( 10.09 , 1.07 ) ( N/A , -0.01 , 0.1 )	1168.6 610.5	0.2133 87.2 109.9	4.7091 [ 4.8478 ]	97.1%			
4:2FTS	( 327.0 / 307.0 ) 3805750 ( 327.0 / 81.0 ) 1988641	( 5.77 , 1.00 ) ( 0.00 , N/A , 0.2 )	820.6 732.9	0.5225 105.8 91.3	20.6590 [ 18.6906 ]	110.5%			
6:2FTS	( 427.0 / 407.0 ) 2411225 ( 427.0 / 81.0 ) 1781168	( 7.51 , 1.00 ) ( 0.00 , N/A , 0.3 )	944.6 859.2	0.7387 94.9 105.9	18.7649 [ 18.9808 ]	98.9%			
8:2FTS	( 527.0 / 507.0 ) 2054619 ( 527.0 / 81.0 ) 1183564	( 8.92 , 1.00 ) ( 0.00 , N/A , 0.1 )	555.5 395.1	0.5761 101.8 104.6	18.6579 [ 19.1658 ]	97.4%			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFOSA	( 498.0 / 78.0 ) 4093972 ( 498.0 / 478.0 ) 71584	( 10.16 , 1.00 ) ( 0.00 , N/A , -0.1)	958.5 295.3	0.0175 83.9 72.1	5.7294 [ 5.0000 ]	114.6%			
NMeFOSA	( 511.9 / 219.0 ) 2655774 ( 511.9 / 169.0 ) 1911600	( 10.60 , 1.00 ) ( 0.00 , N/A , 0.0)	990.5 978.3	0.7198 99.9 106.4	20.1100 [ 20.0000 ]	100.6%			
NEIFOSA	( 526.0 / 219.0 ) 2788650 ( 526.0 / 169.0 ) 2942224	( 10.69 , 1.00 ) ( 0.00 , N/A , 0.0)	1409.4 1627.5	1.0551 99.8 99.5	21.1104 [ 20.0000 ]	105.6%			
NMeFOSAA	( 570.0 / 419.0 ) 522530 ( 570.0 / 483.0 ) 290563	( 9.47 , 1.00 ) ( 0.01 , N/A , 0.2)	474.4 353.5	0.5561 90.5 111.2	5.8470 [ 5.0000 ]	116.9%			
NEIFOSAA	( 584.0 / 419.0 ) 484480 ( 584.0 / 526.0 ) 318236	( 9.66 , 1.00 ) ( 0.01 , N/A , 0.0)	666.2 23248.7	0.6569 89.6 90.4	4.9198 [ 5.0000 ]	98.4%			
NMeFOSE	( 616.1 / 59.0 ) 617715	( 10.57 , 1.00 ) ( 0.01 , N/A , 0.0)	913.0	N/A 0.0 0.0	19.3557 [ 20.0000 ]	96.8%			
NEtFOSE	( 630.0 / 59.0 ) 109538	( 10.66 , 1.00 ) ( 0.01 , N/A , 0.0)	1164.1	N/A 0.0 0.0	18.4772 [ 20.0000 ]	92.4%			
HFPO-DA	( 285.0 / 169.0 ) 947231 ( 285.0 / 185.0 ) 2579833	( 6.45 , 1.00 ) ( 0.00 , N/A , 0.1)	723.0 660.4	2.7236 99.2 104.7	9.8671 [ 10.0000 ]	98.7%			
ADONA	( 377.0 / 85.0 ) 3852795 ( 377.0 / 251.0 ) 488034	( 7.35 , 1.14 ) ( N/A , -0.03 , 0.0)	822.2 608.5	0.1267 101.7 99.2	9.0357 [ 9.4270 ]	95.8%			
9CI-Pr3ONS	( 531.0 / 351.0 ) 9783701 ( 533.0 / 353.0 ) 3295968	( 9.69 , 1.50 ) ( N/A , -0.01 , 0.0)	853.8 692.2	0.3369 113.8 116.1	8.4191 [ 9.3325 ]	90.2%			
11CI-PF3OUDS	( 631.0 / 451.0 ) 5722418 ( 633.0 / 453.0 ) 1886170	( 9.99 , 1.55 ) ( N/A , -0.02 , 0.1)	1202.3 1345.8	0.3296 99.6 102.6	9.6020 [ 9.4321 ]	101.8%			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT- CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
3:3FTCA	(241.0 / 177.0) 129146 (241.0 / 117.0) 200477	(4.42, 0.89) (N/A, -0.03, 0.0)	697.6 492.6	1.5523 92.8 92.4	23.2348 [ 20.0000 ]	116.2%			
5:3FTCA	(341.0 / 236.7) 932913 (341.0 / 217.0) 1418978	(6.75, 1.11) (N/A, -0.02, 0.0)	646.6 613.3	1.5210 103.9 94.7	22.2668 [ 20.0000 ]	111.3%			
7:3FTCA	(441.0 / 317.0) 1119323 (441.0 / 337.0) 879582	(8.55, 1.40) (N/A, -0.03, 0.0)	503.9 478.8	0.7858 93.8 94.2	23.2186 [ 20.0000 ]	116.1%			
PFEESA	(315.0 / 135.0) 2376917 (315.0 / 83.0) 710002	(6.56, 1.07) (N/A, -0.02, -0.1)	651.4 660.6	0.2987 97.3 101.1	9.1562 [ 8.9246 ]	102.6%			
PFMPA	(229.0 / 85.0) 465746	(4.13, 0.83) (N/A, -0.03, 0.0)	792.9	N/A 0.0 0.0	10.5368 [ 10.0000 ]	105.4%			
PFMBA	(279.0 / 85.0) 1503254	(5.33, 1.08) (N/A, -0.02, 0.0)	731.2	N/A 0.0 0.0	9.8392 [ 10.0000 ]	98.4%			
NFDHA	(295.0 / 201.0) 1375282 (295.0 / 85.0) 1242998	(5.98, 0.98) (N/A, -0.02, 0.0)	863.9 1184.5	0.9038 102.4 103.2	11.5029 [ 10.0000 ]	115.0%			
13C3_PFBA_IIS	(216.0 / 172.0) 170602	(3.63, N/A) (N/A, -0.03, N/A)	612.3	N/A	1.2256 [ 1.0000 ]	122.6% { 108.6% }			
13C2_PFHxA_IIS	(315.1 / 270.0) 260602	(6.10, N/A) (N/A, -0.02, N/A)	587.7	N/A	1.1285 [ 1.0000 ]	112.9% { 110.4% }			
13C4_PFOA_IIS	(417.0 / 372.0) 262468	(7.84, N/A) (N/A, -0.03, N/A)	511.9	N/A	1.1939 [ 1.0000 ]	119.4% { 102.2% }			
13C5_PFNxA_IIS	(468.0 / 423.0) 227138	(8.58, N/A) (N/A, -0.04, N/A)	400.2	N/A	1.2266 [ 1.0000 ]	122.7% { 96.8% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDA_IIS	(515.1 / 470.1) 221652	(9.26, N/A) (N/A, -0.03, N/A)	364.0	N/A	1.1994 [ 1.0000 ]	119.9% { 118.4% }			
18O2_PFHxS_IIS	(403.0 / 83.9) 480320	(7.97, N/A) (N/A, -0.03, N/A)	1068.4	N/A	1.1898 [ 1.0000 ]	119.0% { 107.6% }			
13C4_PFOS_IIS	(502.8 / 79.9) 429100	(9.40, N/A) (N/A, -0.03, N/A)	616.6	N/A	1.3444 [ 1.0000 ]	134.4% { 123.8% }			
13C4_PFBA_EIS	(217.0 / 172.0) 1419353	(3.63, N/A) (N/A, -0.03, N/A)	858.0	N/A	8.0835 [ 8.0000 ]	101.0% { 113.0% }			
13C5_PFPeA_EIS	(267.9 / 223.0) 733511	(4.94, N/A) (N/A, -0.02, N/A)	727.8	N/A	4.0453 [ 4.0000 ]	101.1% { 107.9% }			
13C5_PFHxA_EIS	(318.0 / 273.0) 552178	(6.10, N/A) (N/A, -0.02, N/A)	838.4	N/A	1.8413 [ 2.0000 ]	92.1% { 103.0% }			
13C4_PFHpA_EIS	(367.0 / 322.0) 535767	(7.03, N/A) (N/A, -0.02, N/A)	647.3	N/A	2.0479 [ 2.0000 ]	102.4% { 119.1% }			
13C8_PFOA_EIS	(421.0 / 376.0) 563924	(7.85, N/A) (N/A, -0.03, N/A)	567.3	N/A	1.9592 [ 2.0000 ]	98.0% { 94.7% }			
13C9_PFNA_EIS	(472.0 / 427.0) 217392	(8.59, N/A) (N/A, -0.03, N/A)	444.5	N/A	0.8704 [ 1.0000 ]	87.0% { 93.8% }			
13C6_PFDA_EIS	(519.0 / 474.0) 287072	(9.26, N/A) (N/A, -0.03, N/A)	512.7	N/A	0.9106 [ 1.0000 ]	91.1% { 104.3% }			
13C7_PFUnA_EIS	(570.0 / 525.0) 355253	(9.69, N/A) (N/A, -0.02, N/A)	588.0	N/A	0.7923 [ 1.0000 ]	79.2% { 95.5% }			










Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500

Sample I.D.: SB03951-CCV2  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (16)  
 Acquired: 2022/12/22 - 14:37

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT-CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDa_EIS	(615.0 / 570.0) 382764	(9.88, N/A) (N/A, -0.01, N/A)	679.6	N/A	0.8552 [ 1.0000 ]	85.5% { 104.5% }			
13C2_PFTeDA_EIS	(715.0 / 670.0) 300619	(10.11, N/A) (N/A, -0.01, N/A)	628.3	N/A	1.0114 [ 1.0000 ]	101.1% { 117.8% }			
13C3_PFBs_EIS	(302.0 / 80.0) 1499978	(6.05, N/A) (N/A, -0.02, N/A)	731.3	N/A	1.8470 [ 2.0000 ]	92.4% { 112.6% }			
13C3_PFHxS_EIS	(402.0 / 80.0) 782161	(7.97, N/A) (N/A, -0.03, N/A)	736.7	N/A	1.8102 [ 2.0000 ]	90.5% { 101.9% }			
13C8_PFOS_EIS	(507.0 / 80.0) 1279191	(9.40, N/A) (N/A, -0.03, N/A)	215.3	N/A	1.7370 [ 2.0000 ]	86.8% { 114.5% }			
13C2_4:2FTS_EIS	(329.0 / 81.0) 222854	(5.77, N/A) (N/A, -0.02, N/A)	608.9	N/A	3.2400 [ 4.0000 ]	81.0% { 99.0% }			
13C2_6:2FTS_EIS	(429.0 / 81.0) 334292	(7.51, N/A) (N/A, -0.02, N/A)	833.7	N/A	4.0367 [ 4.0000 ]	100.9% { 99.4% }			
13C2_8:2FTS_EIS	(529.0 / 81.0) 278027	(8.92, N/A) (N/A, -0.03, N/A)	348.4	N/A	3.3538 [ 4.0000 ]	83.8% { 88.0% }			
13C8_PFOsa_EIS	(506.0 / 78.0) 1512132	(10.16, N/A) (N/A, -0.02, N/A)	940.6	N/A	1.6244 [ 2.0000 ]	81.2% { 110.8% }			
D3_NMeFOSA_EIS	(515.0 / 169.0) 324017	(10.60, N/A) (N/A, -0.01, N/A)	937.1	N/A	1.5942 [ 2.0000 ]	79.7% { 112.8% }			
D5_NEiFOSA_EIS	(531.1 / 169.0) 292895	(10.68, N/A) (N/A, -0.01, N/A)	899.7	N/A	1.5610 [ 2.0000 ]	78.1% { 96.4% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT- CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
D3_MeFOSAA_EIS	( 573.0 / 419.0 ) 458718	( 9.46 , N/A ) ( N/A , -0.03 , N/A )	937.2	N/A	2.6194 [ 4.0000 ]	65.5% { 86.8% }			
D5_EtFOSAA_EIS	( 589.0 / 419.0 ) 438747	( 9.65 , N/A ) ( N/A , -0.02 , N/A )	358.6	N/A	2.8425 [ 4.0000 ]	71.1% { 105.7% }			
D7_NMeFOSE_EIS	( 623.2 / 58.9 ) 505683	( 10.56 , N/A ) ( N/A , -0.01 , N/A )	1002.6	N/A	17.7191 [ 20.0000 ]	88.6% { 116.3% }			
D9_NEtFOSE_EIS	( 639.2 / 58.9 ) 231561	( 10.66 , N/A ) ( N/A , -0.02 , N/A )	1491.4	N/A	17.8229 [ 20.0000 ]	89.1% { 116.9% }			
13C3_HFPODA_EIS	( 287.0 / 169.0 ) 1263536	( 6.45 , N/A ) ( N/A , -0.02 , N/A )	792.1	N/A	7.9246 [ 8.0000 ]	99.1% { 103.8% }			

# INITIAL AND CONTINUING CALIBRATION CHECK

## EPA 1633

Laboratory: APPL, LLC  
 Client: AECOM  
 Instrument ID: Saphira  
 Standard ID: 22L0304

Work Order: 22L0141  
 Project: Red Hill AFFF Assessment Sampling  
 Calibration: 2252011  
 Sequence: SB03951






















Lab Sample ID	Analyte	True	Found	%R	Units	Control Limit
SB03951-CCV3	PFBA	20.0	21.4	107	ng/mL	+/- 30.00%
	PFPEA	10.0	10.1	101	ng/mL	+/- 30.00%
	PFHXA	5.00	5.14	103	ng/mL	+/- 30.00%
	PFHPA	5.00	4.81	96.1	ng/mL	+/- 30.00%
	PFOA	5.00	4.75	95.0	ng/mL	+/- 30.00%
	PFNA	5.00	4.82	96.4	ng/mL	+/- 30.00%
	PFDA	5.00	4.94	98.8	ng/mL	+/- 30.00%
	PFUnA	5.00	5.31	106	ng/mL	+/- 30.00%
	PFDOA	5.00	5.04	101	ng/mL	+/- 30.00%
	PFTRDA	5.00	4.56	91.2	ng/mL	+/- 30.00%
	PFTEDA	5.00	5.88	118	ng/mL	+/- 30.00%
	PFBS	4.42	4.28	96.8	ng/mL	+/- 30.00%
	PFPEs	4.70	4.73	101	ng/mL	+/- 30.00%
	PFHXS	4.58	4.45	97.1	ng/mL	+/- 30.00%
	PFHPS	4.78	5.82	122	ng/mL	+/- 30.00%
	PFOS	4.65	4.84	104	ng/mL	+/- 30.00%
	PFNS	4.80	5.13	107	ng/mL	+/- 30.00%
	PFDS	4.82	5.61	116	ng/mL	+/- 30.00%
	PFDOS	4.85	5.63	116	ng/mL	+/- 30.00%
	4:2FTS	18.8	17.5	93.2	ng/mL	+/- 30.00%
	6:2FTS	19.0	17.2	90.8	ng/mL	+/- 30.00%
	8:2FTS	19.2	15.7	81.6	ng/mL	+/- 30.00%
	PFOSA	5.00	5.50	110	ng/mL	+/- 30.00%
	NMeFOSA	20.0	20.8	104	ng/mL	+/- 30.00%
	NEtFOSA	20.0	19.9	99.6	ng/mL	+/- 30.00%
	NMeFOSAA	5.00	5.26	105	ng/mL	+/- 30.00%
	NEtFOSAA	5.00	4.52	90.5	ng/mL	+/- 30.00%
	NMeFOSE	20.0	20.8	104	ng/mL	+/- 30.00%
	NEtFOSE	20.0	19.6	98.1	ng/mL	+/- 30.00%
	HFPO-DA	10.0	9.71	97.1	ng/mL	+/- 30.00%























# INITIAL AND CONTINUING CALIBRATION CHECK





















## EPA 1633

















Laboratory:	APPL, LLC	Work Order:	22L0141
Client:	AECOM	Project:	Red Hill AFFF Assessment Sampling
Instrument ID:	Saphira	Calibration:	2252011
Standard ID:	22L0304	Sequence:	SB03951

Lab Sample ID	Analyte	True	Found	%R	Units	Control Limit
SB03951-CCV3	ADONA	9.45	9.06	95.9	ng/mL	+/- 30.00%
	PFEESA	8.90	8.77	98.5	ng/mL	+/- 30.00%
	PFMPA	10.0	10.7	107	ng/mL	+/- 30.00%
	PFMBA	10.0	10.0	100	ng/mL	+/- 30.00%
	NFDHA	10.0	10.8	108	ng/mL	+/- 30.00%
	9CL-PF3ONS	9.35	8.87	94.9	ng/mL	+/- 30.00%
	11CL-PF3OUDS	9.45	9.32	98.6	ng/mL	+/- 30.00%
	3:3FTCA	20.0	23.1	116	ng/mL	+/- 30.00%
	5:3FTCA	20.0	20.2	101	ng/mL	+/- 30.00%
	7:3FTCA	20.0	21.9	110	ng/mL	+/- 30.00%












Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBA	(212.9 / 169.0) 2329567	(3.66, 1.00) (0.00, N/A, 0.0)	74.1	N/A 0.0 0.0	21.3534 [ 20.0000 ]	106.8%			
PFPeA	(262.9 / 219.0) 1588778 (262.9 / 69.0) 16368	(4.98, 1.00) (0.00, N/A, 0.2)	742.9 266.9	0.0103 92.0 99.1	10.0730 [ 10.0000 ]	100.7%			
PFHxA	(313.0 / 269.0) 1265100 (313.0 / 119.0) 123682	(6.14, 1.00) (0.00, N/A, 0.1)	482.2 523.1	0.0978 100.0 109.4	5.1424 [ 5.0000 ]	102.8%			
PFHpA	(363.0 / 319.0) 1106860 (363.0 / 169.0) 316230	(7.06, 1.00) (0.00, N/A, -0.3)	556.8 583.1	0.2857 91.7 92.7	4.8062 [ 5.0000 ]	96.1%			
PFOA	(413.0 / 369.0) 1314240 (413.0 / 169.0) 413034	(7.87, 1.00) (0.00, N/A, 0.1)	686.5 668.7	0.3143 96.2 106.2	4.7522 [ 5.0000 ]	95.0%			
PFNA	(463.0 / 419.0) 1057815 (463.0 / 169.0) 207817	(8.61, 1.00) (0.00, N/A, 0.0)	549.8 113.5	0.1965 101.9 94.3	4.8214 [ 5.0000 ]	96.4%			
PFDA	(513.0 / 469.0) 1295759 (513.0 / 169.0) 135325	(9.28, 1.00) (0.00, N/A, -0.1)	522.9 395.8	0.1044 109.3 106.3	4.9419 [ 5.0000 ]	98.8%			
PFUnA	(563.0 / 519.0) 1462777 (563.0 / 169.0) 144281	(9.69, 1.00) (-0.01, N/A, -0.2)	753.4 416.8	0.0986 113.6 110.0	5.3095 [ 5.0000 ]	106.2%			
PFDoA	(613.0 / 569.0) 1754907 (613.0 / 169.0) 201901	(9.88, 1.00) (0.00, N/A, 0.2)	804.7 485.0	0.1150 82.6 87.5	5.0383 [ 5.0000 ]	100.8%			
PFTrDA	(663.0 / 619.0) 1376291 (663.0 / 169.0) 305542	(10.00, 1.01) (N/A, -0.01, -0.1)	881.9 519.4	0.2220 108.5 97.1	4.5606 [ 5.0000 ]	91.2%			
PFTeDA	(713.0 / 669.0) 1389894 (713.0 / 169.0) 266394	(10.11, 1.00) (0.00, N/A, -0.2)	833.2 648.0	0.1917 94.2 93.4	5.8755 [ 5.0000 ]	117.5%			












Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT- CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBS	(298.9 / 80.0) 1770464 (298.9 / 99.0) 1243235	(6.08, 1.00) (0.00, N/A, 0.0)	658.5 669.6	0.7022 114.1 107.2	4.2801 [ 4.4237 ]	96.8%			
PFPeS	(349.0 / 80.0) 3355149 (349.0 / 99.0) 1155562	(7.12, 0.89) (N/A, 0.01, -0.1)	891.1 678.6	0.3444 96.8 89.7	4.7342 [ 4.6919 ]	100.9%			
PFHxS	(399.0 / 80.0) 2740948 (399.0 / 99.0) 930351	(7.99, 1.00) (0.00, N/A, 0.1)	2730.6 3069.8	0.3394 101.0 102.5	4.4472 [ 4.5549 ]	97.6%			
PFHpS	(449.0 / 80.0) 2771477 (449.0 / 99.0) 697823	(8.76, 0.93) (N/A, -0.01, 0.2)	613.3 463.0	0.2518 92.0 99.0	5.8180 [ 4.7570 ]	122.3%			
PFOS	(499.0 / 80.0) 2869152 (499.0 / 99.0) 718374	(9.43, 1.00) (0.00, N/A, 0.0)	104.3 167.0	0.2504 103.0 109.5	4.8418 [ 4.6375 ]	104.4%			
PFNS	(549.0 / 80.0) 3370808 (549.0 / 99.0) 861335	(9.75, 1.03) (N/A, -0.01, -0.1)	656.2 864.2	0.2555 104.7 100.1	5.1278 [ 4.7994 ]	106.8%			
PFDS	(599.0 / 80.0) 4095524 (599.0 / 99.0) 1029395	(9.90, 1.05) (N/A, -0.01, 0.0)	952.3 850.4	0.2513 111.7 107.4	5.6120 [ 4.8155 ]	116.5%			
PFDoS	(698.9 / 80.0) 1715967 (698.9 / 99.0) 418660	(10.10, 1.07) (N/A, -0.01, 0.2)	950.7 1204.5	0.2440 99.7 125.7	5.6259 [ 4.8478 ]	116.1%			
4:2FTS	(327.0 / 307.0) 3504022 (327.0 / 81.0) 1969471	(5.80, 1.00) (0.00, N/A, 0.1)	849.1 862.4	0.5621 113.8 98.2	17.5197 [ 18.6906 ]	93.7%			
6:2FTS	(427.0 / 407.0) 2241523 (427.0 / 81.0) 1456278	(7.53, 1.00) (0.00, N/A, -0.2)	995.1 969.6	0.6497 83.5 93.2	17.2454 [ 18.9808 ]	90.9%			
8:2FTS	(527.0 / 507.0) 1871197 (527.0 / 81.0) 1111280	(8.94, 1.00) (0.00, N/A, -0.1)	571.1 506.2	0.5939 104.9 107.9	15.6670 [ 19.1658 ]	81.7%			






Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFOSA	( 498.0 / 78.0 ) 4154372 ( 498.0 / 478.0 ) 86834	( 10.17 , 1.00 ) ( 0.00 , N/A , 0.2 )	911.5 352.4	0.0209 100.3 86.2	5.4994 [ 5.0000 ]	110.0%			
NMeFOSA	( 511.9 / 219.0 ) 3089993 ( 511.9 / 169.0 ) 1929702	( 10.60 , 1.00 ) ( 0.00 , N/A , 0.1 )	1291.5 1124.1	0.6245 86.7 92.4	20.8314 [ 20.0000 ]	104.2%			
NEIFOSA	( 526.0 / 219.0 ) 3121180 ( 526.0 / 169.0 ) 3483795	( 10.69 , 1.00 ) ( 0.00 , N/A , 0.0 )	1079.3 1304.0	1.1162 105.5 105.3	19.9228 [ 20.0000 ]	99.6%			
NMeFOSAA	( 570.0 / 419.0 ) 527197 ( 570.0 / 483.0 ) 280214	( 9.48 , 1.00 ) ( 0.00 , N/A , -0.1 )	422.9 504.9	0.5315 86.5 106.3	5.2646 [ 5.0000 ]	105.3%			
NEIFOSAA	( 584.0 / 419.0 ) 455415 ( 584.0 / 526.0 ) 289550	( 9.67 , 1.00 ) ( 0.01 , N/A , 0.4 )	842.8 388032.7	0.6358 86.7 87.5	4.5229 [ 5.0000 ]	90.5%			
NMeFOSE	( 616.1 / 59.0 ) 688149	( 10.57 , 1.00 ) ( 0.01 , N/A , 0.0 )	1101.7	N/A 0.0 0.0	20.8386 [ 20.0000 ]	104.2%			
NEIFOSE	( 630.0 / 59.0 ) 122249	( 10.67 , 1.00 ) ( 0.01 , N/A , 0.0 )	980.7	N/A 0.0 0.0	19.6110 [ 20.0000 ]	98.1%			
HFPO-DA	( 285.0 / 169.0 ) 944262 ( 285.0 / 185.0 ) 2581735	( 6.48 , 1.00 ) ( 0.00 , N/A , 0.0 )	611.5 912.5	2.7341 99.6 105.1	9.7065 [ 10.0000 ]	97.1%			
ADONA	( 377.0 / 85.0 ) 3914647 ( 377.0 / 251.0 ) 517903	( 7.38 , 1.14 ) ( N/A , 0.00 , 0.1 )	778.0 706.6	0.1323 106.2 103.6	9.0597 [ 9.4270 ]	96.1%			
9CI-Pf3ONS	( 531.0 / 351.0 ) 10425825 ( 533.0 / 353.0 ) 3291787	( 9.70 , 1.50 ) ( N/A , -0.01 , -0.1 )	1199.2 1073.9	0.3157 106.7 108.8	8.8697 [ 9.3325 ]	95.0%			
11CI-PF3OUDS	( 631.0 / 451.0 ) 5629636 ( 633.0 / 453.0 ) 1837885	( 9.99 , 1.54 ) ( N/A , -0.02 , -0.1 )	847.8 619.7	0.3265 98.7 101.6	9.3218 [ 9.4321 ]	98.8%			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT-CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
3:3FTCA	(241.0 / 177.0) 125980 (241.0 / 117.0) 205696	(4.46, 0.90) (N/A, 0.02, 0.0)	750.7 620.5	1.6328 97.6 97.2	23.1433 [ 20.0000 ]	115.7%			
5:3FTCA	(341.0 / 236.7) 879247 (341.0 / 217.0) 1433265	(6.77, 1.10) (N/A, 0.01, -0.1)	479.0 621.9	1.6301 111.4 101.4	20.2264 [ 20.0000 ]	101.1%			
7:3FTCA	(441.0 / 317.0) 1095640 (441.0 / 337.0) 951207	(8.58, 1.40) (N/A, -0.01, 0.0)	484.0 483.1	0.8682 103.7 104.1	21.9049 [ 20.0000 ]	109.5%			
PFEESA	(315.0 / 135.0) 2361207 (315.0 / 83.0) 730225	(6.58, 1.07) (N/A, 0.00, -0.1)	892.7 784.8	0.3093 100.7 104.7	8.7666 [ 8.9246 ]	98.2%			
PFMPA	(229.0 / 85.0) 461480	(4.16, 0.84) (N/A, 0.01, 0.0)	923.3	N/A 0.0 0.0	10.6605 [ 10.0000 ]	106.6%			
PFMBA	(279.0 / 85.0) 1500223	(5.37, 1.08) (N/A, 0.02, 0.0)	925.3	N/A 0.0 0.0	10.0264 [ 10.0000 ]	100.3%			
NFDHA	(295.0 / 201.0) 1344733 (295.0 / 85.0) 1200999	(6.01, 0.98) (N/A, 0.01, 0.0)	752.3 1049.1	0.8931 101.2 102.0	10.8404 [ 10.0000 ]	108.4%			
13C3_PFBA_IIS	(216.0 / 172.0) 167706	(3.66, N/A) (N/A, 0.01, N/A)	642.3	N/A	1.2048 [ 1.0000 ]	120.5% { 106.8% }			
13C2_PFHxA_IIS	(315.1 / 270.0) 250241	(6.13, N/A) (N/A, 0.01, N/A)	631.9	N/A	1.0837 [ 1.0000 ]	108.4% { 106.1% }			
13C4_PFOA_IIS	(417.0 / 372.0) 258166	(7.87, N/A) (N/A, 0.00, N/A)	497.3	N/A	1.1743 [ 1.0000 ]	117.4% { 100.5% }			
13C5_PFNA_IIS	(468.0 / 423.0) 207452	(8.60, N/A) (N/A, -0.01, N/A)	334.9	N/A	1.1203 [ 1.0000 ]	112.0% { 88.5% }			



Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDA_IIS	(515.1 / 470.1) 199799	(9.28, N/A) (N/A, -0.01, N/A)	314.0	N/A	1.0811 [ 1.0000 ]	108.1% { 106.7% }			
18O2_PFHxS_IIS	(403.0 / 83.9) 462355	(7.99, N/A) (N/A, 0.00, N/A)	799.7	N/A	1.1453 [ 1.0000 ]	114.5% { 103.6% }			
13C4_PFOS_IIS	(502.8 / 79.9) 386574	(9.43, N/A) (N/A, -0.01, N/A)	419.6	N/A	1.2112 [ 1.0000 ]	121.1% { 111.5% }			
13C4_PFBA_EIS	(217.0 / 172.0) 1337805	(3.66, N/A) (N/A, 0.01, N/A)	726.3	N/A	7.7506 [ 8.0000 ]	96.9% { 106.5% }			
13C5_PFPeA_EIS	(267.9 / 223.0) 718361	(4.98, N/A) (N/A, 0.01, N/A)	631.9	N/A	4.1258 [ 4.0000 ]	103.1% { 105.7% }			
13C5_PFHxA_EIS	(318.0 / 273.0) 572910	(6.13, N/A) (N/A, 0.01, N/A)	597.5	N/A	1.9895 [ 2.0000 ]	99.5% { 106.9% }			
13C4_PFHpA_EIS	(367.0 / 322.0) 505300	(7.06, N/A) (N/A, 0.01, N/A)	635.7	N/A	2.0114 [ 2.0000 ]	100.6% { 112.3% }			
13C8_PFOA_EIS	(421.0 / 376.0) 562459	(7.87, N/A) (N/A, 0.00, N/A)	805.1	N/A	1.9866 [ 2.0000 ]	99.3% { 94.4% }			
13C9_PFNA_EIS	(472.0 / 427.0) 255691	(8.60, N/A) (N/A, -0.01, N/A)	410.6	N/A	1.1209 [ 1.0000 ]	112.1% { 110.3% }			
13C6_PFDA_EIS	(519.0 / 474.0) 275465	(9.29, N/A) (N/A, 0.00, N/A)	467.2	N/A	0.9694 [ 1.0000 ]	96.9% { 100.1% }			
13C7_PFUnA_EIS	(570.0 / 525.0) 348613	(9.70, N/A) (N/A, -0.01, N/A)	419.3	N/A	0.8625 [ 1.0000 ]	86.2% { 93.7% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT- CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDa_EIS	(615.0 / 570.0) 404039	(9.88, N/A) (N/A, -0.02, N/A)	461.4	N/A	1.0015 [ 1.0000 ]	100.2% { 110.3% }			
13C2_PFTeDA_EIS	(715.0 / 670.0) 266914	(10.11, N/A) (N/A, -0.01, N/A)	435.0	N/A	0.9962 [ 1.0000 ]	99.6% { 104.6% }			
13C3_PFBs_EIS	(302.0 / 80.0) 1508996	(6.08, N/A) (N/A, 0.01, N/A)	676.0	N/A	1.9303 [ 2.0000 ]	96.5% { 113.2% }			
13C3_PFHxS_EIS	(402.0 / 80.0) 793420	(7.99, N/A) (N/A, 0.00, N/A)	787.3	N/A	1.9076 [ 2.0000 ]	95.4% { 103.3% }			
13C8_PFOS_EIS	(507.0 / 80.0) 1091884	(9.43, N/A) (N/A, -0.01, N/A)	244.6	N/A	1.6457 [ 2.0000 ]	82.3% { 97.7% }			
13C2_4:2FTS_EIS	(329.0 / 81.0) 241953	(5.80, N/A) (N/A, 0.01, N/A)	634.7	N/A	3.6543 [ 4.0000 ]	91.4% { 107.5% }			
13C2_6:2FTS_EIS	(429.0 / 81.0) 338147	(7.53, N/A) (N/A, 0.00, N/A)	668.6	N/A	4.2420 [ 4.0000 ]	106.0% { 100.5% }			
13C2_8:2FTS_EIS	(529.0 / 81.0) 301545	(8.95, N/A) (N/A, 0.00, N/A)	398.8	N/A	3.7788 [ 4.0000 ]	94.5% { 95.4% }			
13C8_PFOsa_EIS	(506.0 / 78.0) 1598613	(10.17, N/A) (N/A, -0.01, N/A)	905.8	N/A	1.9062 [ 2.0000 ]	95.3% { 117.2% }			
D3_NMeFOSA_EIS	(515.0 / 169.0) 363940	(10.60, N/A) (N/A, -0.01, N/A)	1281.0	N/A	1.9876 [ 2.0000 ]	99.4% { 126.7% }			
D5_NEiFOSA_EIS	(531.1 / 169.0) 347362	(10.69, N/A) (N/A, -0.01, N/A)	956.5	N/A	2.0550 [ 2.0000 ]	102.8% { 114.3% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT- CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
D3_MeFOSAA_EIS	(573.0 / 419.0) 514015	(9.48, N/A) (N/A, -0.01, N/A)	436.0	N/A	3.2581 [ 4.0000 ]	81.5% { 97.2% }			
D5_EtFOSAA_EIS	(589.0 / 419.0) 448621	(9.66, N/A) (N/A, -0.01, N/A)	460.3	N/A	3.2262 [ 4.0000 ]	80.7% { 108.1% }			
D7_NMeFOSE_EIS	(623.2 / 58.9) 523257	(10.57, N/A) (N/A, -0.01, N/A)	783.0	N/A	20.3519 [ 20.0000 ]	101.8% { 120.4% }			
D9_NEtFOSE_EIS	(639.2 / 58.9) 243492	(10.66, N/A) (N/A, -0.01, N/A)	1302.1	N/A	20.8028 [ 20.0000 ]	104.0% { 122.9% }			
13C3_HFPODA_EIS	(287.0 / 169.0) 1280418	(6.47, N/A) (N/A, 0.00, N/A)	658.1	N/A	8.3630 [ 8.0000 ]	104.5% { 105.2% }			

## ANALYSIS SEQUENCE BLANKS

Laboratory: APPL, LLC  
 Client: AECOM  
 Sequence: SB03941  
 Calibration: 2252011

SDG:  
 Project: Red Hill AFFF Assessment Sam  
 Instrument: Saphira

Lab Sample ID	Analyte	Found	Units	RL	C
SB03941-ICB1	PFBA	0.00	ng/mL	0.75	U
	PFPEA	0.00	ng/mL	0.20	U
	PFHXA	0.00	ng/mL	0.10	U
	PFHPA	0.00	ng/mL	0.10	U
	PFOA	0.0144	ng/mL	0.10	U
	PFNA	0.00	ng/mL	0.10	U
	PFDA	0.00	ng/mL	0.10	U
	PFUnA	0.00	ng/mL	0.10	U
	PFDOA	0.00	ng/mL	0.10	U
	PFTRDA	0.00	ng/mL	0.10	U
	PFTEDA	0.00	ng/mL	0.10	U
	PFBS	0.00	ng/mL	0.10	U
	PFPEs	0.00	ng/mL	0.10	U
	PFHXS	0.00	ng/mL	0.10	U
	PFHPS	0.00	ng/mL	0.10	U
	PFOS	0.0146	ng/mL	0.10	U
	PFNS	0.00	ng/mL	0.10	U
	PFDS	0.00	ng/mL	0.10	U
	PFDOS	0.00	ng/mL	0.10	U
	4:2FTS	0.00	ng/mL	0.40	U
	6:2FTS	0.00	ng/mL	0.40	U
	8:2FTS	0.00	ng/mL	0.40	U
	PFOSA	0.0124	ng/mL	0.10	U
	NMeFOSA	0.00	ng/mL	0.40	U
	NEtFOSA	0.00	ng/mL	0.40	U
	NMeFOSAA	0.00	ng/mL	0.10	U
	NEtFOSAA	0.00	ng/mL	0.10	U
	NMeFOSE	0.00	ng/mL	0.40	U
	NEtFOSE	0.00	ng/mL	0.40	U
	HFPO-DA	0.00	ng/mL	0.20	U
	ADONA	0.00	ng/mL	0.20	U
	PFEESA	0.00	ng/mL	0.20	U
	PFMPA	0.00	ng/mL	0.20	U

## ANALYSIS SEQUENCE BLANKS

Laboratory: APPL, LLC  
 Client: AECOM  
 Sequence: SB03941  
 Calibration: 2252011

SDG:  
 Project: Red Hill AFFF Assessment Sam  
 Instrument: Saphira

Lab Sample ID	Analyte	Found	Units	RL	C
SB03941-ICB1	PFMBA	0.00	ng/mL	0.20	U
	NFDHA	0.00	ng/mL	0.20	U
	9CL-PF3ONS	0.00	ng/mL	0.20	U
	11CL-PF3OUDS	0.00	ng/mL	0.20	U
	3:3FTCA	0.00	ng/mL	0.40	U
	5:3FTCA	0.00	ng/mL	0.40	U
	7:3FTCA	0.00	ng/mL	0.40	U
	13C4-PFBA	8.24	ng/mL		
	13C5-PFPEA	4.11	ng/mL		
	13C5-PFHXA	1.95	ng/mL		
	13C4-PFHPA	2.08	ng/mL		
	13C8-PFOA	2.18	ng/mL		
	13C9-PFNA	1.04	ng/mL		
	13C6-PFDA	1.03	ng/mL		
	13C7-PFUnA	1.08	ng/mL		
	13C2-PFDOA	1.09	ng/mL		
	13C2-PFTEDA	1.15	ng/mL		
	13C3-PFBS	2.21	ng/mL		
	13C3-PFHXS	2.21	ng/mL		
	13C8-PFOS	2.47	ng/mL		
	13C2-4:2FTS	4.05	ng/mL		
	13C2-6:2FTS	4.81	ng/mL		
	13C2-8:2FTS	4.00	ng/mL		
	13C8-PFOSA	2.42	ng/mL		
	D5-NETFOSA	2.32	ng/mL		
	D3-NMEFOSA	2.31	ng/mL		
	D3-NMEFOSAA	4.78	ng/mL		
	D5-NETFOSAA	4.58	ng/mL		
	D7-NMEFOSE	21.9	ng/mL		
	D9-NETFOSSE	21.3	ng/mL		
	13C3-HFPO-DA	8.60	ng/mL		



Chemist: ABK  
 Instrument: Saphira  
 Type: Sciex Q3 5500

Sample I.D.: SB03941-ICB1  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - S2022-12-21A  
 Path: S2022-12-21A (9)  
 Acquired: 2022/12/21 - 16:08

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-[min], ΔRT- CV[min], ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBA	(212.9 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A	N/A 0.0 0.0	0.0000	N/A			
PFPeA	(262.9 / 219.0) N/A (262.9 / 69.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFHxA	(313.0 / 269.0) N/A (313.0 / 119.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFHpA	(363.0 / 319.0) N/A (363.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFOA	(413.0 / 369.0) 3496 (413.0 / 169.0) 986	(7.98, 1.00) (0.01, N/A, -0.4)	15.4 42.4	0.2821 86.3 86.3	0.0144	N/A			
PFNA	(463.0 / 419.0) N/A (463.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFDA	(513.0 / 469.0) N/A (513.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFUnA	(563.0 / 519.0) N/A (563.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFDoA	(613.0 / 569.0) N/A (613.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFTrDA	(663.0 / 619.0) N/A (663.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFTeDA	(713.0 / 669.0) N/A (713.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			



Chemist: ABK  
 Instrument: Saphira  
 Type: Sciex Q3 5500

















Sample I.D.: SB03941-ICB1  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam












Quant Method: 1633 - S2022-12-21A  
 Path: S2022-12-21A (9)  
 Acquired: 2022/12/21 - 16:08

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBS	(298.9 / 80.0) N/A (298.9 / 99.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFPeS	(349.0 / 80.0) N/A (349.0 / 99.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFHxS	(399.0 / 80.0) N/A (399.0 / 99.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFHpS	(449.0 / 80.0) N/A (449.0 / 99.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFOS	(499.0 / 80.0) 9898 (499.0 / 99.0) 1897	(9.52, 1.00) (0.00, N/A, -1.2)	48.5 19.3	0.1916 78.8 78.8	0.0146	N/A			MI5 DG 2022-12-21
PFNS	(549.0 / 80.0) N/A (549.0 / 99.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFDS	(599.0 / 80.0) N/A (599.0 / 99.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFDoS	(698.9 / 80.0) N/A (698.9 / 99.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
4:2FTS	(327.0 / 307.0) N/A (327.0 / 81.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
6:2FTS	(427.0 / 407.0) N/A (427.0 / 81.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
8:2FTS	(527.0 / 507.0) N/A (527.0 / 81.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT-CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFOSA	(498.0 / 78.0) 9076 (498.0 / 478.0) 300	(10.20, 1.00) (0.00, N/A, -0.8)	34.8 12.4	0.0330 158.5 158.5	0.0124	N/A			
NMeFOSA	(511.9 / 219.0) N/A (511.9 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NEtFOSA	(526.0 / 219.0) N/A (526.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NMeFOSAA	(570.0 / 419.0) N/A (570.0 / 483.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NEtFOSAA	(584.0 / 419.0) N/A (584.0 / 526.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NMeFOSE	(616.1 / 59.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A	N/A 0.0 0.0	0.0000	N/A			
NEtFOSE	(630.0 / 59.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A	N/A 0.0 0.0	0.0000	N/A			
HFPO-DA	(285.0 / 169.0) N/A (285.0 / 185.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
ADONA	(377.0 / 85.0) N/A (377.0 / 251.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
9Cl-Pf3ONS	(531.0 / 351.0) N/A (533.0 / 353.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
11Cl-Pf3OUDS	(631.0 / 451.0) N/A (633.0 / 453.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			



Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
3:3FTCA	(241.0 / 177.0) N/A (241.0 / 117.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
5:3FTCA	(341.0 / 236.7) N/A (341.0 / 217.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
7:3FTCA	(441.0 / 317.0) N/A (441.0 / 337.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFEESA	(315.0 / 135.0) N/A (315.0 / 83.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFMPA	(229.0 / 85.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A	N/A 0.0 0.0	0.0000	N/A			
PFMBA	(279.0 / 85.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A	N/A 0.0 0.0	0.0000	N/A			
NFDHA	(295.0 / 201.0) N/A (295.0 / 85.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
13C3_PFBA_IIS	(216.0 / 172.0) 137297	(3.70, N/A) (N/A, -0.02, N/A)	766.0	N/A	0.9864 [ 1.0000 ]	98.6% { 90.5% }			
13C2_PFHxA_IIS	(315.1 / 270.0) 223416	(6.20, N/A) (N/A, 0.02, N/A)	460.7	N/A	0.9675 [ 1.0000 ]	96.8% { 95.5% }			
13C4_PFOA_IIS	(417.0 / 372.0) 206725	(7.97, N/A) (N/A, 0.05, N/A)	562.5	N/A	0.9403 [ 1.0000 ]	94.0% { 86.9% }			
13C5_PFNA_IIS	(468.0 / 423.0) 186093	(8.72, N/A) (N/A, 0.05, N/A)	497.6	N/A	1.0049 [ 1.0000 ]	100.5% { 92.0% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDA_IIS	(515.1 / 470.1) 184687	(9.40, N/A) (N/A, 0.05, N/A)	233.6	N/A	0.9993 [ 1.0000 ]	99.9% { 106.2% }			
18O2_PFHxS_IIS	(403.0 / 83.9) 371811	(8.10, N/A) (N/A, 0.05, N/A)	662.9	N/A	0.9210 [ 1.0000 ]	92.1% { 88.0% }			
13C4_PFOS_IIS	(502.8 / 79.9) 294523	(9.53, N/A) (N/A, 0.05, N/A)	539.0	N/A	0.9228 [ 1.0000 ]	92.3% { 89.8% }			
13C4_PFBA_EIS	(217.0 / 172.0) 1164618	(3.70, N/A) (N/A, -0.02, N/A)	949.7	N/A	8.2417 [ 8.0000 ]	103.0% { 97.8% }			
13C5_PFPeA_EIS	(267.9 / 223.0) 639563	(5.02, N/A) (N/A, -0.01, N/A)	719.9	N/A	4.1143 [ 4.0000 ]	102.9% { 91.9% }			
13C5_PFHxA_EIS	(318.0 / 273.0) 500638	(6.20, N/A) (N/A, 0.02, N/A)	697.9	N/A	1.9473 [ 2.0000 ]	97.4% { 92.9% }			
13C4_PFHpA_EIS	(367.0 / 322.0) 466966	(7.15, N/A) (N/A, 0.04, N/A)	691.4	N/A	2.0820 [ 2.0000 ]	104.1% { 95.1% }			
13C8_PFOA_EIS	(421.0 / 376.0) 494304	(7.97, N/A) (N/A, 0.05, N/A)	917.1	N/A	2.1804 [ 2.0000 ]	109.0% { 99.3% }			
13C9_PFNA_EIS	(472.0 / 427.0) 213587	(8.72, N/A) (N/A, 0.05, N/A)	564.9	N/A	1.0438 [ 1.0000 ]	104.4% { 97.6% }			
13C6_PFDA_EIS	(519.0 / 474.0) 271082	(9.40, N/A) (N/A, 0.05, N/A)	432.0	N/A	1.0320 [ 1.0000 ]	103.2% { 96.4% }			
13C7_PFUnA_EIS	(570.0 / 525.0) 404733	(9.75, N/A) (N/A, 0.03, N/A)	435.5	N/A	1.0833 [ 1.0000 ]	108.3% { 101.6% }			








Chemist: ABK  
 Instrument: Saphira  
 Type: Sciex Q3 5500

Sample I.D.: SB03941-ICB1  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - S2022-12-21A  
 Path: S2022-12-21A (9)  
 Acquired: 2022/12/21 - 16:08

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-I[min], ΔRT-CV[min], ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDa_EIS	(615.0 / 570.0) 407883	(9.92, N/A) (N/A, 0.02, N/A)	595.7	N/A	1.0938 [ 1.0000 ]	109.4% { 105.2% }			
13C2_PFTeDA_EIS	(715.0 / 670.0) 285097	(10.15, N/A) (N/A, 0.02, N/A)	425.4	N/A	1.1512 [ 1.0000 ]	115.1% { 117.9% }			
13C3_PFBs_EIS	(302.0 / 80.0) 1390129	(6.16, N/A) (N/A, 0.01, N/A)	781.9	N/A	2.2113 [ 2.0000 ]	110.6% { 101.2% }			
13C3_PFHxS_EIS	(402.0 / 80.0) 737924	(8.10, N/A) (N/A, 0.05, N/A)	828.7	N/A	2.2062 [ 2.0000 ]	110.3% { 97.9% }			
13C8_PFOS_EIS	(507.0 / 80.0) 1246594	(9.53, N/A) (N/A, 0.05, N/A)	598.1	N/A	2.4662 [ 2.0000 ]	123.3% { 104.7% }			
13C2_4:2FTS_EIS	(329.0 / 81.0) 215896	(5.86, N/A) (N/A, 0.01, N/A)	739.4	N/A	4.0548 [ 4.0000 ]	101.4% { 96.3% }			
13C2_6:2FTS_EIS	(429.0 / 81.0) 308341	(7.63, N/A) (N/A, 0.04, N/A)	911.4	N/A	4.8100 [ 4.0000 ]	120.3% { 112.4% }			
13C2_8:2FTS_EIS	(529.0 / 81.0) 256399	(9.06, N/A) (N/A, 0.06, N/A)	310.1	N/A	3.9955 [ 4.0000 ]	99.9% { 86.6% }			
13C8_PFOsa_EIS	(506.0 / 78.0) 1544524	(10.20, N/A) (N/A, 0.02, N/A)	1476.0	N/A	2.4173 [ 2.0000 ]	120.9% { 105.4% }			
D3_NMeFOSA_EIS	(515.0 / 169.0) 322844	(10.62, N/A) (N/A, 0.02, N/A)	1120.4	N/A	2.3142 [ 2.0000 ]	115.7% { 97.8% }			
D5_NEtFOSA_EIS	(531.1 / 169.0) 298222	(10.71, N/A) (N/A, 0.01, N/A)	1079.5	N/A	2.3157 [ 2.0000 ]	115.8% { 104.8% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT- CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
D3_MeFOSAA_EIS	(573.0 / 419.0) 574276	(9.57, N/A) (N/A, 0.04, N/A)	542.0	N/A	4.7778 [ 4.0000 ]	119.4% { 112.5% }			
D5_EtFOSAA_EIS	(589.0 / 419.0) 485417	(9.73, N/A) (N/A, 0.03, N/A)	310.2	N/A	4.5818 [ 4.0000 ]	114.5% { 103.0% }			
D7_NMeFOSE_EIS	(623.2 / 58.9) 428343	(10.59, N/A) (N/A, 0.01, N/A)	811.6	N/A	21.8673 [ 20.0000 ]	109.3% { 99.3% }			
D9_NEtFOSE_EIS	(639.2 / 58.9) 189842	(10.68, N/A) (N/A, 0.01, N/A)	1103.1	N/A	21.2885 [ 20.0000 ]	106.4% { 104.1% }			
13C3_HFPODA_EIS	(287.0 / 169.0) 1175027	(6.56, N/A) (N/A, 0.03, N/A)	697.1	N/A	8.5961 [ 8.0000 ]	107.5% { 100.0% }			

## ANALYSIS SEQUENCE BLANKS

Laboratory: APPL, LLC  
 Client: AECOM  
 Sequence: SB03951  
 Calibration: 2252011

SDG:  
 Project: Red Hill AFFF Assessment Sam  
 Instrument: Saphira

Lab Sample ID	Analyte	Found	Units	RL	C
SB03951-CCB1	PFBA	0.00	ng/mL	0.75	U
	PFPEA	0.00	ng/mL	0.20	U
	PFHXA	0.00	ng/mL	0.10	U
	PFHPA	0.00	ng/mL	0.10	U
	PFOA	0.00	ng/mL	0.10	U
	PFNA	0.00	ng/mL	0.10	U
	PFDA	0.00	ng/mL	0.10	U
	PFUnA	0.00	ng/mL	0.10	U
	PFDOA	0.00	ng/mL	0.10	U
	PFTRDA	0.00	ng/mL	0.10	U
	PFTEDA	0.00	ng/mL	0.10	U
	PFBS	0.00	ng/mL	0.10	U
	PFPEs	0.00	ng/mL	0.10	U
	PFHXS	0.00	ng/mL	0.10	U
	PFHPS	0.00	ng/mL	0.10	U
	PFOS	0.00	ng/mL	0.10	U
	PFNS	0.00	ng/mL	0.10	U
	PFDS	0.00	ng/mL	0.10	U
	PFDOS	0.00	ng/mL	0.10	U
	4:2FTS	0.00	ng/mL	0.40	U
	6:2FTS	0.00	ng/mL	0.40	U
	8:2FTS	0.00	ng/mL	0.40	U
	PFOSA	0.00	ng/mL	0.10	U
	NMeFOSA	0.00	ng/mL	0.40	U
	NEtFOSA	0.00	ng/mL	0.40	U
	NMeFOSAA	0.00	ng/mL	0.10	U
	NEtFOSAA	0.00	ng/mL	0.10	U
	NMeFOSE	0.00	ng/mL	0.40	U
	NEtFOSE	0.00	ng/mL	0.40	U
	HFPO-DA	0.00	ng/mL	0.20	U
	ADONA	0.00	ng/mL	0.20	U
	PFEESA	0.00	ng/mL	0.20	U
	PFMPA	0.00	ng/mL	0.20	U

## ANALYSIS SEQUENCE BLANKS

Laboratory: APPL, LLC  
 Client: AECOM  
 Sequence: SB03951  
 Calibration: 2252011

SDG:  
 Project: Red Hill AFFF Assessment Sam  
 Instrument: Saphira

Lab Sample ID	Analyte	Found	Units	RL	C
SB03951-CCB1	PFMBA	0.00	ng/mL	0.20	U
	NFDHA	0.00	ng/mL	0.20	U
	9CL-PF3ONS	0.00	ng/mL	0.20	U
	11CL-PF3OUDS	0.00	ng/mL	0.20	U
	3:3FTCA	0.00	ng/mL	0.40	U
	5:3FTCA	0.00	ng/mL	0.40	U
	7:3FTCA	0.00	ng/mL	0.40	U
	13C4-PFBA	7.88	ng/mL		
	13C5-PFPEA	4.33	ng/mL		
	13C5-PFHXA	2.02	ng/mL		
	13C4-PFHPA	2.14	ng/mL		
	13C8-PFOA	2.10	ng/mL		
	13C9-PFNA	0.941	ng/mL		
	13C6-PFDA	1.27	ng/mL		
	13C7-PFUnA	1.39	ng/mL		
	13C2-PFDOA	1.12	ng/mL		
	13C2-PFTEDA	1.13	ng/mL		
	13C3-PFBS	1.90	ng/mL		
	13C3-PFHXS	2.05	ng/mL		
	13C8-PFOS	2.01	ng/mL		
	13C2-4:2FTS	4.15	ng/mL		
	13C2-6:2FTS	4.76	ng/mL		
	13C2-8:2FTS	4.52	ng/mL		
	13C8-PFOSA	1.96	ng/mL		
	D5-NETFOSA	1.82	ng/mL		
	D3-NMEFOSA	1.84	ng/mL		
	D3-NMEFOSAA	3.67	ng/mL		
	D5-NETFOSAA	4.36	ng/mL		
	D7-NMEFOSE	18.8	ng/mL		
	D9-NETFOSAE	19.2	ng/mL		
	13C3-HFPO-DA	7.55	ng/mL		



Chemist: DAG  
Instrument: Saphira  
Type: Sciex Q3 5500

Sample I.D.: SB03951-CCB1  
DF, IV: 1, 10.0µL  
Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
Path: S2022-12-22A (1)  
Acquired: 2022/12/22 - 11:01

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-Imin, ΔRT-CVmin, ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration True ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBA	(212.9 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A	N/A 0.0 0.0	0.0000	N/A			
PFPeA	(262.9 / 219.0) N/A (262.9 / 69.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFHxA	(313.0 / 269.0) N/A (313.0 / 119.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFHpA	(363.0 / 319.0) N/A (363.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFOA	(413.0 / 369.0) N/A (413.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFNA	(463.0 / 419.0) N/A (463.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFDA	(513.0 / 469.0) N/A (513.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFUnA	(563.0 / 519.0) N/A (563.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFDoA	(613.0 / 569.0) N/A (613.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFTrDA	(663.0 / 619.0) N/A (663.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFTeDA	(713.0 / 669.0) N/A (713.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			



Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500

Sample I.D.: SB03951-CCB1  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (1)  
 Acquired: 2022/12/22 - 11:01

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-Imin, ΔRT-CVmin, ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration True ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBS	(298.9 / 80.0) N/A (298.9 / 99.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFPeS	(349.0 / 80.0) N/A (349.0 / 99.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFHxS	(399.0 / 80.0) N/A (399.0 / 99.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFHpS	(449.0 / 80.0) N/A (449.0 / 99.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFOS	(499.0 / 80.0) N/A (499.0 / 99.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFNS	(549.0 / 80.0) N/A (549.0 / 99.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFDS	(599.0 / 80.0) N/A (599.0 / 99.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFDoS	(698.9 / 80.0) N/A (698.9 / 99.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
4:2FTS	(327.0 / 307.0) N/A (327.0 / 81.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
6:2FTS	(427.0 / 407.0) N/A (427.0 / 81.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
8:2FTS	(527.0 / 507.0) N/A (527.0 / 81.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			





Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500

Sample I.D.: SB03951-CCB1  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (1)  
 Acquired: 2022/12/22 - 11:01

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-Imin, ΔRT-CVmin, ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration True ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFOSA	(498.0 / 78.0) N/A (498.0 / 478.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NMeFOSA	(511.9 / 219.0) N/A (511.9 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NEIFOSA	(526.0 / 219.0) N/A (526.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NMeFOSAA	(570.0 / 419.0) N/A (570.0 / 483.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NEIFOSAA	(584.0 / 419.0) N/A (584.0 / 526.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NMeFOSE	(616.1 / 59.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A	N/A 0.0 0.0	0.0000	N/A			
NEIFOSE	(630.0 / 59.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A	N/A 0.0 0.0	0.0000	N/A			
HFPO-DA	(285.0 / 169.0) N/A (285.0 / 185.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
ADONA	(377.0 / 85.0) N/A (377.0 / 251.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
9CI-Pf3ONS	(531.0 / 351.0) N/A (533.0 / 353.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
11CI-Pf3OUDS	(631.0 / 451.0) N/A (633.0 / 453.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			














Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500

Sample I.D.: SB03951-CCB1  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (1)  
 Acquired: 2022/12/22 - 11:01

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-Imin, ΔRT-CVmin, ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration True ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
3:3FTCA	(241.0 / 177.0) N/A (241.0 / 117.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
5:3FTCA	(341.0 / 236.7) N/A (341.0 / 217.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
7:3FTCA	(441.0 / 317.0) N/A (441.0 / 337.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFEESA	(315.0 / 135.0) N/A (315.0 / 83.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFMPA	(229.0 / 85.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A	N/A 0.0 0.0	0.0000	N/A			
PFMBA	(279.0 / 85.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A	N/A 0.0 0.0	0.0000	N/A			
NFDHA	(295.0 / 201.0) N/A (295.0 / 85.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
13C3_PFBA_IIS	(216.0 / 172.0) 166872	(3.73, N/A) (N/A, 0.08, N/A)	668.9	N/A	1.1988 [ 1.0000 ]	119.9% { 106.2% }			
13C2_PFHxA_IIS	(315.1 / 270.0) 248906	(6.25, N/A) (N/A, 0.12, N/A)	673.0	N/A	1.0779 [ 1.0000 ]	107.8% { 105.5% }			
13C4_PFOA_IIS	(417.0 / 372.0) 259912	(7.99, N/A) (N/A, 0.11, N/A)	622.9	N/A	1.1822 [ 1.0000 ]	118.2% { 101.2% }			
13C5_PFNA_IIS	(468.0 / 423.0) 205309	(8.72, N/A) (N/A, 0.11, N/A)	380.5	N/A	1.1087 [ 1.0000 ]	110.9% { 87.5% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-Imin, $\Delta$ RT-CVmin, $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration True ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDA_IIS	(515.1 / 470.1) 159980	(9.40, N/A) (N/A, 0.11, N/A)	275.2	N/A	0.8657 [1.0000]	86.6% {85.5%}			
18O2_PFHxS_IIS	(403.0 / 83.9) 436294	(8.11, N/A) (N/A, 0.12, N/A)	668.3	N/A	1.0807 [1.0000]	108.1% {97.8%}			
13C4_PFOS_IIS	(502.8 / 79.9) 345861	(9.52, N/A) (N/A, 0.09, N/A)	448.9	N/A	1.0836 [1.0000]	108.4% {99.8%}			
13C4_PFBA_EIS	(217.0 / 172.0) 1353571	(3.73, N/A) (N/A, 0.08, N/A)	770.7	N/A	7.8812 [8.0000]	98.5% {107.8%}			
13C5_PFPeA_EIS	(267.9 / 223.0) 749143	(5.08, N/A) (N/A, 0.12, N/A)	775.4	N/A	4.3256 [4.0000]	108.1% {110.2%}			
13C5_PFHxA_EIS	(318.0 / 273.0) 578389	(6.25, N/A) (N/A, 0.12, N/A)	869.5	N/A	2.0193 [2.0000]	101.0% {107.9%}			
13C4_PFHpA_EIS	(367.0 / 322.0) 534750	(7.18, N/A) (N/A, 0.12, N/A)	688.5	N/A	2.1401 [2.0000]	107.0% {118.9%}			
13C8_PFOA_EIS	(421.0 / 376.0) 598078	(7.99, N/A) (N/A, 0.12, N/A)	795.5	N/A	2.0983 [2.0000]	104.9% {100.4%}			
13C9_PFNA_EIS	(472.0 / 427.0) 212335	(8.72, N/A) (N/A, 0.10, N/A)	503.8	N/A	0.9405 [1.0000]	94.1% {91.6%}			
13C6_PFDA_EIS	(519.0 / 474.0) 288489	(9.39, N/A) (N/A, 0.10, N/A)	331.5	N/A	1.2679 [1.0000]	126.8% {104.8%}			
13C7_PFUnA_EIS	(570.0 / 525.0) 449096	(9.75, N/A) (N/A, 0.04, N/A)	458.9	N/A	1.3876 [1.0000]	138.8% {120.7%}			



Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500

Sample I.D.: SB03951-CCB1  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (1)  
 Acquired: 2022/12/22 - 11:01

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-Imin, ΔRT-CVmin, ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration True ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDa_EIS	(615.0 / 570.0) 361260	(9.92, N/A) (N/A, 0.03, N/A)	419.7	N/A	1.1184 [1.0000]	111.8% {98.6%}			
13C2_PFTeDA_EIS	(715.0 / 670.0) 242892	(10.14, N/A) (N/A, 0.02, N/A)	421.7	N/A	1.1322 [1.0000]	113.2% {95.2%}			
13C3_PFBs_EIS	(302.0 / 80.0) 1399044	(6.20, N/A) (N/A, 0.13, N/A)	763.7	N/A	1.8966 [2.0000]	94.8% {105.0%}			
13C3_PFHxS_EIS	(402.0 / 80.0) 804774	(8.11, N/A) (N/A, 0.12, N/A)	771.2	N/A	2.0505 [2.0000]	102.5% {104.8%}			
13C8_PFOS_EIS	(507.0 / 80.0) 1194659	(9.53, N/A) (N/A, 0.09, N/A)	445.4	N/A	2.0126 [2.0000]	100.6% {106.9%}			
13C2_4:2FTS_EIS	(329.0 / 81.0) 259168	(5.91, N/A) (N/A, 0.12, N/A)	692.8	N/A	4.1481 [4.0000]	103.7% {115.1%}			
13C2_6:2FTS_EIS	(429.0 / 81.0) 357811	(7.65, N/A) (N/A, 0.12, N/A)	683.0	N/A	4.7568 [4.0000]	118.9% {106.4%}			
13C2_8:2FTS_EIS	(529.0 / 81.0) 340459	(9.05, N/A) (N/A, 0.11, N/A)	515.4	N/A	4.5213 [4.0000]	113.0% {107.8%}			
13C8_PFOsa_EIS	(506.0 / 78.0) 1467261	(10.21, N/A) (N/A, 0.03, N/A)	633.7	N/A	1.9555 [2.0000]	97.8% {107.6%}			
D3_NMeFOSA_EIS	(515.0 / 169.0) 301625	(10.62, N/A) (N/A, 0.01, N/A)	878.6	N/A	1.8412 [2.0000]	92.1% {105.0%}			
D5_NEiFOSA_EIS	(531.1 / 169.0) 275802	(10.71, N/A) (N/A, 0.01, N/A)	1247.5	N/A	1.8237 [2.0000]	91.2% {90.8%}			



Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500

Sample I.D.: SB03951-CCB1  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (1)  
 Acquired: 2022/12/22 - 11:01

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-Imin, ΔRT-CVmin, ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration True ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
D3_MeFOSAA_EIS	(573.0 / 419.0) 517996	(9.57, N/A) (N/A, 0.08, N/A)	320.8	N/A	3.6698 [4.0000]	91.7% {98.0%}			
D5_EtFOSAA_EIS	(589.0 / 419.0) 542345	(9.73, N/A) (N/A, 0.05, N/A)	435.4	N/A	4.3593 [4.0000]	109.0% {130.7%}			
D7_NMeFOSE_EIS	(623.2 / 58.9) 432794	(10.59, N/A) (N/A, 0.02, N/A)	881.6	N/A	18.8149 [20.0000]	94.1% {99.6%}			
D9_NEtFOSE_EIS	(639.2 / 58.9) 200749	(10.69, N/A) (N/A, 0.01, N/A)	1035.5	N/A	19.1700 [20.0000]	95.8% {101.3%}			
13C3_HFPODA_EIS	(287.0 / 169.0) 1149495	(6.59, N/A) (N/A, 0.13, N/A)	803.1	N/A	7.5481 [8.0000]	94.4% {94.4%}			

## ANALYSIS SEQUENCE BLANKS

Laboratory: APPL, LLC  
 Client: AECOM  
 Sequence: SB03951  
 Calibration: 2252011

SDG:  
 Project: Red Hill AFFF Assessment Sam  
 Instrument: Saphira

Lab Sample ID	Analyte	Found	Units	RL	C
SB03951-CCB2	PFBA	0.00	ng/mL	0.75	U
	PFPEA	0.00	ng/mL	0.20	U
	PFHXA	0.00	ng/mL	0.10	U
	PFHPA	0.00	ng/mL	0.10	U
	PFOA	0.0142	ng/mL	0.10	U
	PFNA	0.00	ng/mL	0.10	U
	PFDA	0.00	ng/mL	0.10	U
	PFUnA	0.00	ng/mL	0.10	U
	PFDOA	0.00	ng/mL	0.10	U
	PFTRDA	0.00	ng/mL	0.10	U
	PFTEDA	0.00	ng/mL	0.10	U
	PFBS	0.00	ng/mL	0.10	U
	PFPEs	0.00	ng/mL	0.10	U
	PFHXS	0.00	ng/mL	0.10	U
	PFHPS	0.00	ng/mL	0.10	U
	PFOS	0.00	ng/mL	0.10	U
	PFNS	0.00	ng/mL	0.10	U
	PFDS	0.00	ng/mL	0.10	U
	PFDOS	0.00	ng/mL	0.10	U
	4:2FTS	0.00	ng/mL	0.40	U
	6:2FTS	0.00	ng/mL	0.40	U
	8:2FTS	0.00	ng/mL	0.40	U
	PFOSA	0.00	ng/mL	0.10	U
	NMeFOSA	0.00	ng/mL	0.40	U
	NEtFOSA	0.00	ng/mL	0.40	U
	NMeFOSAA	0.00	ng/mL	0.10	U
	NEtFOSAA	0.00	ng/mL	0.10	U
	NMeFOSE	0.00	ng/mL	0.40	U
	NEtFOSE	0.00	ng/mL	0.40	U
	HFPO-DA	0.00	ng/mL	0.20	U
	ADONA	0.00	ng/mL	0.20	U
	PFEESA	0.00	ng/mL	0.20	U
	PFMPA	0.00	ng/mL	0.20	U

## ANALYSIS SEQUENCE BLANKS

Laboratory: APPL, LLC  
 Client: AECOM  
 Sequence: SB03951  
 Calibration: 2252011

SDG:  
 Project: Red Hill AFFF Assessment Sam  
 Instrument: Saphira

Lab Sample ID	Analyte	Found	Units	RL	C
SB03951-CCB2	PFMBA	0.00	ng/mL	0.20	U
	NFDHA	0.00	ng/mL	0.20	U
	9CL-PF3ONS	0.00	ng/mL	0.20	U
	11CL-PF3OUDS	0.00	ng/mL	0.20	U
	3:3FTCA	0.00	ng/mL	0.40	U
	5:3FTCA	0.00	ng/mL	0.40	U
	7:3FTCA	0.00	ng/mL	0.40	U
	13C4-PFBA	8.03	ng/mL		
	13C5-PFPEA	4.06	ng/mL		
	13C5-PFHXA	2.01	ng/mL		
	13C4-PFHPA	2.09	ng/mL		
	13C8-PFOA	2.14	ng/mL		
	13C9-PFNA	0.971	ng/mL		
	13C6-PFDA	1.17	ng/mL		
	13C7-PFUnA	0.932	ng/mL		
	13C2-PFDOA	1.05	ng/mL		
	13C2-PFTEDA	1.33	ng/mL		
	13C3-PFBS	2.01	ng/mL		
	13C3-PFHXS	1.96	ng/mL		
	13C8-PFOS	1.98	ng/mL		
	13C2-4:2FTS	3.99	ng/mL		
	13C2-6:2FTS	4.50	ng/mL		
	13C2-8:2FTS	3.56	ng/mL		
	13C8-PFOSA	1.71	ng/mL		
	D5-NETFOSA	1.91	ng/mL		
	D3-NMEFOSA	1.85	ng/mL		
	D3-NMEFOSAA	3.75	ng/mL		
	D5-NETFOSAA	3.70	ng/mL		
	D7-NMEFOSE	18.4	ng/mL		
	D9-NETFOSAE	18.5	ng/mL		
	13C3-HFPO-DA	7.76	ng/mL		



Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500

Sample I.D.: SB03951-CCB2  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (4)  
 Acquired: 2022/12/22 - 12:04

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-I[min], ΔRT-CV[min], ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBA	(212.9 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A	N/A 0.0 0.0	0.0000	N/A			
PFPeA	(262.9 / 219.0) N/A (262.9 / 69.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFHxA	(313.0 / 269.0) N/A (313.0 / 119.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFHpA	(363.0 / 319.0) N/A (363.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFOA	(413.0 / 369.0) 4232 (413.0 / 169.0) 1324	(7.96, 1.00) (0.00, N/A, 0.7)	18.2 24.9	0.3129 95.7 105.8	0.0142	N/A			
PFNA	(463.0 / 419.0) N/A (463.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFDA	(513.0 / 469.0) N/A (513.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFUnA	(563.0 / 519.0) N/A (563.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFDoA	(613.0 / 569.0) N/A (613.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFTrDA	(663.0 / 619.0) N/A (663.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFTeDA	(713.0 / 669.0) N/A (713.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			





Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500

Sample I.D.: SB03951-CCB2  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (4)  
 Acquired: 2022/12/22 - 12:04

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-[min], ΔRT-CV[min], ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBS	( 298.9 / 80.0 ) N/A ( 298.9 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFPeS	( 349.0 / 80.0 ) N/A ( 349.0 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFHxS	( 399.0 / 80.0 ) N/A ( 399.0 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFHpS	( 449.0 / 80.0 ) N/A ( 449.0 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFOS	( 499.0 / 80.0 ) N/A ( 499.0 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFNS	( 549.0 / 80.0 ) N/A ( 549.0 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFDS	( 599.0 / 80.0 ) N/A ( 599.0 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFDoS	( 698.9 / 80.0 ) N/A ( 698.9 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
4:2FTS	( 327.0 / 307.0 ) N/A ( 327.0 / 81.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
6:2FTS	( 427.0 / 407.0 ) N/A ( 427.0 / 81.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
8:2FTS	( 527.0 / 507.0 ) N/A ( 527.0 / 81.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			






























Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500












Sample I.D.: SB03951-CCB2  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam






Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (4)  
 Acquired: 2022/12/22 - 12:04

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-I[min], ΔRT-CV[min], ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFOSA	( 498.0 / 78.0 ) N/A ( 498.0 / 478.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NMeFOSA	( 511.9 / 219.0 ) N/A ( 511.9 / 169.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NEIFOSA	( 526.0 / 219.0 ) N/A ( 526.0 / 169.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NMeFOSAA	( 570.0 / 419.0 ) N/A ( 570.0 / 483.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NEIFOSAA	( 584.0 / 419.0 ) N/A ( 584.0 / 526.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NMeFOSE	( 616.1 / 59.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A	N/A 0.0 0.0	0.0000	N/A			
NEIFOSE	( 630.0 / 59.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A	N/A 0.0 0.0	0.0000	N/A			
HFPO-DA	( 285.0 / 169.0 ) N/A ( 285.0 / 185.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
ADONA	( 377.0 / 85.0 ) N/A ( 377.0 / 251.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
9CI-PI3ONS	( 531.0 / 351.0 ) N/A ( 533.0 / 353.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
11CI-PF3OUDS	( 631.0 / 451.0 ) N/A ( 633.0 / 453.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
3:3FTCA	(241.0 / 177.0) N/A (241.0 / 117.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
5:3FTCA	(341.0 / 236.7) N/A (341.0 / 217.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
7:3FTCA	(441.0 / 317.0) N/A (441.0 / 337.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFEESA	(315.0 / 135.0) N/A (315.0 / 83.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFMPA	(229.0 / 85.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A	N/A 0.0 0.0	0.0000	N/A			
PFMBA	(279.0 / 85.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A	N/A 0.0 0.0	0.0000	N/A			
NFDHA	(295.0 / 201.0) N/A (295.0 / 85.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
13C3_PFBA_IIS	(216.0 / 172.0) 157383	(3.72, N/A) (N/A, 0.06, N/A)	696.8	N/A	1.1307 [ 1.0000 ]	113.1% { 100.2% }			
13C2_PFHxA_IIS	(315.1 / 270.0) 252369	(6.19, N/A) (N/A, 0.06, N/A)	857.5	N/A	1.0929 [ 1.0000 ]	109.3% { 107.0% }			
13C4_PFOA_IIS	(417.0 / 372.0) 257792	(7.96, N/A) (N/A, 0.08, N/A)	612.7	N/A	1.1726 [ 1.0000 ]	117.3% { 100.4% }			
13C5_PFNA_IIS	(468.0 / 423.0) 219901	(8.68, N/A) (N/A, 0.06, N/A)	417.5	N/A	1.1875 [ 1.0000 ]	118.7% { 93.8% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDA_IIS	(515.1 / 470.1) 194470	(9.34, N/A) (N/A, 0.05, N/A)	1231.2	N/A	1.0523 [ 1.0000 ]	105.2% { 103.9% }			
18O2_PFHxS_IIS	(403.0 / 83.9) 445410	(8.08, N/A) (N/A, 0.08, N/A)	659.9	N/A	1.1033 [ 1.0000 ]	110.3% { 99.8% }			
13C4_PFOS_IIS	(502.8 / 79.9) 387697	(9.48, N/A) (N/A, 0.04, N/A)	440.2	N/A	1.2147 [ 1.0000 ]	121.5% { 111.9% }			
13C4_PFBA_EIS	(217.0 / 172.0) 1300929	(3.72, N/A) (N/A, 0.06, N/A)	767.7	N/A	8.0313 [ 8.0000 ]	100.4% { 103.6% }			
13C5_PFPeA_EIS	(267.9 / 223.0) 713599	(5.05, N/A) (N/A, 0.08, N/A)	621.4	N/A	4.0639 [ 4.0000 ]	101.6% { 105.0% }			
13C5_PFHxA_EIS	(318.0 / 273.0) 583357	(6.18, N/A) (N/A, 0.06, N/A)	693.5	N/A	2.0087 [ 2.0000 ]	100.4% { 108.8% }			
13C4_PFHpA_EIS	(367.0 / 322.0) 528761	(7.13, N/A) (N/A, 0.07, N/A)	588.0	N/A	2.0871 [ 2.0000 ]	104.4% { 117.6% }			
13C8_PFOA_EIS	(421.0 / 376.0) 604312	(7.96, N/A) (N/A, 0.08, N/A)	788.5	N/A	2.1376 [ 2.0000 ]	106.9% { 101.5% }			
13C9_PFNA_EIS	(472.0 / 427.0) 234804	(8.68, N/A) (N/A, 0.07, N/A)	394.8	N/A	0.9710 [ 1.0000 ]	97.1% { 101.3% }			
13C6_PFDA_EIS	(519.0 / 474.0) 323181	(9.34, N/A) (N/A, 0.05, N/A)	578.9	N/A	1.1685 [ 1.0000 ]	116.8% { 117.4% }			
13C7_PFUnA_EIS	(570.0 / 525.0) 366574	(9.73, N/A) (N/A, 0.02, N/A)	464.6	N/A	0.9318 [ 1.0000 ]	93.2% { 98.5% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT- CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDa_EIS	(615.0 / 570.0) 413637	(9.90, N/A) (N/A, 0.01, N/A)	568.3	N/A	1.0534 [ 1.0000 ]	105.3% { 112.9% }			
13C2_PFTeDA_EIS	(715.0 / 670.0) 345583	(10.12, N/A) (N/A, 0.01, N/A)	442.4	N/A	1.3252 [ 1.0000 ]	132.5% { 135.4% }			
13C3_PFBs_EIS	(302.0 / 80.0) 1514699	(6.14, N/A) (N/A, 0.07, N/A)	700.0	N/A	2.0113 [ 2.0000 ]	100.6% { 113.7% }			
13C3_PFHxS_EIS	(402.0 / 80.0) 785408	(8.07, N/A) (N/A, 0.08, N/A)	749.1	N/A	1.9602 [ 2.0000 ]	98.0% { 102.3% }			
13C8_PFOS_EIS	(507.0 / 80.0) 1314600	(9.48, N/A) (N/A, 0.05, N/A)	422.0	N/A	1.9757 [ 2.0000 ]	98.8% { 117.7% }			
13C2_4:2FTS_EIS	(329.0 / 81.0) 254483	(5.86, N/A) (N/A, 0.07, N/A)	572.1	N/A	3.9898 [ 4.0000 ]	99.7% { 113.1% }			
13C2_6:2FTS_EIS	(429.0 / 81.0) 345555	(7.62, N/A) (N/A, 0.09, N/A)	723.1	N/A	4.4998 [ 4.0000 ]	112.5% { 102.7% }			
13C2_8:2FTS_EIS	(529.0 / 81.0) 273673	(9.01, N/A) (N/A, 0.06, N/A)	502.0	N/A	3.5600 [ 4.0000 ]	89.0% { 86.6% }			
13C8_PFOsa_EIS	(506.0 / 78.0) 1435560	(10.18, N/A) (N/A, 0.01, N/A)	732.1	N/A	1.7068 [ 2.0000 ]	85.3% { 105.2% }			
D3_NMeFOSA_EIS	(515.0 / 169.0) 340399	(10.62, N/A) (N/A, 0.01, N/A)	957.6	N/A	1.8536 [ 2.0000 ]	92.7% { 118.5% }			
D5_NeIFOSA_EIS	(531.1 / 169.0) 323757	(10.71, N/A) (N/A, 0.01, N/A)	1137.1	N/A	1.9098 [ 2.0000 ]	95.5% { 106.5% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT- CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
D3_MeFOSAA_EIS	(573.0 / 419.0) 592584	(9.53, N/A) (N/A, 0.05, N/A)	373.2	N/A	3.7452 [ 4.0000 ]	93.6% { 112.1% }			
D5_EtFOSAA_EIS	(589.0 / 419.0) 516480	(9.70, N/A) (N/A, 0.02, N/A)	600.1	N/A	3.7034 [ 4.0000 ]	92.6% { 124.5% }			
D7_NMeFOSE_EIS	(623.2 / 58.9) 475480	(10.58, N/A) (N/A, 0.01, N/A)	887.6	N/A	18.4400 [ 20.0000 ]	92.2% { 109.4% }			
D9_NEtFOSE_EIS	(639.2 / 58.9) 216790	(10.68, N/A) (N/A, 0.00, N/A)	1384.1	N/A	18.4679 [ 20.0000 ]	92.3% { 109.4% }			
13C3_HFPODA_EIS	(287.0 / 169.0) 1198119	(6.54, N/A) (N/A, 0.07, N/A)	1140.6	N/A	7.7594 [ 8.0000 ]	97.0% { 98.4% }			

## ANALYSIS SEQUENCE BLANKS

Laboratory: APPL, LLC  
 Client: AECOM  
 Sequence: SB03951  
 Calibration: 2252011

SDG:  
 Project: Red Hill AFFF Assessment Sam  
 Instrument: Saphira

Lab Sample ID	Analyte	Found	Units	RL	C
SB03951-CCB3	PFBA	0.00	ng/mL	0.75	U
	PFPEA	0.00	ng/mL	0.20	U
	PFHXA	0.00	ng/mL	0.10	U
	PFHPA	0.00	ng/mL	0.10	U
	PFOA	0.00	ng/mL	0.10	U
	PFNA	0.00	ng/mL	0.10	U
	PFDA	0.00	ng/mL	0.10	U
	PFUnA	0.00	ng/mL	0.10	U
	PFDOA	0.00	ng/mL	0.10	U
	PFTRDA	0.00	ng/mL	0.10	U
	PFTEDA	0.00	ng/mL	0.10	U
	PFBS	0.00	ng/mL	0.10	U
	PFPEs	0.00	ng/mL	0.10	U
	PFHXS	0.00	ng/mL	0.10	U
	PFHPS	0.00	ng/mL	0.10	U
	PFOS	0.0201	ng/mL	0.10	U
	PFNS	0.00	ng/mL	0.10	U
	PFDS	0.00	ng/mL	0.10	U
	PFDOS	0.00	ng/mL	0.10	U
	4:2FTS	0.00	ng/mL	0.40	U
	6:2FTS	0.00	ng/mL	0.40	U
	8:2FTS	0.00	ng/mL	0.40	U
	PFOSA	0.00	ng/mL	0.10	U
	NMeFOSA	0.00	ng/mL	0.40	U
	NEtFOSA	0.00	ng/mL	0.40	U
	NMeFOSAA	0.00	ng/mL	0.10	U
	NEtFOSAA	0.00	ng/mL	0.10	U
	NMeFOSE	0.00	ng/mL	0.40	U
	NEtFOSE	0.00	ng/mL	0.40	U
	HFPO-DA	0.00	ng/mL	0.20	U
	ADONA	0.00	ng/mL	0.20	U
	PFEESA	0.00	ng/mL	0.20	U
	PFMPA	0.00	ng/mL	0.20	U

## ANALYSIS SEQUENCE BLANKS

Laboratory: APPL, LLC  
 Client: AECOM  
 Sequence: SB03951  
 Calibration: 2252011

SDG:  
 Project: Red Hill AFFF Assessment Sam  
 Instrument: Saphira

Lab Sample ID	Analyte	Found	Units	RL	C
SB03951-CCB3	PFMBA	0.00	ng/mL	0.20	U
	NFDHA	0.00	ng/mL	0.20	U
	9CL-PF3ONS	0.00	ng/mL	0.20	U
	11CL-PF3OUDS	0.00	ng/mL	0.20	U
	3:3FTCA	0.00	ng/mL	0.40	U
	5:3FTCA	0.00	ng/mL	0.40	U
	7:3FTCA	0.00	ng/mL	0.40	U
	13C4-PFBA	7.93	ng/mL		
	13C5-PFPEA	4.27	ng/mL		
	13C5-PFHXA	2.01	ng/mL		
	13C4-PFHPA	2.09	ng/mL		
	13C8-PFOA	2.07	ng/mL		
	13C9-PFNA	0.975	ng/mL		
	13C6-PFDA	1.10	ng/mL		
	13C7-PFUnA	1.06	ng/mL		
	13C2-PFDOA	1.10	ng/mL		
	13C2-PFTEDA	1.25	ng/mL		
	13C3-PFBS	2.05	ng/mL		
	13C3-PFHXS	2.02	ng/mL		
	13C8-PFOS	1.64	ng/mL		
	13C2-4:2FTS	3.48	ng/mL		
	13C2-6:2FTS	4.47	ng/mL		
	13C2-8:2FTS	3.96	ng/mL		
	13C8-PFOSA	1.65	ng/mL		
	D5-NETFOSA	1.62	ng/mL		
	D3-NMEFOSA	1.66	ng/mL		
	D3-NMEFOSAA	2.77	ng/mL		
	D5-NETFOSAA	2.63	ng/mL		
	D7-NMEFOSE	17.0	ng/mL		
	D9-NETFOSE	18.6	ng/mL		
	13C3-HFPO-DA	8.35	ng/mL		


























Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500

Sample I.D.: SB03951-CCB3  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (17)  
 Acquired: 2022/12/22 - 14:50

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-I[min], ΔRT-CV[min], ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBA	(212.9 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A	N/A 0.0 0.0	0.0000	N/A			
PFPeA	(262.9 / 219.0) N/A (262.9 / 69.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFHxA	(313.0 / 269.0) N/A (313.0 / 119.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFHpA	(363.0 / 319.0) N/A (363.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFOA	(413.0 / 369.0) N/A (413.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFNA	(463.0 / 419.0) N/A (463.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFDA	(513.0 / 469.0) N/A (513.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFUnA	(563.0 / 519.0) N/A (563.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFDoA	(613.0 / 569.0) N/A (613.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFTTrDA	(663.0 / 619.0) N/A (663.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFTeDA	(713.0 / 669.0) N/A (713.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			



Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500

Sample I.D.: SB03951-CCB3  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (17)  
 Acquired: 2022/12/22 - 14:50

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-I[min], ΔRT-CV[min], ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBS	( 298.9 / 80.0 ) N/A ( 298.9 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFPeS	( 349.0 / 80.0 ) N/A ( 349.0 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFHxS	( 399.0 / 80.0 ) N/A ( 399.0 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFHpS	( 449.0 / 80.0 ) N/A ( 449.0 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFOS	( 499.0 / 80.0 ) 13162 ( 499.0 / 99.0 ) 1431	( 9.39 , 1.00 ) ( -0.02 , N/A , 0.9 )	280.3 18.3	0.1087 44.7 47.5	0.0201	N/A			IR1,
PFNS	( 549.0 / 80.0 ) N/A ( 549.0 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFDS	( 599.0 / 80.0 ) N/A ( 599.0 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFDoS	( 698.9 / 80.0 ) N/A ( 698.9 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
4:2FTS	( 327.0 / 307.0 ) N/A ( 327.0 / 81.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
6:2FTS	( 427.0 / 407.0 ) N/A ( 427.0 / 81.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
8:2FTS	( 527.0 / 507.0 ) N/A ( 527.0 / 81.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			



Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500

Sample I.D.: SB03951-CCB3  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (17)  
 Acquired: 2022/12/22 - 14:50

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-I[min], ΔRT-CV[min], ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFOSA	( 498.0 / 78.0 ) N/A ( 498.0 / 478.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NMeFOSA	( 511.9 / 219.0 ) N/A ( 511.9 / 169.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NEIFOSA	( 526.0 / 219.0 ) N/A ( 526.0 / 169.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NMeFOSAA	( 570.0 / 419.0 ) N/A ( 570.0 / 483.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NEIFOSAA	( 584.0 / 419.0 ) N/A ( 584.0 / 526.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NMeFOSE	( 616.1 / 59.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A	N/A 0.0 0.0	0.0000	N/A			
NEIFOSE	( 630.0 / 59.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A	N/A 0.0 0.0	0.0000	N/A			
HFPO-DA	( 285.0 / 169.0 ) N/A ( 285.0 / 185.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
ADONA	( 377.0 / 85.0 ) N/A ( 377.0 / 251.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
9CI-Pf3ONS	( 531.0 / 351.0 ) N/A ( 533.0 / 353.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
11CI-PF3OUDS	( 631.0 / 451.0 ) N/A ( 633.0 / 453.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			

























Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500

Sample I.D.: SB03951-CCB3  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (17)  
 Acquired: 2022/12/22 - 14:50

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-I[min], ΔRT-CV[min], ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
3:3FTCA	(241.0 / 177.0) N/A (241.0 / 117.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
5:3FTCA	(341.0 / 236.7) N/A (341.0 / 217.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
7:3FTCA	(441.0 / 317.0) N/A (441.0 / 337.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFEESA	(315.0 / 135.0) N/A (315.0 / 83.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFMPA	(229.0 / 85.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A	N/A 0.0 0.0	0.0000	N/A			
PFMBA	(279.0 / 85.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A	N/A 0.0 0.0	0.0000	N/A			
NFDHA	(295.0 / 201.0) N/A (295.0 / 85.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
13C3_PFBA_IIS	(216.0 / 172.0) 173488	(3.63, N/A) (N/A, -0.02, N/A)	742.6	N/A	1.2464 [ 1.0000 ]	124.6% { 110.5% }			
13C2_PFHxA_IIS	(315.1 / 270.0) 254864	(6.09, N/A) (N/A, -0.03, N/A)	650.0	N/A	1.1037 [ 1.0000 ]	110.4% { 108.0% }			
13C4_PFOA_IIS	(417.0 / 372.0) 250555	(7.83, N/A) (N/A, -0.04, N/A)	680.9	N/A	1.1397 [ 1.0000 ]	114.0% { 97.5% }			
13C5_PFNA_IIS	(468.0 / 423.0) 219676	(8.57, N/A) (N/A, -0.04, N/A)	682.2	N/A	1.1863 [ 1.0000 ]	118.6% { 93.7% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDA_IIS	(515.1 / 470.1) 182295	(9.25, N/A) (N/A, -0.04, N/A)	401.5	N/A	0.9864 [ 1.0000 ]	98.6% { 97.4% }			
18O2_PFHxS_IIS	(403.0 / 83.9) 434358	(7.96, N/A) (N/A, -0.04, N/A)	829.4	N/A	1.0759 [ 1.0000 ]	107.6% { 97.3% }			
13C4_PFOS_IIS	(502.8 / 79.9) 428768	(9.40, N/A) (N/A, -0.03, N/A)	464.1	N/A	1.3433 [ 1.0000 ]	134.3% { 123.7% }			
13C4_PFBA_EIS	(217.0 / 172.0) 1415484	(3.63, N/A) (N/A, -0.02, N/A)	954.9	N/A	7.9274 [ 8.0000 ]	99.1% { 112.7% }			
13C5_PFPeA_EIS	(267.9 / 223.0) 757997	(4.93, N/A) (N/A, -0.04, N/A)	803.7	N/A	4.2745 [ 4.0000 ]	106.9% { 111.5% }			
13C5_PFHxA_EIS	(318.0 / 273.0) 588987	(6.09, N/A) (N/A, -0.04, N/A)	798.1	N/A	2.0082 [ 2.0000 ]	100.4% { 109.9% }			
13C4_PFHpA_EIS	(367.0 / 322.0) 534343	(7.02, N/A) (N/A, -0.03, N/A)	708.2	N/A	2.0884 [ 2.0000 ]	104.4% { 118.8% }			
13C8_PFOA_EIS	(421.0 / 376.0) 567503	(7.83, N/A) (N/A, -0.04, N/A)	575.2	N/A	2.0653 [ 2.0000 ]	103.3% { 95.3% }			
13C9_PFNA_EIS	(472.0 / 427.0) 235412	(8.57, N/A) (N/A, -0.04, N/A)	345.2	N/A	0.9745 [ 1.0000 ]	97.5% { 101.6% }			
13C6_PFDA_EIS	(519.0 / 474.0) 285247	(9.25, N/A) (N/A, -0.03, N/A)	571.8	N/A	1.1002 [ 1.0000 ]	110.0% { 103.7% }			
13C7_PFUnA_EIS	(570.0 / 525.0) 390930	(9.69, N/A) (N/A, -0.02, N/A)	467.7	N/A	1.0601 [ 1.0000 ]	106.0% { 105.1% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDa_EIS	(615.0 / 570.0) 404037	(9.88, N/A) (N/A, -0.02, N/A)	828.2	N/A	1.0977 [ 1.0000 ]	109.8% { 110.3% }			
13C2_PFTeDA_EIS	(715.0 / 670.0) 306344	(10.11, N/A) (N/A, -0.01, N/A)	537.0	N/A	1.2532 [ 1.0000 ]	125.3% { 120.0% }			
13C3_PFBs_EIS	(302.0 / 80.0) 1508652	(6.04, N/A) (N/A, -0.03, N/A)	669.5	N/A	2.0543 [ 2.0000 ]	102.7% { 113.2% }			
13C3_PFHxS_EIS	(402.0 / 80.0) 789666	(7.96, N/A) (N/A, -0.04, N/A)	856.2	N/A	2.0209 [ 2.0000 ]	101.0% { 102.8% }			
13C8_PFOS_EIS	(507.0 / 80.0) 1205476	(9.40, N/A) (N/A, -0.03, N/A)	441.0	N/A	1.6382 [ 2.0000 ]	81.9% { 107.9% }			
13C2_4:2FTS_EIS	(329.0 / 81.0) 216699	(5.76, N/A) (N/A, -0.03, N/A)	577.8	N/A	3.4838 [ 4.0000 ]	87.1% { 96.3% }			
13C2_6:2FTS_EIS	(429.0 / 81.0) 334424	(7.50, N/A) (N/A, -0.03, N/A)	627.3	N/A	4.4657 [ 4.0000 ]	111.6% { 99.4% }			
13C2_8:2FTS_EIS	(529.0 / 81.0) 296806	(8.91, N/A) (N/A, -0.03, N/A)	445.0	N/A	3.9592 [ 4.0000 ]	99.0% { 93.9% }			
13C8_PFOsa_EIS	(506.0 / 78.0) 1536538	(10.16, N/A) (N/A, -0.01, N/A)	585.2	N/A	1.6519 [ 2.0000 ]	82.6% { 112.6% }			
D3_NMeFOsa_EIS	(515.0 / 169.0) 337118	(10.60, N/A) (N/A, -0.01, N/A)	675.8	N/A	1.6599 [ 2.0000 ]	83.0% { 117.4% }			
D5_NEiFOsa_EIS	(531.1 / 169.0) 304556	(10.69, N/A) (N/A, -0.01, N/A)	1006.9	N/A	1.6245 [ 2.0000 ]	81.2% { 100.2% }			



Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500

Sample I.D.: SB03951-CCB3  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (17)  
 Acquired: 2022/12/22 - 14:50

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT-CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
D3_MeFOSAA_EIS	( 573.0 / 419.0 ) 484524	( 9.46 , N/A ) ( N/A , -0.03 , N/A )	335.2	N/A	2.7689 [ 4.0000 ]	69.2% { 91.7% }			
D5_EtFOSAA_EIS	( 589.0 / 419.0 ) 405638	( 9.65 , N/A ) ( N/A , -0.03 , N/A )	276.4	N/A	2.6300 [ 4.0000 ]	65.8% { 97.8% }			
D7_NMeFOSE_EIS	( 623.2 / 58.9 ) 485706	( 10.56 , N/A ) ( N/A , -0.01 , N/A )	1046.7	N/A	17.0323 [ 20.0000 ]	85.2% { 111.7% }			
D9_NEtFOSE_EIS	( 639.2 / 58.9 ) 241914	( 10.66 , N/A ) ( N/A , -0.01 , N/A )	1400.0	N/A	18.6341 [ 20.0000 ]	93.2% { 122.1% }			
13C3_HFPODA_EIS	( 287.0 / 169.0 ) 1301587	( 6.43 , N/A ) ( N/A , -0.03 , N/A )	722.9	N/A	8.3470 [ 8.0000 ]	104.3% { 106.9% }			

## ANALYSIS SEQUENCE BLANKS

Laboratory: APPL, LLC  
 Client: AECOM  
 Sequence: SB03951  
 Calibration: 2252011

SDG:  
 Project: Red Hill AFFF Assessment Sam  
 Instrument: Saphira

Lab Sample ID	Analyte	Found	Units	RL	C
SB03951-CCB4	PFBA	0.00	ng/mL	0.75	U
	PFPEA	0.00	ng/mL	0.20	U
	PFHXA	0.00	ng/mL	0.10	U
	PFHPA	0.00	ng/mL	0.10	U
	PFOA	0.0122	ng/mL	0.10	U
	PFNA	0.00	ng/mL	0.10	U
	PFDA	0.00	ng/mL	0.10	U
	PFUnA	0.00	ng/mL	0.10	U
	PFDOA	0.00	ng/mL	0.10	U
	PFTRDA	0.00	ng/mL	0.10	U
	PFTEDA	0.00	ng/mL	0.10	U
	PFBS	0.00	ng/mL	0.10	U
	PFPEs	0.00	ng/mL	0.10	U
	PFHXS	0.00	ng/mL	0.10	U
	PFHPS	0.00	ng/mL	0.10	U
	PFOS	0.00	ng/mL	0.10	U
	PFNS	0.00	ng/mL	0.10	U
	PFDS	0.00	ng/mL	0.10	U
	PFDOS	0.00	ng/mL	0.10	U
	4:2FTS	0.00	ng/mL	0.40	U
	6:2FTS	0.00	ng/mL	0.40	U
	8:2FTS	0.00	ng/mL	0.40	U
	PFOSA	0.00	ng/mL	0.10	U
	NMeFOSA	0.00	ng/mL	0.40	U
	NEtFOSA	0.00	ng/mL	0.40	U
	NMeFOSAA	0.00	ng/mL	0.10	U
	NEtFOSAA	0.00	ng/mL	0.10	U
	NMeFOSE	0.00	ng/mL	0.40	U
	NEtFOSE	0.00	ng/mL	0.40	U
	HFPO-DA	0.00	ng/mL	0.20	U
	ADONA	0.00	ng/mL	0.20	U
	PFEESA	0.00	ng/mL	0.20	U
	PFMPA	0.00	ng/mL	0.20	U



## ANALYSIS SEQUENCE BLANKS

Laboratory: APPL, LLC  
 Client: AECOM  
 Sequence: SB03951  
 Calibration: 2252011

SDG:  
 Project: Red Hill AFFF Assessment Sam  
 Instrument: Saphira

Lab Sample ID	Analyte	Found	Units	RL	C
SB03951-CCB4	PFMBA	0.00	ng/mL	0.20	U
	NFDHA	0.00	ng/mL	0.20	U
	9CL-PF3ONS	0.00	ng/mL	0.20	U
	11CL-PF3OUDS	0.00	ng/mL	0.20	U
	3:3FTCA	0.00	ng/mL	0.40	U
	5:3FTCA	0.00	ng/mL	0.40	U
	7:3FTCA	0.00	ng/mL	0.40	U
	13C4-PFBA	7.93	ng/mL		
	13C5-PFPEA	4.21	ng/mL		
	13C5-PFHXA	2.03	ng/mL		
	13C4-PFHPA	2.13	ng/mL		
	13C8-PFOA	2.06	ng/mL		
	13C9-PFNA	0.970	ng/mL		
	13C6-PFDA	1.19	ng/mL		
	13C7-PFUnA	1.09	ng/mL		
	13C2-PFDOA	1.12	ng/mL		
	13C2-PFTEDA	1.21	ng/mL		
	13C3-PFBS	2.08	ng/mL		
	13C3-PFHXS	1.95	ng/mL		
	13C8-PFOS	1.91	ng/mL		
	13C2-4:2FTS	3.78	ng/mL		
	13C2-6:2FTS	3.67	ng/mL		
	13C2-8:2FTS	3.69	ng/mL		
	13C8-PFOSA	2.05	ng/mL		
	D5-NETFOSA	2.08	ng/mL		
	D3-NMEFOSA	1.93	ng/mL		
	D3-NMEFOSAA	3.55	ng/mL		
	D5-NETFOSAA	3.75	ng/mL		
	D7-NMEFOSE	20.6	ng/mL		
	D9-NETFOSAE	21.6	ng/mL		
	13C3-HFPO-DA	8.16	ng/mL		



Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500

Sample I.D.: SB03951-CCB4  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (34)  
 Acquired: 2022/12/22 - 18:25

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-I[min], ΔRT-CV[min], ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBA	(212.9 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A	N/A 0.0 0.0	0.0000	N/A			
PFPeA	(262.9 / 219.0) N/A (262.9 / 69.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFHxA	(313.0 / 269.0) N/A (313.0 / 119.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFHpA	(363.0 / 319.0) N/A (363.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFOA	(413.0 / 369.0) 3469 (413.0 / 169.0) 814	(7.87, 1.00) (0.01, N/A, -0.1)	15.7 26.2	0.2347 71.8 79.3	0.0122	N/A			
PFNA	(463.0 / 419.0) N/A (463.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFDA	(513.0 / 469.0) N/A (513.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFUnA	(563.0 / 519.0) N/A (563.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFDoA	(613.0 / 569.0) N/A (613.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFTrDA	(663.0 / 619.0) N/A (663.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFTeDA	(713.0 / 669.0) N/A (713.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			



Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500

Sample I.D.: SB03951-CCB4  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (34)  
 Acquired: 2022/12/22 - 18:25

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[min], $\Delta$ RT-CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBS	( 298.9 / 80.0 ) N/A ( 298.9 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFPeS	( 349.0 / 80.0 ) N/A ( 349.0 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFHxS	( 399.0 / 80.0 ) N/A ( 399.0 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFHpS	( 449.0 / 80.0 ) N/A ( 449.0 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFOS	( 499.0 / 80.0 ) N/A ( 499.0 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFNS	( 549.0 / 80.0 ) N/A ( 549.0 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFDS	( 599.0 / 80.0 ) N/A ( 599.0 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFDoS	( 698.9 / 80.0 ) N/A ( 698.9 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
4:2FTS	( 327.0 / 307.0 ) N/A ( 327.0 / 81.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
6:2FTS	( 427.0 / 407.0 ) N/A ( 427.0 / 81.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
8:2FTS	( 527.0 / 507.0 ) N/A ( 527.0 / 81.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			



Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500

Sample I.D.: SB03951-CCB4  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (34)  
 Acquired: 2022/12/22 - 18:25

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-I[min], ΔRT-CV[min], ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFOSA	( 498.0 / 78.0 ) N/A ( 498.0 / 478.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NMeFOSA	( 511.9 / 219.0 ) N/A ( 511.9 / 169.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NEIFOSA	( 526.0 / 219.0 ) N/A ( 526.0 / 169.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NMeFOSAA	( 570.0 / 419.0 ) N/A ( 570.0 / 483.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NEIFOSAA	( 584.0 / 419.0 ) N/A ( 584.0 / 526.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NMeFOSE	( 616.1 / 59.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A	N/A 0.0 0.0	0.0000	N/A			
NEIFOSE	( 630.0 / 59.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A	N/A 0.0 0.0	0.0000	N/A			
HFPO-DA	( 285.0 / 169.0 ) N/A ( 285.0 / 185.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
ADONA	( 377.0 / 85.0 ) N/A ( 377.0 / 251.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
9CI-Pf3ONS	( 531.0 / 351.0 ) N/A ( 533.0 / 353.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
11CI-PF3OUDS	( 631.0 / 451.0 ) N/A ( 633.0 / 453.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			

























Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500






Sample I.D.: SB03951-CCB4  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (34)  
 Acquired: 2022/12/22 - 18:25

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
3:3FTCA	(241.0 / 177.0) N/A (241.0 / 117.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
5:3FTCA	(341.0 / 236.7) N/A (341.0 / 217.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
7:3FTCA	(441.0 / 317.0) N/A (441.0 / 337.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFEESA	(315.0 / 135.0) N/A (315.0 / 83.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFMPA	(229.0 / 85.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A	N/A 0.0 0.0	0.0000	N/A			
PFMBA	(279.0 / 85.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A	N/A 0.0 0.0	0.0000	N/A			
NFDHA	(295.0 / 201.0) N/A (295.0 / 85.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
13C3_PFBA_IIS	(216.0 / 172.0) 170566	(3.67, N/A) (N/A, 0.02, N/A)	728.5	N/A	1.2254 [ 1.0000 ]	122.5% { 108.6% }			
13C2_PFHxA_IIS	(315.1 / 270.0) 251402	(6.13, N/A) (N/A, 0.01, N/A)	635.5	N/A	1.0887 [ 1.0000 ]	108.9% { 106.5% }			
13C4_PFOA_IIS	(417.0 / 372.0) 256265	(7.86, N/A) (N/A, -0.01, N/A)	618.6	N/A	1.1656 [ 1.0000 ]	116.6% { 99.8% }			
13C5_PFNA_IIS	(468.0 / 423.0) 208621	(8.60, N/A) (N/A, -0.02, N/A)	429.5	N/A	1.1266 [ 1.0000 ]	112.7% { 88.9% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDA_IIS	(515.1 / 470.1) 194804	(9.28, N/A) (N/A, -0.01, N/A)	302.4	N/A	1.0541 [ 1.0000 ]	105.4% { 104.1% }			
18O2_PFHxS_IIS	(403.0 / 83.9) 458277	(7.98, N/A) (N/A, -0.01, N/A)	902.1	N/A	1.1352 [ 1.0000 ]	113.5% { 102.7% }			
13C4_PFOS_IIS	(502.8 / 79.9) 396363	(9.42, N/A) (N/A, -0.02, N/A)	445.6	N/A	1.2418 [ 1.0000 ]	124.2% { 114.4% }			
13C4_PFBA_EIS	(217.0 / 172.0) 1391613	(3.67, N/A) (N/A, 0.02, N/A)	736.2	N/A	7.9272 [ 8.0000 ]	99.1% { 110.8% }			
13C5_PFPeA_EIS	(267.9 / 223.0) 736201	(4.98, N/A) (N/A, 0.01, N/A)	907.0	N/A	4.2087 [ 4.0000 ]	105.2% { 108.3% }			
13C5_PFHxA_EIS	(318.0 / 273.0) 587964	(6.13, N/A) (N/A, 0.00, N/A)	539.2	N/A	2.0323 [ 2.0000 ]	101.6% { 109.7% }			
13C4_PFHpA_EIS	(367.0 / 322.0) 537138	(7.05, N/A) (N/A, 0.00, N/A)	514.9	N/A	2.1283 [ 2.0000 ]	106.4% { 119.4% }			
13C8_PFOA_EIS	(421.0 / 376.0) 578390	(7.86, N/A) (N/A, -0.01, N/A)	833.5	N/A	2.0581 [ 2.0000 ]	102.9% { 97.1% }			
13C9_PFNA_EIS	(472.0 / 427.0) 222417	(8.60, N/A) (N/A, -0.01, N/A)	471.8	N/A	0.9695 [ 1.0000 ]	97.0% { 96.0% }			
13C6_PFDA_EIS	(519.0 / 474.0) 330961	(9.27, N/A) (N/A, -0.02, N/A)	504.0	N/A	1.1945 [ 1.0000 ]	119.5% { 120.3% }			
13C7_PFUnA_EIS	(570.0 / 525.0) 429552	(9.70, N/A) (N/A, -0.01, N/A)	940.6	N/A	1.0900 [ 1.0000 ]	109.0% { 115.4% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT- CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDa_EIS	(615.0 / 570.0) 440640	(9.89, N/A) (N/A, -0.01, N/A)	593.1	N/A	1.1202 [ 1.0000 ]	112.0% { 120.3% }			
13C2_PFTeDA_EIS	(715.0 / 670.0) 315877	(10.12, N/A) (N/A, 0.00, N/A)	615.3	N/A	1.2092 [ 1.0000 ]	120.9% { 123.7% }			
13C3_PFBs_EIS	(302.0 / 80.0) 1610648	(6.08, N/A) (N/A, 0.01, N/A)	595.6	N/A	2.0787 [ 2.0000 ]	103.9% { 120.9% }			
13C3_PFHxS_EIS	(402.0 / 80.0) 802676	(7.98, N/A) (N/A, -0.01, N/A)	923.8	N/A	1.9470 [ 2.0000 ]	97.4% { 104.5% }			
13C8_PFOS_EIS	(507.0 / 80.0) 1299719	(9.42, N/A) (N/A, -0.01, N/A)	497.2	N/A	1.9106 [ 2.0000 ]	95.5% { 116.3% }			
13C2_4:2FTS_EIS	(329.0 / 81.0) 248363	(5.80, N/A) (N/A, 0.01, N/A)	708.4	N/A	3.7845 [ 4.0000 ]	94.6% { 110.3% }			
13C2_6:2FTS_EIS	(429.0 / 81.0) 290113	(7.52, N/A) (N/A, -0.01, N/A)	603.3	N/A	3.6718 [ 4.0000 ]	91.8% { 86.3% }			
13C2_8:2FTS_EIS	(529.0 / 81.0) 291532	(8.94, N/A) (N/A, -0.01, N/A)	348.0	N/A	3.6859 [ 4.0000 ]	92.1% { 92.3% }			
13C8_PFOsa_EIS	(506.0 / 78.0) 1764289	(10.17, N/A) (N/A, -0.01, N/A)	884.4	N/A	2.0518 [ 2.0000 ]	102.6% { 129.3% }			
D3_NMeFOSA_EIS	(515.0 / 169.0) 362344	(10.61, N/A) (N/A, 0.00, N/A)	1087.4	N/A	1.9300 [ 2.0000 ]	96.5% { 126.2% }			
D5_NeIFOSA_EIS	(531.1 / 169.0) 360485	(10.69, N/A) (N/A, 0.00, N/A)	1426.8	N/A	2.0800 [ 2.0000 ]	104.0% { 118.6% }			



Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT- CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
D3_MeFOSAA_EIS	( 573.0 / 419.0 ) 573696	( 9.47, N/A ) ( N/A, -0.02, N/A )	344.1	N/A	3.5466 [ 4.0000 ]	88.7% { 108.5% }			
D5_EtFOSAA_EIS	( 589.0 / 419.0 ) 534612	( 9.67, N/A ) ( N/A, -0.01, N/A )	417.4	N/A	3.7496 [ 4.0000 ]	93.7% { 128.8% }			
D7_NMeFOSE_EIS	( 623.2 / 58.9 ) 541882	( 10.57, N/A ) ( N/A, 0.00, N/A )	1203.6	N/A	20.5558 [ 20.0000 ]	102.8% { 124.7% }			
D9_NEtFOSE_EIS	( 639.2 / 58.9 ) 259149	( 10.67, N/A ) ( N/A, 0.00, N/A )	858.2	N/A	21.5937 [ 20.0000 ]	108.0% { 130.8% }			
13C3_HFPODA_EIS	( 287.0 / 169.0 ) 1255716	( 6.47, N/A ) ( N/A, 0.00, N/A )	711.9	N/A	8.1637 [ 8.0000 ]	102.0% { 103.2% }			




PAGE INTENTIONALLY LEFT BLANK

BILE STANDARD CHECK S2022-12-22A/SB03951

TDCA = 7.42  
PFOS = 9.12  
TDCA-PFOS = 1.70 > 1.0 PASS



### S2022-12-22A/SB03951 Column Resolution



# QUALITY CONTROL RAW DATA

## ANALYSIS DATA SHEET

Blank

Laboratory:	APPL, LLC	Work Order:	22L0141
Client:	AECOM	Project:	Red Hill AFFF Assessment Sampling
Matrix:	Water	Laboratory ID:	BBL0403-BLK1
Sampled:		File ID:	S2022-12-22A (18)
Solids:		Prepared:	12/20/22 15:01
Batch:	BBL0403	Analyzed:	12/22/22 15:02
Column:	1	Preparation:	1633
		Dilution:	1
		Calibration:	2252011
		Instrument:	Saphira
		Sequence:	SB03951

COMPOUND	CONC. (ng/L)	LOQ	LOD	DL	Q
PFBA	0.80 U	1.6	0.80	0.21	U
PFPEA	0.40 U	0.80	0.40	0.065	U
PFHXA	0.20 U	0.40	0.20	0.055	U
PFHPA	0.20 U	0.40	0.20	0.041	U
PFOA	0.20 U	0.40	0.20	0.15	U
PFNA	0.20 U	0.40	0.20	0.082	U
PFDA	0.20 U	0.40	0.20	0.10	U
PFUnA	0.20 U	0.40	0.20	0.16	U
PFDOA	0.20 U	0.40	0.20	0.11	U
PFTRDA	0.30 U	0.40	0.30	0.20	U
PFTEDA	0.20 U	0.40	0.20	0.20	U
PFBS	0.20 U	0.40	0.20	0.037	U
PFPEs	0.20 U	0.40	0.20	0.063	U
PFHXS	0.20 U	0.40	0.20	0.032	U
PFHPS	0.20 U	0.40	0.20	0.051	U
PFOS	0.0863 J	0.40	0.20	0.064	J
PFNS	0.20 U	0.40	0.20	0.12	U
PFDS	0.20 U	0.40	0.20	0.15	U
PFDOS	0.20 U	0.40	0.20	0.12	U
4:2FTS	0.80 U	1.6	0.80	0.29	U
6:2FTS	0.80 U	1.6	0.80	0.31	U
8:2FTS	0.80 U	1.6	0.80	0.082	U
PFOSA	0.20 U	0.40	0.20	0.10	U
NMeFOSA	0.80 U	1.6	0.80	0.47	U
NEtFOSA	0.80 U	1.6	0.80	0.41	U
NMeFOSAA	0.20 U	0.40	0.20	0.11	U
NEtFOSAA	0.20 U	0.40	0.20	0.11	U
NMeFOSE	1.2 U	1.6	1.2	1.0	U
NEtFOSE	1.2 U	1.6	1.2	1.0	U
HFPO-DA	0.40 U	0.80	0.40	0.17	U

**ANALYSIS DATA SHEET**

Blank

Laboratory:	APPL, LLC	Work Order:	22L0141
Client:	AECOM	Project:	Red Hill AFFF Assessment Sampling
Matrix:	Water	Laboratory ID:	BBL0403-BLK1
Sampled:		Prepared:	12/20/22 15:01
Solids:		Preparation:	1633
Batch:	BBL0403	Sequence:	SB03951
Column:	1	Calibration:	2252011
		File ID:	S2022-12-22A (18)
		Analyzed:	12/22/22 15:02
		Dilution:	1
		Instrument:	Saphira

COMPOUND	CONC. (ng/L)	LOQ	LOD	DL	Q
ADONA	0.40 U	0.80	0.40	0.12	U
PFEESA	0.40 U	0.80	0.40	0.11	U
PFMPA	0.40 U	0.80	0.40	0.054	U
PFMBA	0.40 U	0.80	0.40	0.091	U
NFDHA	0.40 U	0.80	0.40	0.30	U
9CL-PF3ONS	0.40 U	0.80	0.40	0.21	U
11CL-PF3OUDS	0.40 U	0.80	0.40	0.21	U
3:3FTCA	0.80 U	1.6	0.80	0.57	U
5:3FTCA	0.80 U	1.6	0.80	0.44	U
7:3FTCA	0.80 U	1.6	0.80	0.55	U



Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500

Sample I.D.: BBL0403-BLK1  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (18)  
 Acquired: 2022/12/22 - 15:02

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-I[min], ΔRT-CV[min], ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBA	(212.9 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A	N/A 0.0 0.0	0.0000	N/A			
PFPeA	(262.9 / 219.0) N/A (262.9 / 69.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFHxA	(313.0 / 269.0) N/A (313.0 / 119.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFHpA	(363.0 / 319.0) N/A (363.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFOA	(413.0 / 369.0) N/A (413.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFNA	(463.0 / 419.0) N/A (463.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFDA	(513.0 / 469.0) N/A (513.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFUnA	(563.0 / 519.0) N/A (563.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFDoA	(613.0 / 569.0) N/A (613.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFTrDA	(663.0 / 619.0) N/A (663.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFTeDA	(713.0 / 669.0) N/A (713.0 / 169.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			



Chemist: DAG  
Instrument: Saphira  
Type: Sciex Q3 5500

Sample I.D.: BBL0403-BLK1  
DF, IV: 1, 10.0µL  
Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
Path: S2022-12-22A (18)  
Acquired: 2022/12/22 - 15:02

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-I[min], ΔRT-CV[min], ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBS	( 298.9 / 80.0 ) N/A ( 298.9 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFPeS	( 349.0 / 80.0 ) N/A ( 349.0 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFHxS	( 399.0 / 80.0 ) N/A ( 399.0 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFHpS	( 449.0 / 80.0 ) N/A ( 449.0 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFOS	( 499.0 / 80.0 ) 16427 ( 499.0 / 99.0 ) 4242	( 9.40 , 1.00 ) ( 0.00 , N/A , -0.7 )	49.7 36.0	0.2583 106.2 112.9	0.0216	N/A			MI5 DG 2022-12-27
PFNS	( 549.0 / 80.0 ) N/A ( 549.0 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFDS	( 599.0 / 80.0 ) N/A ( 599.0 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFDoS	( 698.9 / 80.0 ) N/A ( 698.9 / 99.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
4:2FTS	( 327.0 / 307.0 ) N/A ( 327.0 / 81.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
6:2FTS	( 427.0 / 407.0 ) N/A ( 427.0 / 81.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
8:2FTS	( 527.0 / 507.0 ) N/A ( 527.0 / 81.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			





Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500

Sample I.D.: BBL0403-BLK1  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (18)  
 Acquired: 2022/12/22 - 15:02

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-I[min], ΔRT-CV[min], ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFOSA	( 498.0 / 78.0 ) N/A ( 498.0 / 478.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NMeFOSA	( 511.9 / 219.0 ) N/A ( 511.9 / 169.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NEIFOSA	( 526.0 / 219.0 ) N/A ( 526.0 / 169.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NMeFOSAA	( 570.0 / 419.0 ) N/A ( 570.0 / 483.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NEIFOSAA	( 584.0 / 419.0 ) N/A ( 584.0 / 526.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
NMeFOSE	( 616.1 / 59.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A	N/A 0.0 0.0	0.0000	N/A			
NEIFOSE	( 630.0 / 59.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A	N/A 0.0 0.0	0.0000	N/A			
HFPO-DA	( 285.0 / 169.0 ) N/A ( 285.0 / 185.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
ADONA	( 377.0 / 85.0 ) N/A ( 377.0 / 251.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
9CI-Pf3ONS	( 531.0 / 351.0 ) N/A ( 533.0 / 353.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
11CI-PF3OUDS	( 631.0 / 451.0 ) N/A ( 633.0 / 453.0 ) N/A	( N/A , N/A ) ( N/A , N/A , N/A )	N/A N/A	N/A 0.0 0.0	0.0000	N/A			

























Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500






Sample I.D.: BBL0403-BLK1  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (18)  
 Acquired: 2022/12/22 - 15:02

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT-CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
3:3FTCA	(241.0 / 177.0) N/A (241.0 / 117.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
5:3FTCA	(341.0 / 236.7) N/A (341.0 / 217.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
7:3FTCA	(441.0 / 317.0) N/A (441.0 / 337.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFEESA	(315.0 / 135.0) N/A (315.0 / 83.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
PFMPA	(229.0 / 85.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A	N/A 0.0 0.0	0.0000	N/A			
PFMBA	(279.0 / 85.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A	N/A 0.0 0.0	0.0000	N/A			
NFDHA	(295.0 / 201.0) N/A (295.0 / 85.0) N/A	(N/A, N/A) (N/A, N/A, N/A)	N/A N/A	N/A 0.0 0.0	0.0000	N/A			
13C3_PFBA_IIS	(216.0 / 172.0) 213406	(3.67, N/A) (N/A, 0.01, N/A)	1046.4	N/A	1.5332 [ 1.0000 ]	153.3% { 135.9% }			
13C2_PFHxA_IIS	(315.1 / 270.0) 321165	(6.09, N/A) (N/A, -0.03, N/A)	584.7	N/A	1.3908 [ 1.0000 ]	139.1% { 136.1% }			
13C4_PFOA_IIS	(417.0 / 372.0) 337795	(7.84, N/A) (N/A, -0.04, N/A)	468.0	N/A	1.5365 [ 1.0000 ]	153.6% { 131.5% }			
13C5_PFNxA_IIS	(468.0 / 423.0) 264718	(8.58, N/A) (N/A, -0.04, N/A)	505.2	N/A	1.4295 [ 1.0000 ]	143.0% { 112.9% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT- CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDA_IIS	(515.1 / 470.1) 252177	(9.26, N/A) (N/A, -0.03, N/A)	539.8	N/A	1.3645 [ 1.0000 ]	136.5% { 134.7% }			
18O2_PFHxS_IIS	(403.0 / 83.9) 578966	(7.96, N/A) (N/A, -0.04, N/A)	894.2	N/A	1.4341 [ 1.0000 ]	143.4% { 129.7% }			
13C4_PFOS_IIS	(502.8 / 79.9) 473378	(9.41, N/A) (N/A, -0.03, N/A)	438.4	N/A	1.4831 [ 1.0000 ]	148.3% { 136.6% }			
13C4_PFBA_EIS	(217.0 / 172.0) 1661761	(3.67, N/A) (N/A, 0.01, N/A)	878.0	N/A	7.5658 [ 8.0000 ]	94.6% { 132.3% }			
13C5_PFPeA_EIS	(267.9 / 223.0) 842597	(4.94, N/A) (N/A, -0.03, N/A)	733.4	N/A	3.7706 [ 4.0000 ]	94.3% { 123.9% }			
13C5_PFHxA_EIS	(318.0 / 273.0) 681229	(6.09, N/A) (N/A, -0.03, N/A)	646.0	N/A	1.8432 [ 2.0000 ]	92.2% { 127.1% }			
13C4_PFHpA_EIS	(367.0 / 322.0) 584938	(7.02, N/A) (N/A, -0.03, N/A)	609.4	N/A	1.8142 [ 2.0000 ]	90.7% { 130.1% }			
13C8_PFOA_EIS	(421.0 / 376.0) 712681	(7.84, N/A) (N/A, -0.04, N/A)	787.6	N/A	1.9238 [ 2.0000 ]	96.2% { 119.7% }			
13C9_PFNA_EIS	(472.0 / 427.0) 279325	(8.58, N/A) (N/A, -0.04, N/A)	568.9	N/A	0.9596 [ 1.0000 ]	96.0% { 120.5% }			
13C6_PFDA_EIS	(519.0 / 474.0) 322005	(9.26, N/A) (N/A, -0.03, N/A)	387.2	N/A	0.8978 [ 1.0000 ]	89.8% { 117.0% }			
13C7_PFUnA_EIS	(570.0 / 525.0) 468495	(9.69, N/A) (N/A, -0.02, N/A)	719.2	N/A	0.9183 [ 1.0000 ]	91.8% { 125.9% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT- CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDa_EIS	(615.0 / 570.0) 540881	(9.88, N/A) (N/A, -0.01, N/A)	486.8	N/A	1.0622 [ 1.0000 ]	106.2% { 147.7% }			
13C2_PFTeDA_EIS	(715.0 / 670.0) 263868	(10.11, N/A) (N/A, -0.01, N/A)	483.4	N/A	0.7803 [ 1.0000 ]	78.0% { 103.4% }			
13C3_PFBs_EIS	(302.0 / 80.0) 1689642	(6.04, N/A) (N/A, -0.03, N/A)	790.0	N/A	1.7261 [ 2.0000 ]	86.3% { 126.8% }			
13C3_PFHxS_EIS	(402.0 / 80.0) 934282	(7.96, N/A) (N/A, -0.04, N/A)	977.4	N/A	1.7938 [ 2.0000 ]	89.7% { 121.7% }			
13C8_PFOS_EIS	(507.0 / 80.0) 1403204	(9.41, N/A) (N/A, -0.03, N/A)	575.9	N/A	1.7271 [ 2.0000 ]	86.4% { 125.6% }			
13C2_4:2FTS_EIS	(329.0 / 81.0) 296135	(5.76, N/A) (N/A, -0.03, N/A)	692.7	N/A	3.5718 [ 4.0000 ]	89.3% { 131.6% }			
13C2_6:2FTS_EIS	(429.0 / 81.0) 442147	(7.50, N/A) (N/A, -0.03, N/A)	737.7	N/A	4.4294 [ 4.0000 ]	110.7% { 131.5% }			
13C2_8:2FTS_EIS	(529.0 / 81.0) 348908	(8.92, N/A) (N/A, -0.03, N/A)	388.6	N/A	3.4917 [ 4.0000 ]	87.3% { 110.4% }			
13C8_PFOsa_EIS	(506.0 / 78.0) 1657791	(10.17, N/A) (N/A, -0.01, N/A)	850.4	N/A	1.6143 [ 2.0000 ]	80.7% { 121.5% }			
D3_NMeFOSA_EIS	(515.0 / 169.0) 171215	(10.60, N/A) (N/A, -0.01, N/A)	636.6	N/A	0.7636 [ 2.0000 ]	38.2% { 59.6% }			
D5_NEiFOSA_EIS	(531.1 / 169.0) 131232	(10.69, N/A) (N/A, -0.01, N/A)	1041.1	N/A	0.6340 [ 2.0000 ]	31.7% { 43.2% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT- CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
D3_MeFOSAA_EIS	( 573.0 / 419.0 ) 568266	( 9.46 , N/A ) ( N/A , -0.02 , N/A )	545.3	N/A	2.9415 [ 4.0000 ]	73.5% { 107.5% }			
D5_EtFOSAA_EIS	( 589.0 / 419.0 ) 560400	( 9.66 , N/A ) ( N/A , -0.02 , N/A )	306.6	N/A	3.2910 [ 4.0000 ]	82.3% { 135.1% }			
D7_NMeFOSE_EIS	( 623.2 / 58.9 ) 375340	( 10.56 , N/A ) ( N/A , -0.01 , N/A )	1095.4	N/A	11.9217 [ 20.0000 ]	59.6% { 86.3% }			
D9_NEtFOSE_EIS	( 639.2 / 58.9 ) 171627	( 10.66 , N/A ) ( N/A , -0.02 , N/A )	1226.8	N/A	11.9742 [ 20.0000 ]	59.9% { 86.6% }			
13C3_HFPODA_EIS	( 287.0 / 169.0 ) 1400236	( 6.43 , N/A ) ( N/A , -0.03 , N/A )	799.3	N/A	7.1259 [ 8.0000 ]	89.1% { 115.0% }			

## ANALYSIS DATA SHEET

## LCS






















Laboratory:	APPL, LLC	Work Order:	22L0141
Client:	AECOM	Project:	Red Hill AFFF Assessment Sampling
Matrix:	Water	Laboratory ID:	BBL0403-BS1
Sampled:		File ID:	S2022-12-22A (19)
Solids:		Prepared:	12/20/22 15:01
Batch:	BBL0403	Analyzed:	12/22/22 15:15
Column:	1	Preparation:	1633
		Dilution:	1
		Calibration:	2252011
		Instrument:	Saphira
		Sequence:	SB03951

COMPOUND	CONC. (ng/L)	LOQ	DL	Q
PFBA	16.1	1.6	0.21	
PFPEA	7.93	0.80	0.065	
PFHXA	4.27	0.40	0.055	
PFHPA	3.87	0.40	0.041	
PFOA	3.50	0.40	0.15	
PFNA	3.90	0.40	0.082	
PFDA	4.33	0.40	0.10	
PFUnA	4.74	0.40	0.16	
PFDOA	3.75	0.40	0.11	
PFTRDA	3.68	0.40	0.20	
PFTEDA	4.31	0.40	0.20	
PFBS	3.64	0.40	0.037	
PFPEs	3.56	0.40	0.063	
PFHXS	3.53	0.40	0.032	
PFHPS	3.57	0.40	0.051	
PFOS	3.24	0.40	0.064	
PFNS	3.62	0.40	0.12	
PFDS	3.46	0.40	0.15	
PFDOS	3.24	0.40	0.12	
4:2FTS	13.2	1.6	0.29	
6:2FTS	15.2	1.6	0.31	
8:2FTS	14.7	1.6	0.082	
PFOSA	3.46	0.40	0.10	
NMeFOSA	18.4	1.6	0.47	
NEtFOSA	16.9	1.6	0.41	
NMeFOSAA	3.87	0.40	0.11	
NEtFOSAA	3.84	0.40	0.11	
NMeFOSE	17.8	1.6	1.0	
NEtFOSE	15.8	1.6	1.0	
HFPO-DA	7.61	0.80	0.17	

**ANALYSIS DATA SHEET****LCS**

Laboratory:	APPL, LLC	Work Order:	22L0141
Client:	AECOM	Project:	Red Hill AFFF Assessment Sampling
Matrix:	Water	Laboratory ID:	BBL0403-BS1
Sampled:		File ID:	S2022-12-22A (19)
Solids:		Prepared:	12/20/22 15:01
Batch:	BBL0403	Analyzed:	12/22/22 15:15
Column:	1	Preparation:	1633
		Dilution:	1
		Sequence:	SB03951
		Calibration:	2252011
		Instrument:	Saphira

COMPOUND	CONC. (ng/L)	LOQ	DL	Q
ADONA	7.89	0.80	0.12	
PFEESA	7.00	0.80	0.11	
PFMPA	8.31	0.80	0.054	
PFMBA	7.54	0.80	0.091	
NFDHA	8.29	0.80	0.30	
9CL-PF3ONS	6.81	0.80	0.21	
11CL-PF3OUDS	7.94	0.80	0.21	
3:3FTCA	17.4	1.6	0.57	
5:3FTCA	17.2	1.6	0.44	
7:3FTCA	17.9	1.6	0.55	

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBA	(212.9 / 169.0) 545755	(3.68, 1.00) (0.00, N/A, 0.0)	63.6	N/A 0.0 0.0	4.0261	N/A			
PFPeA	(262.9 / 219.0) 372369 (262.9 / 69.0) 4677	(4.97, 1.00) (0.00, N/A, -0.1)	733.5 110.9	0.0126 112.2 120.8	1.9819	N/A			
PFHxA	(313.0 / 269.0) 294538 (313.0 / 119.0) 26696	(6.13, 1.00) (0.00, N/A, 0.0)	521.1 167.6	0.0906 92.7 101.4	1.0683	N/A			
PFHpA	(363.0 / 319.0) 268718 (363.0 / 169.0) 75831	(7.05, 1.00) (0.01, N/A, 0.0)	507.8 335.3	0.2822 90.6 91.5	0.9679	N/A			
PFOA	(413.0 / 369.0) 308801 (413.0 / 169.0) 104004	(7.87, 1.00) (0.00, N/A, -0.1)	555.2 362.0	0.3368 103.1 113.8	0.8758	N/A			
PFNA	(463.0 / 419.0) 232358 (463.0 / 169.0) 47926	(8.61, 1.00) (0.00, N/A, 0.0)	303.2 94.3	0.2063 107.0 99.0	0.9755	N/A			
PFDA	(513.0 / 469.0) 317436 (513.0 / 169.0) 24321	(9.29, 1.00) (0.00, N/A, 0.1)	424.0 146.6	0.0766 80.2 78.0	1.0822	N/A			
PFUnA	(563.0 / 519.0) 398290 (563.0 / 169.0) 33932	(9.70, 1.00) (0.00, N/A, 0.3)	793.8 1085.4	0.0852 98.1 95.0	1.1851	N/A			
PFDoA	(613.0 / 569.0) 356745 (613.0 / 169.0) 42358	(9.88, 1.00) (0.00, N/A, -0.2)	728.6 188.1	0.1187 85.3 90.3	0.9376	N/A			
PFTrDA	(663.0 / 619.0) 303236 (663.0 / 169.0) 53837	(10.01, 1.01) (N/A, 0.00, 0.1)	417.3 273.6	0.1775 86.7 77.7	0.9198	N/A			
PFTeDA	(713.0 / 669.0) 273951 (713.0 / 169.0) 58008	(10.11, 1.00) (-0.01, N/A, 0.0)	430.9 229.3	0.2117 104.1 103.2	1.0767	N/A			





Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500

Sample I.D.: BBL0403-BS1  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (19)  
 Acquired: 2022/12/22 - 15:15

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBS	(298.9 / 80.0) 416632 (298.9 / 99.0) 254354	(6.08, 1.00) (0.00, N/A, -0.2)	654.9 635.4	0.6105 99.2 93.2	0.9112	N/A			
PFPeS	(349.0 / 80.0) 763727 (349.0 / 99.0) 279856	(7.12, 0.89) (N/A, 0.00, 0.1)	812.8 649.9	0.3664 102.9 95.4	0.8889	N/A			
PFHxS	(399.0 / 80.0) 659925 (399.0 / 99.0) 202208	(7.99, 1.00) (0.00, N/A, 0.1)	3783.4 733.9	0.3064 91.2 92.6	0.8832	N/A			
PFHpS	(449.0 / 80.0) 568524 (449.0 / 99.0) 161661	(8.76, 0.93) (N/A, -0.01, 0.0)	558.4 413.8	0.2844 103.9 111.8	0.8924	N/A			
PFOS	(499.0 / 80.0) 641707 (499.0 / 99.0) 157358	(9.43, 1.00) (0.00, N/A, 0.3)	258.3 135.4	0.2452 100.8 107.2	0.8097	N/A			
PFNS	(549.0 / 80.0) 796332 (549.0 / 99.0) 182779	(9.75, 1.03) (N/A, 0.00, 0.1)	658.8 472.6	0.2295 94.1 89.9	0.9058	N/A			
PFDS	(599.0 / 80.0) 843135 (599.0 / 99.0) 199831	(9.90, 1.05) (N/A, -0.01, 0.0)	881.4 454.8	0.2370 105.3 101.3	0.8638	N/A			
PFDoS	(698.9 / 80.0) 330060 (698.9 / 99.0) 66635	(10.10, 1.07) (N/A, -0.01, -0.1)	759.3 358.0	0.2019 82.5 104.0	0.8091	N/A			
4:2FTS	(327.0 / 307.0) 744599 (327.0 / 81.0) 466591	(5.79, 1.00) (0.00, N/A, 0.0)	740.1 500.1	0.6266 126.9 109.4	3.2925	N/A			
6:2FTS	(427.0 / 407.0) 502501 (427.0 / 81.0) 337535	(7.53, 1.00) (0.00, N/A, 0.1)	704.0 482.6	0.6717 86.3 96.3	3.7900	N/A			
8:2FTS	(527.0 / 507.0) 498462 (527.0 / 81.0) 295342	(8.94, 1.00) (0.00, N/A, -0.2)	568.7 428.8	0.5925 104.7 107.6	3.6753	N/A			



Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500

Sample I.D.: BBL0403-BS1  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (19)  
 Acquired: 2022/12/22 - 15:15

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) (ΔRT-I[min], ΔRT-CV[min], ΔRT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFOSA	( 498.0 / 78.0 ) 666153 ( 498.0 / 478.0 ) 16137	( 10.17 , 1.00 ) ( 0.00 , N/A , -0.2)	935.3 518.2	0.0242 116.2 99.9	0.8662	N/A			
NMeFOFA	( 511.9 / 219.0 ) 220913 ( 511.9 / 169.0 ) 150475	( 10.60 , 1.00 ) ( 0.00 , N/A , 0.2)	940.2 663.4	0.6811 94.6 100.7	4.5934	N/A			
NEIFOSA	( 526.0 / 219.0 ) 189488 ( 526.0 / 169.0 ) 197367	( 10.69 , 1.00 ) ( 0.00 , N/A , 0.0)	828.7 757.8	1.0416 98.5 98.2	4.2255	N/A			
NMeFOSAA	( 570.0 / 419.0 ) 118504 ( 570.0 / 483.0 ) 61539	( 9.49 , 1.00 ) ( 0.01 , N/A , 0.1)	233.1 418.3	0.5193 84.5 103.9	0.9667	N/A			
NEIFOSAA	( 584.0 / 419.0 ) 115119 ( 584.0 / 526.0 ) 71319	( 9.67 , 1.00 ) ( 0.00 , N/A , -0.3)	425.7 2230.8	0.6195 84.5 85.3	0.9599	N/A			
NMeFOSE	( 616.1 / 59.0 ) 74971	( 10.57 , 1.00 ) ( 0.01 , N/A , 0.0)	573.5	N/A 0.0 0.0	4.4535	N/A			
NEIFOSE	( 630.0 / 59.0 ) 13157	( 10.67 , 1.00 ) ( 0.01 , N/A , 0.0)	376.4	N/A 0.0 0.0	3.9488	N/A			
HFPO-DA	( 285.0 / 169.0 ) 203876 ( 285.0 / 185.0 ) 579958	( 6.47 , 1.00 ) ( 0.00 , N/A , -0.1)	853.8 697.1	2.8447 103.6 109.3	1.9017	N/A			
ADONA	( 377.0 / 85.0 ) 939409 ( 377.0 / 251.0 ) 126426	( 7.37 , 1.14 ) ( N/A , -0.01 , 0.1)	808.8 329.5	0.1346 108.1 105.4	1.9728	N/A			
9CI-Pf3ONS	( 531.0 / 351.0 ) 2280228 ( 533.0 / 353.0 ) 773043	( 9.70 , 1.50 ) ( N/A , 0.00 , -0.1)	813.7 574.6	0.3390 114.5 116.8	1.7021	N/A			
11CI-PF3OUDS	( 631.0 / 451.0 ) 1320966 ( 633.0 / 453.0 ) 374975	( 9.99 , 1.54 ) ( N/A , -0.01 , -0.1)	741.5 591.4	0.2839 85.8 88.3	1.9848	N/A			

























Chemist: DAG  
 Instrument: Saphira  
 Type: Sciex Q3 5500






Sample I.D.: BBL0403-BS1  
 DF, IV: 1, 10.0µL  
 Acquisition Method: 1633 2022-12-21.dam

Quant Method: 1633 - 2022-12-21  
 Path: S2022-12-22A (19)  
 Acquired: 2022/12/22 - 15:15

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT-CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
3:3FTCA	(241.0 / 177.0) 28249 (241.0 / 117.0) 42258	(4.45, 0.90) (N/A, 0.00, 0.0)	477.1 324.5	1.4959 89.4 89.1	4.3565	N/A			
5:3FTCA	(341.0 / 236.7) 209917 (341.0 / 217.0) 311800	(6.76, 1.10) (N/A, 0.00, 0.0)	658.1 454.4	1.4853 101.5 92.4	4.3091	N/A			
7:3FTCA	(441.0 / 317.0) 251483 (441.0 / 337.0) 211921	(8.58, 1.40) (N/A, -0.01, 0.3)	368.8 342.4	0.8427 100.6 101.0	4.4865	N/A			
PFEESA	(315.0 / 135.0) 528283 (315.0 / 83.0) 158817	(6.58, 1.07) (N/A, 0.00, 0.0)	1051.4 521.0	0.3006 97.9 101.7	1.7502	N/A			
PFMPA	(229.0 / 85.0) 107185	(4.16, 0.84) (N/A, 0.00, 0.0)	850.0	N/A 0.0 0.0	2.0786	N/A			
PFMBA	(279.0 / 85.0) 336120	(5.36, 1.08) (N/A, 0.01, 0.0)	1011.6	N/A 0.0 0.0	1.8858	N/A			
NFDHA	(295.0 / 201.0) 288056 (295.0 / 85.0) 265253	(6.01, 0.98) (N/A, 0.00, 0.0)	613.8 721.3	0.9208 104.3 105.1	2.0721	N/A			
13C3_PFBA_IIS	(216.0 / 172.0) 208102	(3.68, N/A) (N/A, 0.03, N/A)	782.3	N/A	1.4951 [ 1.0000 ]	149.5% { 132.5% }			
13C2_PFHxA_IIS	(315.1 / 270.0) 282997	(6.12, N/A) (N/A, 0.00, N/A)	423.3	N/A	1.2255 [ 1.0000 ]	122.6% { 119.9% }			
13C4_PFOA_IIS	(417.0 / 372.0) 336563	(7.87, N/A) (N/A, -0.01, N/A)	718.5	N/A	1.5309 [ 1.0000 ]	153.1% { 131.0% }			
13C5_PFNxA_IIS	(468.0 / 423.0) 256791	(8.61, N/A) (N/A, -0.01, N/A)	387.9	N/A	1.3867 [ 1.0000 ]	138.7% { 109.5% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDA_IIS	(515.1 / 470.1) 292869	(9.29, N/A) (N/A, 0.00, N/A)	468.6	N/A	1.5847 [ 1.0000 ]	158.5% { 156.5% }			
18O2_PFHxS_IIS	(403.0 / 83.9) 560815	(7.99, N/A) (N/A, 0.00, N/A)	798.4	N/A	1.3892 [ 1.0000 ]	138.9% { 125.7% }			
13C4_PFOS_IIS	(502.8 / 79.9) 445609	(9.43, N/A) (N/A, -0.01, N/A)	431.4	N/A	1.3961 [ 1.0000 ]	139.6% { 128.6% }			
13C4_PFBA_EIS	(217.0 / 172.0) 1662253	(3.68, N/A) (N/A, 0.03, N/A)	871.4	N/A	7.7609 [ 8.0000 ]	97.0% { 132.4% }			
13C5_PFPeA_EIS	(267.9 / 223.0) 855726	(4.97, N/A) (N/A, 0.00, N/A)	742.9	N/A	4.3459 [ 4.0000 ]	108.6% { 125.9% }			
13C5_PFHxA_EIS	(318.0 / 273.0) 642031	(6.13, N/A) (N/A, 0.00, N/A)	560.6	N/A	1.9715 [ 2.0000 ]	98.6% { 119.8% }			
13C4_PFHpA_EIS	(367.0 / 322.0) 609162	(7.05, N/A) (N/A, 0.00, N/A)	625.2	N/A	2.1442 [ 2.0000 ]	107.2% { 135.4% }			
13C8_PFOA_EIS	(421.0 / 376.0) 717080	(7.87, N/A) (N/A, -0.01, N/A)	606.1	N/A	1.9428 [ 2.0000 ]	97.1% { 120.4% }			
13C9_PFNA_EIS	(472.0 / 427.0) 277602	(8.61, N/A) (N/A, -0.01, N/A)	479.2	N/A	0.9831 [ 1.0000 ]	98.3% { 119.8% }			
13C6_PFDA_EIS	(519.0 / 474.0) 308154	(9.28, N/A) (N/A, 0.00, N/A)	391.6	N/A	0.7398 [ 1.0000 ]	74.0% { 112.0% }			
13C7_PFUnA_EIS	(570.0 / 525.0) 425254	(9.70, N/A) (N/A, -0.01, N/A)	664.2	N/A	0.7178 [ 1.0000 ]	71.8% { 114.3% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT- CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDa_EIS	(615.0 / 570.0) 441366	(9.88, N/A) (N/A, -0.01, N/A)	699.2	N/A	0.7464 [ 1.0000 ]	74.6% { 120.5% }			
13C2_PFTeDA_EIS	(715.0 / 670.0) 287092	(10.12, N/A) (N/A, 0.00, N/A)	461.4	N/A	0.7310 [ 1.0000 ]	73.1% { 112.5% }			
13C3_PFBs_EIS	(302.0 / 80.0) 1668057	(6.08, N/A) (N/A, 0.01, N/A)	674.2	N/A	1.7592 [ 2.0000 ]	88.0% { 125.2% }			
13C3_PFHxS_EIS	(402.0 / 80.0) 961855	(7.99, N/A) (N/A, -0.01, N/A)	864.0	N/A	1.9065 [ 2.0000 ]	95.3% { 125.3% }			
13C8_PFOS_EIS	(507.0 / 80.0) 1460322	(9.43, N/A) (N/A, 0.00, N/A)	390.7	N/A	1.9095 [ 2.0000 ]	95.5% { 130.7% }			
13C2_4:2FTS_EIS	(329.0 / 81.0) 273581	(5.79, N/A) (N/A, 0.00, N/A)	703.3	N/A	3.4065 [ 4.0000 ]	85.2% { 121.5% }			
13C2_6:2FTS_EIS	(429.0 / 81.0) 344928	(7.53, N/A) (N/A, 0.00, N/A)	785.2	N/A	3.5673 [ 4.0000 ]	89.2% { 102.6% }			
13C2_8:2FTS_EIS	(529.0 / 81.0) 342416	(8.95, N/A) (N/A, 0.00, N/A)	413.5	N/A	3.5377 [ 4.0000 ]	88.4% { 108.4% }			
13C8_PFOsa_EIS	(506.0 / 78.0) 1627421	(10.17, N/A) (N/A, -0.01, N/A)	1036.4	N/A	1.6835 [ 2.0000 ]	84.2% { 119.3% }			
D3_NMeFOSA_EIS	(515.0 / 169.0) 117999	(10.60, N/A) (N/A, -0.01, N/A)	787.4	N/A	0.5591 [ 2.0000 ]	28.0% { 41.1% }			
D5_NEiFOSA_EIS	(531.1 / 169.0) 99431	(10.69, N/A) (N/A, -0.01, N/A)	760.7	N/A	0.5103 [ 2.0000 ]	25.5% { 32.7% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT- CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
D3_MeFOSAA_EIS	( 573.0 / 419.0 ) 629222	( 9.48, N/A ) ( N/A, -0.01, N/A )	481.0	N/A	3.4600 [ 4.0000 ]	86.5% { 119.0% }			
D5_EtFOSAA_EIS	( 589.0 / 419.0 ) 534358	( 9.67, N/A ) ( N/A, -0.01, N/A )	410.9	N/A	3.3336 [ 4.0000 ]	83.3% { 128.8% }			
D7_NMeFOSE_EIS	( 623.2 / 58.9 ) 266744	( 10.57, N/A ) ( N/A, -0.01, N/A )	1052.3	N/A	9.0004 [ 20.0000 ]	45.0% { 61.4% }			
D9_NEtFOSE_EIS	( 639.2 / 58.9 ) 130149	( 10.66, N/A ) ( N/A, -0.01, N/A )	1684.2	N/A	9.6462 [ 20.0000 ]	48.2% { 65.7% }			
13C3_HFPODA_EIS	( 287.0 / 169.0 ) 1411035	( 6.47, N/A ) ( N/A, 0.00, N/A )	698.3	N/A	8.1493 [ 8.0000 ]	101.9% { 115.9% }			

**ANALYSIS DATA SHEET****MRL Check**

Laboratory:	APPL, LLC	Work Order:	22L0141
Client:	AECOM	Project:	Red Hill AFFF Assessment Sampling
Matrix:	Water	Laboratory ID:	BBL0403-MRL1
Sampled:		File ID:	S2022-12-22A (20)
		Prepared:	12/20/22 15:01
Solids:		Analyzed:	12/22/22 15:28
		Preparation:	1633
Batch:	BBL0403	Dilution:	1
		Sequence:	SB03951
		Calibration:	2252011
Column:	1	Instrument:	Saphira






















COMPOUND	CONC. (ng/L)	LOQ	DL	Q
PFBA	1.51	1.6	0.21	J
PFPEA	0.801	0.80	0.065	
PFHXA	0.370	0.40	0.055	J
PFHPA	0.350	0.40	0.041	J
PFOA	0.403	0.40	0.15	
PFNA	0.333	0.40	0.082	J
PFDA	0.274	0.40	0.10	J
PFUnA	0.345	0.40	0.16	J
PFDOA	0.342	0.40	0.11	J
PFTRDA	0.378	0.40	0.20	IR1, J
PFTEDA	0.329	0.40	0.20	IR2, J
PFBS	0.328	0.40	0.037	J
PFPEs	0.341	0.40	0.063	J
PFHXS	0.355	0.40	0.032	J
PFHPS	0.358	0.40	0.051	J
PFOS	0.401	0.40	0.064	
PFNS	0.321	0.40	0.12	J
PFDS	0.394	0.40	0.15	J
PFDOS	0.382	0.40	0.12	J
4:2FTS	1.43	1.6	0.29	J
6:2FTS	1.31	1.6	0.31	J
8:2FTS	1.16	1.6	0.082	J
PFOSA	0.425	0.40	0.10	
NMeFOSA	1.69	1.6	0.47	
NEtFOSA	1.38	1.6	0.41	J
NMeFOSAA	0.457	0.40	0.11	
NEtFOSAA	0.354	0.40	0.11	J
NMeFOSE	1.40	1.6	1.0	J
NEtFOSE	1.25	1.6	1.0	J
HFPO-DA	0.686	0.80	0.17	J























**ANALYSIS DATA SHEET****MRL Check**





















Laboratory:	APPL, LLC	Work Order:	22L0141
Client:	AECOM	Project:	Red Hill AFFF Assessment Sampling
Matrix:	Water	Laboratory ID:	BBL0403-MRL1
Sampled:		File ID:	S2022-12-22A (20)
		Prepared:	12/20/22 15:01
Solids:		Analyzed:	12/22/22 15:28
		Preparation:	1633
Batch:	BBL0403	Dilution:	1
Column:	1	Sequence:	SB03951
		Calibration:	2252011
		Instrument:	Saphira

















COMPOUND	CONC. (ng/L)	LOQ	DL	Q
ADONA	0.768	0.80	0.12	J
PFEESA	0.627	0.80	0.11	J
PFMPA	0.784	0.80	0.054	J
PFMBA	0.680	0.80	0.091	J
NFDHA	0.877	0.80	0.30	
9CL-PF3ONS	0.598	0.80	0.21	J
11CL-PF3OUDS	0.811	0.80	0.21	
3:3FTCA	1.35	1.6	0.57	J
5:3FTCA	1.88	1.6	0.44	
7:3FTCA	1.79	1.6	0.55	

























Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBA	(212.9 / 169.0) 53718	(3.69, 1.00) (0.00, N/A, 0.0)	52.4	N/A 0.0 0.0	0.3785	N/A			
PFPeA	(262.9 / 219.0) 38518 (262.9 / 69.0) 481	(4.98, 1.00) (0.00, N/A, 0.0)	251.2 14.2	0.0125 111.5 120.0	0.2003	N/A			
PFHxA	(313.0 / 269.0) 25053 (313.0 / 119.0) 2716	(6.13, 1.00) (0.00, N/A, 0.2)	88.4 44.5	0.1084 110.9 121.3	0.0926	N/A			
PFHpA	(363.0 / 319.0) 26608 (363.0 / 169.0) 8046	(7.06, 1.00) (0.00, N/A, 0.0)	84.9 114.7	0.3024 97.1 98.1	0.0876	N/A			
PFOA	(413.0 / 369.0) 38310 (413.0 / 169.0) 10358	(7.87, 1.00) (0.00, N/A, 0.4)	152.4 121.8	0.2704 82.7 91.4	0.1008	N/A			
PFNA	(463.0 / 419.0) 21778 (463.0 / 169.0) 4342	(8.61, 1.00) (0.00, N/A, -0.7)	115.6 119.3	0.1994 103.5 95.7	0.0832	N/A			
PFDA	(513.0 / 469.0) 23464 (513.0 / 169.0) 2418	(9.29, 1.00) (0.00, N/A, 0.1)	80.9 219.5	0.1031 107.8 104.9	0.0685	N/A			
PFUnA	(563.0 / 519.0) 31347 (563.0 / 169.0) 1857	(9.72, 1.00) (0.01, N/A, 0.1)	149.6 1332.4	0.0593 68.2 66.1	0.0863	N/A			
PFDoA	(613.0 / 569.0) 36370 (613.0 / 169.0) 3850	(9.89, 1.00) (0.00, N/A, 0.3)	243.4 45.5	0.1059 76.0 80.5	0.0856	N/A			
PFTTrDA	(663.0 / 619.0) 34801 (663.0 / 169.0) 3626	(10.02, 1.01) (N/A, 0.01, 0.7)	154.3 21.0	0.1042 50.9 45.6	0.0946	N/A			IR1,
PFTeDA	(713.0 / 669.0) 25957 (713.0 / 169.0) 8560	(10.12, 1.00) (0.01, N/A, 0.3)	125.4 73.8	0.3298 162.2 160.7	0.0822	N/A			IR2,






Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFBS	(298.9 / 80.0) 37828 (298.9 / 99.0) 26863	(6.08, 1.00) (0.00, N/A, 0.1)	239.1 133.9	0.7101 115.4 108.4	0.0820	N/A			
PFPeS	(349.0 / 80.0) 72765 (349.0 / 99.0) 26827	(7.12, 0.89) (N/A, 0.00, -0.1)	300.7 318.3	0.3687 103.6 96.0	0.0853	N/A			
PFHxS	(399.0 / 80.0) 65734 (399.0 / 99.0) 21743	(7.99, 1.00) (0.00, N/A, 0.4)	3472.8 74829.3	0.3308 98.4 99.9	0.0886	N/A			
PFHpS	(449.0 / 80.0) 61607 (449.0 / 99.0) 19595	(8.76, 0.93) (N/A, 0.00, -0.1)	200.8 384.6	0.3181 116.2 125.1	0.0895	N/A			
PFOS	(499.0 / 80.0) 85887 (499.0 / 99.0) 15126	(9.44, 1.00) (0.01, N/A, 0.0)	165.4 151.0	0.1761 72.4 77.0	0.1003	N/A			
PFNS	(549.0 / 80.0) 76145 (549.0 / 99.0) 16688	(9.76, 1.03) (N/A, 0.00, 0.0)	146.1 126.3	0.2192 89.8 85.9	0.0802	N/A			
PFDS	(599.0 / 80.0) 103951 (599.0 / 99.0) 18937	(9.91, 1.05) (N/A, 0.00, -0.3)	373.3 86.9	0.1822 80.9 77.9	0.0986	N/A			
PFDoS	(698.9 / 80.0) 42149 (698.9 / 99.0) 6666	(10.11, 1.07) (N/A, 0.00, 0.0)	391.7 157.5	0.1582 64.6 81.5	0.0956	N/A			
4:2FTS	(327.0 / 307.0) 83838 (327.0 / 81.0) 45289	(5.80, 1.00) (0.00, N/A, 0.1)	702.4 172.2	0.5402 109.4 94.3	0.3587	N/A			
6:2FTS	(427.0 / 407.0) 48615 (427.0 / 81.0) 35727	(7.53, 1.00) (0.00, N/A, 0.1)	128.7 122.7	0.7349 94.4 105.4	0.3268	N/A			
8:2FTS	(527.0 / 507.0) 34604 (527.0 / 81.0) 28221	(8.95, 1.00) (0.00, N/A, 0.1)	400.4 147.7	0.8155 144.1 148.1	0.2898	N/A			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-[min], $\Delta$ RT- CV[min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
PFOSA	( 498.0 / 78.0 ) 65854 ( 498.0 / 478.0 ) 1497	( 10.18 , 1.00 ) ( 0.00 , N/A , -2.3)	243.6 16.7	0.0227 109.1 93.7	0.1063	N/A			
NMeFOSA	( 511.9 / 219.0 ) 19851 ( 511.9 / 169.0 ) 12751	( 10.61 , 1.00 ) ( 0.00 , N/A , -0.1)	294.1 267.3	0.6424 89.2 95.0	0.4223	N/A			
NEIFOSA	( 526.0 / 219.0 ) 13924 ( 526.0 / 169.0 ) 17509	( 10.70 , 1.00 ) ( 0.00 , N/A , 0.0)	455.2 194.0	1.2574 118.9 118.6	0.3449	N/A			
NMeFOSAA	( 570.0 / 419.0 ) 13251 ( 570.0 / 483.0 ) 5496	( 9.49 , 1.00 ) ( 0.01 , N/A , -0.7)	148.9 1872.1	0.4147 67.5 83.0	0.1142	N/A			
NEIFOSAA	( 584.0 / 419.0 ) 12504 ( 584.0 / 526.0 ) 10052	( 9.69 , 1.00 ) ( 0.01 , N/A , 0.5)	685.0 153.7	0.8039 109.6 110.6	0.0885	N/A			
NMeFOSE	( 616.1 / 59.0 ) 5024	( 10.58 , 1.00 ) ( 0.01 , N/A , 0.0)	120.0	N/A 0.0 0.0	0.3507	N/A			
NEIFOSE	( 630.0 / 59.0 ) 810	( 10.68 , 1.00 ) ( 0.01 , N/A , 0.0)	41.4	N/A 0.0 0.0	0.3116	N/A			
HFPO-DA	( 285.0 / 169.0 ) 19573 ( 285.0 / 185.0 ) 57839	( 6.47 , 1.00 ) ( 0.00 , N/A , -0.1)	291.7 233.9	2.9550 107.7 113.6	0.1714	N/A			
ADONA	( 377.0 / 85.0 ) 97335 ( 377.0 / 251.0 ) 10740	( 7.38 , 1.14 ) ( N/A , 0.00 , 0.2)	385.7 53.3	0.1103 88.6 86.4	0.1919	N/A			
9CI-Pf3ONS	( 531.0 / 351.0 ) 230857 ( 533.0 / 353.0 ) 75298	( 9.71 , 1.50 ) ( N/A , 0.00 , 0.1)	619.8 271.0	0.3262 110.2 112.4	0.1496	N/A			
11CI-PF3OUDS	( 631.0 / 451.0 ) 143671 ( 633.0 / 453.0 ) 40065	( 10.00 , 1.55 ) ( N/A , 0.00 , 0.2)	74112.8 224.6	0.2789 84.3 86.8	0.2027	N/A			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT-CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
3:3FTCA	(241.0 / 177.0) 2241 (241.0 / 117.0) 3488	(4.46, 0.90) (N/A, 0.01, 0.0)	129.1 47.4	1.5563 93.0 92.7	0.3376	N/A			
5:3FTCA	(341.0 / 236.7) 22466 (341.0 / 217.0) 33225	(6.77, 1.10) (N/A, 0.01, 0.1)	186.3 140.9	1.4789 101.0 92.0	0.4699	N/A			
7:3FTCA	(441.0 / 317.0) 24607 (441.0 / 337.0) 20011	(8.58, 1.40) (N/A, -0.01, 0.5)	130.2 136.7	0.8132 97.1 97.5	0.4473	N/A			
PFEESA	(315.0 / 135.0) 46408 (315.0 / 83.0) 17618	(6.58, 1.07) (N/A, 0.00, 0.3)	409.0 123.5	0.3796 123.7 128.5	0.1567	N/A			
PFMPA	(229.0 / 85.0) 10348	(4.17, 0.84) (N/A, 0.01, 0.0)	332.5	N/A 0.0 0.0	0.1960	N/A			
PFMBA	(279.0 / 85.0) 31039	(5.37, 1.08) (N/A, 0.01, 0.0)	342.6	N/A 0.0 0.0	0.1701	N/A			
NFDHA	(295.0 / 201.0) 29898 (295.0 / 85.0) 26183	(6.01, 0.98) (N/A, 0.00, -0.1)	305.5 86.7	0.8757 99.2 100.0	0.2192	N/A			
13C3_PFBA_IIS	(216.0 / 172.0) 220364	(3.70, N/A) (N/A, 0.04, N/A)	762.6	N/A	1.5831 [ 1.0000 ]	158.3% { 140.3% }			
13C2_PFHxA_IIS	(315.1 / 270.0) 308893	(6.13, N/A) (N/A, 0.01, N/A)	626.5	N/A	1.3377 [ 1.0000 ]	133.8% { 130.9% }			
13C4_PFOA_IIS	(417.0 / 372.0) 324788	(7.87, N/A) (N/A, -0.01, N/A)	538.6	N/A	1.4773 [ 1.0000 ]	147.7% { 126.4% }			
13C5_PFNA_IIS	(468.0 / 423.0) 273024	(8.61, N/A) (N/A, -0.01, N/A)	347.7	N/A	1.4744 [ 1.0000 ]	147.4% { 116.4% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT- CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDA_IIS	(515.1 / 470.1) 259769	(9.29, N/A) (N/A, 0.00, N/A)	405.3	N/A	1.4056 [ 1.0000 ]	140.6% { 138.8% }			
18O2_PFHxS_IIS	(403.0 / 83.9) 589240	(7.99, N/A) (N/A, 0.00, N/A)	721.7	N/A	1.4596 [ 1.0000 ]	146.0% { 132.1% }			
13C4_PFOS_IIS	(502.8 / 79.9) 508401	(9.43, N/A) (N/A, -0.01, N/A)	409.4	N/A	1.5928 [ 1.0000 ]	159.3% { 146.7% }			
13C4_PFBA_EIS	(217.0 / 172.0) 1740189	(3.69, N/A) (N/A, 0.04, N/A)	811.4	N/A	7.6727 [ 8.0000 ]	95.9% { 138.6% }			
13C5_PFPeA_EIS	(267.9 / 223.0) 875987	(4.98, N/A) (N/A, 0.01, N/A)	732.4	N/A	4.0758 [ 4.0000 ]	101.9% { 128.8% }			
13C5_PFHxA_EIS	(318.0 / 273.0) 630069	(6.13, N/A) (N/A, 0.00, N/A)	578.4	N/A	1.7725 [ 2.0000 ]	88.6% { 117.5% }			
13C4_PFHpA_EIS	(367.0 / 322.0) 666733	(7.06, N/A) (N/A, 0.01, N/A)	585.5	N/A	2.1501 [ 2.0000 ]	107.5% { 148.2% }			
13C8_PFOA_EIS	(421.0 / 376.0) 772787	(7.87, N/A) (N/A, 0.00, N/A)	984.8	N/A	2.1696 [ 2.0000 ]	108.5% { 129.7% }			
13C9_PFNA_EIS	(472.0 / 427.0) 304933	(8.61, N/A) (N/A, -0.01, N/A)	421.2	N/A	1.0157 [ 1.0000 ]	101.6% { 131.6% }			
13C6_PFDA_EIS	(519.0 / 474.0) 359728	(9.29, N/A) (N/A, 0.00, N/A)	409.9	N/A	0.9737 [ 1.0000 ]	97.4% { 130.7% }			
13C7_PFUnA_EIS	(570.0 / 525.0) 459582	(9.71, N/A) (N/A, 0.00, N/A)	484.2	N/A	0.8745 [ 1.0000 ]	87.5% { 123.5% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT- CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
13C2_PFDa_EIS	(615.0 / 570.0) 492760	(9.89, N/A) (N/A, 0.00, N/A)	690.6	N/A	0.9395 [ 1.0000 ]	93.9% { 134.5% }			
13C2_PFTeDA_EIS	(715.0 / 670.0) 356477	(10.12, N/A) (N/A, 0.00, N/A)	604.8	N/A	1.0234 [ 1.0000 ]	102.3% { 139.7% }			
13C3_PFBs_EIS	(302.0 / 80.0) 1683162	(6.08, N/A) (N/A, 0.01, N/A)	813.7	N/A	1.6895 [ 2.0000 ]	84.5% { 126.3% }			
13C3_PFHxS_EIS	(402.0 / 80.0) 954703	(7.99, N/A) (N/A, 0.00, N/A)	790.7	N/A	1.8011 [ 2.0000 ]	90.1% { 124.3% }			
13C8_PFOS_EIS	(507.0 / 80.0) 1577950	(9.43, N/A) (N/A, 0.00, N/A)	517.1	N/A	1.8084 [ 2.0000 ]	90.4% { 141.3% }			
13C2_4:2FTS_EIS	(329.0 / 81.0) 282769	(5.80, N/A) (N/A, 0.01, N/A)	575.2	N/A	3.3511 [ 4.0000 ]	83.8% { 125.6% }			
13C2_6:2FTS_EIS	(429.0 / 81.0) 386975	(7.53, N/A) (N/A, 0.00, N/A)	766.6	N/A	3.8091 [ 4.0000 ]	95.2% { 115.1% }			
13C2_8:2FTS_EIS	(529.0 / 81.0) 301510	(8.95, N/A) (N/A, 0.00, N/A)	386.1	N/A	2.9648 [ 4.0000 ]	74.1% { 95.4% }			
13C8_PFOsa_EIS	(506.0 / 78.0) 1310630	(10.18, N/A) (N/A, 0.00, N/A)	699.6	N/A	1.1883 [ 2.0000 ]	59.4% { 96.1% }			
D3_NMeFOSA_EIS	(515.0 / 169.0) 115323	(10.61, N/A) (N/A, 0.00, N/A)	546.6	N/A	0.4789 [ 2.0000 ]	23.9% { 40.2% }			
D5_NeIFOSA_EIS	(531.1 / 169.0) 89526	(10.70, N/A) (N/A, 0.00, N/A)	661.0	N/A	0.4027 [ 2.0000 ]	20.1% { 29.5% }			

Analyte	(Q1 / Q3) Area Counts*min	R.T. (R.T [min], R.R.T.) ( $\Delta$ RT-I[ $\mu$ min], $\Delta$ RT- CV[ $\mu$ min], $\Delta$ RT ion[s])	S / N	Ion Ratio IR Vs MP% IR Vs CV%	Concentration [ True ] ng/mL	Q.C. Rec. {Area%CV}	Primary Transition	Confirmation Transition	Flag
D3_MeFOSAA_EIS	( 573.0 / 419.0 ) 595382	( 9.48 , N/A ) ( N/A , 0.00 , N/A )	395.3	N/A	2.8695 [ 4.0000 ]	71.7% { 112.6% }			
D5_EtFOSAA_EIS	( 589.0 / 419.0 ) 629489	( 9.67 , N/A ) ( N/A , 0.00 , N/A )	298.3	N/A	3.4421 [ 4.0000 ]	86.1% { 151.7% }			
D7_NMeFOSE_EIS	( 623.2 / 58.9 ) 226954	( 10.58 , N/A ) ( N/A , 0.00 , N/A )	1184.1	N/A	6.7120 [ 20.0000 ]	33.6% { 52.2% }			
D9_NEtFOSE_EIS	( 639.2 / 58.9 ) 101534	( 10.67 , N/A ) ( N/A , 0.00 , N/A )	798.1	N/A	6.5959 [ 20.0000 ]	33.0% { 51.2% }			
13C3_HFPODA_EIS	( 287.0 / 169.0 ) 1503102	( 6.47 , N/A ) ( N/A , 0.00 , N/A )	659.3	N/A	7.9533 [ 8.0000 ]	99.4% { 123.5% }			

# PREPARATION BATCH SUMMARY

## EPA 1633

Laboratory:	APPL, LLC	Work Order:	22L0141
Client:	AECOM	Project:	Red Hill AFFF Assessment Sampling
Batch:	BBL0403	Batch Matrix:	Water
		Preparation:	1633

SAMPLE NAME	LAB SAMPLE ID	DATE PREPARED	INITIAL VOL./WEIGHT	FINAL VOL.
			g	ml
AF-RHMW02-WGN01LF-2212W3	22L0141-01	12/20/22 15:01	580.17	2.00
AF-RHMW03-WGN01LF-2212W3	22L0141-02	12/20/22 15:01	570.34	2.00
AF-RHMW225401-WGN01B-2212W3	22L0141-03	12/20/22 15:01	561.73	2.00
Blank	BBL0403-BLK1	12/20/22 15:01	500.00	2.00
LCS	BBL0403-BS1	12/20/22 15:01	500.00	2.00
MRL Check	BBL0403-MRL1	12/20/22 15:01	500.00	2.00



# PREPARATION BENCH SHEET

## Organics

BBL0403

**Matrix: Water**

**Prepared using: PFAS - 1633**

<b>Analyses</b> 1633	<b>Spiking Solution(s)</b> PFAS - MIX 1633 10ng/mL	<b>Surrogate Solution(s)</b> 22L0273 MPFAC-HIF-ES 20.0ng/mL
-------------------------	---	--

Lab Number	Sample and Source ID	Date Due	Extract by	Prepared	Initial (g)	Final (ml)	ul Spike	ul Surrogate	Extraction Comments
22L0134-01	AF-RHMW16-WGN01B-2212W2	12/22/2022	01/13/2023	12/20/2022 3:01:00PM	499.65	2		0	"Report relevant surrogates"
22L0134-01RE1	AF-RHMW16-WGN01B-2212W2	12/22/2022	01/13/2023	12/20/2022 3:01:00PM	499.65	2		0	"Report relevant surrogates"
22L0134-02	AF-RHMW17D-WGN01B-2212W2	12/22/2022	01/13/2023	12/20/2022 3:01:00PM	512.44	2		0	"Report relevant surrogates"
22L0134-02RE1	AF-RHMW17D-WGN01B-2212W2	12/22/2022	01/13/2023	12/20/2022 3:01:00PM	512.44	2		0	"Report relevant surrogates"
22L0134-03	AF-RHMW17D-WGN02B-2212W2	12/22/2022	01/13/2023	12/20/2022 3:01:00PM	523.23	2		0	"Report relevant surrogates"
22L0134-03RE1	AF-RHMW17D-WGN02B-2212W2	12/22/2022	01/13/2023	12/20/2022 3:01:00PM	523.23	2		0	"Report relevant surrogates"
22L0141-01	AF-RHMW02-WGN01LF-2212W3	01/03/2023	01/16/2023	12/20/2022 3:01:00PM	580.17	2		0	"Report relevant surrogates"
22L0141-01RE1	AF-RHMW02-WGN01LF-2212W3	01/03/2023	01/16/2023	12/20/2022 3:01:00PM	580.17	2		0	"Report relevant surrogates"
22L0141-02	AF-RHMW03-WGN01LF-2212W3	01/03/2023	01/16/2023	12/20/2022 3:01:00PM	570.34	2		0	"Report relevant surrogates"
22L0141-02RE1	AF-RHMW03-WGN01LF-2212W3	01/03/2023	01/16/2023	12/20/2022 3:01:00PM	570.34	2		0	"Report relevant surrogates"
22L0141-03	AF-RHMW225401-WGN01B-2212W3	01/03/2023	01/16/2023	12/20/2022 3:01:00PM	561.73	2		0	"Report relevant surrogates"
22L0141-03RE1	AF-RHMW225401-WGN01B-2212W3	01/03/2023	01/16/2023	12/20/2022 3:01:00PM	561.73	2		0	"Report relevant surrogates"
BBL0403-BLK1	Blank			12/20/2022 3:01:00PM	500	2	0	0	
BBL0403-BSI	LCS			12/20/2022 3:01:00PM	500	2	200	0	
BBL0403-MRL1	MRL Check			12/20/2022 3:01:00PM	500	2	20	0	

# PREPARATION BENCH SHEET

## Organics

Print Date/Time: 12/22/2022 3:42 pm

BBL0403

(Continued)

**Matrix: Water**

**Prepared using: PFAS - 1633**

**Analyses**  
1633

**Spiking Solution(s)**  
22L0269 PFAS - MIX 1633 10ng/mL

Start Date/Time \_\_\_\_\_

Stop Date/Time \_\_\_\_\_

Surrogate Solution(s)		
22L0273	MPFAC-HIF-ES	20.0ng/mL

Reagents	Standard	Description	LotNum
	22K0511	Reagent -0.3M Formic Acid	M13H051
	22L0094	Reagent - 0.05MFA wash	x
	22L0360	Am. Ac. preservative	P28T056
	22L0369	Reagent - 1.0% Ammonia Hydroxide	219481

Batch Comments:

Spiked by: DAG 12/20/22 4:20

Balance #: WB2

Cartridge: Biotage

Concentration: 12/21/22 4:10-6:00

Spiking Witnessed By \_\_\_\_\_

Date \_\_\_\_\_

Preparation Reviewed By \_\_\_\_\_

Date \_\_\_\_\_

Extracts Received By \_\_\_\_\_

Date \_\_\_\_\_

# PREPARATION BENCH SHEET

## Organics

BBL0403

**Matrix: Water**

**Prepared using: PFAS - 1633**

Analyses	Spiking Solution(s)	Surrogate Solution(s)
1633		

Lab Number	Sample and Source ID	Date Due	Extract by	Prepared	Initial (g)	Final (ml)	ul Spike	ul Surrogate	Extraction Comments
22L0134-01	AF-RHMW16-WGN01B-2212W2	12/22/2022	01/13/2023	12/20/2022 3:01:00PM	500	2			"Report relevant surrogates"
22L0134-01RE1	AF-RHMW16-WGN01B-2212W2	12/22/2022	01/13/2023	12/20/2022 3:01:00PM	500	2			"Report relevant surrogates"
22L0134-02	AF-RHMW17D-WGN01B-2212W2	12/22/2022	01/13/2023	12/20/2022 3:01:00PM	500	2			"Report relevant surrogates"
22L0134-02RE1	AF-RHMW17D-WGN01B-2212W2	12/22/2022	01/13/2023	12/20/2022 3:01:00PM	500	2			"Report relevant surrogates"
22L0134-03	AF-RHMW17D-WGN02B-2212W2	12/22/2022	01/13/2023	12/20/2022 3:01:00PM	500	2			"Report relevant surrogates"
22L0134-03RE1	AF-RHMW17D-WGN02B-2212W2	12/22/2022	01/13/2023	12/20/2022 3:01:00PM	500	2			"Report relevant surrogates"
22L0141-01	AF-RHMW02-WGN01LF-2212W3	01/03/2023	01/16/2023	12/20/2022 3:01:00PM	500	2			"Report relevant surrogates"
22L0141-01RE1	AF-RHMW02-WGN01LF-2212W3	01/03/2023	01/16/2023	12/20/2022 3:01:00PM	500	2			"Report relevant surrogates"
22L0141-02	AF-RHMW03-WGN01LF-2212W3	01/03/2023	01/16/2023	12/20/2022 3:01:00PM	500	2			"Report relevant surrogates"
22L0141-02RE1	AF-RHMW03-WGN01LF-2212W3	01/03/2023	01/16/2023	12/20/2022 3:01:00PM	500	2			"Report relevant surrogates"
22L0141-03	AF-RHMW225401-WGN01B-2212W3	01/03/2023	01/16/2023	12/20/2022 3:01:00PM	500	2			"Report relevant surrogates"
22L0141-03RE1	AF-RHMW225401-WGN01B-2212W3	01/03/2023	01/16/2023	12/20/2022 3:01:00PM	500	2			"Report relevant surrogates"
BBL0403-BLK1	Blank			12/20/2022 3:01:00PM	500	2			
BBL0403-BSI	LCS			12/20/2022 3:01:00PM	500	2			
BBL0403-MRL1	MRL Check			12/20/2022 3:01:00PM	500	2			

Reagents	Standard	Description	LotNum

Spiking Witnessed By \_\_\_\_\_ Date \_\_\_\_\_ Preparation Reviewed By \_\_\_\_\_ Date \_\_\_\_\_ Extracts Received By \_\_\_\_\_ Date \_\_\_\_\_

# PREPARATION BENCH SHEET

## Organics

Print Date/Time: 12/20/2022 3:13 pm

BBL0403

**Matrix: Water**

**Prepared using: PFAS - 1633**

Analyses 1633		Spiking Solution(s)				Surrogate Solution(s)			
Lab Number	Sample and Source ID	Date Due	Extract by	Prepared	Initial (g)	Final (ml)	ul Spike	ul Surrogate	Extraction Comments
22L0134-01	AF-RHMW16-WGN01B-2212W2	12/22/2022	01/13/2023	12/20/2022 3:01:00PM	500	2			"Report relevant surrogates"
22L0134-02	AF-RHMW17D-WGN01B-2212W2	12/22/2022	01/13/2023	12/20/2022 3:01:00PM	500	2			"Report relevant surrogates"
22L0134-03	AF-RHMW17D-WGN02B-2212W2	12/22/2022	01/13/2023	12/20/2022 3:01:00PM	500	2			"Report relevant surrogates"
22L0141-01	AF-RHMW02-WGN01LF-2212W3	01/03/2023	01/16/2023	12/20/2022 3:01:00PM	500	2			"Report relevant surrogates"
22L0141-02	AF-RHMW03-WGN01LF-2212W3	01/03/2023	01/16/2023	12/20/2022 3:01:00PM	500	2			"Report relevant surrogates"
22L0141-03	AF-RHMW225401-WGN01B-2212W3	01/03/2023	01/16/2023	12/20/2022 3:01:00PM	500	2			"Report relevant surrogates"
BBL0403-BLK1	Blank			12/20/2022 3:01:00PM	500	2			
BBL0403-BSI	LCS			12/20/2022 3:01:00PM	500	2			
BBL0403-MRL1	MRL Check			12/20/2022 3:01:00PM	500	2			

Reagents	Standard	Description	LotNum

Start Date/Time: \_\_\_\_\_  
 Stop Date/Time: \_\_\_\_\_

Spiking Witnessed By: \_\_\_\_\_ Date: \_\_\_\_\_  
 Preparation Reviewed By: \_\_\_\_\_ Date: \_\_\_\_\_  
 Extracts Received By: \_\_\_\_\_ Date: \_\_\_\_\_

# PREPARATION BENCH SHEET

## Organics

Print Date/Time: 12/20/2022 3:02 pm

BBL0403

**Matrix: Water**

**Prepared using: PFAS - 1633**

Analyses 1633		Spiking Solution(s)				Surrogate Solution(s)			
Lab Number	Sample and Source ID	Date Due	Extract by	Prepared	Initial (g)	Final (ml)	ul Spike	ul Surrogate	Extraction Comments
22L0134-01	AF-RHMW16-WGN01B-2212W2	12/22/2022	01/13/2023	12/20/2022 3:01:00PM	500	2			"Report relevant surrogates"
22L0134-02	AF-RHMW17D-WGN01B-2212W2	12/22/2022	01/13/2023	12/20/2022 3:01:00PM	500	2			"Report relevant surrogates"
22L0134-03	AF-RHMW17D-WGN02B-2212W2	12/22/2022	01/13/2023	12/20/2022 3:01:00PM	500	2			"Report relevant surrogates"
22L0141-01	AF-RHMW02-WGN01LF-2212W3	01/03/2023	01/16/2023	12/20/2022 3:01:00PM	500	2			"Report relevant surrogates"
22L0141-02	AF-RHMW03-WGN01LF-2212W3	01/03/2023	01/16/2023	12/20/2022 3:01:00PM	500	2			"Report relevant surrogates"
22L0141-03	AF-RHMW225401-WGN01B-2212W3	01/03/2023	01/16/2023	12/20/2022 3:01:00PM	500	2			"Report relevant surrogates"
BBL0403-BLK1	Blank			12/20/2022 3:01:00PM	500	2			
BBL0403-BSI	LCS			12/20/2022 3:01:00PM	500	2			
BBL0403-MRL1	MRL Check			12/20/2022 3:01:00PM	500	2			

Reagents	Standard	Description	LotNum

Start Date/Time: \_\_\_\_\_  
 Stop Date/Time: \_\_\_\_\_

Spiking Witnessed By: \_\_\_\_\_ Date: \_\_\_\_\_  
 Preparation Reviewed By: \_\_\_\_\_ Date: \_\_\_\_\_  
 Extracts Received By: \_\_\_\_\_ Date: \_\_\_\_\_

# PREPARATION BENCH SHEET

## Organics

Print Date/Time: 12/20/2022 3:02 pm

BBL0403

**Matrix: Water**

**Prepared using: PFAS - 1633**

Analyses 1633		Spiking Solution(s)				Surrogate Solution(s)			
Lab Number	Sample and Source ID	Date Due	Extract by	Prepared	Initial (g)	Final (ml)	ul Spike	ul Surrogate	Extraction Comments
22L0134-01	AF-RHMW16-WGN01B-2212W2	12/22/2022	01/13/2023	12/20/2022 3:01:00PM	500	2			"Report relevant surrogates"
22L0134-02	AF-RHMW17D-WGN01B-2212W2	12/22/2022	01/13/2023	12/20/2022 3:01:00PM	500	2			"Report relevant surrogates"
22L0134-03	AF-RHMW17D-WGN02B-2212W2	12/22/2022	01/13/2023	12/20/2022 3:01:00PM	500	2			"Report relevant surrogates"
22L0141-01	AF-RHMW02-WGN01LF-2212W3	01/03/2023	01/16/2023	12/20/2022 3:01:00PM	500	2			"Report relevant surrogates"
22L0141-02	AF-RHMW03-WGN01LF-2212W3	01/03/2023	01/16/2023	12/20/2022 3:01:00PM	500	2			"Report relevant surrogates"
22L0141-03	AF-RHMW225401-WGN01B-2212W3	01/03/2023	01/16/2023	12/20/2022 3:01:00PM	500	2			"Report relevant surrogates"
BBL0403-BLK1	Blank			12/20/2022 3:01:00PM	500	2			
BBL0403-BSI	LCS			12/20/2022 3:01:00PM	500	2			
BBL0403-MRL1	MRL Check			12/20/2022 3:01:00PM	500	2			

Reagents	Standard	Description	LotNum

Start Date/Time: \_\_\_\_\_  
 Stop Date/Time: \_\_\_\_\_

Spiking Witnessed By: \_\_\_\_\_ Date: \_\_\_\_\_  
 Preparation Reviewed By: \_\_\_\_\_ Date: \_\_\_\_\_  
 Extracts Received By: \_\_\_\_\_ Date: \_\_\_\_\_

# INJECTION LOG - ANALYSIS SEQUENCE SUMMARY

EPA 1633

Laboratory: APPL, LLC  
 Client: AECOM  
 Sequence: SB03941  
 Calibration: 2252011

SDG:  
 Project: Red Hill AFFF Assessment Sampling  
 Instrument: Saphira

Sample Name	Lab Sample ID	Lab File ID	Analysis Date/Time
Cal Standard	SB03941-CAL1	S2022-12-21A (1)	12/21/22 14:26
Cal Standard	SB03941-CAL2	S2022-12-21A (2)	12/21/22 14:39
Cal Standard	SB03941-CAL3	S2022-12-21A (3)	12/21/22 14:51
Cal Standard	SB03941-CAL4	S2022-12-21A (4)	12/21/22 15:04
Cal Standard	SB03941-CAL5	S2022-12-21A (5)	12/21/22 15:17
Cal Standard	SB03941-CAL6	S2022-12-21A (6)	12/21/22 15:30
Cal Standard	SB03941-CAL7	S2022-12-21A (7)	12/21/22 15:42
Cal Standard	SB03941-CAL8	S2022-12-21A (8)	12/21/22 15:55
Initial Cal Blank	SB03941-ICB1	S2022-12-21A (9)	12/21/22 16:08
Secondary Cal Check	SB03941-SCV1	S2022-12-21A (10)	12/21/22 16:20

# INJECTION LOG - ANALYSIS SEQUENCE SUMMARY

EPA 1633

Laboratory: APPL, LLC  
 Client: AECOM  
 Sequence: SB03951  
 Calibration: 2252011

SDG:  
 Project: Red Hill AFFF Assessment Sampling  
 Instrument: Saphira

Sample Name	Lab Sample ID	Lab File ID	Analysis Date/Time
Calibration Blank	SB03951-CCB1	S2022-12-22A (1)	12/22/22 11:01
Low Cal Check	SB03951-LCV1	S2022-12-22A (2)	12/22/22 11:14
Calibration Check	SB03951-CCV1	S2022-12-22A (3)	12/22/22 11:26
Calibration Blank	SB03951-CCB2	S2022-12-22A (4)	12/22/22 12:04
Calibration Check	SB03951-CCV2	S2022-12-22A (16)	12/22/22 14:37
Calibration Blank	SB03951-CCB3	S2022-12-22A (17)	12/22/22 14:50
Blank	BBL0403-BLK1	S2022-12-22A (18)	12/22/22 15:02
LCS	BBL0403-BS1	S2022-12-22A (19)	12/22/22 15:15
MRL Check	BBL0403-MRL1	S2022-12-22A (20)	12/22/22 15:28
AF-RHMW02-WGN01LF-2212W3	22L0141-01	S2022-12-22A (27)	12/22/22 16:57
AF-RHMW03-WGN01LF-2212W3	22L0141-02	S2022-12-22A (29)	12/22/22 17:22
AF-RHMW225401-WGN01B-2212W3	22L0141-03	S2022-12-22A (31)	12/22/22 17:47
Calibration Check	SB03951-CCV3	S2022-12-22A (33)	12/22/22 18:13
Calibration Blank	SB03951-CCB4	S2022-12-22A (34)	12/22/22 18:25






# WELLINGTON LABORATORIES

## CERTIFICATE OF ANALYSIS DOCUMENTATION

**PRODUCT CODE:** N-EtFOSA-M **LOT NUMBER:** NEtFOSA0821M  
**COMPOUND:** N-ethylperfluoro-1-octanesulfonamide

**STRUCTURE:** **CAS #:** 4151-50-2



**MOLECULAR FORMULA:**  $C_{10}H_{17}F_{17}NO_2S$  **MOLECULAR WEIGHT:** 527.20  
**CONCENTRATION:**  $50.0 \pm 2.5 \mu\text{g/mL}$  **SOLVENT(S):** Methanol  
**CHEMICAL PURITY:** >98%  
**LAST TESTED:** (mm/dd/yyyy) 08/12/2021  
**EXPIRY DATE:** (mm/dd/yyyy) 08/12/2026  
**RECOMMENDED STORAGE:** Store ampoule in a cool, dark place

### DOCUMENTATION/ DATA ATTACHED:

Figure 1: LC/MS Data (Full Scan and Mass Spectrum)  
 Figure 2: LC/MS/MS Data (Selected MRM Transitions)

### ADDITIONAL INFORMATION:

- See page 2 for further details.

**FOR LABORATORY USE ONLY: NOT FOR HUMAN OR DRUG USE**

**Certified By:**   
 B.G. Chittim, General Manager

**Date:** 08/16/2021  
 (mm/dd/yyyy)

Wellington Laboratories Inc., 345 Southgate Dr. Guelph ON N1G 3M5 CANADA  
 519-822-2436 • Fax: 519-822-2849 • info@well-labs.com

**INTENDED USE:**

The products prepared by Wellington Laboratories Inc. are for laboratory use only. This certified reference material (CRM) was designed to be used as a standard for the identification and/or quantification of the specific chemical compound it contains.

**HANDLING:**

This product should only be used by qualified personnel familiar with its potential hazards and trained in the handling of hazardous chemicals. Due care should be exercised to prevent unnecessary human contact or ingestion. All procedures should be carried out in a well-functioning fume hood and suitable gloves, eye protection, and clothing should be worn at all times. Waste should be disposed of according to national and regional regulations. Safety Data Sheets (SDSs) are available upon request.

**SYNTHESIS / CHARACTERIZATION:**

Our products are synthesized using single-product unambiguous routes whenever possible. They are then characterized, and their structures and purities confirmed, using a combination of the most relevant techniques, such as NMR, GC/MS, LC/MS/MS, SFC/UV/MS/MS, x-ray crystallography, and melting point. Isotopic purities of mass-labelled compounds are also confirmed using HRGC/HRMS and/or LC/MS/MS.

**HOMOGENEITY:**

Prior to solution preparation, crystalline material is tested for homogeneity using a variety of techniques (as stated above) and its solubility in a given diluent is taken into consideration. Duplicate solutions of a new product are prepared from the same crystalline lot and, after the addition of an appropriate internal standard, they are compared by GC/MS, LC/MS/MS, and/or SFC/UV/MS/MS. The relative response factors of the analyte of interest in each solution are required to be <5% RSD. New solution lots of existing products are compared to older lots in the same manner, which further confirms the homogeneity of the crystalline material as well as the stability and homogeneity of the solutions in the storage containers. In order to maintain the integrity of the assigned value(s), and associated uncertainty, the dilution or injection of a subsample of this product should be performed using calibrated measuring equipment.

**UNCERTAINTY:**

The maximum combined relative standard uncertainty of our reference standard solutions is calculated using the following equation:

The combined relative standard uncertainty,  $u_c(y)$ , of a value  $y$  and the uncertainty of the independent parameters

$x_1, x_2, \dots, x_n$  on which it depends is:

$$u_c(y(x_1, x_2, \dots, x_n)) = \sqrt{\sum_{i=1}^n u(y, x_i)^2}$$

where  $x$  is expressed as a relative standard uncertainty of the individual parameter.

The individual uncertainties taken into account include those associated with weights (calibration of the balance) and volumes (calibration of the volumetric glassware). An expanded maximum combined percent relative uncertainty of  $\pm 5\%$  (calculated with a coverage factor of 2 and a level of confidence of 95%) is stated on the Certificate of Analysis for all of our products.

**TRACEABILITY:**

All reference standard solutions are traceable to specific crystalline lots. The microbalances used for solution preparation are regularly calibrated by an external ISO/IEC 17025 accredited laboratory. In addition, their calibration is verified prior to each weighing using calibrated external weights traceable to an ISO/IEC 17025 accredited laboratory. All volumetric glassware used is calibrated, of Class A tolerance, and traceable to an ISO/IEC 17025 accredited laboratory. For certain products, traceability to international interlaboratory studies has also been established.

**EXPIRY DATE / PERIOD OF VALIDITY:**

Ongoing stability studies of this product have demonstrated stability in its composition and concentration, until the specified expiry date, in the unopened ampoule. Monitoring for any degradation or change in concentration of the listed analyte(s) is performed on a routine basis.

**LIMITED WARRANTY:**

At the time of shipment, all products are warranted to be free of defects in material and workmanship and to conform to the stated technical and purity specifications.



**QUALITY MANAGEMENT:**

This product was produced using a Quality Management System registered to the latest versions of ISO 9001 by SAI Global, ISO/IEC 17025 by the Canadian Association for Laboratory Accreditation Inc. (CALA; A1226), and ISO 17034 by ANSI National Accreditation Board (ANAB; AR-1523).



\*\*For additional information or assistance concerning this or any other products from Wellington Laboratories Inc., please visit our website at [www.well-labs.com](http://www.well-labs.com) or contact us directly at [info@well-labs.com](mailto:info@well-labs.com)\*\*

**Figure 1: N-EtFOSA-M; LC/MS Data (Full Scan and Mass Spectrum)**



**Conditions for Figure 1:**

Waters Acquity Ultra Performance LC  
Waters Xevo TQ-S micro MS

**Chromatographic Conditions:**

Column: Acquity UPLC BEH Shield RP<sub>18</sub>  
1.7  $\mu$ m, 2.1 x 100 mm

Mobile phase: Gradient  
Start: 30% H<sub>2</sub>O / 70% (80:20 MeOH:ACN)  
(both with 10 mM NH<sub>4</sub>OAc buffer)  
Ramp to 90% organic over 8 min and hold for  
2 min before returning to initial conditions in 0.75 min.  
Time: 12 min

Flow: 300  $\mu$ L/min


**MS Parameters:**

Experiment: Full Scan (225 - 850 amu)

Source: Electrospray (negative)  
Capillary Voltage (kV) = 1.00  
Cone Voltage (V) = 44.00  
Desolvation Temperature ( $^{\circ}$ C) = 500  
Desolvation Gas Flow (L/hr) = 1000

NEtFOSA0821M (3 of 4)  
rev0

**Figure 2: N-EtFOSA-M; LC/MS/MS Data (Selected MRM Transitions)**



**Conditions for Figure 2:**

Injection: On-column (N-EtFOSA-M)  
Mobile phase: Same as Figure 1  
Flow: 300  $\mu$ L/min

**MS Parameters:**

Collision Gas (mbar) = 3.29e-3  
Collision Energy (eV) = 24

# Analytical Standard Record

**21J0007**

Description:	PFAS - SAS N-EtFOSA 50ug/mL	Expires:	08/12/2026
Standard Type:	Analyte Spike	Prepared:	08/12/2021
Solvent:	MeOH	Prepared By:	Wellington Laboratories (Lot#:
Final Volume (mls):	1	Department:	PFAS (Lot# OSA0821M)
Vials:	1	Last Edit:	12/07/2021 16:05 by HGH

Analyte	Parent	CAS Number	Concentration	Units
N-ETFOSA		4151-50-2	50	ug/mL




# WELLINGTON LABORATORIES

## CERTIFICATE OF ANALYSIS DOCUMENTATION

**PRODUCT CODE:** N-MeFOSE-M **LOT NUMBER:** NMeFOSE0921M  
**COMPOUND:** 2-(N-methylperfluoro-1-octanesulfonamido)-ethanol

**STRUCTURE:** **CAS #:** 24448-09-7



**MOLECULAR FORMULA:** C<sub>11</sub>H<sub>8</sub>F<sub>17</sub>NO<sub>3</sub>S **MOLECULAR WEIGHT:** 557.22  
**CONCENTRATION:** 50.0 ± 2.5 µg/mL **SOLVENT(S):** Methanol  
**CHEMICAL PURITY:** >98%  
**LAST TESTED:** (mm/dd/yyyy) 09/22/2021 (HRGC/LRMS)  
 09/23/2021 (LC/MS)  
**EXPIRY DATE:** (mm/dd/yyyy) 09/23/2026  
**RECOMMENDED STORAGE:** Store ampoule in a cool, dark place

### DOCUMENTATION/ DATA ATTACHED:

Figure 1: HRGC/LRMS Data (Full Scan and Mass Spectrum)  
 Figure 2: LC/MS Data (Full Scan and Mass Spectrum)  
 Figure 3: LC/MS/MS Data (Selected MRM Transitions)

### ADDITIONAL INFORMATION:

- See page 2 for further details.
- In order to see the molecular ion (adduct free), the LC mobile phase should be free of ammonium acetate buffer.

**FOR LABORATORY USE ONLY: NOT FOR HUMAN OR DRUG USE**

Certified By: \_\_\_\_\_

B.G. Chittim, General Manager

Date: 09/28/2021  
 (mm/dd/yyyy)

Wellington Laboratories Inc., 345 Southgate Dr. Guelph ON N1G 3M5 CANADA  
 519-822-2436 • Fax: 519-822-2849 • info@well-labs.com

**INTENDED USE:**

The products prepared by Wellington Laboratories Inc. are for laboratory use only. This certified reference material (CRM) was designed to be used as a standard for the identification and/or quantification of the specific chemical compound it contains.

**HANDLING:**

This product should only be used by qualified personnel familiar with its potential hazards and trained in the handling of hazardous chemicals. Due care should be exercised to prevent unnecessary human contact or ingestion. All procedures should be carried out in a well-functioning fume hood and suitable gloves, eye protection, and clothing should be worn at all times. Waste should be disposed of according to national and regional regulations. Safety Data Sheets (SDSs) are available upon request.

**SYNTHESIS / CHARACTERIZATION:**

Our products are synthesized using single-product unambiguous routes whenever possible. They are then characterized, and their structures and purities confirmed, using a combination of the most relevant techniques, such as NMR, GC/MS, LC/MS/MS, SFC/UV/MS/MS, x-ray crystallography, and melting point. Isotopic purities of mass-labelled compounds are also confirmed using HRGC/HRMS and/or LC/MS/MS.

**HOMOGENEITY:**

Prior to solution preparation, crystalline material is tested for homogeneity using a variety of techniques (as stated above) and its solubility in a given diluent is taken into consideration. Duplicate solutions of a new product are prepared from the same crystalline lot and, after the addition of an appropriate internal standard, they are compared by GC/MS, LC/MS/MS, and/or SFC/UV/MS/MS. The relative response factors of the analyte of interest in each solution are required to be <5% RSD. New solution lots of existing products are compared to older lots in the same manner, which further confirms the homogeneity of the crystalline material as well as the stability and homogeneity of the solutions in the storage containers. In order to maintain the integrity of the assigned value(s), and associated uncertainty, the dilution or injection of a subsample of this product should be performed using calibrated measuring equipment.

**UNCERTAINTY:**

The maximum combined relative standard uncertainty of our reference standard solutions is calculated using the following equation:

The combined relative standard uncertainty,  $u_c(y)$ , of a value  $y$  and the uncertainty of the independent parameters

$x_1, x_2, \dots, x_n$  on which it depends is:

$$u_c(y(x_1, x_2, \dots, x_n)) = \sqrt{\sum_{i=1}^n u(y, x_i)^2}$$

where  $x$  is expressed as a relative standard uncertainty of the individual parameter.

The individual uncertainties taken into account include those associated with weights (calibration of the balance) and volumes (calibration of the volumetric glassware). An expanded maximum combined percent relative uncertainty of  $\pm 5\%$  (calculated with a coverage factor of 2 and a level of confidence of 95%) is stated on the Certificate of Analysis for all of our products.

**TRACEABILITY:**

All reference standard solutions are traceable to specific crystalline lots. The microbalances used for solution preparation are regularly calibrated by an external ISO/IEC 17025 accredited laboratory. In addition, their calibration is verified prior to each weighing using calibrated external weights traceable to an ISO/IEC 17025 accredited laboratory. All volumetric glassware used is calibrated, of Class A tolerance, and traceable to an ISO/IEC 17025 accredited laboratory. For certain products, traceability to international interlaboratory studies has also been established.

**EXPIRY DATE / PERIOD OF VALIDITY:**

Ongoing stability studies of this product have demonstrated stability in its composition and concentration, until the specified expiry date, in the unopened ampoule. Monitoring for any degradation or change in concentration of the listed analyte(s) is performed on a routine basis.

**LIMITED WARRANTY:**


At the time of shipment, all products are warranted to be free of defects in material and workmanship and to conform to the stated technical and purity specifications.

**QUALITY MANAGEMENT:**

This product was produced using a Quality Management System registered to the latest versions of ISO 9001 by SAI Global, ISO/IEC 17025 by the Canadian Association for Laboratory Accreditation Inc. (CALA; A1226), and ISO 17034 by ANSI National Accreditation Board (ANAB; AR-1523).



\*\*For additional information or assistance concerning this or any other products from Wellington Laboratories Inc., please visit our website at [www.well-labs.com](http://www.well-labs.com) or contact us directly at [info@well-labs.com](mailto:info@well-labs.com)\*\*

**Figure 1:** N-MeFOSE-M; HRGC/LRMS Data (Full Scan and Mass Spectrum)**Conditions for Figure 1:**

Agilent 7890A HRGC  
 Agilent 5975C MSD

**Chromatographic Conditions:**

Column: 30 m DB-5 (0.25 mm id, 0.25  $\mu$ m film thickness) Agilent J&W

Flow: Constant at 1 mL/min



Injector: 250°C (Splitless Injection)

Oven: 100°C (5 min)  
 10°C/min to 310°C  
 310°C (10 min)

Ionization: EI+

Detector: 230°C  
 Full Scan (50-1000 amu)



**Figure 2:** N-MeFOSE-M; LC/MS Data (Full Scan and Mass Spectrum)**Conditions for Figure 2:**

Waters Acquity Ultra Performance LC  
Waters Xevo TQ-S micro MS

**Chromatographic Conditions:**

Column: Acquity UPLC BEH Shield RP<sub>18</sub>  
1.7 µm, 2.1 x 100 mm

Mobile phase: Gradient


Start: 30% H<sub>2</sub>O / 70% MeOH  
Ramp to 90% organic over 8 min and hold for  
1.5 min before returning to initial conditions in 1 min.  
Time: 12 min

Flow: 300 µL/min

**MS Parameters:**

Experiment: Full Scan (250 - 850 amu)

Source: Electrospray (negative)  
Capillary Voltage (kV) = 2.00  
Cone Voltage (V) = 65.00  
Desolvation Temperature (°C) = 450  
Desolvation Gas Flow (L/hr) = 1000

**Figure 3: N-MeFOSE-M; LC/MS/MS Data (Selected MRM Transitions)****Conditions for Figure 3:**

Injection: On-column (N-MeFOSE-M)

**MS Parameters:**

Mobile phase: Same as Figure 2

Collision Gas (mbar) = 3.14e-3

Collision Energy (eV) = 36

Flow: 300  $\mu$ L/min

2  
f  
#

# Analytical Standard Record

**21J0014**

Description:	PFAS - SAS N-MeFOSE 50ug/mL	Expires:	09/23/2026
Standard Type:	Analyte Spike	Prepared:	09/22/2021
Solvent:	MeOH	Prepared By:	Wellington Laboratories (Lot#:
Final Volume (mls):	1.2	Department:	PFAS (N-MeFOSE0921M)
Vials:	1	Last Edit:	12/07/2021 16:06 by HGH

Analyte	Parent	CAS Number	Concentration	Units
N-MEFOSE		24448-09-7	50	ug/mL

# Analytical Standard Record

**21J0014**

Description:	PFAS - SAS N-MeFOSE 50ug/mL	Expires:	09/23/2026
Standard Type:	Analyte Spike	Prepared:	09/22/2021
Solvent:	MeOH	Prepared By:	Wellington Laboratories (Lot#:
Final Volume (mls):	1.2	Department:	N-MEFOSE0921M)
Vials:	1	Last Edit:	12/07/2021 16:06 by HGH


Analyte	Parent	CAS Number	Concentration	Units
N-MEFOSE		24448-09-7	50	ug/mL



# WELLINGTON LABORATORIES

## CERTIFICATE OF ANALYSIS DOCUMENTATION

**PRODUCT CODE:** FPrPA **LOT NUMBER:** FPrPA1020  
**COMPOUND:** 3-Perfluoropropyl propanoic acid  
**STRUCTURE:** **CAS #:** 356-02-5



**MOLECULAR FORMULA:**  $C_8H_5F_7O_2$  **MOLECULAR WEIGHT:** 242.09  
**CONCENTRATION:**  $50.0 \pm 2.5 \mu\text{g/mL}$  **SOLVENT(S):** Methanol  
**CHEMICAL PURITY:** >98%  
**LAST TESTED:** (mm/dd/yyyy) 11/12/2020  
**EXPIRY DATE:** (mm/dd/yyyy) 11/12/2025  
**RECOMMENDED STORAGE:** Refrigerate ampoule

### DOCUMENTATION/ DATA ATTACHED:

Figure 1: LC/MS Data (TIC and Mass Spectrum)  
 Figure 2: LC/MS/MS Data (Selected MRM Transitions)

### ADDITIONAL INFORMATION:

- See page 2 for further details.
- Contains <1% of the unsaturated 3:3 telomer acid ( $C_8H_3F_7O_2$ ) as an impurity determined by  $^{19}\text{F}$  NMR.

**FOR LABORATORY USE ONLY: NOT FOR HUMAN OR DRUG USE**

**Certified By:**   
 B.G. Chittim, General Manager

**Date:** 11/27/2020  
 (mm/dd/yyyy)

Wellington Laboratories Inc., 345 Southgate Dr. Guelph ON N1G 3M5 CANADA  
 519-822-2436 • Fax: 519-822-2849 • info@well-labs.com

**INTENDED USE:**

The products prepared by Wellington Laboratories Inc. are for laboratory use only. This certified reference material (CRM) was designed to be used as a standard for the identification and/or quantification of the specific chemical compound it contains.

**HANDLING:**

This product should only be used by qualified personnel familiar with its potential hazards and trained in the handling of hazardous chemicals. Due care should be exercised to prevent unnecessary human contact or ingestion. All procedures should be carried out in a well-functioning fume hood and suitable gloves, eye protection, and clothing should be worn at all times. Waste should be disposed of according to national and regional regulations. Safety Data Sheets (SDSs) are available upon request.

**SYNTHESIS / CHARACTERIZATION:**

Our products are synthesized using single-product unambiguous routes whenever possible. They are then characterized, and their structures and purities confirmed, using a combination of the most relevant techniques, such as NMR, GC/MS, LC/MS/MS, SFC/UV/MS/MS, x-ray crystallography, and melting point. Isotopic purities of mass-labelled compounds are also confirmed using HRGC/HRMS and/or LC/MS/MS.

**HOMOGENEITY:**

Prior to solution preparation, crystalline material is tested for homogeneity using a variety of techniques (as stated above) and its solubility in a given diluent is taken into consideration. Duplicate solutions of a new product are prepared from the same crystalline lot and, after the addition of an appropriate internal standard, they are compared by GC/MS, LC/MS/MS, and/or SFC/UV/MS/MS. The relative response factors of the analyte of interest in each solution are required to be <5% RSD. New solution lots of existing products are compared to older lots in the same manner, which further confirms the homogeneity of the crystalline material as well as the stability and homogeneity of the solutions in the storage containers. In order to maintain the integrity of the assigned value(s), and associated uncertainty, the dilution or injection of a subsample of this product should be performed using calibrated measuring equipment.

**UNCERTAINTY:**

The maximum combined relative standard uncertainty of our reference standard solutions is calculated using the following equation:

The combined relative standard uncertainty,  $u_c(y)$ , of a value  $y$  and the uncertainty of the independent parameters

$x_1, x_2, \dots, x_n$  on which it depends is:

$$u_c(y(x_1, x_2, \dots, x_n)) = \sqrt{\sum_{i=1}^n u(y, x_i)^2}$$

where  $x$  is expressed as a relative standard uncertainty of the individual parameter.

The individual uncertainties taken into account include those associated with weights (calibration of the balance) and volumes (calibration of the volumetric glassware). An expanded maximum combined percent relative uncertainty of  $\pm 5\%$  (calculated with a coverage factor of 2 and a level of confidence of 95%) is stated on the Certificate of Analysis for all of our products.

**TRACEABILITY:**

All reference standard solutions are traceable to specific crystalline lots. The microbalances used for solution preparation are regularly calibrated by an external ISO/IEC 17025 accredited laboratory. In addition, their calibration is verified prior to each weighing using calibrated external weights traceable to an ISO/IEC 17025 accredited laboratory. All volumetric glassware used is calibrated, of Class A tolerance, and traceable to an ISO/IEC 17025 accredited laboratory. For certain products, traceability to international interlaboratory studies has also been established.

**EXPIRY DATE / PERIOD OF VALIDITY:**

Ongoing stability studies of this product have demonstrated stability in its composition and concentration, until the specified expiry date, in the unopened ampoule. Monitoring for any degradation or change in concentration of the listed analyte(s) is performed on a routine basis.

**LIMITED WARRANTY:**



At the time of shipment, all products are warranted to be free of defects in material and workmanship and to conform to the stated technical and purity specifications.

**QUALITY MANAGEMENT:**

This product was produced using a Quality Management System registered to the latest versions of ISO 9001 by SAI Global, ISO/IEC 17025 by the Canadian Association for Laboratory Accreditation Inc. (CALA; A1226), and ISO 17034 by ANSI-ASQ National Accreditation Board (ANAB; AR-1523).



\*\*For additional information or assistance concerning this or any other products from Wellington Laboratories Inc., please visit our website at [www.well-labs.com](http://www.well-labs.com) or contact us directly at [info@well-labs.com](mailto:info@well-labs.com)\*\*

**Figure 1: FPrPA; LC/MS Data (TIC and Mass Spectrum)****Conditions for Figure 1:**

Waters Acquity Ultra Performance LC  
Waters Xevo TQ-S micro MS

**Chromatographic Conditions:**

Column: Acquity UPLC BEH Shield RP<sub>18</sub>  
1.7  $\mu$ m, 2.1 x 100 mm

Mobile phase: Gradient

Start: 60% H<sub>2</sub>O / 40% (80:20 MeOH:ACN)  
(both with 10 mM NH<sub>4</sub>OAc buffer)  
Ramp to 90% organic over 8 min and hold for 2 min  
before returning to initial conditions in 0.75 min.  
Time: 12 min

Flow: 300  $\mu$ L/min

**MS Parameters:**

Experiment: Full Scan (150 - 850 amu)

Source: Electrospray (negative)


Capillary Voltage (kV) = 0.50

Cone Voltage (V) = 18.50

Desolvation Temperature ( $^{\circ}$ C) = 500

Desolvation Gas Flow (L/hr) = 1000



**Figure 2: FPrPA; LC/MS/MS Data (Selected MRM Transitions)****Conditions for Figure 2:**

Injection: On-column (FPrPA)

Mobile phase: Same as Figure 1

Flow: 300  $\mu$ L/min**MS Parameters:**

Collision Gas (mbar) = 3.49e-3

Collision Energy (eV) = 10

# Analytical Standard Record

**21L0004**

Description:	PFAS - SAS 3:3FTA 50ug/mL	Expires:	06/05/2022
Standard Type:	Analyte Spike	Prepared:	12/07/2021
Solvent:	MeOH	Prepared By:	Hart Hedgpeth
Final Volume (mls):	1	Department:	PFAS
Vials:	1	Last Edit:	12/07/2021 16:03 by HGH
Comments:	3:3 FTCA 50.0ug/mL		

<b>Analyte</b>	<b>Parent</b>	<b>CAS Number</b>	<b>Concentration</b>	<b>Units</b>
3:3 FTA		113507-82-7	50	ug/mL




# WELLINGTON LABORATORIES

## CERTIFICATE OF ANALYSIS DOCUMENTATION

**PRODUCT CODE:** FPePA **LOT NUMBER:** FPePA1120  
**COMPOUND:** 3-Perfluoropentyl propanoic acid

**STRUCTURE:** **CAS #:** 914637-49-3



**MOLECULAR FORMULA:**  $C_8H_5F_{11}O_2$  **MOLECULAR WEIGHT:** 342.11  
**CONCENTRATION:**  $50.0 \pm 2.5 \mu\text{g/mL}$  **SOLVENT(S):** Methanol  
**CHEMICAL PURITY:** >98%  
**LAST TESTED:** (mm/dd/yyyy) 11/11/2020  
**EXPIRY DATE:** (mm/dd/yyyy) 11/11/2025  
**RECOMMENDED STORAGE:** Refrigerate ampoule

### DOCUMENTATION/ DATA ATTACHED:

Figure 1: LC/MS Data (TIC and Mass Spectrum)  
 Figure 2: LC/MS/MS Data (Selected MRM Transitions)

### ADDITIONAL INFORMATION:

- See page 2 for further details.
- Contains <1% of the unsaturated 5:3 telomer acid ( $C_8H_3F_{11}O_2$ ) as an impurity determined by  $^{19}\text{F}$  NMR.

**FOR LABORATORY USE ONLY: NOT FOR HUMAN OR DRUG USE**

**Certified By:**   
 B.G. Chittim, General Manager

**Date:** 11/27/2020  
 (mm/dd/yyyy)

Wellington Laboratories Inc., 345 Southgate Dr. Guelph ON N1G 3M5 CANADA  
 519-822-2436 • Fax: 519-822-2849 • info@well-labs.com

**INTENDED USE:**

The products prepared by Wellington Laboratories Inc. are for laboratory use only. This certified reference material (CRM) was designed to be used as a standard for the identification and/or quantification of the specific chemical compound it contains.

**HANDLING:**

This product should only be used by qualified personnel familiar with its potential hazards and trained in the handling of hazardous chemicals. Due care should be exercised to prevent unnecessary human contact or ingestion. All procedures should be carried out in a well-functioning fume hood and suitable gloves, eye protection, and clothing should be worn at all times. Waste should be disposed of according to national and regional regulations. Safety Data Sheets (SDSs) are available upon request.

**SYNTHESIS / CHARACTERIZATION:**

Our products are synthesized using single-product unambiguous routes whenever possible. They are then characterized, and their structures and purities confirmed, using a combination of the most relevant techniques, such as NMR, GC/MS, LC/MS/MS, SFC/UV/MS/MS, x-ray crystallography, and melting point. Isotopic purities of mass-labelled compounds are also confirmed using HRGC/HRMS and/or LC/MS/MS.

**HOMOGENEITY:**

Prior to solution preparation, crystalline material is tested for homogeneity using a variety of techniques (as stated above) and its solubility in a given diluent is taken into consideration. Duplicate solutions of a new product are prepared from the same crystalline lot and, after the addition of an appropriate internal standard, they are compared by GC/MS, LC/MS/MS, and/or SFC/UV/MS/MS. The relative response factors of the analyte of interest in each solution are required to be <5% RSD. New solution lots of existing products are compared to older lots in the same manner, which further confirms the homogeneity of the crystalline material as well as the stability and homogeneity of the solutions in the storage containers. In order to maintain the integrity of the assigned value(s), and associated uncertainty, the dilution or injection of a subsample of this product should be performed using calibrated measuring equipment.

**UNCERTAINTY:**

The maximum combined relative standard uncertainty of our reference standard solutions is calculated using the following equation:

The combined relative standard uncertainty,  $u_c(y)$ , of a value  $y$  and the uncertainty of the independent parameters

$x_1, x_2, \dots, x_n$  on which it depends is:

$$u_c(y(x_1, x_2, \dots, x_n)) = \sqrt{\sum_{i=1}^n u(y, x_i)^2}$$

where  $x$  is expressed as a relative standard uncertainty of the individual parameter.

The individual uncertainties taken into account include those associated with weights (calibration of the balance) and volumes (calibration of the volumetric glassware). An expanded maximum combined percent relative uncertainty of  $\pm 5\%$  (calculated with a coverage factor of 2 and a level of confidence of 95%) is stated on the Certificate of Analysis for all of our products.

**TRACEABILITY:**

All reference standard solutions are traceable to specific crystalline lots. The microbalances used for solution preparation are regularly calibrated by an external ISO/IEC 17025 accredited laboratory. In addition, their calibration is verified prior to each weighing using calibrated external weights traceable to an ISO/IEC 17025 accredited laboratory. All volumetric glassware used is calibrated, of Class A tolerance, and traceable to an ISO/IEC 17025 accredited laboratory. For certain products, traceability to international interlaboratory studies has also been established.

**EXPIRY DATE / PERIOD OF VALIDITY:**


Ongoing stability studies of this product have demonstrated stability in its composition and concentration, until the specified expiry date, in the unopened ampoule. Monitoring for any degradation or change in concentration of the listed analyte(s) is performed on a routine basis.

**LIMITED WARRANTY:**



At the time of shipment, all products are warranted to be free of defects in material and workmanship and to conform to the stated technical and purity specifications.

**QUALITY MANAGEMENT:**

This product was produced using a Quality Management System registered to the latest versions of ISO 9001 by SAI Global, ISO/IEC 17025 by the Canadian Association for Laboratory Accreditation Inc. (CALA; A1226), and ISO 17034 by ANSI-ASQ National Accreditation Board (ANAB; AR-1523).



\*\*For additional information or assistance concerning this or any other products from Wellington Laboratories Inc., please visit our website at [www.well-labs.com](http://www.well-labs.com) or contact us directly at [info@well-labs.com](mailto:info@well-labs.com)\*\*

**Figure 1: FPePA; LC/MS Data (TIC and Mass Spectrum)****Conditions for Figure 1:**

Waters Acquity Ultra Performance LC  
Waters Xevo TQ-S micro MS

**Chromatographic Conditions:**

Column: Acquity UPLC BEH Shield RP<sub>18</sub>  
1.7  $\mu$ m, 2.1 x 100 mm


Mobile phase: Gradient  
Start: 45% H<sub>2</sub>O / 55% (80:20 MeOH:ACN)  
(both with 10 mM NH<sub>4</sub>OAc buffer)  
Ramp to 90% organic over 8 min and hold for  
2 min before returning to initial conditions in 0.75 min.  
Time: 12 min

Flow: 300  $\mu$ L/min

**MS Parameters:**

Experiment: Full Scan (225 - 850 amu)

Source: Electrospray (negative)  
Capillary Voltage (kV) = 0.50  
Cone Voltage (V) = 18.50  
Desolvation Temperature (°C) = 500  
Desolvation Gas Flow (L/hr) = 1000

**Figure 2: FPePA; LC/MS/MS Data (Selected MRM Transitions)****Conditions for Figure 2:**

Injection: On-column (FPePA)

Mobile phase: Same as Figure 1

Flow: 300  $\mu$ L/min**MS Parameters:**

Collision Gas (mbar) = 3.24e-3

Collision Energy (eV) = 10

# Analytical Standard Record

**21L0005**

Description:	PFAS - SAS 5:3FTA 50ug/mL	Expires:	06/05/2022
Standard Type:	Analyte Spike	Prepared:	12/07/2021
Solvent:	MeOH	Prepared By:	Hart Hedgpeth
Final Volume (mls):	1.2	Department:	PFAS
Vials:	1	Last Edit:	12/07/2021 16:03 by HGH
Comments:	5:3 FTCA 50.0ug/mL		


<b>Analyte</b>	<b>Parent</b>	<b>CAS Number</b>	<b>Concentration</b>	<b>Units</b>
5:3 FTA		914637-49-3	50	ug/mL



# WELLINGTON LABORATORIES

## CERTIFICATE OF ANALYSIS DOCUMENTATION

**PRODUCT CODE:** N-EtFOSE-M **LOT NUMBER:** NEtFOSE0921M  
**COMPOUND:** 2-(N-ethylperfluoro-1-octanesulfonamido)-ethanol  
**STRUCTURE:** **CAS #:** 1691-99-2



**MOLECULAR FORMULA:** C<sub>12</sub>H<sub>10</sub>F<sub>17</sub>NO<sub>3</sub>S **MOLECULAR WEIGHT:** 571.25  
**CONCENTRATION:** 50.0 ± 2.5 µg/mL **SOLVENT(S):** Methanol  
**CHEMICAL PURITY:** >98%  
**LAST TESTED:** (mm/dd/yyyy) 09/22/2021 (HRGC/LRMS)  
 09/23/2021 (LC/MS)  
**EXPIRY DATE:** (mm/dd/yyyy) 09/23/2026  
**RECOMMENDED STORAGE:** Store ampoule in a cool, dark place

### DOCUMENTATION/ DATA ATTACHED:

Figure 1: HRGC/LRMS Data (Full Scan and Mass Spectrum)  
 Figure 2: LC/MS Data (Full Scan and Mass Spectrum)  
 Figure 3: LC/MS/MS Data (Selected MRM Transitions)

### ADDITIONAL INFORMATION:

- See page 2 for further details.
- In order to see the molecular ion (adduct free), the LC mobile phase should be free of ammonium acetate buffer.

**FOR LABORATORY USE ONLY: NOT FOR HUMAN OR DRUG USE**

Certified By:   
 B.G. Chittim, General Manager

Date: 10/20/2021  
 (mm/dd/yyyy)

Wellington Laboratories Inc., 345 Southgate Dr. Guelph ON N1G 3M5 CANADA  
 519-822-2436 • Fax: 519-822-2849 • info@well-labs.com



**INTENDED USE:**

The products prepared by Wellington Laboratories Inc. are for laboratory use only. This certified reference material (CRM) was designed to be used as a standard for the identification and/or quantification of the specific chemical compound it contains.

**HANDLING:**

This product should only be used by qualified personnel familiar with its potential hazards and trained in the handling of hazardous chemicals. Due care should be exercised to prevent unnecessary human contact or ingestion. All procedures should be carried out in a well-functioning fume hood and suitable gloves, eye protection, and clothing should be worn at all times. Waste should be disposed of according to national and regional regulations. Safety Data Sheets (SDSs) are available upon request.

**SYNTHESIS / CHARACTERIZATION:**

Our products are synthesized using single-product unambiguous routes whenever possible. They are then characterized, and their structures and purities confirmed, using a combination of the most relevant techniques, such as NMR, GC/MS, LC/MS/MS, SFC/UV/MS/MS, x-ray crystallography, and melting point. Isotopic purities of mass-labelled compounds are also confirmed using HRGC/HRMS and/or LC/MS/MS.

**HOMOGENEITY:**

Prior to solution preparation, crystalline material is tested for homogeneity using a variety of techniques (as stated above) and its solubility in a given diluent is taken into consideration. Duplicate solutions of a new product are prepared from the same crystalline lot and, after the addition of an appropriate internal standard, they are compared by GC/MS, LC/MS/MS, and/or SFC/UV/MS/MS. The relative response factors of the analyte of interest in each solution are required to be <5% RSD. New solution lots of existing products are compared to older lots in the same manner, which further confirms the homogeneity of the crystalline material as well as the stability and homogeneity of the solutions in the storage containers. In order to maintain the integrity of the assigned value(s), and associated uncertainty, the dilution or injection of a subsample of this product should be performed using calibrated measuring equipment.

**UNCERTAINTY:**

The maximum combined relative standard uncertainty of our reference standard solutions is calculated using the following equation:

The combined relative standard uncertainty,  $u_c(y)$ , of a value  $y$  and the uncertainty of the independent parameters  $x_1, x_2, \dots, x_n$  on which it depends is:

$$u_c(y(x_1, x_2, \dots, x_n)) = \sqrt{\sum_{i=1}^n u(y, x_i)^2}$$

where  $x$  is expressed as a relative standard uncertainty of the individual parameter.

The individual uncertainties taken into account include those associated with weights (calibration of the balance) and volumes (calibration of the volumetric glassware). An expanded maximum combined percent relative uncertainty of  $\pm 5\%$  (calculated with a coverage factor of 2 and a level of confidence of 95%) is stated on the Certificate of Analysis for all of our products.

**TRACEABILITY:**

All reference standard solutions are traceable to specific crystalline lots. The microbalances used for solution preparation are regularly calibrated by an external ISO/IEC 17025 accredited laboratory. In addition, their calibration is verified prior to each weighing using calibrated external weights traceable to an ISO/IEC 17025 accredited laboratory. All volumetric glassware used is calibrated, of Class A tolerance, and traceable to an ISO/IEC 17025 accredited laboratory. For certain products, traceability to international interlaboratory studies has also been established.

**EXPIRY DATE / PERIOD OF VALIDITY:**

Ongoing stability studies of this product have demonstrated stability in its composition and concentration, until the specified expiry date, in the unopened ampoule. Monitoring for any degradation or change in concentration of the listed analyte(s) is performed on a routine basis.

**LIMITED WARRANTY:**


At the time of shipment, all products are warranted to be free of defects in material and workmanship and to conform to the stated technical and purity specifications.

**QUALITY MANAGEMENT:**

This product was produced using a Quality Management System registered to the latest versions of ISO 9001 by SAI Global, ISO/IEC 17025 by the Canadian Association for Laboratory Accreditation Inc. (CALA; A1226), and ISO 17034 by ANSI National Accreditation Board (ANAB; AR-1523).



\*\*For additional information or assistance concerning this or any other products from Wellington Laboratories Inc., please visit our website at [www.well-labs.com](http://www.well-labs.com) or contact us directly at [info@well-labs.com](mailto:info@well-labs.com)\*\*

**Figure 1: N-EtFOSE-M; HRGC/LRMS Data (Full Scan and Mass Spectrum)****Conditions for Figure 1:**

Agilent 7890A HRGC  
 Agilent 5975C MSD

**Chromatographic Conditions:**

Column: 30 m DB-5 (0.25 mm id, 0.25  $\mu$ m film thickness) Agilent J&W



Flow: Constant at 1 mL/min

Injector: 250°C (Splitless Injection)

Oven: 100°C (5 min)  
 10°C/min to 325°C  
 325°C (10 min)

Ionization: EI+

Detector: 230°C  
 Full Scan (50-1000 amu)

**Figure 2: N-EtFOSE-M; LC/MS Data (Full Scan and Mass Spectrum)****Conditions for Figure 2:**

Waters Acquity Ultra Performance LC  
Waters Xevo TQ-S micro MS

**Chromatographic Conditions:**

Column: Acquity UPLC BEH Shield RP<sub>18</sub>  
1.7 µm, 2.1 x 100 mm

Mobile phase: Gradient

Start: 30% H<sub>2</sub>O / 70% MeOH

Ramp to 90% organic over 8 min and hold for  
1.5 min before returning to initial conditions in 1 min.

Time: 12 min

Flow: 300 µL/min

**MS Parameters:**

Experiment: Full Scan (250 - 850 amu)


Source: Electrospray (negative)

Capillary Voltage (kV) = 2.00

Cone Voltage (V) = 65.00

Desolvation Temperature (°C) = 450

Desolvation Gas Flow (L/hr) = 1000

**Figure 3:** N-EtFOSE-M; LC/MS/MS Data (Selected MRM Transitions)**Conditions for Figure 3:**

Injection: On-column (N-EtFOSE-M)

Mobile phase: Same as Figure 2

Flow: 300  $\mu$ L/min**MS Parameters:**

Collision Gas (mbar) = 3.14e-3

Collision Energy (eV) = 32

f

t

# Analytical Standard Record

**21L0006**

Description:	PFAS - SAS EtFOSE 50ug/mL	Expires:	06/05/2022
Standard Type:	Analyte Spike	Prepared:	12/07/2021
Solvent:	MeOH	Prepared By:	Hart Hedgpeth
Final Volume (mls):	1.2	Department:	PFAS
Vials:	1	Last Edit:	12/07/2021 17:22 by HGH
Comments:	5:3 FTCA 50.0ug/mL		

<b>Analyte</b>	<b>Parent</b>	<b>CAS Number</b>	<b>Concentration</b>	<b>Units</b>
N-ETFOSE		1691-99-2	50	ug/mL




# WELLINGTON LABORATORIES

## CERTIFICATE OF ANALYSIS DOCUMENTATION

**PRODUCT CODE:** FHpPA **LOT NUMBER:** FHpPA1020  
**COMPOUND:** 3-Perfluoroheptyl propanoic acid

**STRUCTURE:** **CAS #:** 812-70-4



**MOLECULAR FORMULA:**  $C_{10}H_6F_{16}O_2$  **MOLECULAR WEIGHT:** 442.12  
**CONCENTRATION:**  $50.0 \pm 2.5 \mu\text{g/mL}$  **SOLVENT(S):** Methanol  
**CHEMICAL PURITY:** >98%  
**LAST TESTED:** (mm/dd/yyyy) 11/12/2020  
**EXPIRY DATE:** (mm/dd/yyyy) 11/12/2025  
**RECOMMENDED STORAGE:** Refrigerate ampoule

### DOCUMENTATION/ DATA ATTACHED:

Figure 1: LC/MS Data (TIC and Mass Spectrum)  
 Figure 2: LC/MS/MS Data (Selected MRM Transitions)

### ADDITIONAL INFORMATION:

- See page 2 for further details.

**FOR LABORATORY USE ONLY: NOT FOR HUMAN OR DRUG USE**

Certified By:   
 B.G. Chittim, General Manager

Date: 11/27/2020  
 (mm/dd/yyyy)

Wellington Laboratories Inc., 345 Southgate Dr. Guelph ON N1G 3M5 CANADA  
 519-822-2436 • Fax: 519-822-2849 • info@well-labs.com

**INTENDED USE:**

The products prepared by Wellington Laboratories Inc. are for laboratory use only. This certified reference material (CRM) was designed to be used as a standard for the identification and/or quantification of the specific chemical compound it contains.

**HANDLING:**

This product should only be used by qualified personnel familiar with its potential hazards and trained in the handling of hazardous chemicals. Due care should be exercised to prevent unnecessary human contact or ingestion. All procedures should be carried out in a well-functioning fume hood and suitable gloves, eye protection, and clothing should be worn at all times. Waste should be disposed of according to national and regional regulations. Safety Data Sheets (SDSs) are available upon request.

**SYNTHESIS / CHARACTERIZATION:**

Our products are synthesized using single-product unambiguous routes whenever possible. They are then characterized, and their structures and purities confirmed, using a combination of the most relevant techniques, such as NMR, GC/MS, LC/MS/MS, SFC/UV/MS/MS, x-ray crystallography, and melting point. Isotopic purities of mass-labelled compounds are also confirmed using HRGC/HRMS and/or LC/MS/MS.

**HOMOGENEITY:**

Prior to solution preparation, crystalline material is tested for homogeneity using a variety of techniques (as stated above) and its solubility in a given diluent is taken into consideration. Duplicate solutions of a new product are prepared from the same crystalline lot and, after the addition of an appropriate internal standard, they are compared by GC/MS, LC/MS/MS, and/or SFC/UV/MS/MS. The relative response factors of the analyte of interest in each solution are required to be <5% RSD. New solution lots of existing products are compared to older lots in the same manner, which further confirms the homogeneity of the crystalline material as well as the stability and homogeneity of the solutions in the storage containers. In order to maintain the integrity of the assigned value(s), and associated uncertainty, the dilution or injection of a subsample of this product should be performed using calibrated measuring equipment.

**UNCERTAINTY:**

The maximum combined relative standard uncertainty of our reference standard solutions is calculated using the following equation:

The combined relative standard uncertainty,  $u_c(y)$ , of a value  $y$  and the uncertainty of the independent parameters

$x_1, x_2, \dots, x_n$  on which it depends is:

$$u_c(y(x_1, x_2, \dots, x_n)) = \sqrt{\sum_{i=1}^n u(y, x_i)^2}$$

where  $x$  is expressed as a relative standard uncertainty of the individual parameter.

The individual uncertainties taken into account include those associated with weights (calibration of the balance) and volumes (calibration of the volumetric glassware). An expanded maximum combined percent relative uncertainty of  $\pm 5\%$  (calculated with a coverage factor of 2 and a level of confidence of 95%) is stated on the Certificate of Analysis for all of our products.

**TRACEABILITY:**

All reference standard solutions are traceable to specific crystalline lots. The microbalances used for solution preparation are regularly calibrated by an external ISO/IEC 17025 accredited laboratory. In addition, their calibration is verified prior to each weighing using calibrated external weights traceable to an ISO/IEC 17025 accredited laboratory. All volumetric glassware used is calibrated, of Class A tolerance, and traceable to an ISO/IEC 17025 accredited laboratory. For certain products, traceability to international interlaboratory studies has also been established.

**EXPIRY DATE / PERIOD OF VALIDITY:**

Ongoing stability studies of this product have demonstrated stability in its composition and concentration, until the specified expiry date, in the unopened ampoule. Monitoring for any degradation or change in concentration of the listed analyte(s) is performed on a routine basis.

**LIMITED WARRANTY:**

At the time of shipment, all products are warranted to be free of defects in material and workmanship and to conform to the stated technical and purity specifications.



**QUALITY MANAGEMENT:**

This product was produced using a Quality Management System registered to the latest versions of ISO 9001 by SAI Global, ISO/IEC 17025 by the Canadian Association for Laboratory Accreditation Inc. (CALA; A1226), and ISO 17034 by ANSI-ASQ National Accreditation Board (ANAB; AR-1523).



\*\*For additional information or assistance concerning this or any other products from Wellington Laboratories Inc., please visit our website at [www.well-labs.com](http://www.well-labs.com) or contact us directly at [info@well-labs.com](mailto:info@well-labs.com)\*\*



**Figure 1: FHpPA; LC/MS Data (TIC and Mass Spectrum)****Conditions for Figure 1:**

Waters Acquity Ultra Performance LC  
Waters Xevo TQ-S micro MS

**Chromatographic Conditions:**

Column: Acquity UPLC BEH Shield RP<sub>18</sub>  
1.7  $\mu$ m, 2.1 x 100 mm


Mobile phase: Gradient  
Start: 45% H<sub>2</sub>O / 55% (80:20 MeOH:ACN)  
(both with 10 mM NH<sub>4</sub>OAc buffer)  
Ramp to 90% organic over 8 min and hold for  
2 min before returning to initial conditions in 0.75 min.  
Time: 12 min

Flow: 300  $\mu$ L/min

**MS Parameters:**

Experiment: Full Scan (225 - 850 amu)

Source: Electrospray (negative)  
Capillary Voltage (kV) = 0.50  
Cone Voltage (V) = 28.50  
Desolvation Temperature (°C) = 500  
Desolvation Gas Flow (L/hr) = 1000

**Figure 2: FHpPA; LC/MS/MS Data (Selected MRM Transitions)****Conditions for Figure 2:**

Injection: On-column (FHpPA)

Mobile phase: Same as Figure 1

Flow: 300  $\mu$ L/min**MS Parameters:**

Collision Gas (mbar) = 3.41e-3

Collision Energy (eV) = 8

# Analytical Standard Record

**21L0007**

Description:	PFAS - SAS 7:3FTA 50ug/mL	Expires:	06/05/2022
Standard Type:	Analyte Spike	Prepared:	12/07/2021
Solvent:	MeOH	Prepared By:	Hart Hedgpeth
Final Volume (mls):	1.2	Department:	PFAS
Vials:	1	Last Edit:	12/07/2021 16:16 by HGH
Comments:	7:3 FTCA 50.0ug/mL		

<b>Analyte</b>	<b>Parent</b>	<b>CAS Number</b>	<b>Concentration</b>	<b>Units</b>
7:3 FTA		812-70-4	50	ug/mL




# WELLINGTON LABORATORIES

## CERTIFICATE OF ANALYSIS DOCUMENTATION

**PRODUCT CODE:** N-MeFOSA-M **LOT NUMBER:** NMeFOSA0721M  
**COMPOUND:** N-methylperfluoro-1-octanesulfonamide

**STRUCTURE:** **CAS #:** 31506-32-8



**MOLECULAR FORMULA:**  $C_9H_4F_{17}NO_2S$  **MOLECULAR WEIGHT:** 513.17  
**CONCENTRATION:**  $50.0 \pm 2.5 \mu\text{g/mL}$  **SOLVENT(S):** Methanol  
**CHEMICAL PURITY:** >98%  
**LAST TESTED:** (mm/dd/yyyy) 08/03/2021  
**EXPIRY DATE:** (mm/dd/yyyy) 08/03/2026  
**RECOMMENDED STORAGE:** Store ampoule in a cool, dark place

### DOCUMENTATION/ DATA ATTACHED:

Figure 1: LC/MS Data (Full Scan and Mass Spectrum)  
 Figure 2: LC/MS/MS Data (Selected MRM Transitions)

### ADDITIONAL INFORMATION:

- See page 2 for further details.

**FOR LABORATORY USE ONLY: NOT FOR HUMAN OR DRUG USE**

**Certified By:**   
 B.G. Chittim, General Manager **Date:** 08/04/2021  
 (mm/dd/yyyy)

Wellington Laboratories Inc., 345 Southgate Dr. Guelph ON N1G 3M5 CANADA  
 519-822-2436 • Fax: 519-822-2849 • info@well-labs.com

**INTENDED USE:**

The products prepared by Wellington Laboratories Inc. are for laboratory use only. This certified reference material (CRM) was designed to be used as a standard for the identification and/or quantification of the specific chemical compound it contains.

**HANDLING:**

This product should only be used by qualified personnel familiar with its potential hazards and trained in the handling of hazardous chemicals. Due care should be exercised to prevent unnecessary human contact or ingestion. All procedures should be carried out in a well-functioning fume hood and suitable gloves, eye protection, and clothing should be worn at all times. Waste should be disposed of according to national and regional regulations. Safety Data Sheets (SDSs) are available upon request.

**SYNTHESIS / CHARACTERIZATION:**

Our products are synthesized using single-product unambiguous routes whenever possible. They are then characterized, and their structures and purities confirmed, using a combination of the most relevant techniques, such as NMR, GC/MS, LC/MS/MS, SFC/UV/MS/MS, x-ray crystallography, and melting point. Isotopic purities of mass-labelled compounds are also confirmed using HRGC/HRMS and/or LC/MS/MS.

**HOMOGENEITY:**

Prior to solution preparation, crystalline material is tested for homogeneity using a variety of techniques (as stated above) and its solubility in a given diluent is taken into consideration. Duplicate solutions of a new product are prepared from the same crystalline lot and, after the addition of an appropriate internal standard, they are compared by GC/MS, LC/MS/MS, and/or SFC/UV/MS/MS. The relative response factors of the analyte of interest in each solution are required to be <5% RSD. New solution lots of existing products are compared to older lots in the same manner, which further confirms the homogeneity of the crystalline material as well as the stability and homogeneity of the solutions in the storage containers. In order to maintain the integrity of the assigned value(s), and associated uncertainty, the dilution or injection of a subsample of this product should be performed using calibrated measuring equipment.

**UNCERTAINTY:**

The maximum combined relative standard uncertainty of our reference standard solutions is calculated using the following equation:

The combined relative standard uncertainty,  $u_c(y)$ , of a value  $y$  and the uncertainty of the independent parameters  $x_1, x_2, \dots, x_n$  on which it depends is:

$$u_c(y(x_1, x_2, \dots, x_n)) = \sqrt{\sum_{i=1}^n u(y, x_i)^2}$$

where  $x$  is expressed as a relative standard uncertainty of the individual parameter.

The individual uncertainties taken into account include those associated with weights (calibration of the balance) and volumes (calibration of the volumetric glassware). An expanded maximum combined percent relative uncertainty of  $\pm 5\%$  (calculated with a coverage factor of 2 and a level of confidence of 95%) is stated on the Certificate of Analysis for all of our products.

**TRACEABILITY:**

All reference standard solutions are traceable to specific crystalline lots. The microbalances used for solution preparation are regularly calibrated by an external ISO/IEC 17025 accredited laboratory. In addition, their calibration is verified prior to each weighing using calibrated external weights traceable to an ISO/IEC 17025 accredited laboratory. All volumetric glassware used is calibrated, of Class A tolerance, and traceable to an ISO/IEC 17025 accredited laboratory. For certain products, traceability to international interlaboratory studies has also been established.

**EXPIRY DATE / PERIOD OF VALIDITY:**

Ongoing stability studies of this product have demonstrated stability in its composition and concentration, until the specified expiry date, in the unopened ampoule. Monitoring for any degradation or change in concentration of the listed analyte(s) is performed on a routine basis.

**LIMITED WARRANTY:**



At the time of shipment, all products are warranted to be free of defects in material and workmanship and to conform to the stated technical and purity specifications.

**QUALITY MANAGEMENT:**

This product was produced using a Quality Management System registered to the latest versions of ISO 9001 by SAI Global, ISO/IEC 17025 by the Canadian Association for Laboratory Accreditation Inc. (CALA; A1226), and ISO 17034 by ANSI National Accreditation Board (ANAB; AR-1523).



\*\*For additional information or assistance concerning this or any other products from Wellington Laboratories Inc., please visit our website at [www.well-labs.com](http://www.well-labs.com) or contact us directly at [info@well-labs.com](mailto:info@well-labs.com)\*\*

**Figure 1: N-MeFOSA-M; LC/MS Data (Full Scan and Mass Spectrum)****Conditions for Figure 1:**

Waters Acquity Ultra Performance LC  
Waters Xevo TQ-S micro MS

**Chromatographic Conditions:**

Column: Acquity UPLC BEH Shield RP<sub>18</sub>  
1.7  $\mu$ m, 2.1 x 100 mm


Mobile phase: Gradient  
Start: 40% H<sub>2</sub>O / 60% (80:20 MeOH:ACN)  
(both with 10 mM NH<sub>4</sub>OAc buffer)  
Ramp to 90% organic over 8 min and hold for  
2 min before returning to initial conditions in 0.75 min.  
Time: 12 min

Flow: 300  $\mu$ L/min

**MS Parameters:**

Experiment: Full Scan (250 - 850 amu)

Source: Electrospray (negative)  
Capillary Voltage (kV) = 1.00  
Cone Voltage (V) = 44.00  
Desolvation Temperature (°C) = 500  
Desolvation Gas Flow (L/hr) = 1000

**Figure 2: N-MeFOSA-M; LC/MS/MS Data (Selected MRM Transitions)****Conditions for Figure 2:**

Injection: On-column (N-MeFOSA-M)

Mobile phase: Same as Figure 1

Flow: 300  $\mu$ L/min**MS Parameters:**

Collision Gas (mbar) = 3.41e-3

Collision Energy (eV) = 24

# Analytical Standard Record

**21L0008**

Description:	PFAS - SAS N-MeFOSA 50ug/mL	Expires:	06/05/2022
Standard Type:	Analyte Spike	Prepared:	12/07/2021
Solvent:	MeOH	Prepared By:	Hart Hedgpeth
Final Volume (mls):	1	Department:	PFAS
Vials:	1	Last Edit:	12/07/2021 16:18 by HGH

<b>Analyte</b>	<b>Parent</b>	<b>CAS Number</b>	<b>Concentration</b>	<b>Units</b>
N-MEFOSA		31506-32-8	50	ug/mL






# WELLINGTON LABORATORIES

## CERTIFICATE OF ANALYSIS DOCUMENTATION

**PRODUCT CODE:** M3PFBA **LOT NUMBER:** M3PFBA0721  
**COMPOUND:** Perfluoro-n-(2,3,4-<sup>13</sup>C<sub>3</sub>)butanoic acid

**STRUCTURE:** **CAS #:** Not available



**MOLECULAR FORMULA:** <sup>13</sup>C<sub>3</sub><sup>12</sup>CHF<sub>7</sub>O<sub>2</sub> **MOLECULAR WEIGHT:** 217.02  
**CONCENTRATION:** 50.0 ± 2.5 µg/mL **SOLVENT(S):** Methanol  
 Water (<1%)  
**CHEMICAL PURITY:** >98% **ISOTOPIC PURITY:** ≥99%<sup>13</sup>C  
 (2,3,4-<sup>13</sup>C<sub>3</sub>)  
**LAST TESTED:** (mm/dd/yyyy) 08/19/2021  
**EXPIRY DATE:** (mm/dd/yyyy) 08/19/2026  
**RECOMMENDED STORAGE:** Store ampoule in a cool, dark place

### DOCUMENTATION/ DATA ATTACHED:

Figure 1: LC/MS Data (Full Scan and Mass Spectrum)  
 Figure 2: LC/MS/MS Data (Selected MRM Transitions)

### ADDITIONAL INFORMATION:

- See page 2 for further details.
- Contains 4 mole eq. of NaOH to prevent conversion of the carboxylic acid to the methyl ester.
- Contains ~0.2% of perfluoro-n-(<sup>13</sup>C<sub>3</sub>)propanoic acid and also contains ~1.0% of perfluoro-n-(1,2,3,4-<sup>13</sup>C<sub>4</sub>)butanoic acid due to the naturally occurring isotopic abundance of <sup>13</sup>C in the unlabelled carbon atom.

**FOR LABORATORY USE ONLY: NOT FOR HUMAN OR DRUG USE**

**Certified By:**   
 B.G. Chittim, General Manager

**Date:** 08/25/2021  
 (mm/dd/yyyy)

Wellington Laboratories Inc., 345 Southgate Dr. Guelph ON N1G 3M5 CANADA  
 519-822-2436 • Fax: 519-822-2849 • info@well-labs.com

**INTENDED USE:**

The products prepared by Wellington Laboratories Inc. are for laboratory use only. This certified reference material (CRM) was designed to be used as a standard for the identification and/or quantification of the specific chemical compound it contains.

**HANDLING:**

This product should only be used by qualified personnel familiar with its potential hazards and trained in the handling of hazardous chemicals. Due care should be exercised to prevent unnecessary human contact or ingestion. All procedures should be carried out in a well-functioning fume hood and suitable gloves, eye protection, and clothing should be worn at all times. Waste should be disposed of according to national and regional regulations. Safety Data Sheets (SDSs) are available upon request.

**SYNTHESIS / CHARACTERIZATION:**

Our products are synthesized using single-product unambiguous routes whenever possible. They are then characterized, and their structures and purities confirmed, using a combination of the most relevant techniques, such as NMR, GC/MS, LC/MS/MS, SFC/UV/MS/MS, x-ray crystallography, and melting point. Isotopic purities of mass-labelled compounds are also confirmed using HRGC/HRMS and/or LC/MS/MS.

**HOMOGENEITY:**

Prior to solution preparation, crystalline material is tested for homogeneity using a variety of techniques (as stated above) and its solubility in a given diluent is taken into consideration. Duplicate solutions of a new product are prepared from the same crystalline lot and, after the addition of an appropriate internal standard, they are compared by GC/MS, LC/MS/MS, and/or SFC/UV/MS/MS. The relative response factors of the analyte of interest in each solution are required to be <5% RSD. New solution lots of existing products are compared to older lots in the same manner, which further confirms the homogeneity of the crystalline material as well as the stability and homogeneity of the solutions in the storage containers. In order to maintain the integrity of the assigned value(s), and associated uncertainty, the dilution or injection of a subsample of this product should be performed using calibrated measuring equipment.

**UNCERTAINTY:**

The maximum combined relative standard uncertainty of our reference standard solutions is calculated using the following equation:

The combined relative standard uncertainty,  $u_c(y)$ , of a value  $y$  and the uncertainty of the independent parameters

$x_1, x_2, \dots, x_n$  on which it depends is:

$$u_c(y(x_1, x_2, \dots, x_n)) = \sqrt{\sum_{i=1}^n u(y, x_i)^2}$$

where  $x$  is expressed as a relative standard uncertainty of the individual parameter.

The individual uncertainties taken into account include those associated with weights (calibration of the balance) and volumes (calibration of the volumetric glassware). An expanded maximum combined percent relative uncertainty of  $\pm 5\%$  (calculated with a coverage factor of 2 and a level of confidence of 95%) is stated on the Certificate of Analysis for all of our products.

**TRACEABILITY:**

All reference standard solutions are traceable to specific crystalline lots. The microbalances used for solution preparation are regularly calibrated by an external ISO/IEC 17025 accredited laboratory. In addition, their calibration is verified prior to each weighing using calibrated external weights traceable to an ISO/IEC 17025 accredited laboratory. All volumetric glassware used is calibrated, of Class A tolerance, and traceable to an ISO/IEC 17025 accredited laboratory. For certain products, traceability to international interlaboratory studies has also been established.

**EXPIRY DATE / PERIOD OF VALIDITY:**

Ongoing stability studies of this product have demonstrated stability in its composition and concentration, until the specified expiry date, in the unopened ampoule. Monitoring for any degradation or change in concentration of the listed analyte(s) is performed on a routine basis.

**LIMITED WARRANTY:**



At the time of shipment, all products are warranted to be free of defects in material and workmanship and to conform to the stated technical and purity specifications.

**QUALITY MANAGEMENT:**

This product was produced using a Quality Management System registered to the latest versions of ISO 9001 by SAI Global, ISO/IEC 17025 by the Canadian Association for Laboratory Accreditation Inc. (CALA; A1226), and ISO 17034 by ANSI National Accreditation Board (ANAB; AR-1523).



\*\*For additional information or assistance concerning this or any other products from Wellington Laboratories Inc., please visit our website at [www.well-labs.com](http://www.well-labs.com) or contact us directly at [info@well-labs.com](mailto:info@well-labs.com)\*\*

**Figure 1: M3PFBA; LC/MS Data (Full Scan and Mass Spectrum)****Conditions for Figure 1:**

Waters Acquity Ultra Performance LC  
Waters Xevo TQ-S micro MS

**Chromatographic Conditions:**

Column: Acquity UPLC BEH Shield RP<sub>18</sub>  
1.7  $\mu$ m, 2.1 x 100 mm


Mobile phase: Gradient  
Start: 60% H<sub>2</sub>O / 40% (80:20 MeOH:ACN)  
(both with 10 mM NH<sub>4</sub>OAc buffer)  
Ramp to 90% organic over 8 min and hold for  
2 min before returning to initial conditions in 0.5 min.  
Time: 12 min

Flow: 300  $\mu$ L/min

**MS Parameters:**

Experiment: Full Scan (150 - 850 amu)

Source: Electrospray (negative)  
Capillary Voltage (kV) = 2.00  
Cone Voltage (V) = 10.00  
Desolvation Temperature ( $^{\circ}$ C) = 500  
Desolvation Gas Flow (L/hr) = 1000

**Figure 2: M3PFBA; LC/MS/MS Data (Selected MRM Transitions)****Conditions for Figure 2:**

Injection: On-column (M3PFBA)

Mobile phase: Same as Figure 1

Flow: 300  $\mu\text{L}/\text{min}$ **MS Parameters:**

Collision Gas (mbar) = 3.45e-3

Collision Energy (eV) = 8

# Analytical Standard Record

**22A0116**

Description:	PFAS - IIS M3PFBA 50ug/mL	Expires:	08/19/2026
Standard Type:	Analyte Spike	Prepared:	08/19/2021
Solvent:	MeOH	Prepared By:	Dipti Gokal
Final Volume (mls):	1.2	Department:	PFAS
Vials:	1	Last Edit:	01/20/2022 15:48 by HGH


<b>Analyte</b>	<b>Parent</b>	<b>CAS Number</b>	<b>Concentration</b>	<b>Units</b>
13C3-PFBA		13C3-PFBA	50	ug/mL



# WELLINGTON LABORATORIES

## CERTIFICATE OF ANALYSIS DOCUMENTATION

**PRODUCT CODE:** MPFHxA **LOT NUMBER:** MPFHxA0921  
**COMPOUND:** Perfluoro-n-(1,2-<sup>13</sup>C<sub>2</sub>)hexanoic acid  
**STRUCTURE:** **CAS #:** 960315-47-3



**MOLECULAR FORMULA:** <sup>13</sup>C<sub>2</sub><sup>12</sup>C<sub>4</sub>HF<sub>11</sub>O<sub>2</sub> **MOLECULAR WEIGHT:** 316.04  
**CONCENTRATION:** 50.0 ± 2.5 µg/mL **SOLVENT(S):** Methanol  
 Water (<1%)  
**CHEMICAL PURITY:** >98% **ISOTOPIC PURITY:** ≥99% <sup>13</sup>C  
 (1,2-<sup>13</sup>C<sub>2</sub>)  
**LAST TESTED:** (mm/dd/yyyy) 10/04/2021  
**EXPIRY DATE:** (mm/dd/yyyy) 10/04/2026  
**RECOMMENDED STORAGE:** Store ampoule in a cool, dark place

### DOCUMENTATION/ DATA ATTACHED:

Figure 1: LC/MS Data (Full Scan and Mass Spectrum)  
 Figure 2: LC/MS/MS Data (Selected MRM Transitions)

### ADDITIONAL INFORMATION:

- See page 2 for further details.
- Contains 4 mole eq. of NaOH to prevent conversion of the carboxylic acid to the methyl ester.

**FOR LABORATORY USE ONLY: NOT FOR HUMAN OR DRUG USE**

Certified By: \_\_\_\_\_

B.G. Chittim, General Manager

Date: 10/22/2021  
 (mm/dd/yyyy)

Wellington Laboratories Inc., 345 Southgate Dr. Guelph ON N1G 3M5 CANADA  
 519-822-2436 • Fax: 519-822-2849 • info@well-labs.com

**INTENDED USE:**

The products prepared by Wellington Laboratories Inc. are for laboratory use only. This certified reference material (CRM) was designed to be used as a standard for the identification and/or quantification of the specific chemical compound it contains.

**HANDLING:**

This product should only be used by qualified personnel familiar with its potential hazards and trained in the handling of hazardous chemicals. Due care should be exercised to prevent unnecessary human contact or ingestion. All procedures should be carried out in a well-functioning fume hood and suitable gloves, eye protection, and clothing should be worn at all times. Waste should be disposed of according to national and regional regulations. Safety Data Sheets (SDSs) are available upon request.

**SYNTHESIS / CHARACTERIZATION:**

Our products are synthesized using single-product unambiguous routes whenever possible. They are then characterized, and their structures and purities confirmed, using a combination of the most relevant techniques, such as NMR, GC/MS, LC/MS/MS, SFC/UV/MS/MS, x-ray crystallography, and melting point. Isotopic purities of mass-labelled compounds are also confirmed using HRGC/HRMS and/or LC/MS/MS.

**HOMOGENEITY:**

Prior to solution preparation, crystalline material is tested for homogeneity using a variety of techniques (as stated above) and its solubility in a given diluent is taken into consideration. Duplicate solutions of a new product are prepared from the same crystalline lot and, after the addition of an appropriate internal standard, they are compared by GC/MS, LC/MS/MS, and/or SFC/UV/MS/MS. The relative response factors of the analyte of interest in each solution are required to be <5% RSD. New solution lots of existing products are compared to older lots in the same manner, which further confirms the homogeneity of the crystalline material as well as the stability and homogeneity of the solutions in the storage containers. In order to maintain the integrity of the assigned value(s), and associated uncertainty, the dilution or injection of a subsample of this product should be performed using calibrated measuring equipment.

**UNCERTAINTY:**

The maximum combined relative standard uncertainty of our reference standard solutions is calculated using the following equation:

The combined relative standard uncertainty,  $u_c(y)$ , of a value  $y$  and the uncertainty of the independent parameters  $x_1, x_2, \dots, x_n$  on which it depends is:

$$u_c(y(x_1, x_2, \dots, x_n)) = \sqrt{\sum_{i=1}^n u(y, x_i)^2}$$

where  $x$  is expressed as a relative standard uncertainty of the individual parameter.

The individual uncertainties taken into account include those associated with weights (calibration of the balance) and volumes (calibration of the volumetric glassware). An expanded maximum combined percent relative uncertainty of  $\pm 5\%$  (calculated with a coverage factor of 2 and a level of confidence of 95%) is stated on the Certificate of Analysis for all of our products.

**TRACEABILITY:**

All reference standard solutions are traceable to specific crystalline lots. The microbalances used for solution preparation are regularly calibrated by an external ISO/IEC 17025 accredited laboratory. In addition, their calibration is verified prior to each weighing using calibrated external weights traceable to an ISO/IEC 17025 accredited laboratory. All volumetric glassware used is calibrated, of Class A tolerance, and traceable to an ISO/IEC 17025 accredited laboratory. For certain products, traceability to international interlaboratory studies has also been established.

**EXPIRY DATE / PERIOD OF VALIDITY:**

Ongoing stability studies of this product have demonstrated stability in its composition and concentration, until the specified expiry date, in the unopened ampoule. Monitoring for any degradation or change in concentration of the listed analyte(s) is performed on a routine basis.

**LIMITED WARRANTY:**



At the time of shipment, all products are warranted to be free of defects in material and workmanship and to conform to the stated technical and purity specifications.

**QUALITY MANAGEMENT:**

This product was produced using a Quality Management System registered to the latest versions of ISO 9001 by SAI Global, ISO/IEC 17025 by the Canadian Association for Laboratory Accreditation Inc. (CALA; A1226), and ISO 17034 by ANSI National Accreditation Board (ANAB; AR-1523).



\*\*For additional information or assistance concerning this or any other products from Wellington Laboratories Inc., please visit our website at [www.well-labs.com](http://www.well-labs.com) or contact us directly at [info@well-labs.com](mailto:info@well-labs.com)\*\*

**Figure 1: MPFHxA; LC/MS Data (Full Scan and Mass Spectrum)****Conditions for Figure 1:**

Waters Acquity Ultra Performance LC  
Waters Xevo TQ-S micro MS

**Chromatographic Conditions:**

Column: Acquity UPLC BEH Shield RP<sub>18</sub>  
1.7  $\mu$ m, 2.1 x 100 mm

Mobile phase: Gradient  
Start: 50% H<sub>2</sub>O / 50% (80:20 MeOH:ACN)  
(both with 10 mM NH<sub>4</sub>OAc buffer)  
Ramp to 90% organic over 7 min and hold for  
2 min before returning to initial conditions in 1 min.  
Time: 12 min


Flow: 300  $\mu$ L/min

**MS Parameters:**

Experiment: Full Scan (225 - 850 amu)

Source: Electrospray (negative)  
Capillary Voltage (kV) = 2.00  
Cone Voltage (V) = 10.00  
Desolvation Temperature (°C) = 500  
Desolvation Gas Flow (L/hr) = 1000



**Figure 2: MPFHxA; LC/MS/MS Data (Selected MRM Transitions)****Conditions for Figure 2:**

Injection: On-column (MPFHxA)

Mobile phase: Same as Figure 1

Flow: 300  $\mu\text{L}/\text{min}$ **MS Parameters:**

Collision Gas (mbar) = 3.31e-3

Collision Energy (eV) = 8

# Analytical Standard Record

**22A0117**

Description:	PFAS - IIS MPFHxA 50ug/mL	Expires:	10/04/2026
Standard Type:	Analyte Spike	Prepared:	10/04/2021
Solvent:	MeOH	Prepared By:	Dipti Gokal
Final Volume (mls):	1.2	Department:	PFAS
Vials:	1	Last Edit:	01/20/2022 15:48 by HGH

Analyte	Parent	CAS Number	Concentration	Units
13C2-PFHxA		13C2-PFHxA	50	ug/mL

# Analytical Standard Record

**22A0117**

Description:	PFAS - IIS MPFHxA 50ug/mL	Expires:	10/04/2026
Standard Type:	Analyte Spike	Prepared:	10/04/2021
Solvent:	MeOH	Prepared By:	Dipti Gokal
Final Volume (mls):	1.2	Department:	PFAS
Vials:	1	Last Edit:	01/20/2022 15:48 by HGH


<b>Analyte</b>	<b>Parent</b>	<b>CAS Number</b>	<b>Concentration</b>	<b>Units</b>
13C2-PFHxA		13C2-PFHxA	50	ug/mL



# WELLINGTON LABORATORIES

## CERTIFICATE OF ANALYSIS DOCUMENTATION

**PRODUCT CODE:** MPFNA **LOT NUMBER:** MPFNA1021  
**COMPOUND:** Perfluoro-n-(1,2,3,4,5-<sup>13</sup>C<sub>5</sub>)nonanoic acid  
**STRUCTURE:** **CAS #:** 960315-49-5



**MOLECULAR FORMULA:**  $^{13}\text{C}_5^{12}\text{C}_4\text{HF}_{17}\text{O}_2$  **MOLECULAR WEIGHT:** 469.04  
**CONCENTRATION:** 50.0 ± 2.5 µg/mL **SOLVENT(S):** Methanol  
 Water (<1%)  
**CHEMICAL PURITY:** >98% **ISOTOPIC PURITY:** ≥99% <sup>13</sup>C  
 (1,2,3,4,5-<sup>13</sup>C<sub>5</sub>)  
**LAST TESTED:** (mm/dd/yyyy) 10/29/2021  
**EXPIRY DATE:** (mm/dd/yyyy) 10/29/2026  
**RECOMMENDED STORAGE:** Store ampoule in a cool, dark place

### DOCUMENTATION/ DATA ATTACHED:

Figure 1: LC/MS Data (Full Scan and Mass Spectrum)  
 Figure 2: LC/MS/MS Data (Selected MRM Transitions)

### ADDITIONAL INFORMATION:

- See page 2 for further details.
- Contains 4 mole eq. of NaOH to prevent conversion of the carboxylic acid to the methyl ester.

**FOR LABORATORY USE ONLY: NOT FOR HUMAN OR DRUG USE**

Certified By:   
 B.G. Chittim, General Manager

Date: 11/01/2021  
 (mm/dd/yyyy)

Wellington Laboratories Inc., 345 Southgate Dr. Guelph ON N1G 3M5 CANADA  
 519-822-2436 • Fax: 519-822-2849 • info@well-labs.com

**INTENDED USE:**

The products prepared by Wellington Laboratories Inc. are for laboratory use only. This certified reference material (CRM) was designed to be used as a standard for the identification and/or quantification of the specific chemical compound it contains.

**HANDLING:**

This product should only be used by qualified personnel familiar with its potential hazards and trained in the handling of hazardous chemicals. Due care should be exercised to prevent unnecessary human contact or ingestion. All procedures should be carried out in a well-functioning fume hood and suitable gloves, eye protection, and clothing should be worn at all times. Waste should be disposed of according to national and regional regulations. Safety Data Sheets (SDSs) are available upon request.

**SYNTHESIS / CHARACTERIZATION:**

Our products are synthesized using single-product unambiguous routes whenever possible. They are then characterized, and their structures and purities confirmed, using a combination of the most relevant techniques, such as NMR, GC/MS, LC/MS/MS, SFC/UV/MS/MS, x-ray crystallography, and melting point. Isotopic purities of mass-labelled compounds are also confirmed using HRGC/HRMS and/or LC/MS/MS.

**HOMOGENEITY:**

Prior to solution preparation, crystalline material is tested for homogeneity using a variety of techniques (as stated above) and its solubility in a given diluent is taken into consideration. Duplicate solutions of a new product are prepared from the same crystalline lot and, after the addition of an appropriate internal standard, they are compared by GC/MS, LC/MS/MS, and/or SFC/UV/MS/MS. The relative response factors of the analyte of interest in each solution are required to be <5% RSD. New solution lots of existing products are compared to older lots in the same manner, which further confirms the homogeneity of the crystalline material as well as the stability and homogeneity of the solutions in the storage containers. In order to maintain the integrity of the assigned value(s), and associated uncertainty, the dilution or injection of a subsample of this product should be performed using calibrated measuring equipment.

**UNCERTAINTY:**

The maximum combined relative standard uncertainty of our reference standard solutions is calculated using the following equation:

The combined relative standard uncertainty,  $u_c(y)$ , of a value  $y$  and the uncertainty of the independent parameters  $x_1, x_2, \dots, x_n$ , on which it depends is:

$$u_c(y(x_1, x_2, \dots, x_n)) = \sqrt{\sum_{i=1}^n u(y, x_i)^2}$$

where  $x$  is expressed as a relative standard uncertainty of the individual parameter.

The individual uncertainties taken into account include those associated with weights (calibration of the balance) and volumes (calibration of the volumetric glassware). An expanded maximum combined percent relative uncertainty of  $\pm 5\%$  (calculated with a coverage factor of 2 and a level of confidence of 95%) is stated on the Certificate of Analysis for all of our products.

**TRACEABILITY:**

All reference standard solutions are traceable to specific crystalline lots. The microbalances used for solution preparation are regularly calibrated by an external ISO/IEC 17025 accredited laboratory. In addition, their calibration is verified prior to each weighing using calibrated external weights traceable to an ISO/IEC 17025 accredited laboratory. All volumetric glassware used is calibrated, of Class A tolerance, and traceable to an ISO/IEC 17025 accredited laboratory. For certain products, traceability to international interlaboratory studies has also been established.

**EXPIRY DATE / PERIOD OF VALIDITY:**

Ongoing stability studies of this product have demonstrated stability in its composition and concentration, until the specified expiry date, in the unopened ampoule. Monitoring for any degradation or change in concentration of the listed analyte(s) is performed on a routine basis.

**LIMITED WARRANTY:**



At the time of shipment, all products are warranted to be free of defects in material and workmanship and to conform to the stated technical and purity specifications.

**QUALITY MANAGEMENT:**

This product was produced using a Quality Management System registered to the latest versions of ISO 9001 by SAI Global, ISO/IEC 17025 by the Canadian Association for Laboratory Accreditation Inc. (CALA; A1226), and ISO 17034 by ANSI National Accreditation Board (ANAB; AR-1523).



\*\*For additional information or assistance concerning this or any other products from Wellington Laboratories Inc., please visit our website at [www.well-labs.com](http://www.well-labs.com) or contact us directly at [info@well-labs.com](mailto:info@well-labs.com)\*\*

**Figure 1: MPFNA; LC/MS Data (Full Scan and Mass Spectrum)****Conditions for Figure 1:**

Waters Acquity Ultra Performance LC  
Waters Xevo TQ-S micro MS

**Chromatographic Conditions:**

Column: Acquity UPLC BEH Shield RP<sub>18</sub>  
1.7  $\mu$ m, 2.1 x 100 mm

Mobile phase: Gradient

Start: 40% H<sub>2</sub>O / 60% (80:20 MeOH:ACN)  
(both with 10 mM NH<sub>4</sub>OAc buffer)  
Ramp to 90% organic over 8 min and hold for  
2 min before returning to initial conditions in 0.75 min.  
Time: 12 min

Flow: 300  $\mu$ L/min

**MS Parameters:**

Experiment: Full Scan (250 - 850 amu)


Source: Electrospray (negative)

Capillary Voltage (kV) = 2.00

Cone Voltage (V) = 10.00

Desolvation Temperature (°C) = 500

Desolvation Gas Flow (L/hr) = 1000

**Figure 2: MPFNA; LC/MS/MS Data (Selected MRM Transitions)****Conditions for Figure 2:**

Injection: On-column (MPFNA)

Mobile phase: Same as Figure 1

Flow: 300  $\mu\text{L}/\text{min}$ **MS Parameters:**

Collision Gas (mbar) = 3.16e-3

Collision Energy (eV) = 10

# Analytical Standard Record

**22A0118**

Description:	PFAS - IIS MPFNA 50ug/mL	Expires:	10/29/2026
Standard Type:	Analyte Spike	Prepared:	10/29/2021
Solvent:	MeOH	Prepared By:	Dipti Gokal
Final Volume (mls):	1.2	Department:	PFAS
Vials:	1	Last Edit:	01/20/2022 15:48 by HGH

<b>Analyte</b>	<b>Parent</b>	<b>CAS Number</b>	<b>Concentration</b>	<b>Units</b>
13C5-PFNA		13C5-PFNA	50	ug/mL



# Analytical Standard Record

**22A0118**

Description:	PFAS - IIS MPFNA 50ug/mL	Expires:	10/29/2026
Standard Type:	Analyte Spike	Prepared:	10/29/2021
Solvent:	MeOH	Prepared By:	Dipti Gokal
Final Volume (mls):	1.2	Department:	PFAS
Vials:	1	Last Edit:	01/20/2022 15:48 by HGH


Analyte	Parent	CAS Number	Concentration	Units
13C5-PFNA		13C5-PFNA	50	ug/mL



# WELLINGTON LABORATORIES

## CERTIFICATE OF ANALYSIS DOCUMENTATION

**PRODUCT CODE:** MPFOA      **LOT NUMBER:** MPFOA1121  
**COMPOUND:** Perfluoro-n-(1,2,3,4-<sup>13</sup>C<sub>4</sub>)octanoic acid  
**STRUCTURE:**      **CAS #:** 960315-48-4



**MOLECULAR FORMULA:** <sup>13</sup>C<sub>4</sub><sup>12</sup>C<sub>4</sub>HF<sub>15</sub>O<sub>2</sub>      **MOLECULAR WEIGHT:** 418.04  
**CONCENTRATION:** 50.0 ± 2.5 µg/mL      **SOLVENT(S):** Methanol  
Water (<1%)  
**CHEMICAL PURITY:** >98%      **ISOTOPIC PURITY:** ≥99% <sup>13</sup>C  
(1,2,3,4-<sup>13</sup>C<sub>4</sub>)  
**LAST TESTED:** (mm/dd/yyyy) 12/07/2021  
**EXPIRY DATE:** (mm/dd/yyyy) 12/07/2026  
**RECOMMENDED STORAGE:** Store ampoule in a cool, dark place

### DOCUMENTATION/ DATA ATTACHED:

Figure 1: LC/MS Data (Full Scan and Mass Spectrum)  
Figure 2: LC/MS/MS Data (Selected MRM Transitions)

### ADDITIONAL INFORMATION:

- See page 2 for further details.
- Contains 4 mole eq. of NaOH to prevent conversion of the carboxylic acid to the methyl ester.

**FOR LABORATORY USE ONLY: NOT FOR HUMAN OR DRUG USE**

**Certified By:**       **Date:** 12/20/2021  
B.G. Chittim, General Manager      (mm/dd/yyyy)

Wellington Laboratories Inc., 345 Southgate Dr. Guelph ON N1G 3M5 CANADA  
519-822-2436 • Fax: 519-822-2849 • info@well-labs.com

**INTENDED USE:**

The products prepared by Wellington Laboratories Inc. are for laboratory use only. This certified reference material (CRM) was designed to be used as a standard for the identification and/or quantification of the specific chemical compound it contains.

**HANDLING:**

This product should only be used by qualified personnel familiar with its potential hazards and trained in the handling of hazardous chemicals. Due care should be exercised to prevent unnecessary human contact or ingestion. All procedures should be carried out in a well-functioning fume hood and suitable gloves, eye protection, and clothing should be worn at all times. Waste should be disposed of according to national and regional regulations. Safety Data Sheets (SDSs) are available upon request.

**SYNTHESIS / CHARACTERIZATION:**

Our products are synthesized using single-product unambiguous routes whenever possible. They are then characterized, and their structures and purities confirmed, using a combination of the most relevant techniques, such as NMR, GC/MS, LC/MS/MS, SFC/UV/MS/MS, x-ray crystallography, and melting point. Isotopic purities of mass-labelled compounds are also confirmed using HRGC/HRMS and/or LC/MS/MS.

**HOMOGENEITY:**

Prior to solution preparation, crystalline material is tested for homogeneity using a variety of techniques (as stated above) and its solubility in a given diluent is taken into consideration. Duplicate solutions of a new product are prepared from the same crystalline lot and, after the addition of an appropriate internal standard, they are compared by GC/MS, LC/MS/MS, and/or SFC/UV/MS/MS. The relative response factors of the analyte of interest in each solution are required to be <5% RSD. New solution lots of existing products are compared to older lots in the same manner, which further confirms the homogeneity of the crystalline material as well as the stability and homogeneity of the solutions in the storage containers. In order to maintain the integrity of the assigned value(s), and associated uncertainty, the dilution or injection of a subsample of this product should be performed using calibrated measuring equipment.

**UNCERTAINTY:**

The maximum combined relative standard uncertainty of our reference standard solutions is calculated using the following equation:

The combined relative standard uncertainty,  $u_c(y)$ , of a value  $y$  and the uncertainty of the independent parameters  $x_1, x_2, \dots, x_n$  on which it depends is:

$$u_c(y(x_1, x_2, \dots, x_n)) = \sqrt{\sum_{i=1}^n u(y, x_i)^2}$$

where  $x$  is expressed as a relative standard uncertainty of the individual parameter.

The individual uncertainties taken into account include those associated with weights (calibration of the balance) and volumes (calibration of the volumetric glassware). An expanded maximum combined percent relative uncertainty of  $\pm 5\%$  (calculated with a coverage factor of 2 and a level of confidence of 95%) is stated on the Certificate of Analysis for all of our products.

**TRACEABILITY:**

All reference standard solutions are traceable to specific crystalline lots. The microbalances used for solution preparation are regularly calibrated by an external ISO/IEC 17025 accredited laboratory. In addition, their calibration is verified prior to each weighing using calibrated external weights traceable to an ISO/IEC 17025 accredited laboratory. All volumetric glassware used is calibrated, of Class A tolerance, and traceable to an ISO/IEC 17025 accredited laboratory. For certain products, traceability to international interlaboratory studies has also been established.

**EXPIRY DATE / PERIOD OF VALIDITY:**

Ongoing stability studies of this product have demonstrated stability in its composition and concentration, until the specified expiry date, in the unopened ampoule. Monitoring for any degradation or change in concentration of the listed analyte(s) is performed on a routine basis.

**LIMITED WARRANTY:**



At the time of shipment, all products are warranted to be free of defects in material and workmanship and to conform to the stated technical and purity specifications.

**QUALITY MANAGEMENT:**

This product was produced using a Quality Management System registered to the latest versions of ISO 9001 by SAI Global, ISO/IEC 17025 by the Canadian Association for Laboratory Accreditation Inc. (CALA; A1226), and ISO 17034 by ANSI National Accreditation Board (ANAB; AR-1523).



\*\*For additional information or assistance concerning this or any other products from Wellington Laboratories Inc., please visit our website at [www.well-labs.com](http://www.well-labs.com) or contact us directly at [info@well-labs.com](mailto:info@well-labs.com)\*\*

**Figure 1: MPFOA; LC/MS Data (Full Scan and Mass Spectrum)****Conditions for Figure 1:**

Waters Acquity Ultra Performance LC  
Waters Xevo TQ-S micro MS

**Chromatographic Conditions:**

Column: Acquity UPLC BEH Shield RP<sub>18</sub>  
1.7  $\mu$ m, 2.1 x 100 mm


Mobile phase: Gradient  
Start: 40% H<sub>2</sub>O / 60% (80:20 MeOH:ACN)  
(both with 10 mM NH<sub>4</sub>OAc buffer)  
Ramp to 90% organic over 8 min and hold for 2 min  
before returning to initial conditions in 0.75 min.  
Time: 12 min

Flow: 300  $\mu$ L/min

**MS Parameters:**

Experiment: Full Scan (250 - 850 amu)

Source: Electrospray (negative)  
Capillary Voltage (kV) = 2.00  
Cone Voltage (V) = 10.00  
Desolvation Temperature (°C) = 500  
Desolvation Gas Flow (L/hr) = 1000

**Figure 2: MPFOA; LC/MS/MS Data (Selected MRM Transitions)****Conditions for Figure 2:**

Injection: On-column (MPFOA)

Mobile phase: Same as Figure 1

Flow: 300  $\mu\text{L}/\text{min}$ **MS Parameters:**

Collision Gas (mbar) = 3.39e-3

Collision Energy (eV) = 8

# Analytical Standard Record

**22A0119**

Description:	PFAS - IIS MPFOA 50ug/mL	Expires:	12/07/2026
Standard Type:	Analyte Spike	Prepared:	12/07/2021
Solvent:	MeOH	Prepared By:	Dipti Gokal
Final Volume (mls):	1.2	Department:	PFAS
Vials:	1	Last Edit:	01/20/2022 15:48 by HGH

Analyte	Parent	CAS Number	Concentration	Units
13C4-PFOA		13C4-PFOA	50	ug/mL




# WELLINGTON LABORATORIES

## CERTIFICATE OF ANALYSIS DOCUMENTATION

**PRODUCT CODE:** MPFDA **LOT NUMBER:** MPFDA1221  
**COMPOUND:** Perfluoro-n-(1,2-<sup>13</sup>C<sub>2</sub>)decanoic acid

**STRUCTURE:** **CAS #:** 960315-50-8



**MOLECULAR FORMULA:** <sup>13</sup>C<sub>2</sub><sup>12</sup>C<sub>8</sub>HF<sub>19</sub>O<sub>2</sub> **MOLECULAR WEIGHT:** 516.07  
**CONCENTRATION:** 50.0 ± 2.5 µg/mL **SOLVENT(S):** Methanol  
 Water (<1%)  
**CHEMICAL PURITY:** >98% **ISOTOPIC PURITY:** ≥99% <sup>13</sup>C  
 (1,2-<sup>13</sup>C<sub>2</sub>)  
**LAST TESTED:** (mm/dd/yyyy) 12/08/2021  
**EXPIRY DATE:** (mm/dd/yyyy) 12/08/2026  
**RECOMMENDED STORAGE:** Store ampoule in a cool, dark place

### DOCUMENTATION/ DATA ATTACHED:

Figure 1: LC/MS Data (Full Scan and Mass Spectrum)  
 Figure 2: LC/MS/MS Data (Selected MRM Transitions)

### ADDITIONAL INFORMATION:

- See page 2 for further details.
- Contains 4 mole eq. of NaOH to prevent conversion of the carboxylic acid to the methyl ester.

**FOR LABORATORY USE ONLY: NOT FOR HUMAN OR DRUG USE**

Certified By:   
 B.G. Chittim, General Manager

Date: 12/13/2021  
 (mm/dd/yyyy)

Wellington Laboratories Inc., 345 Southgate Dr. Guelph ON N1G 3M5 CANADA  
 519-822-2436 • Fax: 519-822-2849 • info@well-labs.com

**INTENDED USE:**

The products prepared by Wellington Laboratories Inc. are for laboratory use only. This certified reference material (CRM) was designed to be used as a standard for the identification and/or quantification of the specific chemical compound it contains.

**HANDLING:**

This product should only be used by qualified personnel familiar with its potential hazards and trained in the handling of hazardous chemicals. Due care should be exercised to prevent unnecessary human contact or ingestion. All procedures should be carried out in a well-functioning fume hood and suitable gloves, eye protection, and clothing should be worn at all times. Waste should be disposed of according to national and regional regulations. Safety Data Sheets (SDSs) are available upon request.

**SYNTHESIS / CHARACTERIZATION:**

Our products are synthesized using single-product unambiguous routes whenever possible. They are then characterized, and their structures and purities confirmed, using a combination of the most relevant techniques, such as NMR, GC/MS, LC/MS/MS, SFC/UV/MS/MS, x-ray crystallography, and melting point. Isotopic purities of mass-labelled compounds are also confirmed using HRGC/HRMS and/or LC/MS/MS.

**HOMOGENEITY:**

Prior to solution preparation, crystalline material is tested for homogeneity using a variety of techniques (as stated above) and its solubility in a given diluent is taken into consideration. Duplicate solutions of a new product are prepared from the same crystalline lot and, after the addition of an appropriate internal standard, they are compared by GC/MS, LC/MS/MS, and/or SFC/UV/MS/MS. The relative response factors of the analyte of interest in each solution are required to be <5% RSD. New solution lots of existing products are compared to older lots in the same manner, which further confirms the homogeneity of the crystalline material as well as the stability and homogeneity of the solutions in the storage containers. In order to maintain the integrity of the assigned value(s), and associated uncertainty, the dilution or injection of a subsample of this product should be performed using calibrated measuring equipment.

**UNCERTAINTY:**

The maximum combined relative standard uncertainty of our reference standard solutions is calculated using the following equation:

The combined relative standard uncertainty,  $u_c(y)$ , of a value  $y$  and the uncertainty of the independent parameters  $x_1, x_2, \dots, x_n$  on which it depends is:

$$u_c(y(x_1, x_2, \dots, x_n)) = \sqrt{\sum_{i=1}^n u(y, x_i)^2}$$

where  $x$  is expressed as a relative standard uncertainty of the individual parameter.

The individual uncertainties taken into account include those associated with weights (calibration of the balance) and volumes (calibration of the volumetric glassware). An expanded maximum combined percent relative uncertainty of  $\pm 5\%$  (calculated with a coverage factor of 2 and a level of confidence of 95%) is stated on the Certificate of Analysis for all of our products.

**TRACEABILITY:**

All reference standard solutions are traceable to specific crystalline lots. The microbalances used for solution preparation are regularly calibrated by an external ISO/IEC 17025 accredited laboratory. In addition, their calibration is verified prior to each weighing using calibrated external weights traceable to an ISO/IEC 17025 accredited laboratory. All volumetric glassware used is calibrated, of Class A tolerance, and traceable to an ISO/IEC 17025 accredited laboratory. For certain products, traceability to international interlaboratory studies has also been established.

**EXPIRY DATE / PERIOD OF VALIDITY:**

Ongoing stability studies of this product have demonstrated stability in its composition and concentration, until the specified expiry date, in the unopened ampoule. Monitoring for any degradation or change in concentration of the listed analyte(s) is performed on a routine basis.

**LIMITED WARRANTY:**

At the time of shipment, all products are warranted to be free of defects in material and workmanship and to conform to the stated technical and purity specifications.



**QUALITY MANAGEMENT:**

This product was produced using a Quality Management System registered to the latest versions of ISO 9001 by SAI Global, ISO/IEC 17025 by the Canadian Association for Laboratory Accreditation Inc. (CALA; A1226), and ISO 17034 by ANSI National Accreditation Board (ANAB; AR-1523).



\*\*For additional information or assistance concerning this or any other products from Wellington Laboratories Inc., please visit our website at [www.well-labs.com](http://www.well-labs.com) or contact us directly at [info@well-labs.com](mailto:info@well-labs.com)\*\*



**Figure 1: MPFDA; LC/MS Data (Full Scan and Mass Spectrum)****Conditions for Figure 1:**

Waters Acquity Ultra Performance LC  
Waters Xevo TQ-S micro MS

**Chromatographic Conditions:**

Column: Acquity UPLC BEH Shield RP<sub>18</sub>  
1.7  $\mu$ m, 2.1 x 100 mm

Mobile phase: Gradient


Start: 50% H<sub>2</sub>O / 50% (80:20 MeOH:ACN)  
(both with 10 mM NH<sub>4</sub>OAc buffer)  
Ramp to 90% organic over 9 min and hold for  
1 min before returning to initial conditions in 0.75 min.  
Time: 12 min

Flow: 300  $\mu$ L/min

**MS Parameters:**

Experiment: Full Scan (250 - 850 amu)

Source: Electrospray (negative)  
Capillary Voltage (kV) = 2.00  
Cone Voltage (V) = 10.00  
Desolvation Temperature ( $^{\circ}$ C) = 500  
Desolvation Gas Flow (L/hr) = 1000

**Figure 2: MPFDA; LC/MS/MS Data (Selected MRM Transitions)****Conditions for Figure 2:**

Injection: On-column (MPFDA)

Mobile phase: Same as Figure 1

Flow: 300  $\mu$ L/min**MS Parameters:**

Collision Gas (mbar) = 3.39e-3

Collision Energy (eV) = 10

# Analytical Standard Record

**22A0120**

Description:	PFAS - IIS MPFDA 50ug/mL	Expires:	12/08/2026
Standard Type:	Analyte Spike	Prepared:	12/08/2021
Solvent:	MeOH	Prepared By:	Dipti Gokal
Final Volume (mls):	1.2	Department:	PFAS
Vials:	1	Last Edit:	01/20/2022 15:49 by HGH

Analyte	Parent	CAS Number	Concentration	Units
13C2-PFDA		13C2-PFDA	50	ug/mL




# WELLINGTON LABORATORIES

## CERTIFICATE OF ANALYSIS DOCUMENTATION

**PRODUCT CODE:** MPFOS **LOT NUMBER:** MPFOS0821  
**COMPOUND:** Sodium perfluoro-1-(1,2,3,4-<sup>13</sup>C<sub>4</sub>)octanesulfonate

**STRUCTURE:** **CAS #:** 960315-53-1



**MOLECULAR FORMULA:** <sup>13</sup>C<sub>4</sub><sup>12</sup>C<sub>4</sub>F<sub>17</sub>SO<sub>3</sub>Na **MOLECULAR WEIGHT:** 526.08  
**CONCENTRATION:** 50.0 ± 2.5 µg/mL (Na salt) **SOLVENT(S):** Methanol  
 47.9 ± 2.4 µg/mL (MPFOS acid)  
 47.8 ± 2.4 µg/mL (MPFOS anion)  
**CHEMICAL PURITY:** >98% **ISOTOPIC PURITY:** ≥99% <sup>13</sup>C  
**LAST TESTED:** (mm/dd/yyyy) 08/18/2021 (1,2,3,4-<sup>13</sup>C<sub>4</sub>)  
**EXPIRY DATE:** (mm/dd/yyyy) 08/18/2026  
**RECOMMENDED STORAGE:** Store ampoule in a cool, dark place


### DOCUMENTATION/ DATA ATTACHED:

Figure 1: LC/MS Data (Full Scan and Mass Spectrum)  
 Figure 2: LC/MS/MS Data (Selected MRM Transitions)

### ADDITIONAL INFORMATION:

- See page 2 for further details.
- Contains ~0.4% sodium perfluoro-1-(<sup>13</sup>C<sub>3</sub>)heptanesulfonate.

**FOR LABORATORY USE ONLY: NOT FOR HUMAN OR DRUG USE**

**Certified By:**   
 B.G. Chittim, General Manager **Date:** 08/19/2021  
 (mm/dd/yyyy)

Wellington Laboratories Inc., 345 Southgate Dr. Guelph ON N1G 3M5 CANADA  
 519-822-2436 • Fax: 519-822-2849 • info@well-labs.com

**INTENDED USE:**

The products prepared by Wellington Laboratories Inc. are for laboratory use only. This certified reference material (CRM) was designed to be used as a standard for the identification and/or quantification of the specific chemical compound it contains.

**HANDLING:**

This product should only be used by qualified personnel familiar with its potential hazards and trained in the handling of hazardous chemicals. Due care should be exercised to prevent unnecessary human contact or ingestion. All procedures should be carried out in a well-functioning fume hood and suitable gloves, eye protection, and clothing should be worn at all times. Waste should be disposed of according to national and regional regulations. Safety Data Sheets (SDSs) are available upon request.

**SYNTHESIS / CHARACTERIZATION:**

Our products are synthesized using single-product unambiguous routes whenever possible. They are then characterized, and their structures and purities confirmed, using a combination of the most relevant techniques, such as NMR, GC/MS, LC/MS/MS, SFC/UV/MS/MS, x-ray crystallography, and melting point. Isotopic purities of mass-labelled compounds are also confirmed using HRGC/HRMS and/or LC/MS/MS.

**HOMOGENEITY:**

Prior to solution preparation, crystalline material is tested for homogeneity using a variety of techniques (as stated above) and its solubility in a given diluent is taken into consideration. Duplicate solutions of a new product are prepared from the same crystalline lot and, after the addition of an appropriate internal standard, they are compared by GC/MS, LC/MS/MS, and/or SFC/UV/MS/MS. The relative response factors of the analyte of interest in each solution are required to be <5% RSD. New solution lots of existing products are compared to older lots in the same manner, which further confirms the homogeneity of the crystalline material as well as the stability and homogeneity of the solutions in the storage containers. In order to maintain the integrity of the assigned value(s), and associated uncertainty, the dilution or injection of a subsample of this product should be performed using calibrated measuring equipment.

**UNCERTAINTY:**

The maximum combined relative standard uncertainty of our reference standard solutions is calculated using the following equation:

The combined relative standard uncertainty,  $u_c(y)$ , of a value  $y$  and the uncertainty of the independent parameters  $x_1, x_2, \dots, x_n$  on which it depends is:

$$u_c(y(x_1, x_2, \dots, x_n)) = \sqrt{\sum_{i=1}^n u(y, x_i)^2}$$

where  $x$  is expressed as a relative standard uncertainty of the individual parameter.

The individual uncertainties taken into account include those associated with weights (calibration of the balance) and volumes (calibration of the volumetric glassware). An expanded maximum combined percent relative uncertainty of  $\pm 5\%$  (calculated with a coverage factor of 2 and a level of confidence of 95%) is stated on the Certificate of Analysis for all of our products.

**TRACEABILITY:**

All reference standard solutions are traceable to specific crystalline lots. The microbalances used for solution preparation are regularly calibrated by an external ISO/IEC 17025 accredited laboratory. In addition, their calibration is verified prior to each weighing using calibrated external weights traceable to an ISO/IEC 17025 accredited laboratory. All volumetric glassware used is calibrated, of Class A tolerance, and traceable to an ISO/IEC 17025 accredited laboratory. For certain products, traceability to international interlaboratory studies has also been established.

**EXPIRY DATE / PERIOD OF VALIDITY:**

Ongoing stability studies of this product have demonstrated stability in its composition and concentration, until the specified expiry date, in the unopened ampoule. Monitoring for any degradation or change in concentration of the listed analyte(s) is performed on a routine basis.

**LIMITED WARRANTY:**



At the time of shipment, all products are warranted to be free of defects in material and workmanship and to conform to the stated technical and purity specifications.

**QUALITY MANAGEMENT:**

This product was produced using a Quality Management System registered to the latest versions of ISO 9001 by SAI Global, ISO/IEC 17025 by the Canadian Association for Laboratory Accreditation Inc. (CALA; A1226), and ISO 17034 by ANSI National Accreditation Board (ANAB; AR-1523).



\*\*For additional information or assistance concerning this or any other products from Wellington Laboratories Inc., please visit our website at [www.well-labs.com](http://www.well-labs.com) or contact us directly at [info@well-labs.com](mailto:info@well-labs.com)\*\*

**Figure 1: MPFOS; LC/MS Data (Full Scan and Mass Spectrum)****Conditions for Figure 1:**

Waters Acquity Ultra Performance LC  
Waters Xevo TQ-S micro MS

**Chromatographic Conditions:**

Column: Acquity UPLC BEH Shield RP<sub>18</sub>  
1.7  $\mu$ m, 2.1 x 100 mm


Mobile phase: Gradient  
Start: 40% H<sub>2</sub>O / 60% (80:20 MeOH:ACN)  
(both with 10 mM NH<sub>4</sub>OAc buffer)  
Ramp to 90% organic over 8 min and hold for  
2 min before returning to initial conditions in 0.75 min.  
Time: 12 min

Flow: 300  $\mu$ L/min

**MS Parameters:**

Experiment: Full Scan (250 - 850 amu)

Source: Electrospray (negative)  
Capillary Voltage (kV) = 2.00  
Cone Voltage (V) = 10.00  
Desolvation Temperature (°C) = 500  
Desolvation Gas Flow (L/hr) = 1000

**Figure 2: MPFOS; LC/MS/MS Data (Selected MRM Transitions)****Conditions for Figure 2:**

Injection: On-column (MPFOS)

Mobile phase: Same as Figure 1

Flow: 300  $\mu\text{L}/\text{min}$ **MS Parameters:**

Collision Gas (mbar) = 3.39e-3

Collision Energy (eV) = 42

# Analytical Standard Record

**22A0121**

Description:	PFAS - IIS MPFOS 50ug/mL	Expires:	08/18/2026
Standard Type:	Analyte Spike	Prepared:	08/18/2021
Solvent:	MeOH	Prepared By:	Dipti Gokal
Final Volume (mls):	1.2	Department:	PFAS
Vials:	1	Last Edit:	01/20/2022 15:49 by HGH

Analyte	Parent	CAS Number	Concentration	Units
13C4-PFOS		13C4-PFOS	50	ug/mL






# WELLINGTON LABORATORIES

## CERTIFICATE OF ANALYSIS DOCUMENTATION

**PRODUCT CODE:** MPFHxS **LOT NUMBER:** MPFHxS1021  
**COMPOUND:** Sodium perfluoro-1-hexane(<sup>18</sup>O<sub>2</sub>)sulfonate

**STRUCTURE:** **CAS #:** 1585941-14-5



**MOLECULAR FORMULA:** C<sub>6</sub>F<sub>13</sub>S<sup>18</sup>O<sub>2</sub><sup>16</sup>ONa **MOLECULAR WEIGHT:** 426.10  
**CONCENTRATION:** 50.0 ± 2.5 µg/mL (Na salt) **SOLVENT(S):** Methanol  
 47.4 ± 2.4 µg/mL (MPFHxS acid)  
 47.3 ± 2.4 µg/mL (MPFHxS anion)  
**CHEMICAL PURITY:** >98% **ISOTOPIC PURITY:** >94% (<sup>18</sup>O<sub>2</sub>)  
**LAST TESTED:** (mm/dd/yyyy) 10/29/2021  
**EXPIRY DATE:** (mm/dd/yyyy) 10/29/2026  
**RECOMMENDED STORAGE:** Store ampoule in a cool, dark place

### DOCUMENTATION/ DATA ATTACHED:


Figure 1: LC/MS Data (Full Scan and Mass Spectrum)

Figure 2: LC/MS/MS Data (Selected MRM Transitions)

### ADDITIONAL INFORMATION:

- See page 2 for further details.
- The response factor for MPFHxS (C<sub>6</sub>F<sub>13</sub>S<sup>18</sup>O<sub>2</sub><sup>16</sup>O) has been observed to be up to 10% lower than for PFHxS (C<sub>6</sub>F<sub>13</sub>S<sup>18</sup>O<sub>3</sub>) when both compounds are injected together. This difference may vary between instruments.
- Contains ~0.6% of sodium perfluoro-1-octane(<sup>18</sup>O<sub>2</sub>)sulfonate (<sup>18</sup>O<sub>2</sub>-PFOS) and ~0.3% of sodium perfluoro-1-heptane(<sup>18</sup>O<sub>2</sub>)sulfonate (<sup>18</sup>O<sub>2</sub>-PFHpS).
- Due to the isotopic purity of the starting material (<sup>18</sup>O<sub>2</sub> >94%), MPFHxS contains ~0.3% of PFHxS. This value agrees with the theoretical percent relative abundance that is expected based on the stated isotopic purity.

**FOR LABORATORY USE ONLY: NOT FOR HUMAN OR DRUG USE**

**Certified By:**   
 B.G. Chittim, General Manager **Date:** 11/05/2021  
 (mm/dd/yyyy)

Wellington Laboratories Inc., 345 Southgate Dr. Guelph ON N1G 3M5 CANADA  
 519-822-2436 • Fax: 519-822-2849 • info@well-labs.com

**INTENDED USE:**

The products prepared by Wellington Laboratories Inc. are for laboratory use only. This certified reference material (CRM) was designed to be used as a standard for the identification and/or quantification of the specific chemical compound it contains.

**HANDLING:**

This product should only be used by qualified personnel familiar with its potential hazards and trained in the handling of hazardous chemicals. Due care should be exercised to prevent unnecessary human contact or ingestion. All procedures should be carried out in a well-functioning fume hood and suitable gloves, eye protection, and clothing should be worn at all times. Waste should be disposed of according to national and regional regulations. Safety Data Sheets (SDSs) are available upon request.

**SYNTHESIS / CHARACTERIZATION:**

Our products are synthesized using single-product unambiguous routes whenever possible. They are then characterized, and their structures and purities confirmed, using a combination of the most relevant techniques, such as NMR, GC/MS, LC/MS/MS, SFC/UV/MS/MS, x-ray crystallography, and melting point. Isotopic purities of mass-labelled compounds are also confirmed using HRGC/HRMS and/or LC/MS/MS.

**HOMOGENEITY:**

Prior to solution preparation, crystalline material is tested for homogeneity using a variety of techniques (as stated above) and its solubility in a given diluent is taken into consideration. Duplicate solutions of a new product are prepared from the same crystalline lot and, after the addition of an appropriate internal standard, they are compared by GC/MS, LC/MS/MS, and/or SFC/UV/MS/MS. The relative response factors of the analyte of interest in each solution are required to be <5% RSD. New solution lots of existing products are compared to older lots in the same manner, which further confirms the homogeneity of the crystalline material as well as the stability and homogeneity of the solutions in the storage containers. In order to maintain the integrity of the assigned value(s), and associated uncertainty, the dilution or injection of a subsample of this product should be performed using calibrated measuring equipment.

**UNCERTAINTY:**

The maximum combined relative standard uncertainty of our reference standard solutions is calculated using the following equation:

The combined relative standard uncertainty,  $u_c(y)$ , of a value  $y$  and the uncertainty of the independent parameters  $x_1, x_2, \dots, x_n$  on which it depends is:

$$u_c(y(x_1, x_2, \dots, x_n)) = \sqrt{\sum_{i=1}^n u(y, x_i)^2}$$

where  $x$  is expressed as a relative standard uncertainty of the individual parameter.

The individual uncertainties taken into account include those associated with weights (calibration of the balance) and volumes (calibration of the volumetric glassware). An expanded maximum combined percent relative uncertainty of  $\pm 5\%$  (calculated with a coverage factor of 2 and a level of confidence of 95%) is stated on the Certificate of Analysis for all of our products.

**TRACEABILITY:**

All reference standard solutions are traceable to specific crystalline lots. The microbalances used for solution preparation are regularly calibrated by an external ISO/IEC 17025 accredited laboratory. In addition, their calibration is verified prior to each weighing using calibrated external weights traceable to an ISO/IEC 17025 accredited laboratory. All volumetric glassware used is calibrated, of Class A tolerance, and traceable to an ISO/IEC 17025 accredited laboratory. For certain products, traceability to international interlaboratory studies has also been established.

**EXPIRY DATE / PERIOD OF VALIDITY:**

Ongoing stability studies of this product have demonstrated stability in its composition and concentration, until the specified expiry date, in the unopened ampoule. Monitoring for any degradation or change in concentration of the listed analyte(s) is performed on a routine basis.

**LIMITED WARRANTY:**



At the time of shipment, all products are warranted to be free of defects in material and workmanship and to conform to the stated technical and purity specifications.

**QUALITY MANAGEMENT:**

This product was produced using a Quality Management System registered to the latest versions of ISO 9001 by SAI Global, ISO/IEC 17025 by the Canadian Association for Laboratory Accreditation Inc. (CALA; A1226), and ISO 17034 by ANSI National Accreditation Board (ANAB; AR-1523).



\*\*For additional information or assistance concerning this or any other products from Wellington Laboratories Inc., please visit our website at [www.well-labs.com](http://www.well-labs.com) or contact us directly at [info@well-labs.com](mailto:info@well-labs.com)\*\*

**Figure 1: MPFHxS; LC/MS Data (Full Scan and Mass Spectrum)****Conditions for Figure 1:**

Waters Acquity Ultra Performance LC  
Waters Xevo TQ-S micro MS

**Chromatographic Conditions:**

Column: Acquity UPLC BEH Shield RP<sub>18</sub>  
1.7  $\mu$ m, 2.1 x 100 mm

Mobile phase: Gradient


Start: 50% H<sub>2</sub>O / 50% (80:20 MeOH:ACN)  
(both with 10 mM NH<sub>4</sub>OAc buffer)  
Ramp to 90% organic over 9 min and hold for  
1 min before returning to initial conditions in 0.75 min.  
Time: 12 min

Flow: 300  $\mu$ L/min

**MS Parameters:**

Experiment: Full Scan (225 - 850 amu)

Source: Electrospray (negative)  
Capillary Voltage (kV) = 2.00  
Cone Voltage (V) = 10.00  
Desolvation Temperature ( $^{\circ}$ C) = 500  
Desolvation Gas Flow (L/hr) = 1000

**Figure 2: MPFHxS; LC/MS/MS Data (Selected MRM Transitions)****Conditions for Figure 2:**

Injection: On-column (MPFHxS)

Mobile phase: Same as Figure 1

Flow: 300  $\mu$ L/min**MS Parameters:**

Collision Gas (mbar) = 3.16e-3

Collision Energy (eV) = 32

# Analytical Standard Record

**22A0122**

Description:	PFAS - IIS MPFHxS 50ug/mL	Expires:	10/29/2026
Standard Type:	Analyte Spike	Prepared:	10/29/2021
Solvent:	MeOH	Prepared By:	Dipti Gokal
Final Volume (mls):	1.2	Department:	PFAS
Vials:	1	Last Edit:	01/20/2022 15:49 by HGH

Analyte	Parent	CAS Number	Concentration	Units
1802-PFHXS		1802-PFHXS	50	ug/mL

# Analytical Standard Record

**22A0122**

Description:	PFAS - IIS MPFHxS 50ug/mL	Expires:	10/29/2026
Standard Type:	Analyte Spike	Prepared:	10/29/2021
Solvent:	MeOH	Prepared By:	Dipti Gokal
Final Volume (mls):	1.2	Department:	PFAS
Vials:	1	Last Edit:	01/20/2022 15:49 by HGH

Analyte	Parent	CAS Number	Concentration	Units
1802-PFHXS		1802-PFHXS	50	ug/mL

# Analytical Standard Record

**22A0234**

Description:	PFAS IIS 7C 5ug/mL	Expires:	01/20/2023
Standard Type:	Internal Standard	Prepared:	01/20/2022
Solvent:	MeOH/61252	Prepared By:	Dipti Gokal
Final Volume (mL):	12	Department:	PFAS
Vials:	1	Last Edit:	01/20/2022 15:49 by HGH
Comments:	mpfna had more left over than others.		

Analyte	Parent	CAS Number	Concentration	Units
13C3-PFBA	22A0116	13C3-PFBA	5	ug/mL
13C2-PFHxA	22A0117	13C2-PFHxA	5	ug/mL
13C5-PFNA	22A0118	13C5-PFNA	5	ug/mL
13C4-PFOA	22A0119	13C4-PFOA	5	ug/mL
13C2-PFDA	22A0120	13C2-PFDA	5	ug/mL
13C4-PFOS	22A0121	13C4-PFOS	5	ug/mL
18O2-PFHxS	22A0122	18O2-PFHxS	5	ug/mL

**Parent Standards used:**

Standard	Description	Prepared	Prepared By	Lot Nbr	Expires	Last Edit	(mLs)
22A0116	PFAS - IIS M3PFBA 50ug/mL	08/19/2021	Wellington Laboratories	M3PFBA0721	08/19/2026	01/20/2022 15:48 by HGH	1.2
22A0117	PFAS - IIS MPFHxA 50ug/mL	10/04/2021	Wellington Laboratories	MPFHxA0921	10/04/2026	01/20/2022 15:48 by HGH	1.2
22A0118	PFAS - IIS MPFNA 50ug/mL	10/29/2021	Wellington Laboratories	MPFNA1021	10/29/2026	01/20/2022 15:48 by HGH	1.2
22A0119	PFAS - IIS MPFOA 50ug/mL	12/07/2021	Wellington Laboratories	MPFOA1121	12/07/2026	01/20/2022 15:48 by HGH	1.2
22A0120	PFAS - IIS MPFDA 50ug/mL	12/08/2021	Wellington Laboratories	MPFDA1221	12/08/2026	01/20/2022 15:49 by HGH	1.2
22A0121	PFAS - IIS MPFOS 50ug/mL	08/18/2021	Wellington Laboratories	MPFOS0821	08/18/2026	01/20/2022 15:49 by HGH	1.2
22A0122	PFAS - IIS MPFHxS 50ug/mL	10/29/2021	Wellington Laboratories	MPFHxS1021	10/29/2026	01/20/2022 15:49 by HGH	1.2

# Analytical Standard Record

**22A0234**

Description:	PFAS IIS 7C 5ug/mL	Expires:	01/20/2023
Standard Type:	Internal Standard	Prepared:	01/20/2022
Solvent:	MeOH/61252	Prepared By:	Dipti Gokal
Final Volume (mL):	12	Department:	PFAS
Vials:	1	Last Edit:	01/20/2022 15:49 by HGH
Comments:	mpfna had more left over than others.		

Analyte	Parent	CAS Number	Concentration	Units
13C3-PFBA	22A0116	13C3-PFBA	5	ug/mL
13C2-PFHxA	22A0117	13C2-PFHxA	5	ug/mL
13C5-PFNA	22A0118	13C5-PFNA	5	ug/mL
13C4-PFOA	22A0119	13C4-PFOA	5	ug/mL
13C2-PFDA	22A0120	13C2-PFDA	5	ug/mL
13C4-PFOS	22A0121	13C4-PFOS	5	ug/mL
18O2-PFHxS	22A0122	18O2-PFHxS	5	ug/mL

**Parent Standards used:**

Standard	Description	Prepared	Prepared By	Lot Nbr	Expires	Last Edit	(mL)
22A0116	PFAS - IIS M3PFBA 50ug/mL	08/19/2021	Wellington Laboratories	M3PFBA0721	08/19/2026	01/20/2022 15:48 by HGH	1.2
22A0117	PFAS - IIS MPFHxA 50ug/mL	10/04/2021	Wellington Laboratories	MPFHxA0921	10/04/2026	01/20/2022 15:48 by HGH	1.2
22A0118	PFAS - IIS MPFNA 50ug/mL	10/29/2021	Wellington Laboratories	MPFNA1021	10/29/2026	01/20/2022 15:48 by HGH	1.2
22A0119	PFAS - IIS MPFOA 50ug/mL	12/07/2021	Wellington Laboratories	MPFOA1121	12/07/2026	01/20/2022 15:48 by HGH	1.2
22A0120	PFAS - IIS MPFDA 50ug/mL	12/08/2021	Wellington Laboratories	MPFDA1221	12/08/2026	01/20/2022 15:49 by HGH	1.2
22A0121	PFAS - IIS MPFOS 50ug/mL	08/18/2021	Wellington Laboratories	MPFOS0821	08/18/2026	01/20/2022 15:49 by HGH	1.2
22A0122	PFAS - IIS MPFHxS 50ug/mL	10/29/2021	Wellington Laboratories	MPFHxS1021	10/29/2026	01/20/2022 15:49 by HGH	1.2



# Analytical Standard Record

**22A0234**

Description:	PFAS IIS 7C 5ug/mL	Expires:	01/20/2023
Standard Type:	Internal Standard	Prepared:	01/20/2022
Solvent:	MeOH/61252	Prepared By:	Dipti Gokal
Final Volume (mL):	12	Department:	PFAS
Vials:	1	Last Edit:	01/20/2022 15:49 by HGH
Comments:	mpfna had more left over than others.		

Analyte	Parent	CAS Number	Concentration	Units
13C3-PFBA	22A0116	13C3-PFBA	5	ug/mL
13C2-PFHxA	22A0117	13C2-PFHxA	5	ug/mL
13C5-PFNA	22A0118	13C5-PFNA	5	ug/mL
13C4-PFOA	22A0119	13C4-PFOA	5	ug/mL
13C2-PFDA	22A0120	13C2-PFDA	5	ug/mL
13C4-PFOS	22A0121	13C4-PFOS	5	ug/mL
18O2-PFHxS	22A0122	18O2-PFHxS	5	ug/mL

**Parent Standards used:**

Standard	Description	Prepared	Prepared By	Lot Nbr	Expires	Last Edit	(mL)
22A0116	PFAS - IIS M3PFBA 50ug/mL	08/19/2021	Wellington Laboratories	M3PFBA0721	08/19/2026	01/20/2022 15:48 by HGH	1.2
22A0117	PFAS - IIS MPFHxA 50ug/mL	10/04/2021	Wellington Laboratories	MPFHxA0921	10/04/2026	01/20/2022 15:48 by HGH	1.2
22A0118	PFAS - IIS MPFNA 50ug/mL	10/29/2021	Wellington Laboratories	MPFNA1021	10/29/2026	01/20/2022 15:48 by HGH	1.2
22A0119	PFAS - IIS MPFOA 50ug/mL	12/07/2021	Wellington Laboratories	MPFOA1121	12/07/2026	01/20/2022 15:48 by HGH	1.2
22A0120	PFAS - IIS MPFDA 50ug/mL	12/08/2021	Wellington Laboratories	MPFDA1221	12/08/2026	01/20/2022 15:49 by HGH	1.2
22A0121	PFAS - IIS MPFOS 50ug/mL	08/18/2021	Wellington Laboratories	MPFOS0821	08/18/2026	01/20/2022 15:49 by HGH	1.2
22A0122	PFAS - IIS MPFHxS 50ug/mL	10/29/2021	Wellington Laboratories	MPFHxS1021	10/29/2026	01/20/2022 15:49 by HGH	1.2




# WELLINGTON LABORATORIES

## CERTIFICATE OF ANALYSIS DOCUMENTATION

**PRODUCT CODE:** N-MeFOSE-M **LOT NUMBER:** NMeFOSE0921M  
**COMPOUND:** 2-(N-methylperfluoro-1-octanesulfonamido)-ethanol **22C0307**

**STRUCTURE:** **CAS #:** 24448-09-7



**MOLECULAR FORMULA:** C<sub>11</sub>H<sub>8</sub>F<sub>17</sub>NO<sub>3</sub>S **MOLECULAR WEIGHT:** 557.22  
**CONCENTRATION:** 50.0 ± 2.5 µg/mL **SOLVENT(S):** Methanol  
**CHEMICAL PURITY:** >98%  
**LAST TESTED:** (mm/dd/yyyy) 09/22/2021 (HRGC/LRMS)  
 09/23/2021 (LC/MS)  
**EXPIRY DATE:** (mm/dd/yyyy) 09/23/2026  
**RECOMMENDED STORAGE:** Store ampoule in a cool, dark place

### DOCUMENTATION/ DATA ATTACHED:

Figure 1: HRGC/LRMS Data (Full Scan and Mass Spectrum)  
 Figure 2: LC/MS Data (Full Scan and Mass Spectrum)  
 Figure 3: LC/MS/MS Data (Selected MRM Transitions)

### ADDITIONAL INFORMATION:

- See page 2 for further details.
- In order to see the molecular ion (adduct free), the LC mobile phase should be free of ammonium acetate buffer.

**FOR LABORATORY USE ONLY: NOT FOR HUMAN OR DRUG USE**

Certified By:   
 B.G. Chittim, General Manager

Date: 09/28/2021  
 (mm/dd/yyyy)

Wellington Laboratories Inc., 345 Southgate Dr. Guelph ON N1G 3M5 CANADA  
 519-822-2436 • Fax: 519-822-2849 • info@well-labs.com

**INTENDED USE:**

The products prepared by Wellington Laboratories Inc. are for laboratory use only. This certified reference material (CRM) was designed to be used as a standard for the identification and/or quantification of the specific chemical compound it contains.

**HANDLING:**

This product should only be used by qualified personnel familiar with its potential hazards and trained in the handling of hazardous chemicals. Due care should be exercised to prevent unnecessary human contact or ingestion. All procedures should be carried out in a well-functioning fume hood and suitable gloves, eye protection, and clothing should be worn at all times. Waste should be disposed of according to national and regional regulations. Safety Data Sheets (SDSs) are available upon request.

**SYNTHESIS / CHARACTERIZATION:**

Our products are synthesized using single-product unambiguous routes whenever possible. They are then characterized, and their structures and purities confirmed, using a combination of the most relevant techniques, such as NMR, GC/MS, LC/MS/MS, SFC/UV/MS/MS, x-ray crystallography, and melting point. Isotopic purities of mass-labelled compounds are also confirmed using HRGC/HRMS and/or LC/MS/MS.

**HOMOGENEITY:**

Prior to solution preparation, crystalline material is tested for homogeneity using a variety of techniques (as stated above) and its solubility in a given diluent is taken into consideration. Duplicate solutions of a new product are prepared from the same crystalline lot and, after the addition of an appropriate internal standard, they are compared by GC/MS, LC/MS/MS, and/or SFC/UV/MS/MS. The relative response factors of the analyte of interest in each solution are required to be <5% RSD. New solution lots of existing products are compared to older lots in the same manner, which further confirms the homogeneity of the crystalline material as well as the stability and homogeneity of the solutions in the storage containers. In order to maintain the integrity of the assigned value(s), and associated uncertainty, the dilution or injection of a subsample of this product should be performed using calibrated measuring equipment.

**UNCERTAINTY:**

The maximum combined relative standard uncertainty of our reference standard solutions is calculated using the following equation:

The combined relative standard uncertainty,  $u_c(y)$ , of a value  $y$  and the uncertainty of the independent parameters

$x_1, x_2, \dots, x_n$  on which it depends is:

$$u_c(y(x_1, x_2, \dots, x_n)) = \sqrt{\sum_{i=1}^n u(y, x_i)^2}$$

where  $x$  is expressed as a relative standard uncertainty of the individual parameter.

The individual uncertainties taken into account include those associated with weights (calibration of the balance) and volumes (calibration of the volumetric glassware). An expanded maximum combined percent relative uncertainty of  $\pm 5\%$  (calculated with a coverage factor of 2 and a level of confidence of 95%) is stated on the Certificate of Analysis for all of our products.

**TRACEABILITY:**

All reference standard solutions are traceable to specific crystalline lots. The microbalances used for solution preparation are regularly calibrated by an external ISO/IEC 17025 accredited laboratory. In addition, their calibration is verified prior to each weighing using calibrated external weights traceable to an ISO/IEC 17025 accredited laboratory. All volumetric glassware used is calibrated, of Class A tolerance, and traceable to an ISO/IEC 17025 accredited laboratory. For certain products, traceability to international interlaboratory studies has also been established.

**EXPIRY DATE / PERIOD OF VALIDITY:**

Ongoing stability studies of this product have demonstrated stability in its composition and concentration, until the specified expiry date, in the unopened ampoule. Monitoring for any degradation or change in concentration of the listed analyte(s) is performed on a routine basis.

**LIMITED WARRANTY:**


At the time of shipment, all products are warranted to be free of defects in material and workmanship and to conform to the stated technical and purity specifications.

**QUALITY MANAGEMENT:**

This product was produced using a Quality Management System registered to the latest versions of ISO 9001 by SAI Global, ISO/IEC 17025 by the Canadian Association for Laboratory Accreditation Inc. (CALA; A1226), and ISO 17034 by ANSI National Accreditation Board (ANAB; AR-1523).



\*\*For additional information or assistance concerning this or any other products from Wellington Laboratories Inc., please visit our website at [www.well-labs.com](http://www.well-labs.com) or contact us directly at [info@well-labs.com](mailto:info@well-labs.com)\*\*

**Figure 1: N-MeFOSE-M; HRGC/LRMS Data (Full Scan and Mass Spectrum)****Conditions for Figure 1:**

Agilent 7890A HRGC  
 Agilent 5975C MSD

**Chromatographic Conditions:**

Column: 30 m DB-5 (0.25 mm id, 0.25  $\mu$ m film thickness) Agilent J&W



Flow: Constant at 1 mL/min

Injector: 250°C (Splitless Injection)

Oven: 100°C (5 min)  
 10°C/min to 310°C  
 310°C (10 min)

Ionization: EI+

Detector: 230°C  
 Full Scan (50-1000 amu)

**Figure 2: N-MeFOSE-M; LC/MS Data (Full Scan and Mass Spectrum)****Conditions for Figure 2:**

Waters Acquity Ultra Performance LC  
Waters Xevo TQ-S micro MS

**Chromatographic Conditions:**

Column: Acquity UPLC BEH Shield RP<sub>18</sub>  
1.7 µm, 2.1 x 100 mm

Mobile phase: Gradient

Start: 30% H<sub>2</sub>O / 70% MeOH

Ramp to 90% organic over 8 min and hold for

1.5 min before returning to initial conditions in 1 min.

Time: 12 min

Flow: 300 µL/min

**MS Parameters:**

Experiment: Full Scan (250 - 850 amu)


Source: Electrospray (negative)

Capillary Voltage (kV) = 2.00

Cone Voltage (V) = 65.00

Desolvation Temperature (°C) = 450

Desolvation Gas Flow (L/hr) = 1000

**Figure 3: N-MeFOSE-M; LC/MS/MS Data (Selected MRM Transitions)****Conditions for Figure 3:**

Injection: On-column (N-MeFOSE-M)

Mobile phase: Same as Figure 2

Flow: 300  $\mu$ L/min**MS Parameters:**

Collision Gas (mbar) = 3.14e-3

Collision Energy (eV) = 36

•

•

# Analytical Standard Record

**22C0307**

Description:	PFAS - SAS N-MeFOSE 50ug/mL	Expires:	09/23/2026
Standard Type:	Analyte Spike	Prepared:	03/15/2022
Solvent:	Methanol	Prepared By:	Wellington Laboratories (Lot#: NMeFOSE0921M)
Final Volume (mls):	1	Department:	PFAS
Vials:	1	Last Edit:	03/15/2022 15:59 by DAG

Analyte	Parent	CAS Number	Concentration	Units
NMeFOSE		24448-09-7	50	ug/mL





**INTENDED USE:**

The products prepared by Wellington Laboratories Inc. are for laboratory use only. This certified reference material (CRM) was designed to be used as a standard for the identification and/or quantification of the specific chemical compound it contains.

**HANDLING:**

This product should only be used by qualified personnel familiar with its potential hazards and trained in the handling of hazardous chemicals. Due care should be exercised to prevent unnecessary human contact or ingestion. All procedures should be carried out in a well-functioning fume hood and suitable gloves, eye protection, and clothing should be worn at all times. Waste should be disposed of according to national and regional regulations. Safety Data Sheets (SDSs) are available upon request.

**SYNTHESIS / CHARACTERIZATION:**

Our products are synthesized using single-product unambiguous routes whenever possible. They are then characterized, and their structures and purities confirmed, using a combination of the most relevant techniques, such as NMR, GC/MS, LC/MS/MS, SFC/UV/MS/MS, x-ray crystallography, and melting point. Isotopic purities of mass-labelled compounds are also confirmed using HRGC/HRMS and/or LC/MS/MS.

**HOMOGENEITY:**

Prior to solution preparation, crystalline material is tested for homogeneity using a variety of techniques (as stated above) and its solubility in a given diluent is taken into consideration. Duplicate solutions of a new product are prepared from the same crystalline lot and, after the addition of an appropriate internal standard, they are compared by GC/MS, LC/MS/MS, and/or SFC/UV/MS/MS. The relative response factors of the analyte of interest in each solution are required to be <5% RSD. New solution lots of existing products are compared to older lots in the same manner, which further confirms the homogeneity of the crystalline material as well as the stability and homogeneity of the solutions in the storage containers. In order to maintain the integrity of the assigned value(s), and associated uncertainty, the dilution or injection of a subsample of this product should be performed using calibrated measuring equipment.

**UNCERTAINTY:**

The maximum combined relative standard uncertainty of our reference standard solutions is calculated using the following equation:

The combined relative standard uncertainty,  $u_c(y)$ , of a value  $y$  and the uncertainty of the independent parameters  $x_1, x_2, \dots, x_n$  on which it depends is:

$$u_c(y(x_1, x_2, \dots, x_n)) = \sqrt{\sum_{i=1}^n u(y, x_i)^2}$$

where  $x$  is expressed as a relative standard uncertainty of the individual parameter.

The individual uncertainties taken into account include those associated with weights (calibration of the balance) and volumes (calibration of the volumetric glassware). An expanded maximum combined percent relative uncertainty of  $\pm 5\%$  (calculated with a coverage factor of 2 and a level of confidence of 95%) is stated on the Certificate of Analysis for all of our products.

**TRACEABILITY:**

All reference standard solutions are traceable to specific crystalline lots. The microbalances used for solution preparation are regularly calibrated by an external ISO/IEC 17025 accredited laboratory. In addition, their calibration is verified prior to each weighing using calibrated external weights traceable to an ISO/IEC 17025 accredited laboratory. All volumetric glassware used is calibrated, of Class A tolerance, and traceable to an ISO/IEC 17025 accredited laboratory. For certain products, traceability to international interlaboratory studies has also been established.

**EXPIRY DATE / PERIOD OF VALIDITY:**

Ongoing stability studies of this product have demonstrated stability in its composition and concentration, until the specified expiry date, in the unopened ampoule. Monitoring for any degradation or change in concentration of the listed analyte(s) is performed on a routine basis.

**LIMITED WARRANTY:**



At the time of shipment, all products are warranted to be free of defects in material and workmanship and to conform to the stated technical and purity specifications.

**QUALITY MANAGEMENT:**

This product was produced using a Quality Management System registered to the latest versions of ISO 9001 by SAI Global, ISO/IEC 17025 by the Canadian Association for Laboratory Accreditation Inc. (CALA; A1226), and ISO 17034 by ANSI National Accreditation Board (ANAB; AR-1523).



\*\*For additional information or assistance concerning this or any other products from Wellington Laboratories Inc., please visit our website at [www.well-labs.com](http://www.well-labs.com) or contact us directly at [info@well-labs.com](mailto:info@well-labs.com)\*\*

**Figure 1: FPrPA; LC/MS Data (Full Scan and Mass Spectrum)****Conditions for Figure 1:**

Waters Acquity Ultra Performance LC  
Waters Xevo TQ-S micro MS

**Chromatographic Conditions:**

Column: Acquity UPLC BEH Shield RP<sub>18</sub>  
1.7 µm, 2.1 x 100 mm

Mobile phase: Gradient

Start: 60% H<sub>2</sub>O / 40% (80:20 MeOH:ACN)  
(both with 10 mM NH<sub>4</sub>OAc buffer)  
Ramp to 90% organic over 8 min and hold for 2 min  
before returning to initial conditions in 0.75 min.  
Time: 12 min

Flow: 300 µL/min

**MS Parameters:**

Experiment: Full Scan (225 - 850 amu)


Source: Electrospray (negative)

Capillary Voltage (kV) = 2.00

Cone Voltage (V) = 10.00

Desolvation Temperature (°C) = 500

Desolvation Gas Flow (L/hr) = 1000

**Figure 2: FPrPA; LC/MS/MS Data (Selected MRM Transitions)****Conditions for Figure 2:**

Injection: On-column (FPrPA)

**MS Parameters:**

Mobile phase: Same as Figure 1

Collision Gas (mbar) = 3.33e-3

Flow: 300  $\mu$ L/min

Collision Energy (eV) = 10

# Analytical Standard Record

**22C0308**

Description:	PFAS - SAS FPrPA 50ug/mL	Expires:	02/03/2027
Standard Type:	Analyte Spike	Prepared:	03/15/2022
Solvent:	Methanol	Prepared By:	Wellington Laboratories (Lot#: FPrPA0122)
Final Volume (mls):	1	Department:	PFAS
Vials:	1	Last Edit:	03/15/2022 15:59 by DAG

Analyte	Parent	CAS Number	Concentration	Units
3:3FTCA		113507-82-7	50	ug/mL



**INTENDED USE:**

The products prepared by Wellington Laboratories Inc. are for laboratory use only. This certified reference material (CRM) was designed to be used as a standard for the identification and/or quantification of the specific chemical compound it contains.

**HANDLING:**

This product should only be used by qualified personnel familiar with its potential hazards and trained in the handling of hazardous chemicals. Due care should be exercised to prevent unnecessary human contact or ingestion. All procedures should be carried out in a well-functioning fume hood and suitable gloves, eye protection, and clothing should be worn at all times. Waste should be disposed of according to national and regional regulations. Safety Data Sheets (SDSs) are available upon request.

**SYNTHESIS / CHARACTERIZATION:**

Our products are synthesized using single-product unambiguous routes whenever possible. They are then characterized, and their structures and purities confirmed, using a combination of the most relevant techniques, such as NMR, GC/MS, LC/MS/MS, SFC/UV/MS/MS, x-ray crystallography, and melting point. Isotopic purities of mass-labelled compounds are also confirmed using HRGC/HRMS and/or LC/MS/MS.

**HOMOGENEITY:**

Prior to solution preparation, crystalline material is tested for homogeneity using a variety of techniques (as stated above) and its solubility in a given diluent is taken into consideration. Duplicate solutions of a new product are prepared from the same crystalline lot and, after the addition of an appropriate internal standard, they are compared by GC/MS, LC/MS/MS, and/or SFC/UV/MS/MS. The relative response factors of the analyte of interest in each solution are required to be <5% RSD. New solution lots of existing products are compared to older lots in the same manner, which further confirms the homogeneity of the crystalline material as well as the stability and homogeneity of the solutions in the storage containers. In order to maintain the integrity of the assigned value(s), and associated uncertainty, the dilution or injection of a subsample of this product should be performed using calibrated measuring equipment.

**UNCERTAINTY:**

The maximum combined relative standard uncertainty of our reference standard solutions is calculated using the following equation:

The combined relative standard uncertainty,  $u_c(y)$ , of a value  $y$  and the uncertainty of the independent parameters

$x_1, x_2, \dots, x_n$  on which it depends is:

$$u_c(y(x_1, x_2, \dots, x_n)) = \sqrt{\sum_{i=1}^n u(y, x_i)^2}$$

where  $x$  is expressed as a relative standard uncertainty of the individual parameter.

The individual uncertainties taken into account include those associated with weights (calibration of the balance) and volumes (calibration of the volumetric glassware). An expanded maximum combined percent relative uncertainty of  $\pm 5\%$  (calculated with a coverage factor of 2 and a level of confidence of 95%) is stated on the Certificate of Analysis for all of our products.

**TRACEABILITY:**

All reference standard solutions are traceable to specific crystalline lots. The microbalances used for solution preparation are regularly calibrated by an external ISO/IEC 17025 accredited laboratory. In addition, their calibration is verified prior to each weighing using calibrated external weights traceable to an ISO/IEC 17025 accredited laboratory. All volumetric glassware used is calibrated, of Class A tolerance, and traceable to an ISO/IEC 17025 accredited laboratory. For certain products, traceability to international interlaboratory studies has also been established.

**EXPIRY DATE / PERIOD OF VALIDITY:**

Ongoing stability studies of this product have demonstrated stability in its composition and concentration, until the specified expiry date, in the unopened ampoule. Monitoring for any degradation or change in concentration of the listed analyte(s) is performed on a routine basis.

**LIMITED WARRANTY:**



At the time of shipment, all products are warranted to be free of defects in material and workmanship and to conform to the stated technical and purity specifications.

**QUALITY MANAGEMENT:**

This product was produced using a Quality Management System registered to the latest versions of ISO 9001 by SAI Global, ISO/IEC 17025 by the Canadian Association for Laboratory Accreditation Inc. (CALA; A1226), and ISO 17034 by ANSI National Accreditation Board (ANAB; AR-1523).



\*\*For additional information or assistance concerning this or any other products from Wellington Laboratories Inc., please visit our website at [www.well-labs.com](http://www.well-labs.com) or contact us directly at [info@well-labs.com](mailto:info@well-labs.com)\*\*

**Figure 1: FPePA; LC/MS Data (Full Scan and Mass Spectrum)****Conditions for Figure 1:**

Waters Acquity Ultra Performance LC  
 Waters Xevo TQ-S micro MS

**Chromatographic Conditions:**

Column: Acquity UPLC BEH Shield RP<sub>18</sub>  
 1.7 µm, 2.1 x 100 mm

Mobile phase: Gradient  
 Start: 45% H<sub>2</sub>O / 55% (80:20 MeOH:ACN)  
 (both with 10 mM NH<sub>4</sub>OAc buffer)  
 Ramp to 90% organic over 7 min and hold for  
 3 min before returning to initial conditions in 0.75 min.  
 Time: 12 min


Flow: 300 µL/min

**MS Parameters:**

Experiment: Full Scan (250 - 850 amu)

Source: Electrospray (negative)  
 Capillary Voltage (kV) = 0.50  
 Cone Voltage (V) = 18.50  
 Desolvation Temperature (°C) = 500  
 Desolvation Gas Flow (L/hr) = 1000



**Figure 2:** FPePA; LC/MS/MS Data (Selected MRM Transitions)**Conditions for Figure 2:**

Injection: On-column (FPePA)  
 Mobile phase: Same as Figure 1  
 Flow: 300  $\mu$ L/min

**MS Parameters:**

Collision Gas (mbar) = 3.09e-3  
 Collision Energy (eV) = 10

# Analytical Standard Record

**22C0309**

Description:	PFAS - SAS FPePA 50ug/mL	Expires:	01/05/2027
Standard Type:	Analyte Spike	Prepared:	03/15/2022
Solvent:	Methanol	Prepared By:	Wellington Laboratories (Lot#:
Final Volume (mls):	1	Department:	PFAS1221)
Vials:	1	Last Edit:	03/15/2022 15:59 by DAG


Analyte	Parent	CAS Number	Concentration	Units
5:3FTCA		914637-49-3	50	ug/mL



# WELLINGTON LABORATORIES

## CERTIFICATE OF ANALYSIS DOCUMENTATION

**PRODUCT CODE:** N-EtFOSE-M **LOT NUMBER:** NEtFOSE0921M  
**COMPOUND:** 2-(N-ethylperfluoro-1-octanesulfonamido)-ethanol **22C0310**  
**STRUCTURE:** **CAS #:** 1691-99-2



**MOLECULAR FORMULA:**  $C_{12}H_{10}F_{17}NO_3S$  **MOLECULAR WEIGHT:** 571.25  
**CONCENTRATION:**  $50.0 \pm 2.5 \mu\text{g/mL}$  **SOLVENT(S):** Methanol  
**CHEMICAL PURITY:** >98%  
**LAST TESTED:** (mm/dd/yyyy) 09/22/2021 (HRGC/LRMS)  
 09/23/2021 (LC/MS)  
**EXPIRY DATE:** (mm/dd/yyyy) 09/23/2026  
**RECOMMENDED STORAGE:** Store ampoule in a cool, dark place

### DOCUMENTATION/ DATA ATTACHED:

Figure 1: HRGC/LRMS Data (Full Scan and Mass Spectrum)  
 Figure 2: LC/MS Data (Full Scan and Mass Spectrum)  
 Figure 3: LC/MS/MS Data (Selected MRM Transitions)

### ADDITIONAL INFORMATION:

- See page 2 for further details.
- In order to see the molecular ion (adduct free), the LC mobile phase should be free of ammonium acetate buffer.

**FOR LABORATORY USE ONLY: NOT FOR HUMAN OR DRUG USE**

Certified By:   
 B.G. Chittim, General Manager

Date: 10/20/2021  
 (mm/dd/yyyy)

Wellington Laboratories Inc., 345 Southgate Dr. Guelph ON N1G 3M5 CANADA  
 519-822-2436 • Fax: 519-822-2849 • info@well-labs.com

**INTENDED USE:**

The products prepared by Wellington Laboratories Inc. are for laboratory use only. This certified reference material (CRM) was designed to be used as a standard for the identification and/or quantification of the specific chemical compound it contains.

**HANDLING:**

This product should only be used by qualified personnel familiar with its potential hazards and trained in the handling of hazardous chemicals. Due care should be exercised to prevent unnecessary human contact or ingestion. All procedures should be carried out in a well-functioning fume hood and suitable gloves, eye protection, and clothing should be worn at all times. Waste should be disposed of according to national and regional regulations. Safety Data Sheets (SDSs) are available upon request.

**SYNTHESIS / CHARACTERIZATION:**

Our products are synthesized using single-product unambiguous routes whenever possible. They are then characterized, and their structures and purities confirmed, using a combination of the most relevant techniques, such as NMR, GC/MS, LC/MS/MS, SFC/UV/MS/MS, x-ray crystallography, and melting point. Isotopic purities of mass-labelled compounds are also confirmed using HRGC/HRMS and/or LC/MS/MS.

**HOMOGENEITY:**

Prior to solution preparation, crystalline material is tested for homogeneity using a variety of techniques (as stated above) and its solubility in a given diluent is taken into consideration. Duplicate solutions of a new product are prepared from the same crystalline lot and, after the addition of an appropriate internal standard, they are compared by GC/MS, LC/MS/MS, and/or SFC/UV/MS/MS. The relative response factors of the analyte of interest in each solution are required to be <5% RSD. New solution lots of existing products are compared to older lots in the same manner, which further confirms the homogeneity of the crystalline material as well as the stability and homogeneity of the solutions in the storage containers. In order to maintain the integrity of the assigned value(s), and associated uncertainty, the dilution or injection of a subsample of this product should be performed using calibrated measuring equipment.

**UNCERTAINTY:**

The maximum combined relative standard uncertainty of our reference standard solutions is calculated using the following equation:

The combined relative standard uncertainty,  $u_c(y)$ , of a value  $y$  and the uncertainty of the independent parameters  $x_1, x_2, \dots, x_n$  on which it depends is:

$$u_c(y(x_1, x_2, \dots, x_n)) = \sqrt{\sum_{i=1}^n u(y, x_i)^2}$$

where  $x$  is expressed as a relative standard uncertainty of the individual parameter.

The individual uncertainties taken into account include those associated with weights (calibration of the balance) and volumes (calibration of the volumetric glassware). An expanded maximum combined percent relative uncertainty of  $\pm 5\%$  (calculated with a coverage factor of 2 and a level of confidence of 95%) is stated on the Certificate of Analysis for all of our products.

**TRACEABILITY:**

All reference standard solutions are traceable to specific crystalline lots. The microbalances used for solution preparation are regularly calibrated by an external ISO/IEC 17025 accredited laboratory. In addition, their calibration is verified prior to each weighing using calibrated external weights traceable to an ISO/IEC 17025 accredited laboratory. All volumetric glassware used is calibrated, of Class A tolerance, and traceable to an ISO/IEC 17025 accredited laboratory. For certain products, traceability to international interlaboratory studies has also been established.

**EXPIRY DATE / PERIOD OF VALIDITY:**

Ongoing stability studies of this product have demonstrated stability in its composition and concentration, until the specified expiry date, in the unopened ampoule. Monitoring for any degradation or change in concentration of the listed analyte(s) is performed on a routine basis.

**LIMITED WARRANTY:**


At the time of shipment, all products are warranted to be free of defects in material and workmanship and to conform to the stated technical and purity specifications.

**QUALITY MANAGEMENT:**

This product was produced using a Quality Management System registered to the latest versions of ISO 9001 by SAI Global, ISO/IEC 17025 by the Canadian Association for Laboratory Accreditation Inc. (CALA; A1226), and ISO 17034 by ANSI National Accreditation Board (ANAB; AR-1523).



\*\*For additional information or assistance concerning this or any other products from Wellington Laboratories Inc., please visit our website at [www.well-labs.com](http://www.well-labs.com) or contact us directly at [info@well-labs.com](mailto:info@well-labs.com)\*\*

**Figure 1: N-EtFOSE-M; HRGC/LRMS Data (Full Scan and Mass Spectrum)****Conditions for Figure 1:**

Agilent 7890A HRGC  
 Agilent 5975C MSD

**Chromatographic Conditions:**

Column: 30 m DB-5 (0.25 mm id, 0.25  $\mu$ m film thickness) Agilent J&W



Flow: Constant at 1 mL/min

Injector: 250°C (Splitless Injection)

Oven: 100°C (5 min)  
 10°C/min to 325°C  
 325°C (10 min)

Ionization: EI+

Detector: 230°C  
 Full Scan (50-1000 amu)

**Figure 2: N-EtFOSE-M; LC/MS Data (Full Scan and Mass Spectrum)****Conditions for Figure 2:**

Waters Acquity Ultra Performance LC  
Waters Xevo TQ-S micro MS

**Chromatographic Conditions:**

Column: Acquity UPLC BEH Shield RP<sub>18</sub>  
1.7 µm, 2.1 x 100 mm

Mobile phase: Gradient


Start: 30% H<sub>2</sub>O / 70% MeOH  
Ramp to 90% organic over 8 min and hold for  
1.5 min before returning to initial conditions in 1 min.  
Time: 12 min

Flow: 300 µL/min

**MS Parameters:**

Experiment: Full Scan (250 - 850 amu)

Source: Electrospray (negative)  
Capillary Voltage (kV) = 2.00  
Cone Voltage (V) = 65.00  
Desolvation Temperature (°C) = 450  
Desolvation Gas Flow (L/hr) = 1000

**Figure 3: N-EtFOSE-M; LC/MS/MS Data (Selected MRM Transitions)****Conditions for Figure 3:**

Injection: On-column (N-EtFOSE-M)

Mobile phase: Same as Figure 2

Flow: 300  $\mu$ L/min**MS Parameters:**

Collision Gas (mbar) = 3.14e-3

Collision Energy (eV) = 32






# Analytical Standard Record

**22C0310**

Description:	PFAS - SAS NtFOSE 50ug/mL	Expires:	09/23/2026
Standard Type:	Analyte Spike	Prepared:	03/15/2022
Solvent:	Methanol	Prepared By:	Wellington Laboratories (Lot#:
Final Volume (mls):	1	Department:	PFAS (Lot# PFAS0921M)
Vials:	1	Last Edit:	03/15/2022 15:59 by DAG


Analyte	Parent	CAS Number	Concentration	Units
NETFOSE		1691-99-2	50	ug/mL



# WELLINGTON LABORATORIES

## CERTIFICATE OF ANALYSIS DOCUMENTATION

**PRODUCT CODE:** FHpPA      **LOT NUMBER:** FHpPA1020  
**COMPOUND:** 3-Perfluoroheptyl propanoic acid      **22C0311**  
**STRUCTURE:**      **CAS #:** 812-70-4



**MOLECULAR FORMULA:** C<sub>10</sub>H<sub>6</sub>F<sub>16</sub>O<sub>2</sub>      **MOLECULAR WEIGHT:** 442.12  
**CONCENTRATION:** 50.0 ± 2.5 µg/mL      **SOLVENT(S):** Methanol  
**CHEMICAL PURITY:** >98%  
**LAST TESTED:** (mm/dd/yyyy) 11/12/2020  
**EXPIRY DATE:** (mm/dd/yyyy) 11/12/2025  
**RECOMMENDED STORAGE:** Refrigerate ampoule

### DOCUMENTATION/ DATA ATTACHED:


Figure 1: LC/MS Data (TIC and Mass Spectrum)  
Figure 2: LC/MS/MS Data (Selected MRM Transitions)

### ADDITIONAL INFORMATION:

- See page 2 for further details.

**FOR LABORATORY USE ONLY: NOT FOR HUMAN OR DRUG USE**

Certified By:

  
B.G. Chittim, General Manager

Date: 11/27/2020  
(mm/dd/yyyy)

Wellington Laboratories Inc., 345 Southgate Dr. Guelph ON N1G 3M5 CANADA  
519-822-2436 • Fax: 519-822-2849 • info@well-labs.com

**INTENDED USE:**

The products prepared by Wellington Laboratories Inc. are for laboratory use only. This certified reference material (CRM) was designed to be used as a standard for the identification and/or quantification of the specific chemical compound it contains.

**HANDLING:**

This product should only be used by qualified personnel familiar with its potential hazards and trained in the handling of hazardous chemicals. Due care should be exercised to prevent unnecessary human contact or ingestion. All procedures should be carried out in a well-functioning fume hood and suitable gloves, eye protection, and clothing should be worn at all times. Waste should be disposed of according to national and regional regulations. Safety Data Sheets (SDSs) are available upon request.

**SYNTHESIS / CHARACTERIZATION:**

Our products are synthesized using single-product unambiguous routes whenever possible. They are then characterized, and their structures and purities confirmed, using a combination of the most relevant techniques, such as NMR, GC/MS, LC/MS/MS, SFC/UV/MS/MS, x-ray crystallography, and melting point. Isotopic purities of mass-labelled compounds are also confirmed using HRGC/HRMS and/or LC/MS/MS.

**HOMOGENEITY:**

Prior to solution preparation, crystalline material is tested for homogeneity using a variety of techniques (as stated above) and its solubility in a given diluent is taken into consideration. Duplicate solutions of a new product are prepared from the same crystalline lot and, after the addition of an appropriate internal standard, they are compared by GC/MS, LC/MS/MS, and/or SFC/UV/MS/MS. The relative response factors of the analyte of interest in each solution are required to be <5% RSD. New solution lots of existing products are compared to older lots in the same manner, which further confirms the homogeneity of the crystalline material as well as the stability and homogeneity of the solutions in the storage containers. In order to maintain the integrity of the assigned value(s), and associated uncertainty, the dilution or injection of a subsample of this product should be performed using calibrated measuring equipment.

**UNCERTAINTY:**

The maximum combined relative standard uncertainty of our reference standard solutions is calculated using the following equation:

The combined relative standard uncertainty,  $u_c(y)$ , of a value  $y$  and the uncertainty of the independent parameters  $x_1, x_2, \dots, x_n$  on which it depends is:

$$u_c(y(x_1, x_2, \dots, x_n)) = \sqrt{\sum_{i=1}^n u(y, x_i)^2}$$

where  $x$  is expressed as a relative standard uncertainty of the individual parameter.

The individual uncertainties taken into account include those associated with weights (calibration of the balance) and volumes (calibration of the volumetric glassware). An expanded maximum combined percent relative uncertainty of  $\pm 5\%$  (calculated with a coverage factor of 2 and a level of confidence of 95%) is stated on the Certificate of Analysis for all of our products.

**TRACEABILITY:**

All reference standard solutions are traceable to specific crystalline lots. The microbalances used for solution preparation are regularly calibrated by an external ISO/IEC 17025 accredited laboratory. In addition, their calibration is verified prior to each weighing using calibrated external weights traceable to an ISO/IEC 17025 accredited laboratory. All volumetric glassware used is calibrated, of Class A tolerance, and traceable to an ISO/IEC 17025 accredited laboratory. For certain products, traceability to international interlaboratory studies has also been established.

**EXPIRY DATE / PERIOD OF VALIDITY:**

Ongoing stability studies of this product have demonstrated stability in its composition and concentration, until the specified expiry date, in the unopened ampoule. Monitoring for any degradation or change in concentration of the listed analyte(s) is performed on a routine basis.

**LIMITED WARRANTY:**



At the time of shipment, all products are warranted to be free of defects in material and workmanship and to conform to the stated technical and purity specifications.

**QUALITY MANAGEMENT:**

This product was produced using a Quality Management System registered to the latest versions of ISO 9001 by SAI Global, ISO/IEC 17025 by the Canadian Association for Laboratory Accreditation Inc. (CALA; A1226), and ISO 17034 by ANSI-ASQ National Accreditation Board (ANAB; AR-1523).



\*\*For additional information or assistance concerning this or any other products from Wellington Laboratories Inc., please visit our website at [www.well-labs.com](http://www.well-labs.com) or contact us directly at [info@well-labs.com](mailto:info@well-labs.com)\*\*

**Figure 1: FHpPA; LC/MS Data (TIC and Mass Spectrum)****Conditions for Figure 1:**

Waters Acquity Ultra Performance LC  
Waters Xevo TQ-S micro MS

**Chromatographic Conditions:**

Column: Acquity UPLC BEH Shield RP<sub>18</sub>  
1.7  $\mu$ m, 2.1 x 100 mm

Mobile phase: Gradient

Start: 45% H<sub>2</sub>O / 55% (80:20 MeOH:ACN)  
(both with 10 mM NH<sub>4</sub>OAc buffer)  
Ramp to 90% organic over 8 min and hold for  
2 min before returning to initial conditions in 0.75 min.  
Time: 12 min

Flow: 300  $\mu$ L/min

**MS Parameters:**

Experiment: Full Scan (225 - 850 amu)


Source: Electrospray (negative)

Capillary Voltage (kV) = 0.50

Cone Voltage (V) = 28.50

Desolvation Temperature ( $^{\circ}$ C) = 500

Desolvation Gas Flow (L/hr) = 1000

**Figure 2: FHpPA; LC/MS/MS Data (Selected MRM Transitions)****Conditions for Figure 2:**

Injection: On-column (FHpPA)

Mobile phase: Same as Figure 1

Flow: 300  $\mu$ L/min**MS Parameters:**

Collision Gas (mbar) = 3.41e-3

Collision Energy (eV) = 8

# Analytical Standard Record

**22C0311**

Description:	PFAS - SAS FHpPA 50ug/mL	Expires:	11/12/2025
Standard Type:	Analyte Spike	Prepared:	03/15/2022
Solvent:	Methanol	Prepared By:	Wellington Laboratories (Lot#: FHpPA1020)
Final Volume (mls):	1	Department:	PFAS
Vials:	1	Last Edit:	03/15/2022 16:00 by DAG

Analyte	Parent	CAS Number	Concentration	Units
7:3FTCA		812-70-4	50	ug/mL

# Analytical Standard Record

**22C0311**

Description:	PFAS - SAS FHpPA 50ug/mL	Expires:	11/12/2025
Standard Type:	Analyte Spike	Prepared:	03/15/2022
Solvent:	Methanol	Prepared By:	Wellington Laboratories (Lot#: FHpPA1020)
Final Volume (mls):	1	Department:	FHpPA
Vials:	1	Last Edit:	03/15/2022 16:00 by DAG


Analyte	Parent	CAS Number	Concentration	Units
7:3FTCA		812-70-4	50	ug/mL



# WELLINGTON LABORATORIES

## CERTIFICATE OF ANALYSIS DOCUMENTATION

**PRODUCT CODE:** N-MeFOSA-M      **LOT NUMBER:** NMeFOSA0721M  
**COMPOUND:** N-methylperfluoro-1-octanesulfonamide      22C0312  
**STRUCTURE:**      **CAS #:** 31506-32-8



**MOLECULAR FORMULA:** C<sub>9</sub>H<sub>4</sub>F<sub>17</sub>NO<sub>2</sub>S      **MOLECULAR WEIGHT:** 513.17  
**CONCENTRATION:** 50.0 ± 2.5 µg/mL      **SOLVENT(S):** Methanol  
**CHEMICAL PURITY:** >98%  
**LAST TESTED:** (mm/dd/yyyy) 08/03/2021  
**EXPIRY DATE:** (mm/dd/yyyy) 08/03/2026  
**RECOMMENDED STORAGE:** Store ampoule in a cool, dark place

### DOCUMENTATION/ DATA ATTACHED:

Figure 1: LC/MS Data (Full Scan and Mass Spectrum)  
 Figure 2: LC/MS/MS Data (Selected MRM Transitions)

### ADDITIONAL INFORMATION:

- See page 2 for further details.

**FOR LABORATORY USE ONLY: NOT FOR HUMAN OR DRUG USE**

Certified By: \_\_\_\_\_

B.G. Chittim, General Manager

Date: 08/04/2021  
 (mm/dd/yyyy)

Wellington Laboratories Inc., 345 Southgate Dr. Guelph ON N1G 3M5 CANADA  
 519-822-2436 • Fax: 519-822-2849 • info@well-labs.com



**INTENDED USE:**

The products prepared by Wellington Laboratories Inc. are for laboratory use only. This certified reference material (CRM) was designed to be used as a standard for the identification and/or quantification of the specific chemical compound it contains.

**HANDLING:**

This product should only be used by qualified personnel familiar with its potential hazards and trained in the handling of hazardous chemicals. Due care should be exercised to prevent unnecessary human contact or ingestion. All procedures should be carried out in a well-functioning fume hood and suitable gloves, eye protection, and clothing should be worn at all times. Waste should be disposed of according to national and regional regulations. Safety Data Sheets (SDSs) are available upon request.

**SYNTHESIS / CHARACTERIZATION:**

Our products are synthesized using single-product unambiguous routes whenever possible. They are then characterized, and their structures and purities confirmed, using a combination of the most relevant techniques, such as NMR, GC/MS, LC/MS/MS, SFC/UV/MS/MS, x-ray crystallography, and melting point. Isotopic purities of mass-labelled compounds are also confirmed using HRGC/HRMS and/or LC/MS/MS.

**HOMOGENEITY:**

Prior to solution preparation, crystalline material is tested for homogeneity using a variety of techniques (as stated above) and its solubility in a given diluent is taken into consideration. Duplicate solutions of a new product are prepared from the same crystalline lot and, after the addition of an appropriate internal standard, they are compared by GC/MS, LC/MS/MS, and/or SFC/UV/MS/MS. The relative response factors of the analyte of interest in each solution are required to be <5% RSD. New solution lots of existing products are compared to older lots in the same manner, which further confirms the homogeneity of the crystalline material as well as the stability and homogeneity of the solutions in the storage containers. In order to maintain the integrity of the assigned value(s), and associated uncertainty, the dilution or injection of a subsample of this product should be performed using calibrated measuring equipment.

**UNCERTAINTY:**

The maximum combined relative standard uncertainty of our reference standard solutions is calculated using the following equation:

The combined relative standard uncertainty,  $u_c(y)$ , of a value  $y$  and the uncertainty of the independent parameters  $x_1, x_2, \dots, x_n$  on which it depends is:

$$u_c(y(x_1, x_2, \dots, x_n)) = \sqrt{\sum_{i=1}^n u(y, x_i)^2}$$

where  $x$  is expressed as a relative standard uncertainty of the individual parameter.

The individual uncertainties taken into account include those associated with weights (calibration of the balance) and volumes (calibration of the volumetric glassware). An expanded maximum combined percent relative uncertainty of  $\pm 5\%$  (calculated with a coverage factor of 2 and a level of confidence of 95%) is stated on the Certificate of Analysis for all of our products.

**TRACEABILITY:**

All reference standard solutions are traceable to specific crystalline lots. The microbalances used for solution preparation are regularly calibrated by an external ISO/IEC 17025 accredited laboratory. In addition, their calibration is verified prior to each weighing using calibrated external weights traceable to an ISO/IEC 17025 accredited laboratory. All volumetric glassware used is calibrated, of Class A tolerance, and traceable to an ISO/IEC 17025 accredited laboratory. For certain products, traceability to international interlaboratory studies has also been established.

**EXPIRY DATE / PERIOD OF VALIDITY:**

Ongoing stability studies of this product have demonstrated stability in its composition and concentration, until the specified expiry date, in the unopened ampoule. Monitoring for any degradation or change in concentration of the listed analyte(s) is performed on a routine basis.

**LIMITED WARRANTY:**



At the time of shipment, all products are warranted to be free of defects in material and workmanship and to conform to the stated technical and purity specifications.

**QUALITY MANAGEMENT:**

This product was produced using a Quality Management System registered to the latest versions of ISO 9001 by SAI Global, ISO/IEC 17025 by the Canadian Association for Laboratory Accreditation Inc. (CALA; A1226), and ISO 17034 by ANSI National Accreditation Board (ANAB; AR-1523).



\*\*For additional information or assistance concerning this or any other products from Wellington Laboratories Inc., please visit our website at [www.well-labs.com](http://www.well-labs.com) or contact us directly at [info@well-labs.com](mailto:info@well-labs.com)\*\*

**Figure 1: N-MeFOSA-M; LC/MS Data (Full Scan and Mass Spectrum)****Conditions for Figure 1:**

Waters Acquity Ultra Performance LC  
Waters Xevo TQ-S micro MS

**Chromatographic Conditions:**

Column: Acquity UPLC BEH Shield RP<sub>18</sub>  
1.7  $\mu$ m, 2.1 x 100 mm


Mobile phase: Gradient  
Start: 40% H<sub>2</sub>O / 60% (80:20 MeOH:ACN)  
(both with 10 mM NH<sub>4</sub>OAc buffer)  
Ramp to 90% organic over 8 min and hold for  
2 min before returning to initial conditions in 0.75 min.  
Time: 12 min

Flow: 300  $\mu$ L/min

**MS Parameters:**

Experiment: Full Scan (250 - 850 amu)

Source: Electrospray (negative)  
Capillary Voltage (kV) = 1.00  
Cone Voltage (V) = 44.00  
Desolvation Temperature (°C) = 500  
Desolvation Gas Flow (L/hr) = 1000

**Figure 2: N-MeFOSA-M; LC/MS/MS Data (Selected MRM Transitions)****Conditions for Figure 2:**

Injection: On-column (N-MeFOSA-M)

Mobile phase: Same as Figure 1

Flow: 300  $\mu$ L/min**MS Parameters:**

Collision Gas (mbar) = 3.41e-3

Collision Energy (eV) = 24

# Analytical Standard Record

**22C0312**

Description:	PFAS - SAS NMeFOSA 50ug/mL	Expires:	08/03/2026
Standard Type:	Analyte Spike	Prepared:	03/15/2022
Solvent:	Methanol	Prepared By:	Dipti Gokal
Final Volume (mls):	1	Department:	PFAS
Vials:	1	Last Edit:	03/15/2022 16:00 by DAG


Analyte	Parent	CAS Number	Concentration	Units
NMeFOSA		31506-32-8	50	ug/mL



# WELLINGTON LABORATORIES

## CERTIFICATE OF ANALYSIS DOCUMENTATION

**PRODUCT CODE:** N-EtFOSA-M      **LOT NUMBER:** NEtFOSA0821M  
**COMPOUND:** N-ethylperfluoro-1-octanesulfonamide      **22C0313**  
**STRUCTURE:**      **CAS #:** 4151-50-2



**MOLECULAR FORMULA:**  $C_{10}H_{17}F_{17}NO_2S$       **MOLECULAR WEIGHT:** 527.20  
**CONCENTRATION:**  $50.0 \pm 2.5 \mu\text{g/mL}$       **SOLVENT(S):** Methanol  
**CHEMICAL PURITY:** >98%  
**LAST TESTED:** (mm/dd/yyyy) 08/12/2021  
**EXPIRY DATE:** (mm/dd/yyyy) 08/12/2026  
**RECOMMENDED STORAGE:** Store ampoule in a cool, dark place

### DOCUMENTATION/ DATA ATTACHED:

Figure 1: LC/MS Data (Full Scan and Mass Spectrum)  
Figure 2: LC/MS/MS Data (Selected MRM Transitions)

### ADDITIONAL INFORMATION:

- See page 2 for further details.



**FOR LABORATORY USE ONLY: NOT FOR HUMAN OR DRUG USE**

Certified By: \_\_\_\_\_

B.G. Chittim, General Manager

Date: 08/16/2021  
(mm/dd/yyyy)

Wellington Laboratories Inc., 345 Southgate Dr. Guelph ON N1G 3M5 CANADA  
519-822-2436 • Fax: 519-822-2849 • info@well-labs.com

**Figure 1: N-EtFOSA-M; LC/MS Data (Full Scan and Mass Spectrum)****Conditions for Figure 1:**

Waters Acquity Ultra Performance LC  
Waters Xevo TQ-S micro MS

**Chromatographic Conditions:**

Column: Acquity UPLC BEH Shield RP<sub>18</sub>  
1.7  $\mu$ m, 2.1 x 100 mm

**Mobile phase: Gradient**

Start: 30% H<sub>2</sub>O / 70% (80:20 MeOH:ACN)  
(both with 10 mM NH<sub>4</sub>OAc buffer)  
Ramp to 90% organic over 8 min and hold for  
2 min before returning to initial conditions in 0.75 min.  
Time: 12 min

Flow: 300  $\mu$ L/min

**MS Parameters:**

Experiment: Full Scan (225 - 850 amu)

Source: Electrospray (negative)  
Capillary Voltage (kV) = 1.00  
Cone Voltage (V) = 44.00  
Desolvation Temperature ( $^{\circ}$ C) = 500  
Desolvation Gas Flow (L/hr) = 1000

# Analytical Standard Record

**22C0313**

Description:	PFAS - SAS NETFOSA 50ug/mL	Expires:	08/12/2026
Standard Type:	Other	Prepared:	03/15/2022
Solvent:	Methanol	Prepared By:	Wellington Laboratories (Lot#:
Final Volume (mls):	1	Department:	NETFOSA0821M)
Vials:	1	Last Edit:	08/17/2022 10:49 by LYA

Analyte	Parent	CAS Number	Concentration	Units
NETFOSA		4151-50-2	50	ug/mL



# WELLINGTON LABORATORIES

## CERTIFICATE OF ANALYSIS DOCUMENTATION

**PFAC-MXF** 22F0058

**Native Replacement PFAS  
Solution/Mixture**

**PRODUCT CODE:** PFAC-MXF  
**LOT NUMBER:** PFACMXF0122  
**SOLVENT(S):** Methanol / Water (<1%)  
**DATE PREPARED:** (mm/dd/yyyy) 01/10/2022  
**LAST TESTED:** (mm/dd/yyyy) 01/11/2022  
**EXPIRY DATE:** (mm/dd/yyyy) 01/11/2025  
**RECOMMENDED STORAGE:** Refrigerate ampoule

**DESCRIPTION:**

PFAC-MXF is a solution/mixture of sodium dodecafluoro-3H-4,8-dioxanonanoate (NaDONA), the major and minor components of F-53B (9Cl-PF3ONS and 11Cl-PF3OUdS), and GenX (HFPO-DA). The components and their concentrations are given in Table A.

The individual native components of this mixture all have chemical purities of >98%.

**DOCUMENTATION/ DATA ATTACHED:**

Table A: Components and Concentrations of the Solution/Mixture  
 Figure 1: LC/MS Data (SIR)  
 Figure 2: LC/MS/MS Data (Selected MRM Transitions)

**ADDITIONAL INFORMATION:**

- See page 2 for further details.
- Contains 4 mole eq. of NaOH to prevent conversion of the carboxylic acid to the methyl ester.

**FOR LABORATORY USE ONLY: NOT FOR HUMAN OR DRUG USE**

Wellington Laboratories Inc., 345 Southgate Dr. Guelph ON N1G 3M5 CANADA  
 519-822-2436 • Fax: 519-822-2849 • info@well-labs.com



**INTENDED USE:**

The products prepared by Wellington Laboratories Inc. are for laboratory use only. This certified reference material (CRM) was designed to be used as a standard for the identification and/or quantification of the specific chemical compounds it contains.

**HANDLING:**

This product should only be used by qualified personnel familiar with its potential hazards and trained in the handling of hazardous chemicals. Due care should be exercised to prevent unnecessary human contact or ingestion. All procedures should be carried out in a well-functioning fume hood and suitable gloves, eye protection, and clothing should be worn at all times. Waste should be disposed of according to national and regional regulations. Safety Data Sheets (SDSs) are available upon request.

**SYNTHESIS / CHARACTERIZATION:**

Our products are synthesized using single-product unambiguous routes whenever possible. They are then characterized, and their structures and purities confirmed, using a combination of the most relevant techniques, such as NMR, GC/MS, LC/MS/MS, SFC/UV/MS/MS, x-ray crystallography, and melting point. Isotopic purities of mass-labelled compounds are also confirmed using HRGC/HRMS and/or LC/MS/MS.

**HOMOGENEITY:**

Prior to solution preparation, crystalline material is tested for homogeneity using a variety of techniques (as stated above) and its solubility in a given diluent is taken into consideration. Duplicate solutions of a new product are prepared from the same crystalline lot and, after the addition of an appropriate internal standard, they are compared by GC/MS, LC/MS/MS, and/or SFC/UV/MS/MS. The relative response factors of the analyte of interest in each solution are required to be <5% RSD. New solution lots of existing products, as well as mixtures and calibration solutions, are compared to older lots in a similar manner. This further confirms the homogeneity of the crystalline material as well as the stability and homogeneity of the solutions in the storage containers. In order to maintain the integrity of the assigned value(s), and associated uncertainty, the dilution or injection of a subsample of this product should be performed using calibrated measuring equipment.

**UNCERTAINTY:**

The maximum combined relative standard uncertainty of our reference standard solutions is calculated using the following equation:

The combined relative standard uncertainty,  $u_c(y)$ , of a value  $y$  and the uncertainty of the independent parameters  $x_1, x_2, \dots, x_n$  on which it depends is:

$$u_c(y(x_1, x_2, \dots, x_n)) = \sqrt{\sum_{i=1}^n u(y, x_i)^2}$$

where  $x$  is expressed as a relative standard uncertainty of the individual parameter.

The individual uncertainties taken into account include those associated with weights (calibration of the balance) and volumes (calibration of the volumetric glassware). An expanded maximum combined percent relative uncertainty of  $\pm 5\%$  (calculated with a coverage factor of 2 and a level of confidence of 95%) is stated on the Certificate of Analysis for all of our products.

**TRACEABILITY:**

All reference standard solutions are traceable to specific crystalline lots. The microbalances used for solution preparation are regularly calibrated by an external ISO/IEC 17025 accredited laboratory. In addition, their calibration is verified prior to each weighing using calibrated external weights traceable to an ISO/IEC 17025 accredited laboratory. All volumetric glassware used is calibrated, of Class A tolerance, and traceable to an ISO/IEC 17025 accredited laboratory. For certain products, traceability to international interlaboratory studies has also been established.

**EXPIRY DATE / PERIOD OF VALIDITY:**

Ongoing stability studies of this product have demonstrated stability in its composition and concentration, until the specified expiry date, in the unopened ampoule. Monitoring for any degradation or change in concentration of the listed analyte(s) is performed on a routine basis.

**LIMITED WARRANTY:**

At the time of shipment, all products are warranted to be free of defects in material and workmanship and to conform to the stated technical and purity specifications.

**QUALITY MANAGEMENT:**

This product was produced using a Quality Management System registered to the latest versions of ISO 9001 by SAI Global, ISO/IEC 17025 by the Canadian Association for Laboratory Accreditation Inc. (CALA; A1226), and ISO 17034 by ANSI National Accreditation Board (ANAB; AR-1523).



\*\*For additional information or assistance concerning this or any other products from Wellington Laboratories Inc., please visit our website at [www.well-labs.com](http://www.well-labs.com) or contact us directly at [info@well-labs.com](mailto:info@well-labs.com)\*\*

**Table A: PFAC-MXF; Components and Concentrations (ng/mL;  $\pm$  5% in Methanol/Water (<1%))**


Compound	Acronym	Concentration* (ng/ml)		Peak Assignment in Figure 1
		as the salt	as the acid	
2,3,3,3-Tetrafluoro-2-(1,1,2,2,3,3,3-heptafluoropropoxy)-propanoic acid	HFPO-DA	2000		A
Sodium dodecafluoro-3H-4,8-dioxanonanoate	NaDONA	2000	1890	B
Potassium 9-chlorohexadecafluoro-3-oxanonane-1-sulfonate	9Cl-PF3ONS	2000	1870	C
Potassium 11-chloroeicosafluoro-3-oxaundecane-1-sulfonate	11Cl-PF3OUdS	2000	1890	D

\* Concentrations have been rounded to three significant figures.

Certified By: 

B.G. Chittim, General Manager

Date: 01/12/2022  
(mm/dd/yyyy)

**Figure 1: PFAC-MXF; LC/MS Data (SIR)****Conditions for Figure 1:**

Waters Acquity Ultra Performance LC  
Waters Xevo TQ-S micro MS

**Chromatographic Conditions:**

Column: Acquity UPLC BEH Shield RP<sub>18</sub>  
1.7  $\mu$ m, 2.1 x 100 mm


Mobile phase: Gradient  
Start: 45% H<sub>2</sub>O / 55% (80:20 MeOH:ACN)  
(both with 10 mM NH<sub>4</sub>OAc buffer)  
Ramp to 90% organic over 8 min and hold for 2 min  
before returning to initial conditions in 0.75 min.  
Time: 12 min

Flow: 300  $\mu$ L/min

**MS Parameters:**

Experiment: SIR

Source: Electrospray (negative)  
Capillary Voltage (kV) = 2.00  
Cone Voltage (V) = variable (15-74)  
Desolvation Temperature ( $^{\circ}$ C) = 325  
Desolvation Gas Flow (L/hr) = 1000

**Figure 2: PFAC-MXF; LC/MS/MS Data (Selected MRM Transitions)****Conditions for Figure 2:**

Injection: On-column (PFAC-MXF)

Mobile phase: Same as Figure 1

Flow: 300  $\mu$ L/min**MS Parameters:**

Collision Gas (mbar) = 3.43e-3

Collision Energy (eV) = 6-60 (variable)



# Analytical Standard Record

**22F0058**

Description:	PFAS - MIX MXF 2ug/mL	Expires:	01/11/2025
Standard Type:	Other	Prepared:	01/10/2022
Solvent:	MeOH	Prepared By:	Lizbeth Andres
Final Volume (mls):	1.2	Department:	PFAS
Vials:	1	Last Edit:	09/15/2022 09:32 by DAG

Analyte	Parent	CAS Number	Concentration	Units
11CL-PF3OUDS		763051-92-9	1.89	ug/mL
9CL-PF3ONS		756426-58-1	1.87	ug/mL
ADONA		919005-14-4	1.89	ug/mL
HFPO-DA		13252-13-6	2	ug/mL



# WELLINGTON LABORATORIES

## CERTIFICATE OF ANALYSIS DOCUMENTATION

**PFAC-MXH** 22F0059

**Native Per- and Poly-fluoroalkyl Substance  
Solution/Mixture**

**PRODUCT CODE:** PFAC-MXH  
**LOT NUMBER:** PFACMXH0921  
**SOLVENT(S):** Methanol / Isopropanol (2%) / Water (<1%)  
**DATE PREPARED:** (mm/dd/yyyy) 09/09/2021  
**LAST TESTED:** (mm/dd/yyyy) 09/14/2021  
**EXPIRY DATE:** (mm/dd/yyyy) 09/14/2026  
**RECOMMENDED STORAGE:** Refrigerate ampoule

**DESCRIPTION:**

PFAC-MXH is a solution/mixture of eleven native linear perfluoroalkylcarboxylic acids (C<sub>4</sub>-C<sub>14</sub>), eight native perfluoroalkanesulfonates (C<sub>4</sub>, C<sub>5</sub>, C<sub>7</sub>, C<sub>9</sub>, C<sub>10</sub> and C<sub>12</sub> linear; C<sub>6</sub> and C<sub>8</sub> linear and branched), three native fluorotelomer sulfonates (4:2, 6:2, and 8:2), two native linear and branched perfluorooctanesulfonamidoacetic acids, and perfluoro-1-octanesulfonamide (FOSA). The components and their concentrations are given in Table A.

The individual components of this mixture all have chemical purities of >98%.

**DOCUMENTATION/ DATA ATTACHED:**

Table A: Components and Concentrations of the Solution/Mixture  
 Table B: Isomeric Components and Percent Composition of br-NMeFOSAA  
 Table C: Isomeric Components and Percent Composition of br-NEtFOSAA  
 Table D: Isomeric Components and Percent Composition of PFHxSK  
 Table E: Isomeric Components and Percent Composition of PFOSK  
 Figure 1: LC/MS Data (SIR)  
 Figure 2: LC/MS/MS Data (Selected MRM Transitions)

**ADDITIONAL INFORMATION:**

- See page 2 for further details.
- Contains 4 mole eq. of NaOH to prevent conversion of the carboxylic acids to their respective methyl esters.

**FOR LABORATORY USE ONLY: NOT FOR HUMAN OR DRUG USE**

Wellington Laboratories Inc., 345 Southgate Dr. Guelph ON N1G 3M5 CANADA  
 519-822-2436 • Fax: 519-822-2849 • info@well-labs.com

**INTENDED USE:**

The products prepared by Wellington Laboratories Inc. are for laboratory use only. This certified reference material (CRM) was designed to be used as a standard for the identification and/or quantification of the specific chemical compounds it contains.

**HANDLING:**

This product should only be used by qualified personnel familiar with its potential hazards and trained in the handling of hazardous chemicals. Due care should be exercised to prevent unnecessary human contact or ingestion. All procedures should be carried out in a well-functioning fume hood and suitable gloves, eye protection, and clothing should be worn at all times. Waste should be disposed of according to national and regional regulations. Safety Data Sheets (SDSs) are available upon request.

**SYNTHESIS / CHARACTERIZATION:**

Our products are synthesized using single-product unambiguous routes whenever possible. They are then characterized, and their structures and purities confirmed, using a combination of the most relevant techniques, such as NMR, GC/MS, LC/MS/MS, SFC/UV/MS/MS, x-ray crystallography, and melting point. Isotopic purities of mass-labelled compounds are also confirmed using HRGC/HRMS and/or LC/MS/MS.

**HOMOGENEITY:**

Prior to solution preparation, crystalline material is tested for homogeneity using a variety of techniques (as stated above) and its solubility in a given diluent is taken into consideration. Duplicate solutions of a new product are prepared from the same crystalline lot and, after the addition of an appropriate internal standard, they are compared by GC/MS, LC/MS/MS, and/or SFC/UV/MS/MS. The relative response factors of the analyte of interest in each solution are required to be <5% RSD. New solution lots of existing products, as well as mixtures and calibration solutions, are compared to older lots in a similar manner. This further confirms the homogeneity of the crystalline material as well as the stability and homogeneity of the solutions in the storage containers. In order to maintain the integrity of the assigned value(s), and associated uncertainty, the dilution or injection of a subsample of this product should be performed using calibrated measuring equipment.

**UNCERTAINTY:**

The maximum combined relative standard uncertainty of our reference standard solutions is calculated using the following equation:

The combined relative standard uncertainty,  $u_c(y)$ , of a value  $y$  and the uncertainty of the independent parameters

$x_1, x_2, \dots, x_n$  on which it depends is:

$$u_c(y(x_1, x_2, \dots, x_n)) = \sqrt{\sum_{i=1}^n u(y, x_i)^2}$$

where  $x$  is expressed as a relative standard uncertainty of the individual parameter.

The individual uncertainties taken into account include those associated with weights (calibration of the balance) and volumes (calibration of the volumetric glassware). An expanded maximum combined percent relative uncertainty of  $\pm 5\%$  (calculated with a coverage factor of 2 and a level of confidence of 95%) is stated on the Certificate of Analysis for all of our products.

**TRACEABILITY:**

All reference standard solutions are traceable to specific crystalline lots. The microbalances used for solution preparation are regularly calibrated by an external ISO/IEC 17025 accredited laboratory. In addition, their calibration is verified prior to each weighing using calibrated external weights traceable to an ISO/IEC 17025 accredited laboratory. All volumetric glassware used is calibrated, of Class A tolerance, and traceable to an ISO/IEC 17025 accredited laboratory. For certain products, traceability to international interlaboratory studies has also been established.

**EXPIRY DATE / PERIOD OF VALIDITY:**

Ongoing stability studies of this product have demonstrated stability in its composition and concentration, until the specified expiry date, in the unopened ampoule. Monitoring for any degradation or change in concentration of the listed analyte(s) is performed on a routine basis.

**LIMITED WARRANTY:**

At the time of shipment, all products are warranted to be free of defects in material and workmanship and to conform to the stated technical and purity specifications.

**QUALITY MANAGEMENT:**

This product was produced using a Quality Management System registered to the latest versions of ISO 9001 by SAI Global, ISO/IEC 17025 by the Canadian Association for Laboratory Accreditation Inc. (CALA; A1226), and ISO 17034 by ANSI National Accreditation Board (ANAB; AR-1523).



\*\*For additional information or assistance concerning this or any other products from Wellington Laboratories Inc., please visit our website at [www.well-labs.com](http://www.well-labs.com) or contact us directly at [info@well-labs.com](mailto:info@well-labs.com)\*\*



**Table A: PFAC-MXH; Components and Concentrations**  
( $\mu\text{g/mL}$ ,  $\pm 5\%$  in methanol / isopropanol (2%) / water (<1%))

Compound	Acronym	Concentration* ( $\mu\text{g/mL}$ )		Peak Assignment in Figure 1
		as the salt	as the acid	
Perfluoro-n-butanoic acid	PFBA	4.00		1
Perfluoro-n-pentanoic acid	PFPeA	2.00		2
Perfluoro-n-hexanoic acid	PFHxA	1.00		5
Perfluoro-n-heptanoic acid	PFHpA	1.00		7
Perfluoro-n-octanoic acid	PFOA	1.00		11
Perfluoro-n-nonanoic acid	PFNA	1.00		14
Perfluoro-n-decanoic acid	PFDA	1.00		18
Perfluoro-n-undecanoic acid	PFUdA	1.00		23
Perfluoro-n-dodecanoic acid	PFDoA	1.00		26
Perfluoro-n-tridecanoic acid	PFTTrDA	1.00		27
Perfluoro-n-tetradecanoic acid	PFTeDA	1.00		29
Perfluoro-1-octanesulfonamide	FOSA	1.00		25
N-methylperfluorooctanesulfonamidoacetic acid <sup>a</sup>	N-MeFOSAA: linear isomer	0.760		20
	N-MeFOSAA: $\Sigma$ branched isomers	0.240		17
N-ethylperfluorooctanesulfonamidoacetic acid <sup>b</sup>	N-EtFOSAA: linear isomer	0.775		22
	N-EtFOSAA: $\Sigma$ branched isomers	0.225		21
Compound	Acronym	Concentration* ( $\mu\text{g/mL}$ )		Peak Assignment in Figure 1
		as the salt	as the acid	
Potassium perfluoro-1-butanedisulfonate	L-PFBS	1.00	0.887	3
Sodium perfluoro-1-pentadisulfonate	L-PFPeS	1.00	0.941	6
Potassium perfluorohexanedisulfonate <sup>c</sup>	PFHxSK: linear isomer	0.811	0.741	9
	PFHxSK: $\Sigma$ branched isomers	0.189	0.173	8
Sodium perfluoro-1-heptadisulfonate	L-PFHpS	1.00	0.953	12
Potassium perfluorooctanedisulfonate <sup>d</sup>	PFOSK: linear isomer	0.788	0.732	15
	PFOSK: $\Sigma$ branched isomers	0.211	0.196	13
Sodium perfluoro-1-nonanedisulfonate	L-PFNS	1.00	0.962	19
Sodium perfluoro-1-decanedisulfonate	L-PFDs	1.00	0.965	24
Sodium perfluoro-1-dodecanedisulfonate	L-PFDoS	1.00	0.970	28
Sodium 1H,1H,2H,2H-perfluorohexanesulfonate	4:2Fts	4.00	3.75	4
Sodium 1H,1H,2H,2H-perfluorooctanesulfonate	6:2Fts	4.00	3.80	10
Sodium 1H,1H,2H,2H-perfluorodecanedisulfonate	8:2Fts	4.00	3.84	16

<sup>a</sup> See Table B for percent composition of linear and branched N-MeFOSAA isomers.


<sup>b</sup> See Table C for percent composition of linear and branched N-EtFOSAA isomers.

<sup>c</sup> See Table D for percent composition of linear and branched PFHxSK isomers.

<sup>d</sup> See Table E for percent composition of linear and branched PFOSK isomers.

\* Concentrations have been rounded to three significant figures.

Certified By: \_\_\_\_\_

  
B.G. Chittim, General Manager

Date: 09/23/2021

(mm/dd/yyyy)

**Table B:** br-NMeFOSAA; Isomeric Components and Percent Composition (by  $^{19}\text{F}$ -NMR)\*

Isomer	Compound	Structure	Percent Composition by $^{19}\text{F}$ -NMR	
1	N-methylperfluoro-1-octanesulfonamidoacetic acid	$\text{CF}_3(\text{CF}_2)_7\text{SO}_2\text{N}(\text{CH}_3)\text{CH}_2\text{CO}_2\text{H}$	76.0	76.0
2	N-methylperfluoro-3-methylheptanesulfonamidoacetic acid	$\text{CF}_3(\text{CF}_2)_3\text{CF}(\text{CF}_2)_2\text{SO}_2\text{N}(\text{CH}_3)\text{CH}_2\text{CO}_2\text{H}$	0.7	24.0
3	N-methylperfluoro-4-methylheptanesulfonamidoacetic acid	$\text{CF}_3(\text{CF}_2)_2\text{CF}(\text{CF}_2)_3\text{SO}_2\text{N}(\text{CH}_3)\text{CH}_2\text{CO}_2\text{H}$	2.0	
4	N-methylperfluoro-5-methylheptanesulfonamidoacetic acid	$\text{CF}_3\text{CF}_2\text{CF}(\text{CF}_2)_4\text{SO}_2\text{N}(\text{CH}_3)\text{CH}_2\text{CO}_2\text{H}$	6.0	
5	N-methylperfluoro-6-methylheptanesulfonamidoacetic acid	$\text{CF}_3\text{CF}(\text{CF}_2)_5\text{SO}_2\text{N}(\text{CH}_3)\text{CH}_2\text{CO}_2\text{H}$	14.0	
6	N-methylperfluoro-5,5-dimethylhexanesulfonamidoacetic acid	$\text{CF}_3\text{C}(\text{CF}_3)_2(\text{CF}_2)_4\text{SO}_2\text{N}(\text{CH}_3)\text{CH}_2\text{CO}_2\text{H}$	0.2	
7	Other Unidentified Isomers		1.1	

\* Percent of total N-methylperfluorooctanesulfonamidoacetic acid isomers only.

**Table C: br-NEtFOSAA; Isomeric Components and Percent Composition (by <sup>19</sup>F-NMR)\***

Isomer	Compound	Structure	Percent Composition by <sup>19</sup> F-NMR	
1	N-ethylperfluoro-1-octanesulfonamidoacetic acid	$\text{CF}_3(\text{CF}_2)_7\text{SO}_2\text{NCH}_2\text{CO}_2\text{H}$ $\quad \quad \quad  $ $\quad \quad \quad \text{C}_2\text{H}_5$	77.5	77.5
2	N-ethylperfluoro-3-methylheptanesulfonamidoacetic acid	$\text{CF}_3(\text{CF}_2)_3\text{CF}(\text{CF}_2)_2\text{SO}_2\text{NCH}_2\text{CO}_2\text{H}$ $\quad \quad \quad   \quad \quad \quad  $ $\quad \quad \quad \text{CF}_3 \quad \quad \quad \text{C}_2\text{H}_5$	2.3	22.5
3	N-ethylperfluoro-4-methylheptanesulfonamidoacetic acid	$\text{CF}_3(\text{CF}_2)_2\text{CF}(\text{CF}_2)_3\text{SO}_2\text{NCH}_2\text{CO}_2\text{H}$ $\quad \quad \quad   \quad \quad \quad  $ $\quad \quad \quad \text{CF}_3 \quad \quad \quad \text{C}_2\text{H}_5$	2.2	
4	N-ethylperfluoro-5-methylheptanesulfonamidoacetic acid	$\text{CF}_3\text{CF}_2\text{CF}(\text{CF}_2)_4\text{SO}_2\text{NCH}_2\text{CO}_2\text{H}$ $\quad \quad \quad   \quad \quad \quad  $ $\quad \quad \quad \text{CF}_3 \quad \quad \quad \text{C}_2\text{H}_5$	5.4	
5	N-ethylperfluoro-6-methylheptanesulfonamidoacetic acid	$\text{CF}_3\text{CF}(\text{CF}_2)_5\text{SO}_2\text{NCH}_2\text{CO}_2\text{H}$ $\quad \quad \quad   \quad \quad \quad  $ $\quad \quad \quad \text{CF}_3 \quad \quad \quad \text{C}_2\text{H}_5$	10.4	
6	N-ethylperfluoro-5,5-dimethylhexanesulfonamidoacetic acid	$\quad \quad \quad \text{CF}_3$ $\text{CF}_3\text{C}(\text{CF}_2)_4\text{SO}_2\text{NCH}_2\text{CO}_2\text{H}$ $\quad \quad \quad   \quad \quad \quad  $ $\quad \quad \quad \text{CF}_3 \quad \quad \quad \text{C}_2\text{H}_5$	0.3	
7	N-ethylperfluoro-4,5-dimethylhexanesulfonamidoacetic acid	$\quad \quad \quad \text{CF}_3$ $\text{CF}_3\text{CFCF}(\text{CF}_2)_3\text{SO}_2\text{NCH}_2\text{CO}_2\text{H}$ $\quad \quad \quad   \quad \quad \quad  $ $\quad \quad \quad \text{CF}_3 \quad \quad \quad \text{C}_2\text{H}_5$	0.3	
8	N-ethylperfluoro-3,5-dimethylhexanesulfonamidoacetic acid	$\quad \quad \quad \text{CF}_3$ $\text{CF}_3\text{CFCF}_2\text{CF}(\text{CF}_2)_2\text{SO}_2\text{NCH}_2\text{CO}_2\text{H}$ $\quad \quad \quad   \quad \quad \quad  $ $\quad \quad \quad \text{CF}_3 \quad \quad \quad \text{C}_2\text{H}_5$	0.3	
9	Other Unidentified Isomers		1.3	

\* Percent of total N-ethylperfluorooctanesulfonamidoacetic acid isomers only.

**Table D: PFHxSK; Isomeric Components and Percent Composition (by  $^{19}\text{F}$ -NMR)\***

Isomer	Compound	Structure	Percent Composition by $^{19}\text{F}$ -NMR	
1	Potassium perfluoro-1-hexanesulfonate	$\text{CF}_3\text{CF}_2\text{CF}_2\text{CF}_2\text{CF}_2\text{CF}_2\text{SO}_3^-\text{K}^+$	81.1	81.1
2	Potassium 1-trifluoromethylperfluoropentanesulfonate**	$\begin{array}{c} \text{CF}_3\text{CF}_2\text{CF}_2\text{CF}_2\text{CF}(\text{SO}_3^-\text{K}^+) \\   \\ \text{CF}_3 \end{array}$	2.9	18.9
3	Potassium 2-trifluoromethylperfluoropentanesulfonate	$\begin{array}{c} \text{CF}_3\text{CF}_2\text{CF}_2\text{CF}(\text{CF}_3)\text{CF}_2\text{SO}_3^-\text{K}^+ \\   \\ \text{CF}_3 \end{array}$	1.4	
4	Potassium 3-trifluoromethylperfluoropentanesulfonate	$\begin{array}{c} \text{CF}_3\text{CF}_2\text{CF}(\text{CF}_3)\text{CF}_2\text{CF}_2\text{SO}_3^-\text{K}^+ \\   \\ \text{CF}_3 \end{array}$	5.0	
5	Potassium 4-trifluoromethylperfluoropentanesulfonate	$\begin{array}{c} \text{CF}_3\text{CF}(\text{CF}_3)\text{CF}_2\text{CF}_2\text{CF}_2\text{SO}_3^-\text{K}^+ \\   \\ \text{CF}_3 \end{array}$	8.9	
6	Potassium 3,3-di(trifluoromethyl)perfluorobutanesulfonate	$\begin{array}{c} \text{CF}_3 \\   \\ \text{CF}_3\text{C}(\text{CF}_3)\text{CF}_2\text{CF}_2\text{SO}_3^-\text{K}^+ \\   \\ \text{CF}_3 \end{array}$	0.2	
7	Other Unidentified Isomers		0.5	

\* Percent of total perfluorohexanesulfonate isomers only.


\*\* Systematic Name: Potassium perfluorohexane-2-sulfonate.

**Table E: PFOSK; Isomeric Components and Percent Composition (by <sup>19</sup>F-NMR)\***

Isomer	Compound	Structure	Percent Composition by <sup>19</sup> F-NMR	
1	Potassium perfluoro-1-octanesulfonate	CF <sub>3</sub> CF <sub>2</sub> CF <sub>2</sub> CF <sub>2</sub> CF <sub>2</sub> CF <sub>2</sub> CF <sub>2</sub> CF <sub>2</sub> SO <sub>3</sub> <sup>-</sup> K <sup>+</sup>	78.8	78.8
2	Potassium 1-trifluoromethylperfluoroheptanesulfonate**	CF <sub>3</sub> CF <sub>2</sub> CF <sub>2</sub> CF <sub>2</sub> CF <sub>2</sub> CF <sub>2</sub> CF(SO <sub>3</sub> <sup>-</sup> )K <sup>+</sup>   CF <sub>3</sub>	1.2	21.1
3	Potassium 2-trifluoromethylperfluoroheptanesulfonate	CF <sub>3</sub> CF <sub>2</sub> CF <sub>2</sub> CF <sub>2</sub> CF <sub>2</sub> CF(CF <sub>3</sub> )SO <sub>3</sub> <sup>-</sup> K <sup>+</sup>   CF <sub>3</sub>	0.6	
4	Potassium 3-trifluoromethylperfluoroheptanesulfonate	CF <sub>3</sub> CF <sub>2</sub> CF <sub>2</sub> CF <sub>2</sub> CF(CF <sub>3</sub> )CF <sub>2</sub> SO <sub>3</sub> <sup>-</sup> K <sup>+</sup>   CF <sub>3</sub>	1.9	
5	Potassium 4-trifluoromethylperfluoroheptanesulfonate	CF <sub>3</sub> CF <sub>2</sub> CF <sub>2</sub> CF(CF <sub>3</sub> )CF <sub>2</sub> CF <sub>2</sub> SO <sub>3</sub> <sup>-</sup> K <sup>+</sup>   CF <sub>3</sub>	2.2	
6	Potassium 5-trifluoromethylperfluoroheptanesulfonate	CF <sub>3</sub> CF <sub>2</sub> CF(CF <sub>3</sub> )CF <sub>2</sub> CF <sub>2</sub> CF <sub>2</sub> SO <sub>3</sub> <sup>-</sup> K <sup>+</sup>   CF <sub>3</sub>	4.5	
7	Potassium 6-trifluoromethylperfluoroheptanesulfonate	CF <sub>3</sub> CF(CF <sub>3</sub> )CF <sub>2</sub> CF <sub>2</sub> CF <sub>2</sub> CF <sub>2</sub> SO <sub>3</sub> <sup>-</sup> K <sup>+</sup>   CF <sub>3</sub>	10.0	
8	Potassium 5,5-di(trifluoromethyl)perfluorohexanesulfonate	CF <sub>3</sub>   CF <sub>3</sub> CCF <sub>2</sub> CF <sub>2</sub> CF <sub>2</sub> CF <sub>2</sub> SO <sub>3</sub> <sup>-</sup> K <sup>+</sup>   CF <sub>3</sub>	0.2	
9	Potassium 4,4-di(trifluoromethyl)perfluorohexanesulfonate	CF <sub>3</sub>   CF <sub>3</sub> CF <sub>2</sub> CCF <sub>2</sub> CF <sub>2</sub> CF <sub>2</sub> SO <sub>3</sub> <sup>-</sup> K <sup>+</sup>   CF <sub>3</sub>	0.03	
10	Potassium 4,5-di(trifluoromethyl)perfluorohexanesulfonate	CF <sub>3</sub>   CF <sub>3</sub> CF(CF <sub>3</sub> )CF <sub>2</sub> CF <sub>2</sub> CF <sub>2</sub> SO <sub>3</sub> <sup>-</sup> K <sup>+</sup>   CF <sub>3</sub>	0.4	
11	Potassium 3,5-di(trifluoromethyl)perfluorohexanesulfonate	CF <sub>3</sub>   CF <sub>3</sub> CF(CF <sub>3</sub> )CF <sub>2</sub> CF(CF <sub>3</sub> )CF <sub>2</sub> SO <sub>3</sub> <sup>-</sup> K <sup>+</sup>   CF <sub>3</sub>	0.07	

\* Percent of total perfluorooctanesulfonate isomers only.

\*\* Systematic Name: Potassium perfluorooctane-2-sulfonate.

**Figure 1: PFAC-MXH; LC/MS Data (SIR)****Conditions for Figure 1:**

Waters Acquity Ultra Performance LC  
Waters Xevo TQ-S micro MS

**Chromatographic Conditions:**

Column: Acquity UPLC BEH Shield RP<sub>18</sub>  
1.7  $\mu$ m, 2.1 x 100 mm

Mobile phase: Gradient


Start: 50% H<sub>2</sub>O / 50% (80:20 MeOH:ACN)  
(both with 10 mM NH<sub>4</sub>OAc buffer)  
Ramp to 90% organic over 9 min and hold for 2 min  
before returning to initial conditions in 1 min.  
Time: 15 min


Flow: 300  $\mu$ L/min

**MS Parameters:**


Experiment: SIR

Source: Electrospray (negative)  
Capillary Voltage (kV) = 2.50  
Cone Voltage (V) = variable (2-74)  
Desolvation Temperature ( $^{\circ}$ C) = 350  
Desolvation Gas Flow (L/hr) = 1000

**Figure 2: PFAC-MXH; LC/MS/MS Data (Selected MRM Transitions)**

**Figure 2: PFAC-MXH; LC/MS/MS Data (Selected MRM Transitions)**



**Figure 2: PFAC-MXH; LC/MS/MS Data (Selected MRM Transitions)****Conditions for Figure 2:**

Injection: On-column (PFAC-MXH)

Mobile phase: Same as Figure 1

Flow: 300  $\mu$ L/min**MS Parameters:**

Collision Gas (mbar) = 3.31e-3

Collision Energy (eV) = 6-60 (variable)



# Analytical Standard Record

**22F0059**

Description:	PFAS - MIX MXH 2ug/mL	Expires:	09/14/2026
Standard Type:	Other	Prepared:	09/09/2021
Solvent:	MeOH	Prepared By:	Lizbeth Andres
Final Volume (mls):	1.2	Department:	PFAS
Vials:	1	Last Edit:	09/15/2022 09:33 by DAG

Analyte	Parent	CAS Number	Concentration	Units
4:2FTS		757124-72-4	3.75	ug/mL
6:2FTS		27619-97-2	3.8	ug/mL
8:2FTS		39108-34-4	3.84	ug/mL
NETFOSAA		2991-50-6	1	ug/mL
NMeFOSAA		2355-31-9	1	ug/mL
PFBA		375-22-4	4	ug/mL
PFBS		375-73-5	0.887	ug/mL
PFDA		335-76-2	1	ug/mL
PFDOA		307-55-1	1	ug/mL
PFDOS		79780-39-5	0.97	ug/mL
PFDS		335-77-3	0.965	ug/mL
PFHPA		375-85-9	1	ug/mL
PFHPS		375-92-8	0.953	ug/mL
PFHXA		307-24-4	1	ug/mL
PFHXS		355-46-4	0.914	ug/mL
PFNA		375-95-1	1	ug/mL
PFNS		68259-12-1	0.962	ug/mL
PFOA		335-67-1	1	ug/mL
PFOS		1763-23-1	0.928	ug/mL
PFOSA		754-91-6	1	ug/mL
PFPEA		2706-90-3	2	ug/mL
PFPEs		630402-22-1	0.941	ug/mL
PFTEDA		376-06-7	1	ug/mL
PFTRDA		72629-94-8	1	ug/mL
PFUnA		2058-94-8	1	ug/mL

**WELLINGTON  
LABORATORIES****CERTIFICATE OF ANALYSIS  
DOCUMENTATION****PFAC-MXG** 22F0061**Native Perfluoroalkyl Ether Carboxylic  
Acids and Sulfonate Solution/Mixture**

**PRODUCT CODE:** PFAC-MXG  
**LOT NUMBER:** PFACMXG0222  
**SOLVENT(S):** Methanol/Water (<1%)  
**DATE PREPARED:** (mm/dd/yyyy) 02/07/2022  
**LAST TESTED:** (mm/dd/yyyy) 02/22/2022  
**EXPIRY DATE:** (mm/dd/yyyy) 02/22/2027  
**RECOMMENDED STORAGE:** Store ampoule in a cool, dark place

**DESCRIPTION:**

PFAC-MXG is a solution/mixture of three native perfluoroalkyl ether carboxylic acids and a native perfluoroalkyl ether sulfonate. The components and their concentrations are given in Table A.

The individual components all have chemical purities of >98%.

**DOCUMENTATION/ DATA ATTACHED:**

Table A: Components and Concentrations of the Solution/Mixture  
Figure 1: LC/MS Data (SIR)  
Figure 2: LC/MS/MS Data (Selected MRM Transitions)

**ADDITIONAL INFORMATION:**

- See page 2 for further details.
- Contains 4 mole eq. of NaOH to prevent conversion of the carboxylic acids to their respective methyl esters.

**FOR LABORATORY USE ONLY: NOT FOR HUMAN OR DRUG USE**

**Wellington Laboratories Inc., 345 Southgate Dr. Guelph ON N1G 3M5 CANADA  
519-822-2436 • Fax: 519-822-2849 • info@well-labs.com**

**INTENDED USE:**

The products prepared by Wellington Laboratories Inc. are for laboratory use only. This certified reference material (CRM) was designed to be used as a standard for the identification and/or quantification of the specific chemical compounds it contains.

**HANDLING:**

This product should only be used by qualified personnel familiar with its potential hazards and trained in the handling of hazardous chemicals. Due care should be exercised to prevent unnecessary human contact or ingestion. All procedures should be carried out in a well-functioning fume hood and suitable gloves, eye protection, and clothing should be worn at all times. Waste should be disposed of according to national and regional regulations. Safety Data Sheets (SDSs) are available upon request.

**SYNTHESIS / CHARACTERIZATION:**

Our products are synthesized using single-product unambiguous routes whenever possible. They are then characterized, and their structures and purities confirmed, using a combination of the most relevant techniques, such as NMR, GC/MS, LC/MS/MS, SFC/UV/MS/MS, x-ray crystallography, and melting point. Isotopic purities of mass-labelled compounds are also confirmed using HRGC/HRMS and/or LC/MS/MS.

**HOMOGENEITY:**

Prior to solution preparation, crystalline material is tested for homogeneity using a variety of techniques (as stated above) and its solubility in a given diluent is taken into consideration. Duplicate solutions of a new product are prepared from the same crystalline lot and, after the addition of an appropriate internal standard, they are compared by GC/MS, LC/MS/MS, and/or SFC/UV/MS/MS. The relative response factors of the analyte of interest in each solution are required to be <5% RSD. New solution lots of existing products, as well as mixtures and calibration solutions, are compared to older lots in a similar manner. This further confirms the homogeneity of the crystalline material as well as the stability and homogeneity of the solutions in the storage containers. In order to maintain the integrity of the assigned value(s), and associated uncertainty, the dilution or injection of a subsample of this product should be performed using calibrated measuring equipment.

**UNCERTAINTY:**

The maximum combined relative standard uncertainty of our reference standard solutions is calculated using the following equation:

The combined relative standard uncertainty,  $u_c(y)$ , of a value  $y$  and the uncertainty of the independent parameters

$x_1, x_2, \dots, x_n$  on which it depends is:

$$u_c(y(x_1, x_2, \dots, x_n)) = \sqrt{\sum_{i=1}^n u(y, x_i)^2}$$

where  $x$  is expressed as a relative standard uncertainty of the individual parameter.

The individual uncertainties taken into account include those associated with weights (calibration of the balance) and volumes (calibration of the volumetric glassware). An expanded maximum combined percent relative uncertainty of  $\pm 5\%$  (calculated with a coverage factor of 2 and a level of confidence of 95%) is stated on the Certificate of Analysis for all of our products.

**TRACEABILITY:**

All reference standard solutions are traceable to specific crystalline lots. The microbalances used for solution preparation are regularly calibrated by an external ISO/IEC 17025 accredited laboratory. In addition, their calibration is verified prior to each weighing using calibrated external weights traceable to an ISO/IEC 17025 accredited laboratory. All volumetric glassware used is calibrated, of Class A tolerance, and traceable to an ISO/IEC 17025 accredited laboratory. For certain products, traceability to international interlaboratory studies has also been established.

**EXPIRY DATE / PERIOD OF VALIDITY:**

Ongoing stability studies of this product have demonstrated stability in its composition and concentration, until the specified expiry date, in the unopened ampoule. Monitoring for any degradation or change in concentration of the listed analyte(s) is performed on a routine basis.

**LIMITED WARRANTY:**

At the time of shipment, all products are warranted to be free of defects in material and workmanship and to conform to the stated technical and purity specifications.

**QUALITY MANAGEMENT:**

This product was produced using a Quality Management System registered to the latest versions of ISO 9001 by SAI Global, ISO/IEC 17025 by the Canadian Association for Laboratory Accreditation Inc. (CALA; A1226), and ISO 17034 by ANSI National Accreditation Board (ANAB; AR-1523).




\*\*For additional information or assistance concerning this or any other products from Wellington Laboratories Inc., please visit our website at [www.well-labs.com](http://www.well-labs.com) or contact us directly at [info@well-labs.com](mailto:info@well-labs.com)\*\*

**Table A: PFAC-MXG; Components and Concentrations (ng/mL;  $\pm$  5% in methanol/water (<1%))**


Compound	Acronym	Concentration (ng/mL)		Peak Assignment in Figure 1
		as the salt	as the acid	
Perfluoro-4-oxapentanoic acid	PF4OPeA	2000		A
Perfluoro-5-oxahexanoic acid	PF5OHxA	2000		B
Perfluoro-3,6-dioxaheptanoic acid	3,6-OPFHpA	2000		D
Compound	Acronym	Concentration* (ng/mL)		Peak Assignment in Figure 1
		as the salt	as the acid	
Potassium perfluoro(2-ethoxyethane)sulfonate	PFEESA	2000	1780	C

\* Concentrations have been rounded to three significant figures.

Certified By: \_\_\_\_\_

  
B.G. Chittim, General Manager

Date: 03/03/2022  
(mm/dd/yyyy)

**Figure 1: PFAC-MXG; LC/MS Data (SIR)****Conditions for Figure 1:**

Waters Acquity Ultra Performance LC  
Waters Xevo TQ-S micro MS

**Chromatographic Conditions:**

Column: Acquity UPLC BEH Shield RP<sub>18</sub>  
1.7  $\mu$ m, 2.1 x 100 mm


Mobile phase: Gradient  
Start: 50% H<sub>2</sub>O / 50% (80:20 MeOH:ACN)  
(both with 10 mM NH<sub>4</sub>OAc buffer)  
Ramp to 90% organic over 8 min and hold for 2 min  
before returning to initial conditions in 0.75 min.  
Time: 12 min

Flow: 300  $\mu$ L/min

**MS Parameters:**

Experiment: SIR

Source: Electrospray (negative)  
Capillary Voltage (kV) = 1.00  
Cone Voltage (V) = variable (15-35)  
Desolvation Temperature ( $^{\circ}$ C) = 500  
Desolvation Gas Flow (L/hr) = 1000

**Figure 2: PFAC-MXG; LC/MS/MS Data (Selected MRM Transitions)****Conditions for Figure 2:**

Injection: On-column (PFAC-MXG)

Mobile phase: Same as Figure 1

Flow: 300  $\mu$ L/min**MS Parameters:**

Collision Gas (mbar) = 3.33e-3

Collision Energy (eV) = 8-48 (variable)





# Analytical Standard Record

**22F0061**

Description: PFAS - MIX MXG 2ug/mL Expires: 02/22/2027  
Standard Type: Other Prepared: 02/07/2022  
Solvent: MeOH Prepared By: Lizbeth Andres  
Final Volume (mls): 1 Department: PFAS  
Vials: 1 Last Edit: 09/15/2022 09:34 by DAG  
Comments: contains NFDHA PFMBA PFMPA PFEESA @ 2ug/mL

Analyte	Parent	CAS Number	Concentration	Units
NFDHA		151772-58-6	2	ug/mL
PFEESA		113507-82-7	1.78	ug/mL
PFMBA		863090-89-5	2	ug/mL
PFMPA		377-73-1	2	ug/mL

# Analytical Standard Record

**22I0153**

Description:	PFAS - MIX 1633 200ng/mL	Expires:	01/11/2025
Standard Type:	Analyte Spike	Prepared:	09/13/2022
Solvent:	MeOH	Prepared By:	Dipti Gokal
Final Volume (mls):	6	Department:	PFAS
Vials:	1	Last Edit:	09/15/2022 09:34 by DAG

Analyte	Parent	CAS Number	Concentration	Units
NMeFOSE	22C0307	24448-09-7	0.8	ug/mL
3:3FTCA	22C0308	113507-82-7	0.8	ug/mL
5:3FTCA	22C0309	914637-49-3	0.8	ug/mL
NETFOSE	22C0310	1691-99-2	0.8	ug/mL
7:3FTCA	22C0311	812-70-4	0.8	ug/mL
NMeFOSA	22C0312	31506-32-8	0.8	ug/mL
NETFOSA	22C0313	4151-50-2	0.8	ug/mL
11CL-PF3OUDS	22F0058	763051-92-9	0.378	ug/mL
9CL-PF3ONS	22F0058	756426-58-1	0.374	ug/mL
ADONA	22F0058	919005-14-4	0.378	ug/mL
HFPO-DA	22F0058	13252-13-6	0.4	ug/mL
4:2FTS	22F0059	757124-72-4	0.75	ug/mL
6:2FTS	22F0059	27619-97-2	0.76	ug/mL
8:2FTS	22F0059	39108-34-4	0.768	ug/mL
NETFOSAA	22F0059	2991-50-6	0.2	ug/mL
NMeFOSAA	22F0059	2355-31-9	0.2	ug/mL
PFBA	22F0059	375-22-4	0.8	ug/mL
PFBS	22F0059	375-73-5	0.177	ug/mL
PFDA	22F0059	335-76-2	0.2	ug/mL
PFDOA	22F0059	307-55-1	0.2	ug/mL
PFDOS	22F0059	79780-39-5	0.194	ug/mL
PFDS	22F0059	335-77-3	0.193	ug/mL
PFHPA	22F0059	375-85-9	0.2	ug/mL
PFHPS	22F0059	375-92-8	0.191	ug/mL
PFHXA	22F0059	307-24-4	0.2	ug/mL
PFHXS	22F0059	355-46-4	0.183	ug/mL
PFNA	22F0059	375-95-1	0.2	ug/mL
PFNS	22F0059	68259-12-1	0.192	ug/mL
PFOA	22F0059	335-67-1	0.2	ug/mL
PFOS	22F0059	1763-23-1	0.186	ug/mL
PFOSA	22F0059	754-91-6	0.2	ug/mL
PFPEA	22F0059	2706-90-3	0.4	ug/mL
PFPEs	22F0059	630402-22-1	0.188	ug/mL
PFTEDA	22F0059	376-06-7	0.2	ug/mL
PFTRDA	22F0059	72629-94-8	0.2	ug/mL
PFUnA	22F0059	2058-94-8	0.2	ug/mL
NFDHA	22F0061	151772-58-6	0.4	ug/mL
PFEESA	22F0061	113507-82-7	0.356	ug/mL
PFMBA	22F0061	863090-89-5	0.4	ug/mL
PFMPA	22F0061	377-73-1	0.4	ug/mL

# Analytical Standard Record

22I0153

## Parent Standards used:

Standard	Description	Prepared	Prepared By	Lot Nbr	Expires	Last Edit		(mls)
22C0307	PFAS - SAS N-MeFOSE 50ug/mL	03/15/2022	Wellington Laboratories	NMeFOSE0921M	09/23/2026	03/15/2022 15:59	by DAG	0.096
22C0308	PFAS - SAS FPrPA 50ug/mL	03/15/2022	Wellington Laboratories	FPrPA0122	02/03/2027	03/15/2022 15:59	by DAG	0.096
22C0309	PFAS - SAS FPePA 50ug/mL	03/15/2022	Wellington Laboratories	FPePA1221	01/05/2027	03/15/2022 15:59	by DAG	0.096
22C0310	PFAS - SAS NEtFOSE 50ug/mL	03/15/2022	Wellington Laboratories	NEtFOSE0921M	09/23/2026	03/15/2022 15:59	by DAG	0.096
22C0311	PFAS - SAS FHpPA 50ug/mL	03/15/2022	Wellington Laboratories	HHpPA1020	11/12/2025	03/15/2022 16:00	by DAG	0.096
22C0312	PFAS - SAS NMeFOSA 50ug/mL	03/15/2022	Wellington Laboratories	NMeFOSA0721M	08/03/2026	03/15/2022 16:00	by DAG	0.096
22C0313	PFAS - SAS NEtFOSA 50ug/mL	03/15/2022	Wellington Laboratories	NEtFOSA0821M	08/12/2026	08/17/2022 10:49	by LYA	0.096
22F0058	PFAS - MIX MXF 2ug/mL	01/10/2022	Wellington Laboratories	PFACMXF0122	01/11/2025	09/15/2022 09:32	by DAG	1.2
22F0059	PFAS - MIX MXH 2ug/mL	09/09/2021	Wellington Laboratories	PFACMXH0921	09/14/2026	09/15/2022 09:33	by DAG	1.2
22F0061	PFAS - MIX MXG 2ug/mL	02/07/2022	Wellington Laboratories	PFACMXG0222	02/22/2027	09/15/2022 09:34	by DAG	1.2



# WELLINGTON LABORATORIES

## CERTIFICATE OF ANALYSIS DOCUMENTATION

### PFAC-MXG

#### Native Perfluoroalkyl Ether Carboxylic Acids and Sulfonate Solution/Mixture

<b><u>PRODUCT CODE:</u></b>	PFAC-MXG
<b><u>LOT NUMBER:</u></b>	PFACMXG0222
<b><u>SOLVENT(S):</u></b>	Methanol/Water (<1%)
<b><u>DATE PREPARED:</u></b> (mm/dd/yyyy)	02/07/2022
<b><u>LAST TESTED:</u></b> (mm/dd/yyyy)	02/22/2022
<b><u>EXPIRY DATE:</u></b> (mm/dd/yyyy)	02/22/2027
<b><u>RECOMMENDED STORAGE:</u></b>	Store ampoule in a cool, dark place

#### DESCRIPTION:

PFAC-MXG is a solution/mixture of three native perfluoroalkyl ether carboxylic acids and a native perfluoroalkyl ether sulfonate. The components and their concentrations are given in Table A.

The individual components all have chemical purities of >98%.

#### DOCUMENTATION/ DATA ATTACHED:

Table A: Components and Concentrations of the Solution/Mixture  
Figure 1: LC/MS Data (SIR)  
Figure 2: LC/MS/MS Data (Selected MRM Transitions)

#### ADDITIONAL INFORMATION:

- See page 2 for further details.
- Contains 4 mole eq. of NaOH to prevent conversion of the carboxylic acids to their respective methyl esters.

**FOR LABORATORY USE ONLY: NOT FOR HUMAN OR DRUG USE**

Wellington Laboratories Inc., 345 Southgate Dr. Guelph ON N1G 3M5 CANADA  
519-822-2436 • Fax: 519-822-2849 • info@well-labs.com

**Table A: PFAC-MXG; Components and Concentrations (ng/mL; ± 5% in methanol/water (<1%))**

Compound	Acronym	Concentration (ng/mL)		Peak Assignment in Figure 1
		as the salt	as the acid	
Perfluoro-4-oxapentanoic acid	PF4OPeA	2000		A
Perfluoro-5-oxahexanoic acid	PF5OHxA	2000		B
Perfluoro-3,6-dioxaheptanoic acid	3,6-OPFHpA	2000		D
Compound	Acronym	Concentration* (ng/mL)		Peak Assignment in Figure 1
		as the salt	as the acid	
Potassium perfluoro(2-ethoxyethane)sulfonate	PFEESA	2000	1780	C

\* Concentrations have been rounded to three significant figures.

Certified By: \_\_\_\_\_

B.G. Chittim, General Manager

Date: 03/03/2022

(mm/dd/yyyy)

# Analytical Standard Record

**22I0342**

Description:	PFAS - MIX MXG 2ug/mL	Expires:	02/22/2027
Standard Type:	Other	Prepared:	02/07/2022
Solvent:	MeOH	Prepared By:	Dipti Gokal
Final Volume (mls):	1	Department:	PFAS
Vials:	1	Last Edit:	09/26/2022 09:55 by DAG
Comments:	contains NFDHA PFMBA PFMPA PFEESA @ 2ug/mL		

Analyte	Parent	CAS Number	Concentration	Units
NFDHA		151772-58-6	2	ug/mL
PFEESA		113507-82-7	1.78	ug/mL
PFMBA		863090-89-5	2	ug/mL
PFMPA		377-73-1	2	ug/mL

# Analytical Standard Record

**22I0343**

Description:	PFAS - MIX MXF 2ug/mL	Expires:	01/11/2025
Standard Type:	Other	Prepared:	09/26/2022
Solvent:	MeOH	Prepared By:	Dipti Gokal
Final Volume (mls):	1.2	Department:	PFAS
Vials:	1	Last Edit:	09/26/2022 09:47 by DAG

Analyte	Parent	CAS Number	Concentration	Units
11CL-PF3OUDS		763051-92-9	1.89	ug/mL
9CL-PF3ONS		756426-58-1	1.87	ug/mL
ADONA		919005-14-4	1.89	ug/mL
HFPO-DA		13252-13-6	2	ug/mL





# WELLINGTON LABORATORIES

## CERTIFICATE OF ANALYSIS DOCUMENTATION

### PFAC-MXF

#### Native Replacement PFAS Solution/Mixture

<b><u>PRODUCT CODE:</u></b>	PFAC-MXF
<b><u>LOT NUMBER:</u></b>	PFACMXF0122
<b><u>SOLVENT(S):</u></b>	Methanol / Water (<1%)
<b><u>DATE PREPARED:</u></b> (mm/dd/yyyy)	01/10/2022
<b><u>LAST TESTED:</u></b> (mm/dd/yyyy)	01/11/2022
<b><u>EXPIRY DATE:</u></b> (mm/dd/yyyy)	01/11/2025
<b><u>RECOMMENDED STORAGE:</u></b>	Refrigerate ampoule

#### DESCRIPTION:

PFAC-MXF is a solution/mixture of sodium dodecafluoro-3H-4,8-dioxanonanoate (NaDONA), the major and minor components of F-53B (9Cl-PF3ONS and 11Cl-PF3OUdS), and GenX (HFPO-DA). The components and their concentrations are given in Table A.

The individual native components of this mixture all have chemical purities of >98%.

#### DOCUMENTATION/ DATA ATTACHED:

Table A: Components and Concentrations of the Solution/Mixture  
 Figure 1: LC/MS Data (SIR)  
 Figure 2: LC/MS/MS Data (Selected MRM Transitions)

#### ADDITIONAL INFORMATION:

- See page 2 for further details.
- Contains 4 mole eq. of NaOH to prevent conversion of the carboxylic acid to the methyl ester.

**FOR LABORATORY USE ONLY: NOT FOR HUMAN OR DRUG USE**

Wellington Laboratories Inc., 345 Southgate Dr. Guelph ON N1G 3M5 CANADA  
 519-822-2436 • Fax: 519-822-2849 • info@well-labs.com

**Table A: PFAC-MXF; Components and Concentrations (ng/mL;  $\pm$  5% in Methanol/Water (<1%))**

Compound	Acronym	Concentration* (ng/ml)		Peak Assignment in Figure 1
		as the salt	as the acid	
2,3,3,3-Tetrafluoro-2-(1,1,2,2,3,3,3-heptafluoropropoxy)-propanoic acid	HFPO-DA	2000		A
Sodium dodecafluoro-3H-4,8-dioxananoate	NaDONA	2000	1890	B
Potassium 9-chlorohexadecafluoro-3-oxanonane-1-sulfonate	9Cl-PF3ONS	2000	1870	C
Potassium 11-chloroeicosafluoro-3-oxaundecane-1-sulfonate	11Cl-PF3OUdS	2000	1890	D

\* Concentrations have been rounded to three significant figures.

Certified By:   
B.G. Chittim, General Manager

Date: 01/12/2022  
(mm/dd/yyyy)

# Analytical Standard Record

**22I0343**

Description:	PFAS - MIX MXF 2ug/mL	Expires:	01/11/2025
Standard Type:	Other	Prepared:	01/10/2022
Solvent:	MeOH	Prepared By:	Dipti Gokal
Final Volume (mls):	1.2	Department:	PFAS
Vials:	1	Last Edit:	09/26/2022 09:54 by DAG

Analyte	Parent	CAS Number	Concentration	Units
11CL-PF3OUDS		763051-92-9	1.89	ug/mL
9CL-PF3ONS		756426-58-1	1.87	ug/mL
ADONA		919005-14-4	1.89	ug/mL
HFPO-DA		13252-13-6	2	ug/mL



# WELLINGTON LABORATORIES

## CERTIFICATE OF ANALYSIS DOCUMENTATION

APPL ID:2210334

### PFAC-MXH

Native PFAS  
Solution/Mixture

<b><u>PRODUCT CODE:</u></b>	PFAC-MXH
<b><u>LOT NUMBER:</u></b>	PFACMXH0822
<b><u>SOLVENT(S):</u></b>	Methanol/Isopropanol (2%)/Water (<1%)
<b><u>DATE PREPARED:</u></b> (mm/dd/yyyy)	08/05/2022
<b><u>LAST TESTED:</u></b> (mm/dd/yyyy)	08/08/2022
<b><u>EXPIRY DATE:</u></b> (mm/dd/yyyy)	08/08/2027
<b><u>RECOMMENDED STORAGE:</u></b>	Refrigerate ampoule

### DESCRIPTION:

PFAC-MXH is a solution/mixture of 11 native linear perfluoroalkylcarboxylic acids (C<sub>4</sub>-C<sub>14</sub>), eight native perfluoroalkanesulfonates (C<sub>4</sub>, C<sub>5</sub>, C<sub>7</sub>, C<sub>9</sub>, C<sub>10</sub> and C<sub>12</sub> linear; C<sub>6</sub> and C<sub>8</sub> linear and branched), three native fluorotelomer sulfonates (4:2, 6:2, and 8:2), two native linear and branched perfluorooctanesulfonamidoacetic acids, and perfluoro-1-octanesulfonamide (FOSA). The components and their concentrations are given in Table A.

The individual components of this mixture all have chemical purities of >98%.

### DOCUMENTATION/ DATA ATTACHED:

Table A: Components and Concentrations of the Solution/Mixture  
 Table B: Isomeric Components and Percent Composition of N-MeFOSAA  
 Table C: Isomeric Components and Percent Composition of N-EtFOSAA  
 Table D: Isomeric Components and Percent Composition of PFHxSK  
 Table E: Isomeric Components and Percent Composition of PFOSK  
 Figure 1: LC/MS Data (SIR)  
 Figure 2: LC/MS/MS Data (Selected MRM Transitions)

### ADDITIONAL INFORMATION:

- See page 2 for further details.
- Contains 4 mole eq. of NaOH to prevent conversion of the carboxylic acids to their respective methyl esters.

**FOR LABORATORY USE ONLY: NOT FOR HUMAN OR DRUG USE**

Wellington Laboratories Inc., 345 Southgate Dr. Guelph ON N1G 3M5 CANADA  
 519-822-2436 • Fax: 519-822-2849 • info@well-labs.com

**Table A: PFAC-MXH; Components and Concentrations**  
(ng/mL,  $\pm$  5% in methanol/isopropanol (2%)/water (<1%))

Compound	Acronym	Concentration* (ng/mL)		Peak Assignment in Figure 1
		as the salt	as the acid	
Perfluoro-n-butanoic acid	PFBA	4000		1
Perfluoro-n-pentanoic acid	PFPeA	2000		2
Perfluoro-n-hexanoic acid	PFHxA	1000		5
Perfluoro-n-heptanoic acid	PFHpA	1000		7
Perfluoro-n-octanoic acid	PFOA	1000		11
Perfluoro-n-nonanoic acid	PFNA	1000		14
Perfluoro-n-decanoic acid	PFDA	1000		18
Perfluoro-n-undecanoic acid	PFUdA	1000		24
Perfluoro-n-dodecanoic acid	PFDoA	1000		26
Perfluoro-n-tridecanoic acid	PFTrDA	1000		27
Perfluoro-n-tetradecanoic acid	PFTeDA	1000		29
Perfluoro-1-octanesulfonamide	FOSA	1000		23
N-methylperfluorooctanesulfonamidoacetic acid <sup>a</sup>	N-MeFOSAA: linear isomer	760		20
	N-MeFOSAA: $\Sigma$ branched isomers	240		17
N-ethylperfluorooctanesulfonamidoacetic acid <sup>b</sup>	N-EtFOSAA: linear isomer	775		22
	N-EtFOSAA: $\Sigma$ branched isomers	225		21
Compound	Acronym	Concentration* (ng/mL)		Peak Assignment in Figure 1
		as the salt	as the acid	
Potassium perfluoro-1-butanedisulfonate	L-PFBS	1000	887	3
Sodium perfluoro-1-pentadisulfonate	L-PFPeS	1000	941	6
Potassium perfluorohexadisulfonate <sup>c</sup>	PFHxSK: linear isomer	811	741	9
	PFHxSK: $\Sigma$ branched isomers	189	173	8
Sodium perfluoro-1-heptadisulfonate	L-PFHpS	1000	953	12
Potassium perfluorooctadisulfonate <sup>d</sup>	PFOSK: linear isomer	788	732	15
	PFOSK: $\Sigma$ branched isomers	211	196	13
Sodium perfluoro-1-nonadisulfonate	L-PFNS	1000	962	19
Sodium perfluoro-1-decadisulfonate	L-PFDS	1000	965	25
Sodium perfluoro-1-dodecadisulfonate	L-PFDoS	1000	970	28
Sodium 1H,1H,2H,2H-perfluorohexanesulfonate	4:2FTS	4000	3750	4
Sodium 1H,1H,2H,2H-perfluorooctanesulfonate	6:2FTS	4000	3800	10
Sodium 1H,1H,2H,2H-perfluorodecane sulfonate	8:2FTS	4000	3840	16

<sup>a</sup> See Table B for percent composition of linear and branched N-MeFOSAA isomers.

<sup>b</sup> See Table C for percent composition of linear and branched N-EtFOSAA isomers.

<sup>c</sup> See Table D for percent composition of linear and branched PFHxSK isomers.

<sup>d</sup> See Table E for percent composition of linear and branched PFOSK isomers.

\* Concentrations have been rounded to three significant figures.

Certified By: 

B.G. Chittim, General Manager

Date: 08/09/2022

(mm/dd/yyyy)

# Analytical Standard Record

**22I0344**

Description:	PFAS - MIX MXH 1-4ug/mL	Expires:	08/08/2027
Standard Type:	Other	Prepared:	08/05/2022
Solvent:	MeOH	Prepared By:	Dipti Gokal
Final Volume (mls):	1.2	Department:	PFAS
Vials:	1	Last Edit:	09/26/2022 09:59 by DAG

Analyte	Parent	CAS Number	Concentration	Units
4:2FTS		757124-72-4	3.75	ug/mL
6:2FTS		27619-97-2	3.8	ug/mL
8:2FTS		39108-34-4	3.84	ug/mL
NETFOSAA		2991-50-6	1	ug/mL
NMeFOSAA		2355-31-9	1	ug/mL
PFBA		375-22-4	4	ug/mL
PFBS		375-73-5	0.887	ug/mL
PFDA		335-76-2	1	ug/mL
PFDOA		307-55-1	1	ug/mL
PFDOS		79780-39-5	0.97	ug/mL
PFDS		335-77-3	0.965	ug/mL
PFHPA		375-85-9	1	ug/mL
PFHPS		375-92-8	0.953	ug/mL
PFHXA		307-24-4	1	ug/mL
PFHXS		355-46-4	0.914	ug/mL
PFNA		375-95-1	1	ug/mL
PFNS		68259-12-1	0.962	ug/mL
PFOA		335-67-1	1	ug/mL
PFOS		1763-23-1	0.928	ug/mL
PFOSA		754-91-6	1	ug/mL
PFPEA		2706-90-3	2	ug/mL
PFPEs		630402-22-1	0.941	ug/mL
PFTEDA		376-06-7	1	ug/mL
PFTRDA		72629-94-8	1	ug/mL
PFUnA		2058-94-8	1	ug/mL

# Analytical Standard Record

**22J0448**

Description:	PFAS - MIX 1633 20ng/mL	Expires:	04/25/2023
Standard Type:	Analyte Spike	Prepared:	10/27/2022
Solvent:	MeOH	Prepared By:	Dipti Gokal
Final Volume (mls):	10	Department:	PFAS
Vials:	1	Last Edit:	10/27/2022 08:51 by DAG

Analyte	Parent	CAS Number	Concentration	Units
11CL-PF3OUDS	22I0153	763051-92-9	0.0378	ug/mL
3:3FTCA	22I0153	113507-82-7	0.08	ug/mL
4:2FTS	22I0153	757124-72-4	0.075	ug/mL
5:3FTCA	22I0153	914637-49-3	0.08	ug/mL
6:2FTS	22I0153	27619-97-2	0.076	ug/mL
7:3FTCA	22I0153	812-70-4	0.08	ug/mL
8:2FTS	22I0153	39108-34-4	0.0768	ug/mL
9CL-PF3ONS	22I0153	756426-58-1	0.0374	ug/mL
ADONA	22I0153	919005-14-4	0.0378	ug/mL
HFPO-DA	22I0153	13252-13-6	0.04	ug/mL
NETFOSA	22I0153	4151-50-2	0.08	ug/mL
NETFOSAA	22I0153	2991-50-6	0.02	ug/mL
NETFOSE	22I0153	1691-99-2	0.08	ug/mL
NFDHA	22I0153	151772-58-6	0.04	ug/mL
NMeFOSA	22I0153	31506-32-8	0.08	ug/mL
NMeFOSAA	22I0153	2355-31-9	0.02	ug/mL
NMeFOSE	22I0153	24448-09-7	0.08	ug/mL
PFBA	22I0153	375-22-4	0.08	ug/mL
PFBS	22I0153	375-73-5	0.0177	ug/mL
PFDA	22I0153	335-76-2	0.02	ug/mL
PFDOA	22I0153	307-55-1	0.02	ug/mL
PFDOS	22I0153	79780-39-5	0.0194	ug/mL
PFDS	22I0153	335-77-3	0.0193	ug/mL
PFEESA	22I0153	113507-82-7	0.0356	ug/mL
PFHPA	22I0153	375-85-9	0.02	ug/mL
PFHPS	22I0153	375-92-8	0.0191	ug/mL
PFHXA	22I0153	307-24-4	0.02	ug/mL
PFHXS	22I0153	355-46-4	0.0183	ug/mL
PFMBA	22I0153	863090-89-5	0.04	ug/mL
PFMPA	22I0153	377-73-1	0.04	ug/mL
PFNA	22I0153	375-95-1	0.02	ug/mL
PFNS	22I0153	68259-12-1	0.0192	ug/mL
PFOA	22I0153	335-67-1	0.02	ug/mL
PFOS	22I0153	1763-23-1	0.0186	ug/mL
PFOSA	22I0153	754-91-6	0.02	ug/mL
PFPEA	22I0153	2706-90-3	0.04	ug/mL
PFPEs	22I0153	630402-22-1	0.0188	ug/mL
PFTEDA	22I0153	376-06-7	0.02	ug/mL
PFTRDA	22I0153	72629-94-8	0.02	ug/mL
PFUnA	22I0153	2058-94-8	0.02	ug/mL

# Analytical Standard Record

**22J0448****Parent Standards used:**

<b>Standard</b>	<b>Description</b>	<b>Prepared</b>	<b>Prepared By</b>	<b>Lot Nbr</b>	<b>Expires</b>	<b>Last Edit</b>	<b>(mls)</b>
22I0153	PFAS - MIX 1633 200ng/mL	09/13/2022	In house	x	01/11/2025	09/15/2022 09:34 by DAG	1



# Analytical Standard Record

**22J0552**

Description: PFAS - MIX 1633 200ng/mL  
 Standard Type: Analyte Spike  
 Solvent: MeOH 62244  
 Final Volume (mL): 6  
 Vials: 1

Expires: 01/11/2025  
 Prepared: 10/31/2022  
 Prepared By: Dipti Gokal  
 Department: PFAS  
 Last Edit: 10/31/2022 14:57 by DAG

Analyte	Parent	CAS Number	Concentration	Units
NETFOSA	21J0007	4151-50-2	0.8	ug/mL
NMeFOSE	21J0014	24448-09-7	0.8	ug/mL
3:3FTCA	21L0004	113507-82-7	0.8	ug/mL
5:3FTCA	21L0005	914637-49-3	0.8	ug/mL
NETFOSE	21L0006	1691-99-2	0.8	ug/mL
7:3FTCA	21L0007	812-70-4	0.8	ug/mL
NMeFOSA	21L0008	31506-32-8	0.8	ug/mL
NFDHA	22I0342	151772-58-6	0.4	ug/mL
PFEESA	22I0342	113507-82-7	0.356	ug/mL
PFMBA	22I0342	863090-89-5	0.4	ug/mL
PFMPA	22I0342	377-73-1	0.4	ug/mL
11CL-PF3OUDS	22I0343	763051-92-9	0.378	ug/mL
9CL-PF3ONS	22I0343	756426-58-1	0.374	ug/mL
ADONA	22I0343	919005-14-4	0.378	ug/mL
HFPO-DA	22I0343	13252-13-6	0.4	ug/mL
4:2FTS	22I0344	757124-72-4	0.75	ug/mL
6:2FTS	22I0344	27619-97-2	0.76	ug/mL
8:2FTS	22I0344	39108-34-4	0.768	ug/mL
NETFOSAA	22I0344	2991-50-6	0.2	ug/mL
NMeFOSAA	22I0344	2355-31-9	0.2	ug/mL
PFBA	22I0344	375-22-4	0.8	ug/mL
PFBS	22I0344	375-73-5	0.177	ug/mL
PFDA	22I0344	335-76-2	0.2	ug/mL
PFDOA	22I0344	307-55-1	0.2	ug/mL
PFDOS	22I0344	79780-39-5	0.194	ug/mL
PFDS	22I0344	335-77-3	0.193	ug/mL
PFHPA	22I0344	375-85-9	0.2	ug/mL
PFHPS	22I0344	375-92-8	0.191	ug/mL
PFHXA	22I0344	307-24-4	0.2	ug/mL
PFHXS	22I0344	355-46-4	0.183	ug/mL
PFNA	22I0344	375-95-1	0.2	ug/mL
PFNS	22I0344	68259-12-1	0.192	ug/mL
PFOA	22I0344	335-67-1	0.2	ug/mL
PFOS	22I0344	1763-23-1	0.186	ug/mL
PFOSA	22I0344	754-91-6	0.2	ug/mL
PFPEA	22I0344	2706-90-3	0.4	ug/mL
PFPEs	22I0344	630402-22-1	0.188	ug/mL
PFTEDA	22I0344	376-06-7	0.2	ug/mL
PFTRDA	22I0344	72629-94-8	0.2	ug/mL
PFUnA	22I0344	2058-94-8	0.2	ug/mL

# Analytical Standard Record

22J0552

**Parent Standards used:**

Standard	Description	Prepared	Prepared By	Lot Nbr	Expires	Last Edit		(mls)
21J0007	PFAS - SAS N-EtFOSA 50ug/mL	08/12/2021	Wellington Laboratories	NEtFOSA0821M	08/12/2026	10/31/2022 14:36	by DAG	0.096
21J0014	PFAS - SAS N-MeFOSE 50ug/mL	09/22/2021	Wellington Laboratories	NMeFOSE0921M	09/23/2026	10/31/2022 14:35	by DAG	0.096
21L0004	PFAS - SAS 3:3FTA 50ug/mL	12/07/2021	Wellington Laboratories	FPrPA1020	11/12/2025	10/31/2022 14:39	by DAG	0.096
21L0005	PFAS - SAS 5:3FTA 50ug/mL	12/07/2021	Wellington Laboratories	FPePA1120	11/11/2025	10/31/2022 14:41	by DAG	0.096
21L0006	PFAS - SAS EtFOSE 50ug/mL	12/07/2021	Wellington Laboratories	FPePA1120	09/23/2026	10/31/2022 14:41	by DAG	0.096
21L0007	PFAS - SAS 7:3FTA 50ug/mL	12/07/2021	Wellington Laboratories	FHpPA1020	11/12/2025	10/31/2022 14:42	by DAG	0.096
21L0008	PFAS - SAS N-MeFOSA 50ug/mL	12/07/2021	Wellington Laboratories	NMeFOSA0721M	08/03/2026	10/31/2022 14:42	by DAG	0.096
22I0342	PFAS - MIX MXG 2ug/mL	02/07/2022	Wellington Laboratories	PFACMXG0222	02/22/2027	10/31/2022 14:48	by DAG	1.2
22I0343	PFAS - MIX MXF 2ug/mL	01/10/2022	Wellington Laboratories	PFACMXF0122	01/11/2025	10/31/2022 14:55	by DAG	1.2
22I0344	PFAS - MIX MXH 1-4ug/mL	08/05/2022	Wellington Laboratories	PFACMXH0822	08/08/2027	10/31/2022 14:56	by DAG	1.2



# WELLINGTON LABORATORIES

## CERTIFICATE OF ANALYSIS DOCUMENTATION

### MPFAC-HIF-ES

#### Mass-Labelled PFAS Extraction Standard Solution/Mixture

<b><u>PRODUCT CODE:</u></b>	MPFAC-HIF-ES
<b><u>LOT NUMBER:</u></b>	MPFACHIFES0822
<b><u>SOLVENT(S):</u></b>	Methanol/Isopropanol (1%)/Water (<1%)
<b><u>DATE PREPARED:</u></b> (mm/dd/yyyy)	07/20/2022
<b><u>LAST TESTED:</u></b> (mm/dd/yyyy)	08/02/2022
<b><u>EXPIRY DATE:</u></b> (mm/dd/yyyy)	08/02/2025
<b><u>RECOMMENDED STORAGE:</u></b>	Refrigerate ampoule

#### **DESCRIPTION:**

MPFAC-HIF-ES is a solution/mixture of ten mass-labelled ( $^{13}\text{C}$ ) perfluoroalkylcarboxylic acids ( $\text{C}_4$ - $\text{C}_{12}$ ,  $\text{C}_{14}$ ), three mass-labelled ( $^{13}\text{C}$ ) perfluoroalkanesulfonates ( $\text{C}_4$ ,  $\text{C}_6$ , and  $\text{C}_8$ ), three mass-labelled (one  $^{13}\text{C}$  and two  $^2\text{H}$ ) perfluoro-1-octanesulfonamides, three mass-labelled ( $^{13}\text{C}$ ) fluorotelomer sulfonates (4:2, 6:2, and 8:2), two mass-labelled ( $^2\text{H}$ ) perfluorooctanesulfonamidoacetic acids, two mass-labelled ( $^2\text{H}$ ) perfluorooctanesulfonamidoethanols, and mass-labelled ( $^{13}\text{C}$ ) hexafluoropropylene oxide dimer acid (GenX, M3HFPO-DA). The components and their concentrations are given in Table A.

The individual  $^{13}\text{C}$ -labelled components all have chemical purities >98% and isotopic purities of  $\geq 99\%$ . The individual  $^2\text{H}$ -labelled components all have chemical purities >98% and isotopic purities of  $\geq 98\%$ .

#### **DOCUMENTATION/ DATA ATTACHED:**

Table A: Components and Concentrations of the Solution/Mixture  
Figure 1: LC/MS Data (SIR)  
Figure 2: LC/MS/MS Data (Selected MRM Transitions)

#### **ADDITIONAL INFORMATION:**

- See page 2 for further details.
- Contains 4 mole eq. of NaOH to prevent conversion of the carboxylic acids to their respective methyl esters.


**FOR LABORATORY USE ONLY: NOT FOR HUMAN OR DRUG USE**

Wellington Laboratories Inc., 345 Southgate Dr. Guelph ON N1G 3M5 CANADA  
519-822-2436 • Fax: 519-822-2849 • info@well-labs.com

**Table A: MPFAC-HIF-ES; Components and Concentrations**  
(ng/mL, ± 5% in methanol/isopropanol (1%)/water (<1%))

Compound	Acronym	Concentration (ng/mL)		Peak Assignment in Figure 1
		as the salt	as the acid	
Perfluoro-n-( <sup>13</sup> C <sub>4</sub> )butanoic acid	MPFBA	2000		1
Perfluoro-n-( <sup>13</sup> C <sub>5</sub> )pentanoic acid	M5PFPeA	1000		2
Perfluoro-n-(1,2,3,4,6- <sup>13</sup> C <sub>5</sub> )hexanoic acid	M5PFHxA	500		5
Perfluoro-n-(1,2,3,4- <sup>13</sup> C <sub>4</sub> )heptanoic acid	M4PFHpA	500		7
Perfluoro-n-( <sup>13</sup> C <sub>8</sub> )octanoic acid	M8PFOA	500		10
Perfluoro-n-( <sup>13</sup> C <sub>9</sub> )nonanoic acid	M9PFNA	250		11
Perfluoro-n-(1,2,3,4,5,6- <sup>13</sup> C <sub>6</sub> )decanoic acid	M6PFDA	250		14
Perfluoro-n-(1,2,3,4,5,6,7- <sup>13</sup> C <sub>7</sub> )undecanoic acid	M7PFUdA	250		17
Perfluoro-n-(1,2- <sup>13</sup> C <sub>2</sub> )dodecanoic acid	MPFD <sub>o</sub> A	250		19
Perfluoro-n-(1,2- <sup>13</sup> C <sub>2</sub> )tetradecanoic acid	M2PFTeDA	250		23
Perfluoro-1-( <sup>13</sup> C <sub>8</sub> )octanesulfonamide	M8FOSA	500		18
N-methyl-d <sub>3</sub> -perfluoro-1-octanesulfonamide	d-N-MeFOSA	500		21
N-ethyl-d <sub>5</sub> -perfluoro-1-octanesulfonamide	d-N-EtFOSA	500		24
N-methyl-d <sub>3</sub> -perfluoro-1-octanesulfonamidoacetic acid	d3-N-MeFOSAA	1000		15
N-ethyl-d <sub>5</sub> -perfluoro-1-octanesulfonamidoacetic acid	d5-N-EtFOSAA	1000		16
2-(N-methyl-d <sub>3</sub> -perfluoro-1-octanesulfonamido)ethan-d <sub>4</sub> -ol	d7-N-MeFOSE	5000		20
2-(N-ethyl-d <sub>5</sub> -perfluoro-1-octanesulfonamido)ethan-d <sub>4</sub> -ol	d9-N-EtFOSE	5000		22
2,3,3,3-Tetrafluoro-2-(1,1,2,2,3,3,3-heptafluoropropoxy)( <sup>13</sup> C <sub>3</sub> )propanoic acid	M3HFPO-DA	2000		6
Compound	Acronym	Concentration* (ng/mL)		Peak Assignment in Figure 1
		as the salt	as the acid	
Sodium perfluoro-1-(2,3,4- <sup>13</sup> C <sub>3</sub> )butanesulfonate	M3PFBS	500	466	3
Sodium perfluoro-1-(1,2,3- <sup>13</sup> C <sub>3</sub> )hexanesulfonate	M3PFHxS	500	474	8
Sodium perfluoro-1-( <sup>13</sup> C <sub>8</sub> )octanesulfonate	M8PFOS	500	479	12
Sodium 1H,1H,2H,2H-perfluoro-(1,2- <sup>13</sup> C <sub>2</sub> )hexanesulfonate	M2-4:2FTS	1000	938	4
Sodium 1H,1H,2H,2H-perfluoro-(1,2- <sup>13</sup> C <sub>2</sub> )octanesulfonate	M2-6:2FTS	1000	951	9
Sodium 1H,1H,2H,2H-perfluoro-(1,2- <sup>13</sup> C <sub>2</sub> )decanesulfonate	M2-8:2FTS	1000	960	13

\* Concentrations have been rounded to three significant figures.

Certified By:   
B.G. Chittim, General Manager

Date: 08/02/2022  
(mm/dd/yyyy)

# Analytical Standard Record

22K0502

Description:	PFAS IIS 7C 40ng/mL	Expires:	01/20/2023
Standard Type:	Internal Standard	Prepared:	11/28/2022
Solvent:	MeOH/62286	Prepared By:	Dipti Gokal
Final Volume (mls):	25	Department:	PFAS
Vials:	1	Last Edit:	11/28/2022 15:10 by DAG

Analyte	Parent	CAS Number	Concentration	Units
13C2-PFDA	22A0234	13C2-PFDA	0.04	ug/mL
13C2-PFHXA	22A0234	13C2-PFHxA	0.04	ug/mL
13C3-PFBA	22A0234	13C3-PFBA	0.04	ug/mL
13C4-PFOA	22A0234	13C4-PFOA	0.04	ug/mL
13C4-PFOS	22A0234	13C4-PFOS	0.04	ug/mL
13C5-PFNA	22A0234	13C5-PFNA	0.04	ug/mL
18O2-PFHXS	22A0234	18O2-PFHXS	0.04	ug/mL

### Parent Standards used:

Standard	Description	Prepared	Prepared By	Lot Nbr	Expires	Last Edit	(mls)
22A0234	PFAS IIS 7C 5ug/mL	01/20/2022	In house	*	01/20/2023	01/20/2022 15:49	by HGH 0.2

# Analytical Standard Record

**22K0503**

Description:	1633- IIS Static 1ng/mL	Expires:	01/20/2023
Standard Type:	Internal Standard	Prepared:	11/28/2022
Solvent:	MeOH/62286	Prepared By:	Dipti Gokal
Final Volume (mL):	2	Department:	PFAS
Vials:	1	Last Edit:	11/28/2022 15:11 by DAG

Analyte	Parent	CAS Number	Concentration	Units
13C2-PFDA	22K0502	13C2-PFDA	0.001	ug/mL
13C2-PFHXA	22K0502	13C2-PFHxA	0.001	ug/mL
13C3-PFBA	22K0502	13C3-PFBA	0.001	ug/mL
13C4-PFOA	22K0502	13C4-PFOA	0.001	ug/mL
13C4-PFOS	22K0502	13C4-PFOS	0.001	ug/mL
13C5-PFNA	22K0502	13C5-PFNA	0.001	ug/mL
18O2-PFHXS	22K0502	18O2-PFHXS	0.001	ug/mL

**Parent Standards used:**

Standard	Description	Prepared	Prepared By	Lot Nbr	Expires	Last Edit	(mL)
22K0502	PFAS IIS 7C 40ng/mL	11/28/2022	In house	*	01/20/2023	11/28/2022 15:10 by DAG	0.05

# Analytical Standard Record

**22L0269**

Description:	PFAS - MIX 1633 10ng/mL	Expires:	06/12/2023
Standard Type:	Analyte Spike	Prepared:	12/14/2022
Solvent:	MeOH	Prepared By:	Dipti Gokal
Final Volume (mls):	10	Department:	PFAS
Vials:	1	Last Edit:	12/14/2022 12:00 by DAG

Analyte	Parent	CAS Number	Concentration	Units
11CL-PF3OUDS	22J0552	763051-92-9	0.0189	ug/mL
3:3FTCA	22J0552	113507-82-7	0.04	ug/mL
4:2FTS	22J0552	757124-72-4	0.0375	ug/mL
5:3FTCA	22J0552	914637-49-3	0.04	ug/mL
6:2FTS	22J0552	27619-97-2	0.038	ug/mL
7:3FTCA	22J0552	812-70-4	0.04	ug/mL
8:2FTS	22J0552	39108-34-4	0.0384	ug/mL
9CL-PF3ONS	22J0552	756426-58-1	0.0187	ug/mL
ADONA	22J0552	919005-14-4	0.0189	ug/mL
HFPO-DA	22J0552	13252-13-6	0.02	ug/mL
NETFOSA	22J0552	4151-50-2	0.04	ug/mL
NETFOSAA	22J0552	2991-50-6	0.01	ug/mL
NETFOSE	22J0552	1691-99-2	0.04	ug/mL
NFDHA	22J0552	151772-58-6	0.02	ug/mL
NMeFOSA	22J0552	31506-32-8	0.04	ug/mL
NMeFOSAA	22J0552	2355-31-9	0.01	ug/mL
NMeFOSE	22J0552	24448-09-7	0.04	ug/mL
PFBA	22J0552	375-22-4	0.04	ug/mL
PFBS	22J0552	375-73-5	0.00885	ug/mL
PFDA	22J0552	335-76-2	0.01	ug/mL
PFDOA	22J0552	307-55-1	0.01	ug/mL
PFDOS	22J0552	79780-39-5	0.0097	ug/mL
PFDS	22J0552	335-77-3	0.00965	ug/mL
PFEESA	22J0552	113507-82-7	0.0178	ug/mL
PFHPA	22J0552	375-85-9	0.01	ug/mL
PFHPS	22J0552	375-92-8	0.00955	ug/mL
PFHXA	22J0552	307-24-4	0.01	ug/mL
PFHXS	22J0552	355-46-4	0.00915	ug/mL
PFMBA	22J0552	863090-89-5	0.02	ug/mL
PFMPA	22J0552	377-73-1	0.02	ug/mL
PFNA	22J0552	375-95-1	0.01	ug/mL
PFNS	22J0552	68259-12-1	0.0096	ug/mL
PFOA	22J0552	335-67-1	0.01	ug/mL
PFOS	22J0552	1763-23-1	0.0093	ug/mL
PFOSA	22J0552	754-91-6	0.01	ug/mL
PFPEA	22J0552	2706-90-3	0.02	ug/mL
PFPEs	22J0552	630402-22-1	0.0094	ug/mL
PFTEDA	22J0552	376-06-7	0.01	ug/mL
PFTRDA	22J0552	72629-94-8	0.01	ug/mL
PFUnA	22J0552	2058-94-8	0.01	ug/mL

# Analytical Standard Record

**22L0269****Parent Standards used:**

<b>Standard</b>	<b>Description</b>	<b>Prepared</b>	<b>Prepared By</b>	<b>Lot Nbr</b>	<b>Expires</b>	<b>Last Edit</b>	<b>(mls)</b>
22J0552	PFAS - MIX 1633 200ng/mL	10/31/2022	In house	x	01/11/2025	10/31/2022 15:40 by DAG	0.5



# Analytical Standard Record

**22L0272**

Description:	MPFAC-HIF-ES 20.0ng/mL	Expires:	06/12/2023
Standard Type:	Surrogate Spike	Prepared:	12/14/2022
Solvent:	MeOH/62244	Prepared By:	Andonios Karas
Final Volume (mls):	10	Department:	PFAS
Vials:	3	Last Edit:	12/14/2022 13:55 by ABK
Comments:	Half the concentration of previous EIS solution used for 1633/B-15. Double the spiking volume from 100 uL to 200 uL		

Analyte	Parent	CAS Number	Concentration	Units
13C2-4:2FTS	22K0095	13C2-4:2FTS	0.04	ug/mL
13C2-6:2FTS	22K0095	13C2-6:2FTS	0.04	ug/mL
13C2-8:2FTS	22K0095	13C2-8:2FTS	0.04	ug/mL
13C2-PFDOA	22K0095	13C2-PFDOA	0.01	ug/mL
13C2-PFTEDA	22K0095	13C2-PFTEDA	0.01	ug/mL
13C3-HFPO-DA	22K0095	13C3-HFPO-DA	0.08	ug/mL
13C3-PFBS	22K0095	13C3-PFBS	0.02	ug/mL
13C3-PFHXS	22K0095	13C3-PFHXS	0.02	ug/mL
13C4-PFBA	22K0095	13C4-PFBA	0.08	ug/mL
13C4-PFHPA	22K0095	13C4-PFHPA	0.02	ug/mL
13C5-PFHXA	22K0095	13C5-PFHXA	0.02	ug/mL
13C5-PFPEA	22K0095	13C5-PFPEA	0.04	ug/mL
13C6-PFDA	22K0095	13C6-PFDA	0.01	ug/mL
13C7-PFUHA	22K0095	13C7-PFUHA	0.01	ug/mL
13C8-PFOA	22K0095	13C8-PFOA	0.02	ug/mL
13C8-PFOS	22K0095	13C8-PFOS	0.02	ug/mL
13C8-PFOSA	22K0095	13C8-PFOSA	0.02	ug/mL
13C9-PFNA	22K0095	13C9-PFNA	0.01	ug/mL
D3-NMEFOSA	22K0095	D3-NMEFOSA	0.02	ug/mL
D3-NMEFOSAA	22K0095	D3-NMEFOSAA	0.04	ug/mL
D5-NETFOSA	22K0095	D5-NETFOSA	0.02	ug/mL
D5-NETFOSAA	22K0095	D5-NETFOSAA	0.04	ug/mL
D7-NMEFOSE	22K0095	D7-NMEFOSE	0.2	ug/mL
D9-NETFOSSE	22K0095	D9-NETFOSSE	0.2	ug/mL

**Parent Standards used:**

Standard	Description	Prepared	Prepared By	Lot Nbr	Expires	Last Edit	(mls)
22K0095	MPFAC-HIF-ES-EIS	07/20/2022	Wellington Laboratories	MPFACHIFES0822	08/02/2025	11/04/2022 12:16 by DAG	0.4

# Analytical Standard Record

**22L0273**

Description:	MPFAC-HIF-ES 20.0ng/mL	Expires:	06/12/2023
Standard Type:	Surrogate Spike	Prepared:	12/14/2022
Solvent:	MeOH/62244	Prepared By:	Andonios Karas
Final Volume (mls):	10	Department:	PFAS
Vials:	3	Last Edit:	12/14/2022 13:55 by ABK
Comments:	Half the concentration of previous EIS solution used for 1633/B-15. Double the spiking volume from 100 uL to 200 uL		

Analyte	Parent	CAS Number	Concentration	Units
13C2-4:2FTS	22K0095	13C2-4:2FTS	0.04	ug/mL
13C2-6:2FTS	22K0095	13C2-6:2FTS	0.04	ug/mL
13C2-8:2FTS	22K0095	13C2-8:2FTS	0.04	ug/mL
13C2-PFDOA	22K0095	13C2-PFDOA	0.01	ug/mL
13C2-PFTEDA	22K0095	13C2-PFTEDA	0.01	ug/mL
13C3-HFPO-DA	22K0095	13C3-HFPO-DA	0.08	ug/mL
13C3-PFBS	22K0095	13C3-PFBS	0.02	ug/mL
13C3-PFHXS	22K0095	13C3-PFHXS	0.02	ug/mL
13C4-PFBA	22K0095	13C4-PFBA	0.08	ug/mL
13C4-PFHPA	22K0095	13C4-PFHPA	0.02	ug/mL
13C5-PFHXA	22K0095	13C5-PFHXA	0.02	ug/mL
13C5-PFPEA	22K0095	13C5-PFPEA	0.04	ug/mL
13C6-PFDA	22K0095	13C6-PFDA	0.01	ug/mL
13C7-PFUHA	22K0095	13C7-PFUHA	0.01	ug/mL
13C8-PFOA	22K0095	13C8-PFOA	0.02	ug/mL
13C8-PFOS	22K0095	13C8-PFOS	0.02	ug/mL
13C8-PFOSA	22K0095	13C8-PFOSA	0.02	ug/mL
13C9-PFNA	22K0095	13C9-PFNA	0.01	ug/mL
D3-NMEFOSA	22K0095	D3-NMEFOSA	0.02	ug/mL
D3-NMEFOSAA	22K0095	D3-NMEFOSAA	0.04	ug/mL
D5-NETFOSA	22K0095	D5-NETFOSA	0.02	ug/mL
D5-NETFOSAA	22K0095	D5-NETFOSAA	0.04	ug/mL
D7-NMEFOSE	22K0095	D7-NMEFOSE	0.2	ug/mL
D9-NETFOSSE	22K0095	D9-NETFOSSE	0.2	ug/mL

**Parent Standards used:**

Standard	Description	Prepared	Prepared By	Lot Nbr	Expires	Last Edit	(mls)
22K0095	MPFAC-HIF-ES-EIS	07/20/2022	Wellington Laboratories	MPFACHIFES0822	08/02/2025	11/04/2022 12:16 by DAG	0.4